[{"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThe ICR chief executive, Prof Paul Workman, said the test could \u201cusher in a new era of precision medicine for prostate cancer\u201d.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\nThe test, developed by researchers at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS foundation trust, picks out men suitable for treatment with olaparib, part of a revolutionary class of drugs called \u201cPARP-inhibitors\u201d, which stops damaged cells from repairing themselves.\nThe researchers collected blood samples from 49 men at the Royal Marsden with advanced prostate cancer enrolled in the phase II clinical trial of olaparib.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article makes no mention about alternatives. It doesn\u2019t make clear what current standard therapy is for prostate cancer or how patients are currently selected for treatment with the targeted cancer drug.\nIt also didn\u2019t discuss that the drug itself\u2013olaparib\u2013is still being researched for effectiveness.", "answer": 0}, {"article": "Lung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nThe experimental medicine, taken twice a day, goes by the code name VX-770.\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nThe improvement at six months was still present almost a year after the study's start.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Nothing on existing alternatives.\u00a0 We wish the story had included even one line as the NY Times did: \u201cTwo inhaled antibiotics and one drug that loosens mucus are approved to treat cystic fibrosis, but nothing that directly improves chloride ion transport.\u201d", "answer": 0}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the\u00a0story mentioned one other category of drug used in the treatment of insomnia, it did not mention that a range of treatment options exist including lifestyle changes that may be of benefit.", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As mentioned above, the story discusses several options and ends with two good graphs that actually rely on the lead doctor in the most recent study to show the benefits of high-def colonscopy, a doctor who \"receives research funding from Olympus Corp., a manufacturer of HD\u00a0scopes.\" He\u00a0helps\u00a0emphasize the importance of colonscopy\u00a0technique and\u00a0provides specifics that could help patients\u00a0ask tough questions of their own physicians. \nThe last graph in the story is about a cheaper alternative that is described as a \"reasonable alternative\" that has to be performed with more frequency. But why no mention of fecal occult blood stool tests? FOBT is the only screening test for colon cancer showed by randomized clinical trial to decrease colon cancer mortality and incidence.\u00a0 As good as the story may have been on other points, this story joins many journalistic efforts that don\u2019t seem to give FOBT its due. And for that we must rule this criterion unsatisfactory. ", "answer": 0}, {"article": "Biopsies may be performed via open surgery on the breast or with a less invasive core-needle biopsy in which a small sample of breast tissue from the affected area is removed through a special needle inserted through the skin.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story is a recent meta-analysis that adds to a body of evidence sugesting core needle biopsies are as accurate and less risky compared with surgical open biopsies for diagnosing\u00a0 breast cancer.\u00a0 Since the focus of the story was less invasive methods of biopsy,\u00a0 it would have been good to describe the different kinds of core needle biopsies, as well as fine needle aspiration, which is even less invasive than the core biopsy and can be used for palpable masses. Nonethless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states\nMice fed night milk were more inclined to explore open spaces, an indication of reduced anxiety that was comparable to the effects from consuming diazepam\u2026\nThe design of the study, however, does not support this claim\u00a0because a direct\u00a0comparison is never made between night milk and diazepam. Since we\u2019ve already addressed this issue above, however, we\u2019ll give the story credit here.", "answer": 1}, {"article": "\"The goal is to create cells that are missing or defective in people.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of treatment options; however this story was not actually about a treatment but a highly-experimental approach in mice.", "answer": 2}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, we\u2019ll give the story the benefit of the doubt with this one. The story did note that the tincture performed better than alcohol or\u00a0benzoyl peroxide.\nAgain, barely satisfactory.", "answer": 1}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThey verified that detailed quantification of the tested and retested tracer in those five patients with Alzheimer's and five older controls generated good and reproducible results.\nTwo studies will be published back-to-back in the December issue of Journal of Nuclear Medicine--one as featured article of the month--describing testing of three candidate molecules in patients with Alzheimer's disease, as well as the use of one molecule to measure the accumulation of tau proteins.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\nIn the second part of the study, researchers tested the optimal tracer, called F-18 RO948, with additional brain imaging in five patients with Alzheimer's and five older controls, with follow-up of previously seen patients to evaluate the potential progression of tau protein tangling after an average span of approximately 16 months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release accurately notes that there is no definitive diagnostic tool for Alzheimer\u2019s disease other than an autopsy of the brain. It also refers to a \u201ccurrently used\u201d tau tracer.\nWe wish it had been clearer that the research being described is not the only work being done in this area. For example, this 2015 paper in the journal Alzheimer\u2019s and Dementia describes a number of innovative approaches being explored in this field.", "answer": 1}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nAnd it can boost older people's strength and balance.\nThe sport is also associated with good mental health and improving the overall health of those with disabilities.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Golf is often referred to as \u201ca good walk spoiled.\u201d\nCommon sense would suggest many of the benefits touted in this news release might also hold for a good walk or hike; unfortunately, no alternatives are mentioned.", "answer": 0}, {"article": "METs, or metabolic equivalents, are a measure of physiological measure expressing the energy cost of physical activities.\nThese differences in risk were statistically significant.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nThere were other significant findings too - notably that starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions various forms of exercise and physical activity, and\u00a0the comparison of very active to inactive (and various levels within these extremes) is made clear. But there is no attempt to broaden the discussion to related factors that might also impact longevity in old age, including diet, body weight, alcohol consumption, and social engagement.\u00a0This could have been accomplished in a broad sweep with just a few additional words.", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned that the current therapies for heart failure were limited and expensive, including such things as artificial hearts, heart transplants, and left ventricular assist devices. \u00a0However \u2013 it neglected to mention the medical therapy that is available to treat heart failure \u2013 which is comparatively not expensive. \u00a0It also failed to indicate that the treatments mentioned are the current therapies for severe heart failure. \u00a0There are current therapies for managing heart failure that enable many people to do well.\u00a0", "answer": 0}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nSamit Hirawat, head of Novartis\u2019s cancer drug development, said in an interview the side-effects profile of alpelisib held up.\nEven though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumor growth have largely disappointed including on safety issues.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study is comparing the combination of Faslodex and\u00a0BYL719/alpelisib to Faslodex alone. It\u2019s not clear if there are other treatment options for this patient population or if Faslodex alone would be the standard of care for these patients at this point in their treatment.", "answer": 0}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\nSpecialty testing for dry eye is performed at the Dry Eye Relief Clinic at UAB Eye Care, in the School of Optometry.\nKelly Nichols, O.D., Ph.D., a dry eye expert and dean of the University of Alabama at Birmingham School of Optometry, conducted research studies for the parent drug company to explore the efficacy and safety of lifitegrast in treating this eye condition that affects more than 16 million adults in the United States.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release notes that researchers are working to find new treatments for dry eye, with more than 30 studies under way. But it makes no mention of the currently available treatments or how this product compares with them.\nOther available treatments including artificial tears; Restasis, a drop that that induces tear production; and there are many other eye drops on the market that treat some of the side effects of eye dryness.", "answer": 0}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nBut you can also tell by the ads: TV spots selling remedies for drippy, congested noses, itchy eyes and other symptoms are in heavy rotation.\nPeople with mild to moderate symptoms have the best chance of full relief, he says.\nHere's what some top allergists say you need to know about these non-prescription options.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did a great job comparing the various over-the-counter alternatives out there, from steroid nasal sprays like Flonase to antihistamines like Claritin to decongestants like Sudafed.", "answer": 1}, {"article": "?\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\nThat's because hot flashes have a high placebo-response rate: Symptoms often improve, at least temporarily, with a dummy treatment.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other options for dealing with menopausal hot flashes are reviewed, along with their shortcomings. However, this section was brief and could have discussed many other options which have known benefit. ", "answer": 1}, {"article": "Relatively few women at high risk of breast cancer take tamoxifen, and some patient advocates question whether they should, saying many women are exposed to side effects for each case of cancer prevented.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\nBut Dr. Ganz said that side effects of both drugs were generally mild and that it was important that women at high risk of breast cancer take one of them.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\nThe new data are not likely to settle the debate about which drug is better.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s not clear from the article whether women have other options for lowering breast cancer risk. Explaining how few options there are would have helped readers to understand why these findings are important. ", "answer": 0}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nIf so, this could change the nature of medicine.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\nAll that's needed is a little help from one's own heart stem cells.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison to alternative treatments. What do patients typically do after suffering a heart attack? Given what modern medicine has achieved so far with heart care, how long can someone expect to live after having a heart attack? Are there surgical options, pharmaceutical treatments or lifestyle changes that could make a difference? Even in a short, 511-word story, some of the space devoted to the lead researcher\u2019s quotes could have been given to even one sentence about alternatives.\n\u00a0\n\u00a0", "answer": 0}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nStimulating the hippocampus -- a brain region next to the entorhinal cortex which helps form and store memories -- produced no effect during this experiment, however.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have made some mention of the drugs currently available to improve memory function of people with Alzheimer\u2019s disease. Although these drugs do not alter the progression of the disease, a comparison of their memory-enhancing effects to the level of improvement seen in this test would have given readers a useful way to better understand the size and duration of the effect these researchers saw.", "answer": 0}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n\"The five-year survival rate is really low, so that makes prevention and identifying risk factors or predictors associated with pancreatic cancer very important.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The focus of this release is on a study that tries to compare the effect of meeting RDAs of magnesium and not meeting that daily target.\nBut the release doesn\u2019t mention any other suspected risk factors for pancreatic cancer such as obesity, smoking, alcohol abuse, inactivity, genetics, and so on, which might have been helpful.", "answer": 0}, {"article": "In a study published in the Sept. 28 issue of the journal Menopause, scientists reported that about half the women in the study reduced the frequency of hot flashes, while half did not.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\nForty-seven percent of the study group reported a 47 percent reduction over this same time frame.\nFunding for the study was provided by grant R01AT005854 from the National Center for Complementary and Integrative Health, at NIH.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a number of pharmaceutical options that are used to provide patients with some relief from hot flashes, and these are not mentioned at all. A release needs to note what a given treatment option (acupuncture in this case) brings to the table that other treatment options do not. How is it different? How might it be better? Or worse? That sort of context is invaluable for readers.", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nOf melatonin, Dr. Seres warned, \u201cIf you take it while you\u2019re driving a car, you will find yourself in a ditch.\u201d\n\nMaybe.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nBut some medical professionals are concerned that the chocolate taste might encourage indiscriminate gobbling.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable.\u00a0 It isn\u2019t possible to compare existing alternatives to these products because there is no information documenting efficacy of the products.", "answer": 2}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nPrevious efforts in Ingber's team at the Wyss Institute have established FcMBL as a key component of an advanced dialysis-like, pathogen-extracting therapeutic device, and of a method for the fast retrieval of infectious pathogens from complex clinical samples to enable their identification and antibody susceptibilities.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes some alternatives to this new technology. It describes briefly that current blood cultures are often not adequate, both from a timing and sensitivity perspective. It would have been even more thorough to note that there are other diagnostic tools in the research pipeline.", "answer": 1}, {"article": "Dialysis can cost more than $88,000 a year, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nNew, less toxic treatments for hepatitis C opened the door for transplanting infected kidneys and then successfully treating the infection, Reese said.\nBut the cost effectiveness of using these kidneys versus remaining on dialysis would be significant, he noted.\nUsing hepatitis C-infected kidneys would expand the organ pool and save lives, said lead researcher Dr. Peter Reese.\nAbout 15 percent of dialysis patients have HCV, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made it clear that the alternative to receiving an infected kidney is waiting more than a year on average for a healthy kidney or remaining on dialysis.", "answer": 1}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nThe study appears in the latest issue of the journal Ophthalmology.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, we\u2019ll give the story the benefit of the doubt for at least nodding in the direction of other alternatives.\u00a0 For example:", "answer": 1}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nAlthough the story does mention that people with diabetes can manage blood glucose levels with multiple daily injections of insulin, without a pump, it leaves out a critical piece of information. Patients who could successfully manage their blood sugar levels without a pump were excluded from the study. Readers should be told how often people with diabetes can achieve treatment targets without using a pump. This story does not make clear that the trial results apply only to people who are unable to achieve treatment goals by using multiple daily insulin injections.\n", "answer": 0}, {"article": "But it is also relevant to anyone who takes their weight management seriously and wants to stay lean and healthy.\"\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nBoth diets were restricted by 500 kilocalories per day compared to an isocaloric intake for each individual.\nHowever, subfascial fat was only reduced in response to the vegetarian diet, and intramuscular fat was more greatly reduced by the vegetarian diet.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does mention one alternative to the vegetarian diet \u2014 the\u00a0anti-diabetic conventional diet which\u00a0adheres to\u00a0official recommendations of the European Association for the Study of Diabetes.\u00a0 ", "answer": 1}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nThese analyses with tramiprosate in the APOE4 subgroups are compelling, and suggest a meaningful clinical benefit, on top of the existing symptomatic AD treatments, in Alzheimer's patients who are in great need of new treatments.\nThe results published in JPAD are the first evidence from a large clinical trial to associate efficacy of an amyloid-targeted agent with APOE4 status in AD patients.\nThe efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThe manuscript, titled \"Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The 'APOE4 Gene-Dose Effect',\" is featured in the advanced online publication of The Journal of the Prevention of Alzheimer's Disease (JPAD) with lead authors from Alzheon, Inc., a biopharmaceutical company focused on treatments for neurodegenerative and neuropsychiatric disorders.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release summarizing the research study did not include comparisons with existing drugs \u2014 but we won\u2019t fault them for that. There are no known therapies that \u201ctreat\u201d Alzheimer\u2019s, only those that relieve some of its underlying symptoms.\nBut a\u00a0 mention of preventative strategies would have been welcomed here.\nMany researchers are pointing out that Alzheimer\u2019s is not a disease simply due to overload of amyloid but its causes may be multifactorial, with, for example, blood vessel disease (narrowing of small arteries) and high blood pressure being significant risk factors. Lifestyle changes, including regular exercise, may do more to help prevent Alzheimer\u2019s than any drug now available, and a discussion of that is included in a HealthNewsReview.org blog post from earlier this year.", "answer": 2}, {"article": "For the study, researchers led by Dr. Xiang Gao, of Brigham and Women's Hospital and Harvard University School of Public Health in Boston, analyzed data on more than 38,000 men and almost 91,000 women enrolled in the Health Professionals Follow-up Study and the Nurses' Health Study in 1994.\n\"Right now we don't have any good evidence that there is anything we can do to reduce the risk of developing Parkinson's disease, but research is ongoing,\" added Isaacson, also an associate professor of neurology at Florida International University's Herbert Wertheim College of Medicine in Miami.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At the moment there are no alternative strategies to reduce the risk of developing Parkinson\u2019s.\u00a0 Dr. Isaacson\u2019s comment, \u201cRight now we don\u2019t have any good evidence that there is anything we can do to reduce the risk of developing Parkinson\u2019s disease, but research is ongoing,\u201d says it all.", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not put this trial in any context with the existing evidence on other types of physical activity or other methods of reducing the risk of falls by older people. \n", "answer": 0}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nQuitting smoking, limiting alcohol and avoiding carbonated drinks are also important protective measures.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address several other available treatments for acid reflux or GERD. For example, over-the-counter antacids can be useful tools for addressing heartburn in patients with infrequent acid reflux. Prescription strength and over-the-counter H2 receptor blockers are also often used to address acid reflux and GERD. The story also doesn\u2019t discuss surgical options for GERD.", "answer": 0}, {"article": "If necessary, he suggests finding an indoor place to move, whether it's the gym, a staircase or a shopping mall.\n\"Just 30 minutes a day of walking, riding a bike, doing yoga -- anything active, really -- can result in significant reduction of asthma symptoms.\"\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A bit of context was missing here. The news release quotes the study\u2019s lead author saying, \u201cIt would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\u201d but the news release doesn\u2019t detail what those drugs are. According to the National Heart, Lung and Blood Institute, asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines,\u00a0like inhaled corticosteroids, help reduce airway inflammation and prevent asthma symptoms. Quick-relief inhalers, or \u201crescue,\u201d medicines relieve asthma symptoms that may flare up.\nAnother problem here is that this study really doesn\u2019t provide anything to support the author\u2019s desire to see physicians recommending more exercise. Should we simply tell patients with severe asthma to exercise? Or do we need to treat them in a way that permits them to exercise safely? This study isn\u2019t designed to answer these questions, so it really can\u2019t compare alternatives. We would have given credit if the release had simply said that \u201conly interventional studies designed to examine the combination of physical activity and medication recommendations can determine how best to see if this observation can lead to better patient outcomes.\u201d", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nA team of researchers from the National Cancer Institute reported yesterday that they have successfully treated two cancer patients using gene therapy, the introduction of genes into the human body for medical purposes.\nAnd cancer sometimes returns even after that much time has elapsed.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of the use of autologous tumor infiltrating lymphocyte treatment which, although effective in roughly half the patients for whom it is an option, is not a possibility for all patients. There was no mention of the surgery, chemotherapy, radiation therapy, and biologic therapy that are currently used in the treatment of melanoma. The story did not mention that at least some of these treatments were used in conjunction with the experimental treatment.", "answer": 0}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n\"While complication rates are low, there are some cases with serious consequences that include infection, joint dislocation, blood clots and even death.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was just about comparing joint replacement outcomes in different groups of patients, so it is understandable that it did not delve into alternative treatment.\n\u00a0", "answer": 2}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nStecker says if he had it to do over again, he would have waited for more research.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nAlthough the doctor who treated him in New York found a significant blockage, he was unable to correct it, Stecker says.\nSeveral patients have even died as a result.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study focuses exclusively on this novel surgical procedure. It should have at least mentioned that there are FDA-approved drug treatments for MS.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the primary treatment option for people with kidney failure, that is dialysis. However, the article doesn\u2019t describe it any more than naming it. There is no assessment of effectiveness of dialysis and, indeed, it is painted in a very negative manner \u2013 \u201c\u2026slowly dying on dialysis.\u201d While dialysis is by no means a cure, it does allow people to live who would otherwise die due to kidney failure. ", "answer": 0}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nA far less expensive alternative proved roughly as effective as Genentech\u2019s costly drug Lucentis in preserving or improving vision in elderly people with a common eye disease, according to two people familiar with the results of a closely watched clinical trial.\nPatients in the trial are being followed for a second year.\nYet Medicare paid only $20 million for the Avastin compared to $537 million for the smaller number of Lucentis injections.\nHowever, experts say that with only 1,200 patients, the trial will be able to detect only major differences in safety.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article is about a comparison of an off-label approach to the approved one.", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article, like the study upon which it is based, compares only two treatment options\u2013miniminally invasive laparoscopic surgery and traditional \"open\" surgery to remove the prostate.\nIt would have been helpful, but not necessary, to place these two approaches in the context of the many choices men with prostate cancer face based on age, severity, co-morbidities, personal preference and other factors.\u00a0 ", "answer": 1}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\nBlood tests similar to the one investigated in this study have been found to be useful to gauge how well patients who already have metastatic cancer will do.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nAccording to Lucci, circulating tumor cells are also showing promise in predicting melanoma prognosis, so the method may be \"effective in several different tumor systems.\"\nAccording to Bernik, though, \"it makes sense that women who have circulating tumor cells would potentially be at higher risk of distant disease at some later date.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers are told that lymph node status is currently the best predictor of survival for women with breast cancer but there is no mention of other predictors, such as tumor size and grade, estrogen receptor status, and\u00a0HER2 status,\u00a0that are also\u00a0used to help women make their surgery and treatment decisions.\nThere is no mention of existing tests such as Oncotype DX that can be used for many women with early stage breast cancer.", "answer": 0}, {"article": "D.C.I.S.\nShe compared the drugs to statins and blood pressure drugs, which people take even though they feel well, to lower their risks of heart attacks and strokes.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nIn the meantime, Dr. Ford said, at least tamoxifen and raloxifene give women at risk the chance to do something.\nBased on those findings, it is easy to see why raloxifene was declared the winner.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions tamoxifen as the alternative to raloxifene.", "answer": 1}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nIn a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although there is no cure for Alzheimer\u2019s, several drug and non-drug options are available to treat symptoms of the disease, including medications for memory loss and treatments for behavioral and sleep changes associated with this condition. None of these are addressed in the news release.", "answer": 0}, {"article": "So you do not get the impression that the world is moving or that you are moving, you actually do not feel anything,\u201d Bergquist explained.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nNearly all patients diagnosed with the disease are treated with levodopa, a drug that stimulates the production of dopamine in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that levodopa is commonly used to treat the symptoms associated with Parkinson\u2019s, and notes that the drug\u2019s efficacy tends to wane over time.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\nA previous study by the same scientists in 2001 led the federal Food and Drug Administration to recommend ways to limit scans and risks in children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Two other scanning methods -MRI and ultrasound \u2013 were briefly mentioned.\u00a0 ", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention other current drugs and alternate approaches to treating patients with migraines so it gets a satisfactory in this category.\nHowever, most of these remedies are supported by poor or medium quality evidence and the article does not separate those that\u00a0have more robust evidence and those that have been supported by tenuous or flawed evidence only.", "answer": 1}, {"article": ".\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release goes into some detail about the current methods used by surgeons and pathologists to assess the extent of a tumor and the likely outer border of margins.\nWe\u2019ll rate this Satisfactory, although there is no discussion of an existing device \u2014 the Dune Medical Margin Probe \u2014 that uses different technology but is used for the same purpose. The new device is meant to be used in-vivo (on the lumpectomy or mastectomy bed) versus on the tumor specimen removed during surgery.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses other flu treatments, specifically Tamiflu and the experimental drug, peramivir, so we\u2019ll give it a satisfactory grade on this criterion.\u00a0 But it could have mentioned other treatments in the hospital that also affect mortality, including type of ventilation, antibiotics for secondary infection and extracorporeal membrane oxygenation.\u00a0\u00a0 ", "answer": 1}, {"article": "For more information on healthful eating for kids, visit the U.S. Department of Agriculture.\nA more health-conscious diet was associated with small increases in IQ, she said.\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have mentioned\u00a0other techniques that can encourage better neurodevelopment. Most notably, time spent\u00a0talking to and interacting with children in early childhood has been\u00a0associated with striking differences in later IQ.", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nFor Dr. Douglas C. Bauer, a professor at the University of California-San Francisco and a researcher who also treats many osteoporosis patients, the hardest decision is when to stop the drugs in patients who still have low bone density after five years of treatment but are not especially frail.\nHowever, the most extensive study on the calcium question, done by the Women\u2019s Health Initiative as a randomized controlled trial, was inconclusive.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article discussed multiple treatments: bisphosphonates, calcium, and vitamin D. It would have been useful to at least mention some other drug treatments that were discussed in the recent report of the US Preventive Services Task Force: estrogen replacement therapy, parathyroid hormone, and raloxifene.\n\u00a0\n ", "answer": 0}, {"article": "\"This is certainly a provocative study,\" said Dr. Gerald Weissmann, a physician and biochemist at New York University.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\nJoe Vinson, the University of Scranton chemist who conducted the pilot study, said the findings should pave the way for more rigorous research on coffee bean extract's effects.\nThough Vinson identified polyphenols and chlorogenic acid as the agents that appear to promote weight loss, Grollman said that claim needed further study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare green coffee extract with other approaches to weight loss, such as dietary changes or drugs.", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nSo the doctor recommended tonsillectomy.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nThey'd recommend surgery if a child has five or more throat infections a year for two years, or three or more in three years.\nToday, the most common reason for the surgery is \"sleep disordered breathing,\" a broad diagnosis that includes sleep apnea and snoring.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful discussion comparing alternative treatments.\nThe story was focused on surgery.\u00a0 There was no discussion of prevention \u2013 of indoor allergens (and avoiding/treating them with antihistamines) or of obesity.", "answer": 0}, {"article": "The American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nThe task force first suggested in 2009 that breast cancer screening begin at 50 instead of 40, touching off enormous criticism.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations.\nCongress has sided with proponents of earlier screening.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternatives in a story like this one are the recommendations from other organizations. And the story does explain varying recommendations from the USPSTF and two other groups: the American College of Obstetricians and Gynecologists, and the American Cancer Society.", "answer": 1}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\nThursday, Woodcock held out the possibility that Avastin might eventually prove helpful in a targeted group of patients.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The outcomes, both potential benefits and harms, were described relative to standard chemotherapy. A bit more flesh here would\u2019ve helped describe exactly what (and how many) other options are available.", "answer": 1}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of other approaches to reduce cardiovascular risk, either in the general population or men with a history of heart disease. Options include other lifestyle changes, drug therapy, surgery, and quitting\u00a0smoking. This could have been accomplished in just a few more words.", "answer": 0}, {"article": "However, the same cannot be said yet for other conditions.\nBut most importantly, the study found no difference in effectiveness between the two therapies.\nFMTs are not yet common practice, though Kao noted that it is becoming the standard of care for C. difficile infections.\nOther efforts to take the \u201cpoop\u201d out of the poop pills\u2014to just include the bacteria thought to be behind the benefits\u2014have failed.\nAn emerging treatment for a common hospital-acquired infection could be (slightly) less gross in the future.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Standard treatment for C. diff is antibiotics. This should have been mentioned.", "answer": 0}, {"article": "In Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story presents daily low-dose aspirin as the way to go\u2026 without any serious consideration of alternatives available to people concerned about their risk of dying from cancer.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not discuss any existing alternatives to treat neuroblastoma. Conventional therapy includes chemotherapy for those with advanced-stage neuroblastoma. Commonly used agents include cisplatin, doxorubicin, cyclophosphamide and epipodophyllotoxins. For those with early-stage neuroblastoma, surgery is often an option.\nSome patients are also given adrenocortical hormone to treat their symptoms.\nWe give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure,\u201d he says.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\nThe case study is published in the Jan. 25 issue of Neurology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention lifestyle changes that are recommended for patients with high blood pressure, including those who don\u2019t respond to medication. These include losing weight, lowering sodium intake, and reducing alcohol consumption.", "answer": 0}, {"article": "Drs.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nWith the data pooled, the researchers could see a clear difference in outcomes for women in the two groups.\nDr. Berghella and colleagues compiled data from seven small clinical trials that collectively included a total of 1,215 women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The analysis compared increased levels of hydration during labor with levels used in \u201cgeneral practice in the United States.\u201d That\u2019s explained in the release.", "answer": 1}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nThe findings should be considered preliminary because research presented at meetings has not undergone the rigorous scrutiny given to research published in medical journals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As the story noted, the study compared the combination pill to \u201cusual care.\u201d However, the story doesn\u2019t state what \u201cusual care\u201d means.\nThe story should have explained what \u201cusual care\u201d meant and whether there were differences in the intensity of therapy between the groups. Maybe the intensity of usual care just needs to be increased.", "answer": 0}, {"article": "\u201cThey seem credible to me, and they might hint that there are other mechanisms, besides just inflammation, linking the GI tract to the brain,\u201d he says.\nStudies have looked at various types of probiotics for IBS patients, the authors wrote, and a recent review found that seemed to work better for gastrointestinal symptoms than another common probiotic, .\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does address another type of probiotic,\u00a0lactobacilli,\u00a0noting that previous research has found the type of probiotic used in the current research,\u00a0bifidobacteria,\u00a0to be better at improving gastrointestinal symptoms.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address other treatment options for anxiety or depression, such as talk therapy or other pharmaceutical interventions.", "answer": 0}, {"article": "New Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nA complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.\nComplete tables of content and a sample issue may be viewed on the JACM website.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t describe potential benefits for ASD patients, so it\u2019s not clear what alternatives are relevant in this context. Alternatives to what? Ergo, we\u2019ll rank this as not applicable.", "answer": 2}, {"article": "The Walter and Eliza Hall Institute is the research powerhouse of the Victorian Comprehensive Cancer Centre, an alliance of leading Victorian hospitals and research centres committed to controlling cancer.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nThe research team showed that RANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.\nProfessor Visvader said the discovery had its basis in more than a decade of investigations of breast stem cell function.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that: \u201cThis is potentially a very important discovery for women who carry a faulty BRCA1 gene, who have few other options. Current cancer prevention strategies for these women include surgical removal of the breasts and/or ovaries.\u201d That\u2019s enough to merit a satisfactory rating. However, the release would have been much stronger if it had mentioned other options for women with the BRCA1 mutation, such as enhanced screening or chemo-preventive drugs (such as tamoxifen), which may also reduce risk.", "answer": 1}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nThese study results are essential to new approaches in cancer prevention, particularly those that are investigating combined approaches of cervical screening and vaccination in adult women.\nThe study showed that women in this age group were still protected from HPV infections.\nThis study focused on the benefit of vaccinating women 26 years and older.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It is difficult to gather from the news release what alternatives were considered in the study.\u00a0Clearly one group of women received HPV vaccinations. We can only assume the other group did not.\nAlternatives to this vaccine strategy include achieving higher rates of vaccination in younger women and expanding cervical cancer screening services.\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Avastin, laser treatment, and phototherapy as alternatives. The story could have provided more information on the advantages and disadvantages of the different approaches. The story should have also\u00a0mentioned that Avastin isn't approved for this indication.", "answer": 1}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nIt is the first and only device that identifies in a reliable way the 3-D region where the tumor was removed.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is a novel device and there aren\u2019t any similar devices it can be compared with.", "answer": 2}, {"article": "For more information on statins, visit the U.S. National Library of Medicine.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\n\"Although the study does not have immediate clinical implications, our findings may suggest that patients who were prescribed statins and take it persistently may benefit from the many effects of statins, which go far beyond cholesterol reduction, including the reduction of rheumatoid arthritis risk,\" Chodick said.\nAmong those taking statins, there was only a small, short-term reduction in risk of development of osteoarthritis.\n\"Patients who were covered for more than 80 percent of the time, had a 40 percent lower risk of developing rheumatoid arthritis,\" Chodick said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story provides no background information about rheumatoid arthritis, its prevention or its treatments. There are four known risk factors for RA; gender (women develop RA about twice as frequently as men), family history, age (most people with RA develop symptoms between age 40 and 50 years) and smoking. A complete story would have included a few words on other preventive approaches. ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned that the authors of the study reported on did not compare robotic surgery complication rates to traditional surgery rates.\u00a0 In a perfect world, we would have hoped that the story would have investigated these data points anyway. ", "answer": 1}, {"article": "Tuberculosis is a chronic bacterial infection that's spread through the air and usually infects the lungs, although other organs of the body can be involved.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFurther trials of the new test are planned, the researchers said.\nA report on the researchers' work was published in the Sept. 2 issue of the New England Journal of Medicine.\nThe test diagnosed tuberculosis in 99.2 percent of the patients, the researchers found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that\u00a0current testing for tuberculosis (TB) involves looking at\u00a0respiratory mucus under a microscope. However, it didn\u2019t mention the fact that there are several\u00a0other rapid nucleic acid tests for diagnosing TB that are similar to the test covered in the story. These alternative tests are not as simple to conduct and can\u2019t be deployed on a wide scale with very high accuracy. Nevertheless, making mention of these tests would have added some of the context that we felt was generally lacking in this story.", "answer": 0}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Brief mention is made of self-reporting and behavior as current options for diagnosing illnesses like migraines, depression, and bipolar disorder but there\u2019s no mention of their limitations or how a new diagnostic test might compare.", "answer": 0}, {"article": "(A white light signals a \"moderate\" likelihood, while a blue light means the odds are low.)\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nStill, Mehta agreed that the technology could prove helpful to some people with epilepsy.\nBut experts said the results are promising, and should prompt further studies.\nTwo patients ultimately had the implants removed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We were pleased that the story briefly mentioned, \u201cEpilepsy is usually managed with medication, but for 30 percent to 40 percent of people with the condition, drugs don\u2019t keep seizures at bay. The new study included 15 people who were having at least two to 12 \u201cdisabling\u201d seizures a month that were resistant to drug therapy.\u201d But, we would have liked to have seen a comment or two about Vagal Nerve Stimulation (see http://www.epilepsy.com/epilepsy/vns ) as an additional piece of information.", "answer": 1}, {"article": "\"It's just like physical exercise -- when we are approaching the new year we will buy a pass for the gym and go fervently in January and then slack off,\" Willis said.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nThe participants in the study ranged from age 65 to their early 90s, but Marsiske said the findings apply to people in their 50s or even younger.\nSally Shumaker, a professor of public health science at Wake Forest University in North Carolina who wrote an editorial accompanying the study, said it pointed the way to a future in which mental training is made widely available.\nSherry L. Willis, the lead author of the study and a Pennsylvania State University professor of human development, said those who had the training also reported greater confidence in their ability to solve everyday problems, and this was especially true of the group that got the reasoning training.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not mention other sorts of lifestyle interventions that have been postulated to help individuals age successfully.", "answer": 0}, {"article": "Androgens, including testosterone, are thought to contribute to the growth and development of prostate cancer.\nA commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.\nBut the new finding indicates it could also be a valuable add-on treatment to surgery if the cancer returns.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nMore research will be needed to confirm which men benefit most from taking the drug.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers get a solid description of the standard of care, including typical procedures in the first occurrence, and how radiation therapy is typically used after a recurrence. Hormone blockers are not oversold as some revolutionary new advancement, but an existing treatment that needed long-term study to determine if they were beneficial.", "answer": 1}, {"article": "Their systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.\nPeople in the second group were placed on a three-month test of the fasting-mimicking diet.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\nThe research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not include any discussion on how people can manage long-term health risks through many other kinds of diets, exercise or medications to lower blood pressure. Even one line on such alternatives would have satisfied this criterion.", "answer": 0}, {"article": "She\u2019s healed, basically,\u201d she said.\nIt was of tremendous magnitude in the last [blood] draw.\u201d\n\nThe next step will be to take bone and CT scans to see if the cancer is disappearing internally as well as externally, which Young will receive in a couple of weeks.\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nSo far, while Diamond has noted an immune response in patients given the combination treatment in clinical trials, he has not seen a clinical benefit.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The only alternative mentioned in this release was hospice. Because this type of cancer is considered a terminal, non-curable disease if the patient has not responded to surgery, radiation and standard chemotherapy, that may be appropriate. However, the vaccine described here isn\u2019t the only\u00a0experimental treatment in development.\u00a0There have been mixed results in studies of iniparib combined with\u00a0chemotherapy, and immunotherapy.\u00a0Some other experimental treatments\u00a0could have been mentioned, along with palliative care.", "answer": 0}, {"article": "This is sent to the USB stick, which shows the result on a computer or electronic device.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nCurrent AIDS drugs, called anti-retrovirals, reduce virus levels in a patients blood to near zero.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers are told \u201ccurrent tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory,\u201d which is basic but we\u2019ll mark this one satisfactory. However, knowing how often the WHO recommends viral-load tests be taken, and how sensitive and specific they are, would have made this story stronger.", "answer": 1}, {"article": "It takes an hour or less,\" he said.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\nInfection, bruising or bleeding required a follow-up operation in 31 of those patients.\nKrahn said the rate of complications from surgical removal will surprise doctors, because replacing a defibrillator is considered a minor procedure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It is clear from the article that leaving a \u2018recalled\u2019 device in place is an option. Other options for treating heart rhythm problems are not noted. However, there are often not good options.", "answer": 1}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nThe new test, a next-generation stool test known as a DNA methylation test, detects tumor-specific alterations or methylations in the DNA in the cells shed into the stool from cancerous or precancerous lesions.\nAt the same meeting, other researchers reported that they have new clues about how DNA characteristics can help predict colon cancer risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison with existing colon cancer screening tests and no acknowledgement that there are other new tests now in development.", "answer": 0}, {"article": "\u201cI wouldn\u2019t use the word excited too much,\u201d said Anthony Fauci, director of the NIH\u2019s National Institute of Allergy and Infectious Diseases.\nThe mosaic approach seems promising in very early clinical research\n\nIn the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\nThe mosaic strategy is the fifth concept, and one of only two HIV vaccines that\u2019s currently part of clinical trials of efficacy in humans.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions many of the other important public health measures to control HIV (education, public awareness campaigns, condom use, etc) and other vaccines in trials.", "answer": 1}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\nDr. Sherman recommended taking an intensive stretching class, then establishing a routine at home.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The New York Times\u00a0feature did not mention a full range of alternative treatments for chronic back pain. However,\u00a0it did mention several other potential therapies, including medications, physical therapy, and strengthening exercises.\n\n\n\n\n\n\n", "answer": 1}, {"article": "\"The band has a spotty history,\" Deveney said.\n\"[I] therefore think patients will continue to ask for the procedure.\"\nBut he cautioned that patients undergoing band surgery should do so knowing that they need to commit themselves to rigorous long-term follow-up.\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\nAnd that it'll take longer to achieve the weight loss, because with gastric bypass most of the weight loss occurs over the first year, while with a band it takes five to six years.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story relied on a critique published alongside the study from Dr. Clifford W. Deveney, a professor of surgery in the department of surgery at Oregon Health and Science University in Portland, to provide readers some good comparison information between\u00a0 gastric bypass surgery and gastric banding. We would have liked to have seen\u00a0a more detailed discussion of the evidence for both and also\u00a0at lesat some mention of diet and exercise.", "answer": 1}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\n\"The children that received the interventions normal in their communities continued to show the reversed pattern.\"\nNormal child development depends on interactions with parents and other people.\nWithout such interactions, language and social skills do not develop.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019re giving the story a pass here because the reporter and Dawson acknowledged that there are other therapies available. \u201cAlthough she and her colleagues developed the ESDM treatment, Dawson is quick to point out that it\u2019s not the only effective autism treatment. The key, she says, isn\u2019t the treatment \u2014 it\u2019s the timing.\u201d", "answer": 1}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\nThe hairs were removed in a diffuse pattern, so there were no bald spots on the legs after the procedure.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does talk about how transplants are most often done, but it does not explain that there are a wide variety of techniques being used, many of which have very little in the way of peer reviewed evidence supporting them. After introducing the concept that hair loss creates \u201cenormous stress\u201d for men, the story might have talked with a researcher who has studied male self-esteem to find out whether cosmetic procedures can create their own anxiety because of exactly what this story describes: outcomes that \u201cend up looking harsh and pluggy\u201d. The story also does not mention that the men chosen for this surgery were men who the doctor describes as having hair thick enough on their legs to work for a transplant to the head. Not all men would be candidates.\nThe story also doesn\u2019t mention any of the alternative strategies used in hair transplant.\u00a0 In addition to transplanting hair from other areas of the scalp, chest, thigh, leg and pubic hair have been used.", "answer": 0}, {"article": "\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\nMarban and colleagues developed a technique in which they loaded cardiac stem cells with microscopic bits of iron.\nMarban and his wife, Linda, are founders of a company that has filed patents for the techniques.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No such comparison. No context given on other related stem cell research. ", "answer": 0}, {"article": "\"Everything still goes through pathology,\" Boolbol said.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\n\"We looked at whether we could lower the [repeat surgery] rate by using this device,\" Boolbol said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Several \u00a0times in the story, readers are told about the current method of surgery, which is the alternative to using the MarginProbe.\u00a0 The story clearly informs readers that the new device may reduce the need for repeat surgeries, which are typically needed by 40% of women having a lumpectomy.\u00a0 Patients usually have to wait days, if not a week or more, to find out the pathology report on their tissue.\u00a0 With the new device, surgeons in the operating room\u00a0have results in\u00a0about five minutes.\u00a0 Importantly, the story also notes that the tissue is examined by a pathologist after the surgery and that repeat surgeries are sometimes still needed even with use of the device.\nMany women who have a lumpectomy are concerned about the cosmetic results of the surgery.\u00a0 The story notes that the lead researcher for the study, Dr. Susan Boolbol, chief of breast surgery at Beth Israel Medical Center in New York City, reported that the volume of tissue excised during the initial surgery using the device was only slightly more than the volume of tissue removed during an initial and repeat surgery or surgeries in the control group.", "answer": 1}, {"article": "But when it comes to mental health benefits, \u201cthe majority of the protective effect comes from the first one or two hours of exercise each week,\u201d said study author Samuel Harvey, associate professor of workplace mental health at the Black Dog Institute and the University of New South Wales, in an email.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study does mention that exercise, if it is proven to have a positive effect on depression, should be used along with medications and counseling in people who already have been diagnosed.\nHowever, it does not discuss methods for preventing depression. Are there any? Even if there are none, that should be mentioned.", "answer": 1}, {"article": "Anderson Cancer Center in Houston, at a Wednesday news conference.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nIt's also possible, however, that metformin is working more directly on the tumor process, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This job did a better job of at least mentioning alternative approaches and also other research.\u00a0 This quote even touched on the possible future decision-making impact of this research: \"All other things being equal, many diabetics face a choice of oral agents, and early evidence that metformin may have an effect on the oncology side may increasingly play a role in decision-making.\" \nBut, importantly, the story ended with another quote about the new research:\u00a0 \"interesting and thought-provoking, what\u2019s proven in humans is totally another level.\" ", "answer": 1}, {"article": "Of these, 85 percent were mild or moderate.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\nThe keys to the safety of the drug, bapineuzumab, may be lowering the dose and not giving it to patients with ApoE4, a gene mutation linked to Alzheimer's, according to two studies scheduled for presentation Wednesday at the Alzheimer's Association International Conference on Alzheimer's Disease in Paris.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to explain how patients taking\u00a0bapineuzumab compared with those who did not take the drug. \u00a0Without this information, it is impossible to evaluate the value this medication may have to patients. The story also should have put the findings seen with bapineuzumab in context with those of the other approved drugs (Aricept, etc) that have limited efficacy or perhaps mentioned the other drugs that are in testing.", "answer": 0}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nDuring the time when the immune system is depleted, there is a risk of infection over eight to 12 weeks, including herpes infections, he said.\nBut the authors of a new study believe giving it early may slow and even reverse some disease-related disability.\n\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This study was comparing the new drug against interferon beta-1a, though we don\u2019t get any sense of how it might have fared against the whole range of MS drugs currently being used.", "answer": 0}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\nApproved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus \u2014 called Imlygic, which was developed in part in a Massachusetts lab \u2014 is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.\nJohn O\u2019Donnell, a retired math teacher in Piscataway, N.J., was one of those who tried the combination therapy, but ultimately responded only to Imlygic.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\n\u201cThis is huge for the whole field, and for cancer patients,\u201d said John Bell, a senior scientist at the Ottawa Hospital Research Institute in Canada.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions another drug called Yervoy and also mentions conventional treatments. It also describes other virus-based treatments that are under development.", "answer": 1}, {"article": "Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\nThe study, however, has some limitations, Bernik noted.\nNearly 36 percent of these women had never had a mammogram.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives to \u201croutine mammograms\u201d although the article does mention the debate as to the best schedule and age to begin. The clear alternative is not to be screened.\n\u00a0\n\u00a0", "answer": 0}, {"article": "With relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\nOf the 80 patients treated, 81 percent were pain free one year after a single 10-minute treatment session.\nThe single-center prospective study included 80 patients experiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\nNinety percent of the patients were able to avoid surgical treatment.\nThe patients underwent a minimally invasive interventional radiology procedure in which, with the help of CT imaging, a needle is guided to the location of the bulging disc and nerve root.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that the study included 80 patients \u201cexperiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\u201d But that\u2019s an inadequate description of accepted alternatives. Patients with persistent pain due to a disc herniation have a number of well accepted alternative treatments including epidural steroid injections, surgical discectomy as well as other minimally invasive procedures.", "answer": 0}, {"article": "Both groups went to their V.A.\nBased on the study results, it could be that patients need to renew their regimen with the cream every year.\nThe study did show a significant decrease in the risk of needing Mohs surgery to treat a BCC in the first year.\nIn his clinical work, Weinstock said that for particularly high-risk patients, he has recommended 5-FU treatment.\nBut after six months and again at the end of the four-year trial, 87 percent of participants in the 5-FU group said they'd be willing to repeat the treatment if it proved effective in reducing skin cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study mentions that surgery is the normal response to these skin cancers and that Mohs surgery is the procedure of choice in many cases. It also points out that \u201ccurrent means for preventing new carcinomas in high-risk patients \u2014 sunscreen or oral medications\u201d \u2014 are available.", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\nAfter one year, 9.6 percent of the patients treated with the surgery experienced another ischemic stroke or died, compared with 21.2 percent of patients in a matched control group who received only intensive medical management.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release covers alternatives to the EDAS surgery with the following:\u00a0 \u201cCurrent ICAD therapies \u2014 in addition to intensive medical management \u2014 include bypass surgery to connect a blood vessel from outside the brain to a vessel inside the brain, as well as angioplasty with stenting, which involves inflating a tiny balloon inside a cerebral artery to open it up and placing a stent device inside the artery. Despite advances in medical care, annual rates of recurrent stroke and death remain high, at 15 percent or more for ICAD patients, according to published research.\u201d\nSince the therapy was compared to intensive medical therapy\u00a0only, it is not clear how this procedure compares to other vascular surgical therapies (such as bypass surgery or angioplasty with stenting, both named in the release).\u00a0 If 52 patients with 9.6% recurrent stroke (5 patients) were compared to 52 hypothetical patients with a 15% recurrent stroke rate (8 patients), the results would\u00a0not be statistically significant and would have a significantly high likelihood that they occurred by chance alone. This kind of statistics manipulation can mislead readers into believing there is a big difference between this new therapy and older vascular surgical therapies.", "answer": 1}, {"article": "But \u201cbefore starting to take aspirin long term, it is important to discuss the implications with your family doctor or specialist.\u201d\nEarlier studies had suggested that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help protect against colorectal cancer, but it wasn\u2019t clear how much had to be taken, and for how long, to achieve those benefits.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\nNow, using data on more than 113,000 individuals, researchers have been trying to sort out the relationship between aspirin and NSAIDs, duration of treatment, and colorectal cancer rates.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no reference to colonoscopy as a means of identifying and removing polyps before they become cancerous. Other screening approaches that could have been mentioned include\u00a0sigmoidoscopy and fecal blood tests.", "answer": 0}, {"article": "This website is archived for historical purposes and is no longer being maintained or updated.\nHHS\u2019 Health Resources Services Administration recently released a grant opportunity aimed at reducing opioid overdose deaths in rural communities through funding for communities to purchase naloxone and train health care professionals and emergency medical staff on its use.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019re giving the release points here because it does something that most releases never do. It actually gives a nod to alternatives. In a quote from CDC Director Tom Frieden, it says,\u00a0\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\u201d", "answer": 1}, {"article": "\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n\"Sometimes, a very simple intervention can have a powerful effect,\" wrote Lindsey Turner, of Boise State University, in Idaho, and Erin Hager, from the University of Maryland School of Medicine, in Baltimore.\nModern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains how water jets may be more effective than old-fashioned water fountains, due to concerns over water quality and fountain cleanliness. Drinking fountains also are less efficient at serving large numbers of children, the article adds.", "answer": 1}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nAddiction specialists not involved in the study said the findings are promising, although side effects such as trouble concentrating, tingling and itching caused about one in five people to drop out of the study.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nBy the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story did not name names, it did mention that there were three other medications currently approved for use in the treatment of alcoholism.\u00a0 The story couched one benefit for use of the study drug as something for people who want to see their \"own doctors, rather than enter a rehab clinic to dry out.\"\u00a0\u00a0This is misleading as it makes it seem as though for the other medications currently approved for the treatment of alcoholism,\u00a0it is necessary to attend a specialized alcohol treatment program. \n\u00a0The story did not mention any 12-step programs that some use for treating alcoholism.", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nAmid these concerns, Abbott and others began developing dissolving stents that would slowly melt away like stitches, presumably reducing complications.\nThe new stent is designed to gradually dissolve over three years.\nOther complications with the new device include allergic reactions, infections and internal bleeding.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reporter\u2019s efforts to emphasize the long-term safety questions of\u00a0this new stent lead her/him to make clear comparisons between the dissolvable stent and both metal stents and drugs.\u00a0 For example, at one point the story notes that recent research showed that treating chest pain with drugs leads to outcomes similar to those that result from use of stents. \u00a0Missing from this comparative information are the efficacy of metal stents with polymer coatings that deliver a drug to prevent arterial re-clogging.", "answer": 1}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nAn ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.\nThe new drug works by blocking a protein specifically implicated in psoriasis, called interluekin 23; older drugs affect the immune process more generally.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses only two potential treatments: the drugs guselkumab and adalimumab. There are many additional options. Other medications include methotrexate, cyclosporine, and retinoids, among others. There are also a number of topical treatments and several forms of light therapy. The release would have been stronger if it had explained why guselkumab (or adalimumab, for that matter) are important treatment options or when physicians may incorporate medications like these into their treatment plans.", "answer": 0}, {"article": "CNN Films Presents:\" Glen Campbell ...\nIf resveratrol does pan out in further research, it may add to the medications that are currently available, such as Aricept and Exelon, which slow, but do not halt, progression of the disease, Hendrix said.\nUltimately, it will probably be a combination of several drugs, as well as diet, exercise and social and mental stimulation that help stave off the rapid mental decline that is often associated with Alzheimer's, he added.\nA large, phase 3 clinical trial getting at these issues could start in as soon as a year, Turner said.\nAnd anecdotally, patients who took resveratrol told the researchers that they felt like they were maintaining their mental ability.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions both drugs used in Alzheimer\u2019s treatment and lifestyle factors \u2014 such as diet and exercise \u2014 that may help slow mental decline in Alzheimer\u2019s patients.\nHowever, we thought one of the comments from Dr. Turner on this subject was confusing and not backed by evidence.\nOne glass of red wine a day could help those with mild Alzheimer\u2019s, \u201cbut no more than that,\u201d Turner said.", "answer": 1}, {"article": "The average age of children in the study was 7.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\nThey also want to find out how early in life such a test might be used.\nIt wasn't clear if this impairment would show up in a test of the sniff response, however.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release infers that a new tool for early diagnosis of ASD in children would be valuable, but it doesn\u2019t tell readers why. Readers would be better able to appreciate the significance of the new work if it had addressed \u2014 even in broad terms \u2014 the challenges involved in current approaches to diagnosing ASD. What do ASD screening and diagnostic techniques look like for infants? Toddlers? Older children? That information would be valuable context for understanding the potential importance of the new study.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Article mentioned that \nlupus patients are usually treated with immunosuppressive drugs and that for 5-10% of patients, these drugs are ineffective. \nWhile the original article was clear in presenting that HSCT was used as a treatment for this population for whom the \nstandard approach was no longer effective, this was not explicit in the article.", "answer": 0}, {"article": "Separate strands of material become stronger when they link up.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give a Satisfactory in this category since the story states that the problem of undereye bags\u2013which the story seems to focus on\u2013is normally addressed by surgery, and clearly a topical product is preferable to an invasive approach. \u00a0Another obvious alternative, with no risks or costs, is\u00a0leaving the normally aging skin alone, but that\u2019s not discussed.", "answer": 1}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\nAs for O'Brien-Murphy, she remains free of back pain, but not without some effort on her part.\nFor an active person, this was devastating.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We like how the story ended, explaining more about the patient profiled in the story:\n\u201cshe remains free of back pain, but not without some effort on her part. Other studies have shown that building strong and flexible muscles can help prevent back pain. O\u2019Brien-Murphy never exercised before. But now she does weight training, muscle stretches and aerobic exercise \u2014 activities all shown to help prevent recurrence of lower back pain.\u201d\nHowever, these facts put her story in a different light.\u00a0 The wonderful results of massage for this patient may have a lot to do with other treatments she received after the massage was over. So massage may not have cured her. It provided a means to engaging in physical activity which she hadn\u2019t been able to do. That\u2019s dramatic \u2013 not the massage, but that she has been able to maintain her improvement through hard work!", "answer": 1}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nShe said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\nThe boxes are a new idea for many Americans.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We think the headline and most of the story makes the boxes seem very important.\nThis is the only sentence that hints there are alternatives. \u201cThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\u201d (Italics by reviewers.)\nIf the boxes are just part of a broader education, then perhaps it isn\u2019t \u201cditching the crib\u201d as the headline says that leads to safer infant sleep but parent training that advises a firm mattress, bumper-free cribs and absence of clutter that are keys to a safer sleeping environment.", "answer": 0}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a slightly better job than the Reuters piece of explaining how type 1 diabetes is currently managed and why nighttime hypoglycemia can be a problem. Barely enough for a satisfactory rating", "answer": 1}, {"article": "The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\nIn a separate group of 33 patients with a mutation of the BRAF gene involved in cancer cell growth, the overall response rate was 52 percent for the combination.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story focuses solely on immunotherapy, and does not address surgery, chemotherapy, radiation therapy or other treatment techniques at all.\u00a0The story would have been stronger if it had touched on, at least briefly, a\u00a0fundamental question for readers: how is immunotherapy\u00a0potentially better than other treatment techniques?\u00a0We also think that a word about prevention would have been helpful to the reader.", "answer": 0}, {"article": "\"Everyone heals differently.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nThe goal of the home-exercise program was to improve movement in the neck area.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The trial was set up as a direct comparison of popular treatments for neck pain, and that is just how the story presents it. It even includes a comment from an independent source that this sort of neck pain tends to improve on its own. As mentioned above, the story could have provided more details about the potential harms of the various treatment options.", "answer": 1}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\n\u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\nThis work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.\nNCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release earns a Satisfactory rating by speaking to the current treatments that are available: \u201cCurrent therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability.\u201d\nTo earn extra credit here, the release could have provided a comment about other research into improving myelin production. This includes ongoing clinical trials being conducted by Biogen and others targeting myelin production in MS.", "answer": 1}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nBut is it something that we are in position to sort of ramrod down people's throats?\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\n\"Even if you think you aren't at risk, you are,\" adds Audrey.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives, most notably, regular pap smears.", "answer": 0}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThese forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications.\nThis suggests the assays may provide better risk stratification than that available using PSA tests for men with actual or suspected PCA, leading to better patient management and fewer unnecessary biopsies.\nAt 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release directly compares this experimental blood test to current practice employing the PSA blood test, but there aren\u2019t enough details about how the comparison was made for readers to get a sense of whether the claim of superiority has a reasonable basis. There is no justification for stating it is 94% accurate compared to PSA testing being 33% accurate at identifying high-grade tumors at this preliminary stage.\nIt is well known that the PSA is not a very accurate screening test. There are other attempts to improve upon it., including using MRIs to determine whether someone has a lesion that corresponds to the elevated PSA or not.", "answer": 0}, {"article": "It doesn't stay around long enough to cause hypoglycemia,\" he said.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nAfrezza may have an impact on lung function, but Leone-Bay said once people stopped taking Afrezza, this effect went away.\nIt will only replace meal-time insulin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare Afrezza to available injectable insulin. However, there are a number of different short-acting injectable insulins available, and it\u2019s not clear what is being compared here. The claim of its superiority \u2014 it \"keeps blood sugar levels at a closer to normal level\u2026than currently available injectible insulin\" \u2014 is entirely unsubstantiated. We can\u2019t rate it Satisfactory for making this critical comparison in an unclear, unsupported fashion.\nWhile it also compares Afrezza to Exubera, Exubera is no longer an available alternative. The main issue here is that Afrezza needs to be compared to short-acting, injectable insulin designed for preprandial use, not a medication that has been discontinued.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says up high that \"there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\" The study itself compared three different approaches, and the story also makes this important note:\u00a0\"The countervailing theory is that people value things more when they pay for them, and that the mere act of ponying up $1,600 for three months of a diet program may make you take it more seriously.\"", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other established, safe and effective treatments for depression such as psychotherapy and antidepressant medications.", "answer": 1}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\nSpellberg also said people who used the drug this way would be exposing the bacteria they have in their gastro-intestinal tracts \u2014 their own gut flora \u2014 to regular doses of doxycycline.\nMolina noted that antibiotic resistance to doxycycline has not been seen in chlamydia or syphilis, despite the fact that the drug has been used to treat these infections for decades.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have noted that this study did not compare the approach of routinely taking a pill after sex to a more conventional approach of regular testing followed by treatment when an infection is found.", "answer": 0}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\nJ&J is positioning Tremfya as a better alternative to Cosentyx as it seeks to take market share away from Novartis\u2019s drug, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Another weakness of this story is that alternatives are not mentioned. In addition to a multitude of other immunosuppressant drugs, there are a host of treatments available for adults with moderate to severe plaque psoriasis, including:\nLight therapy, Vitamin A & D derivatives, as well as other medications that don\u2019t work via immune system suppression.\nAlso, bear in mind, these are symptomatic treatments only, since there is no known cure for psoriasis.", "answer": 0}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\n\"We found that laparoscopic surgery is associated with significantly lower costs.\n\"Anti-reflux surgery should be considered in patients who do not achieve complete control of their symptoms [regurgitation or cough] with medications; who do not want to take medications for the rest of their lives; or who experience complications of medical therapy.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does a good job here. It compares different surgical methods and it also names alternatives for treating GERD such as medications and changes in the diet.\nIt also states which group of patients the surgery is aimed at: \u201cAnti-reflux surgery should be considered in patients who do not achieve complete control of their symptoms [regurgitation or cough] with medications; who do not want to take medications for the rest of their lives; or who experience complications of medical therapy.\u201d", "answer": 1}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nPatients don't care much about the finer points of diagnostic accuracy.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\nBut some pain experts defend the value of the diagnostic tests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No discussion of alternatives \u2013 not for diagnostic testing nor for treatment of the underlying back pain. ", "answer": 0}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nHalf of them received traditional acupuncture treatment.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No discussion of other research in this field, including lots on acupuncture.", "answer": 0}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nExperts found that the stem cells of patients who took metformin were able to promote the repair of the blood vessels and there was an improvement in how vascular stem cells worked.\nResearchers studied a treatment group of 23 people aged 19-64 who had Type 1 diabetes for up to 23 years and had no evidence of heart disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no mentions in the release of possible alternatives to metformin as a means to reduce the risk of cardiovascular disease in type 1 diabetes patients. It would be of interest to patients to know if intensive dietary and exercise counseling had been studied and what the results were.", "answer": 0}, {"article": "Thanks to members Drs.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nThere is a general consensus that the initial management of knee OA treatment should include weight loss and strengthening exercises.\nUsing a network meta-analysis we are able to compare the multiple studies done on viscosupplementation and have found that people are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that \u201cpeople are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids. This is different than studies recently published that say the average response differs.\u201d Unfortunately, the release doesn\u2019t provide any data supporting that claim.\nReviewers agreed that most every credible source of information on the management of osteoarthritis of the knee suggest a step-wise progression of treatments including weight reduction, braces, analgesics, and the like. \u00a0While the release does mention steroid injections it does so dismissively.\nWeight loss and strengthening exercises are also mentioned as initial management recommendations, but are quickly glazed over because of \u201ccontroversial\u201d treatment aspects. What is controversial about current OA treatment?", "answer": 0}, {"article": "No question,\u201d he said.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\nThe best overall tumor response rate, of 20 percent, was in those given Erbitux.\nIt is the first time researchers have shown that a drug like Erbitux, which targets a protein called epidermal growth factor involved in cancer cell growth, can provide substantial benefit in difficult-to-treat \u201ctriple negative\u201d breast cancer.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 2}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article describes the challenges with existing techniques, proceeding to invasive procedures following X-rays, and the outside source mentions CT scans. ", "answer": 1}, {"article": "Depression rates in patients taking ketamine remained low.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that depression is currently treated with \u201cfive classes of antidepressants, most commonly serotonin uptake inhibitors.\u201d\nThe release could also have included psychotherapy and other common non-pharmaceutical therapies for depression.", "answer": 1}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nThe MIND diet recommends eating berries at least twice a week.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story compares two of the alternatives to the MIND diet, the DASH diet and the Mediterranean diet, so we\u2019ll give it a pass here. However, it is unclear from the story what these diets are being compared to and one might assume it is a standard American diet, but it is really a low-fat control diet.\u00a0 The story does not make this clear. The story could have discussed the scoring system used in the study, which was clearly described in the scientific article. In addition, the story goes into quite a bit of detail about what might be okay for people to do with their diet, beyond what the scientific study actually stated.", "answer": 1}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The standard treatment for choking is the Heimlich maneuver. Representatives from Dechoker want to present the device as a fail-safe to the Heimlich maneuver.", "answer": 1}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\nA typical heart failure patient is on seven such drugs, which Torre characterized as \"the limit.\"\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says heart failure\u00a0is currently treated by oral medications, almost all of which lower blood pressure, and it adds that Mr. Bardwell is on the heart transplant list \u2014 another option for advanced heart failure patients. It could\u00a0have mentioned the availability of the left ventricular assist device, or LVAD, which also can play a role.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nThe new study looked at a highly sensitive type of troponin I test that may be more accurate in less time.\nAnother measure, specificity, rules in disease with a high degree of confidence.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only comparisons are very broad and lack substantiation with actual data. The study compared the existing test for troponin l and a more specific test and examined the data using different break points and time.\u00a0 Here\u2019s the authors conclusions, \u201cAmong patients with suspected acute coronary syndrome, hsTnl (the new test) or cTnl (the existing test) determination 3 hours after admission may facilitate early rule out of MI (heart attack).\u00a0 A serial change in hsTnl or cTnl levels form admission (using the 99th percentile cut off value) to 3 hours after admission may facilitate early diagnosis of AMI.\u201d\u00a0 The story conclusions don\u2019t seem to match those of the authors.", "answer": 0}, {"article": "The disease is characterized by an itching, oozing rash that can cover almost all of the skin.\nNearly 40 percent of participants getting the drug saw all or almost all of their rash disappear.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that many creams and lotions fail to provide relief to people with moderate to severe eczema. It also reports that many patients try off-label treatment with immunosuppressive drugs or steroids, which can have serious side effects.\nThe story would have been stronger is it had pointed out that any patient who went to any other course of therapy would be taken out of the study, discouraging any\u00a0patient from using another therapy if they are still symptomatic.", "answer": 1}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nFuture studies should assess respiratory symptoms objectively and on unselected samples of vapers.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\nSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Smoking cessation programs that incorporate counseling, nicotine replacement therapy such as patches or gum, and antidepressants are considered to be cost-effective and relatively safe. The news release does not mention this.\nThe healthiest and most cost-effective strategy is to avoid both smoking and e-cigarettes.", "answer": 0}, {"article": "But if we tailor treatments to the individual biology of the tumor and characteristics of the patient, we'll get the best results,\" Wolf says.\nThe non-responders who were immediately referred for surgery had better outcomes too.\nAs part of a Specialized Program of Research Excellence, or SPORE, grant, the team was already maintaining long-term follow-up data on patients.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\nOver 10 years, 153 stage 3 and 4 laryngeal cancer patients were treated at Michigan Medicine, with about half receiving the induction chemotherapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Our main take-away from the release is that there are many treatment alternatives and room for patient and physician joint decision-making. ", "answer": 1}, {"article": "Cocoa contains flavanols, plant-based compounds that also are credited with giving red wine its heart-healthy benefits.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nTests suggested that steady exposure to dark chocolate prompted chemical changes that helped dilate blood vessels and regulate blood pressure, the researchers said.\nThey also kept food diaries so researchers could see if other foods might have influenced the results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This report did not mention other methods for obtaining comparable reductions in blood pressure such as adhering to the DASH diet http://dashdiet.org/, exercise http://www.nlm.nih.gov/medlineplus/ency/imagepages/19233.htm, or medications.", "answer": 0}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nMany other strategies will also reduce the risk of cancer, he says.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nThe new analysis is published in the Journal of the National Cancer Institute.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story included this line:\u00a0 \u201cMany other strategies will also reduce the risk of cancer.\u00a0 Among them:\u00a0 engaging in regular physical activity, maintaining a healthy diet and not smoking cigarettes.\u201d", "answer": 1}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison to alternatives in this story.", "answer": 0}, {"article": "The American Diabetes Association has more about diabetes-related eye complications.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No comparison with the cheaper alternative \u2013 part of the important controversy raised in the NYT story. ", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nPatients with Crohn\u2019s disease should not use Siliq.\nHealth care providers should also evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Siliq.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since Siliq is recommended as a last resort drug of sorts, the news release hints there are other alternatives available. These include other topical treatments like anti-inflammatory drugs, light therapy and oral/injected medications, such as immunosuppressants.\nAlthough we would have liked more elaboration on other treatment options, we feel the news release did just enough for a Satisfactory rating here.", "answer": 1}, {"article": "This level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Our expectation is that the release would at least\u00a0share some basic alternatives. For example, this National Institute on Aging education page states regular aerobic exercise is associated with reduced risk of cognitive decline, and that many other lifestyle and dietary factors (such as a plant-based diet) are believed to reduce risk.", "answer": 0}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since there is no comparison to standard therapy it\u2019s hard for the reader to come away knowing what the pros and cons are for the drug and how advantageous a tumor cell inhibitor might be to a patient\u2019s specific cancer.  ", "answer": 0}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nSpecifically, no link was found between aspirin use and a lower risk of breast cancer, advanced prostate cancer or lung cancer, the researchers said.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\nThere was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin, said lead researcher Yin Cao, a postdoctoral research fellow at the Harvard School of Public Health in Boston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not say what other interventions\u00a0have been shown or are under investigation to reduce the incidence of colorectal cancer. They include colonoscopy/polyp removal, increased activity, weight loss, cessation of cigarette smoking, and cutting back on excessive alcohol use.", "answer": 0}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\n\"The qualities of a good video game, things that hook you, what makes the brain \u2014 snap \u2014 engage and go, could be a perfect vessel for actually delivering medicine,\" he says.\nHere, Ehlers touches on a broader controversy around games like Project Evo.\nBut, Ehlers still thinks game designers should go through the same FDA tests and trials as drug manufacturers.\nRight now, screening for Alzheimer's is subjective.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes a claim that video game therapy might replace drug treatment, but there is no clear comparison made between the approaches. Behavioral therapy is mentioned only indirectly. Such comparisons would have welcome even in a story whose main objective is describing\u00a0the approval process.", "answer": 0}, {"article": "Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nIn addition, the MRI-detected multicentric cancers were greater than 1 centimeter in size in 25 percent of the 73 patients.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted above, the release does not mention other studies that have indicated that cancers found on preoperative MRI scans don\u2019t affect at least short-term patient outcomes. It also does not discuss using ultrasound to check the breasts of patients prior to surgery for a breast tumor discovered through mammography.", "answer": 0}, {"article": "Drs.\nAsher and Burri, along with their co-investigators, now recommend that patients with one to three brain metastases should no longer receive routine whole brain radiation therapy, and should be treated with focused therapy alone to better preserve cognitive function and quality of life.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nHowever, the data from our study shows that clinicians can no longer simply rely on the results of traditional lab tests or scans to assess the value of care; we have to understand the total impact of cancer therapies on our patients.\"\nAlong with Dr. Paul Brown at Mayo Clinic, they spearheaded an international, multi-institutional, randomized trial that will ultimately improve the standard of care for patients with a specific type of brain tumor, brain metastases, by reducing the toxicity of their treatment without reducing the effectiveness.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is clear that the point of the study was a direct comparison of two commonly-used treatments. The release also points out that surgery is a treatment option for these patients.", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned there are 126 therapies in clinical development, according to\u00a0 the Alzheimer\u2019s Drug Discovery Foundation, with beta amyloid being the most common drug target being tested in human trials. It also mentioned approved therapies that \u201conly relieve symptoms temporarily.\u201d\nThere is also evidence that a healthy lifestyle can be of benefit to people at risk for Alzheimer\u2019s and those with early symptoms.", "answer": 1}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nThe trial involved 691 patients, some of whom had both eyes treated, resulting in 854 total eyes.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nThe steroid treatment did not improve eyesight more than laser therapy alone and caused side effects.\nAbout 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0In presenting the outcome of the study, the story mentioned in passing treatments currently used for treating diabetic macular edema. \u00a0The story also mentioned the existence of another drug, Avastin, which was reported as working the same way as the study medication. \u00a0(A more accurate description comparing Avastin and Lucentis is that they contain the nearly identical active ingredient but the production methods are a little different.)\nIt would have been nice to mention that there is an on-going trial comparing the effectiveness of these two medications for the treatment of macular degeneration (not the condition which was the disease in the study reported on.)\u00a0 ", "answer": 1}, {"article": "Oxidative stress refers to a situation where levels of reactive oxygen species or \u201cfree radicals\u201d \u2014 damaging byproducts of energy use in cells \u2014 rise beyond the body\u2019s capacity to neutralize them.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\nThe study, of 123 middle-aged and older adults, found that those who added yoga classes to standard diabetes care shed a handful of pounds over three months.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discusion about how adding other lifestyle changes in addition to the other management strategies in place affect the health of those with type II diabetes. For example, prior studies have examined the benefits of regular light exercise. A discussion of exercise alternatives and their relative benefits would have helped the readers judge the benefit of yoga in context.", "answer": 0}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\n\"Breast cancer can be treated more successfully if detected in its early phases, while it is small and has not yet spread,\" said Dr. Kathryn Evers, director of mammography at Fox Chase Cancer Center in Philadelphia.\nOlder age is a leading risk factor for breast cancer.\nThere are three tests often used to look for breast cancer, Evers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll will give the story credit for noting that there are several screening methods, and for pointing out that not all women who have symptoms get breast cancer.", "answer": 1}, {"article": "\u201cYou\u2019re fighting for your life.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nThe rising use of magnetic resonance imaging, MRI, is likely contributing to the increase in double mastectomies, said Dr. Joseph Leach, a medical oncologist with Park Nicollet Health Services.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article sufficiently compares bilateral and single mastectomy, and reports that the lumpectomy with radiation option is more common.\u00a0 \n\u00a0", "answer": 1}, {"article": "Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\nCognitive behavioural therapy has significant positive effects on a mother\u2019s mental health, income, employment and parenting skills even seven years after the birth of the child, according to the first study of its kind.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nThe international research project into the impact of depression on pregnant mothers and their babies, led by Professor Sonia Bhalotra from the Institute for Social and Economic Research at the University of Essex, could have major implications for public policy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that people are often prescribed drugs for depression, and that CBT may be a better alternative.", "answer": 1}, {"article": "SOURCE: bit.ly/qhsaZ0 Journal of the American College of Cardiology, October 10, 2011.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\nAmong those with the highest weekly chocolate intake \u2014 more than 45 grams \u2014 there were 2.5 strokes per 1,000 women per year.\nFor those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "\"Therefore the physical therapy is easy to do and it's quick and it's not very painful for them at all.\"\nO'Brien spent just a few hours in the hospital after surgery before she was well enough to go home.\nHelp for O'Brien finally arrived in a new kind of knee surgery, developed and perfected at Chicago's Rush University Medical Center by Dr. Richard Berger.\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than categorizing traditional knee replacement as requiring \u2018a long and painful recovery period\u2019 there was no mention of other treatment options for osteoarthritis of the knee.", "answer": 0}, {"article": "\"But I will say that I don't know of any study looking at acupuncture and vision.\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\nThe study authors noted that anywhere from less than 1 percent to 5 percent of people worldwide are affected with the condition.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\nAfter about four months of treatment, the research team found that overall visual acuity improved markedly more among the acupuncture group relative to the patch group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that standard treatment for younger children with amblyopia involves eyeglasses or contact lens designed to correct problems with focus.\u00a0Patch therapy is\u00a0useful\u00a0for older children,\u00a0according to the story,\u00a0but may be tougher for children to adhere to and has potential adverse effects.", "answer": 1}, {"article": "Sales rose 82 percent from 2008 to 2009, reaching $430 million.\nBut, the committee concluded, a level of 20 to 30 nanograms is all that is needed for bone health, and nearly everyone is in that range.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\nAnd there is evidence that excess calcium can increase the risk of heart disease, the group wrote.\nWith that as a standard, 80 percent of the population would be deemed deficient of vitamin D, Dr. Rosen said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not\u00a0applicable for this story. The approaches discussed are not new, and there\u2019s not\u00a0really any alternative to getting adequate amounts\u00a0of these essential nutrients.", "answer": 2}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nThat would then lead\u2014if all goes well\u2014to the first human trials in three to four years.\u201d\n\nAt present, the researchers are focusing on the adiposity, rather than bone loss, for drug development: \u201cI think obesity is a more prevalent disease\u2014but osteoporosis at the tail end can be tagged on.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nThey found some of these hormones had an effect on bone mass.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given how far removed this is from clinical trials, much less a clearly defined treatment, it\u2019s very difficult to determine what the alternatives would be. For example, would we expect the story to list alternatives for osteoporosis treatment? Or for weight loss? Both? As such, we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Hormone therapy is the only FDA-approved treatment for hot flashes related to menopause, but many women are reluctant to undergo hormone therapy because its long-term use has been linked to an increased risk for breast cancer and stroke .\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\nIn a manufacturer-funded study, the drug Serada proved to be more effective than placebo for preventing hot flashes and reducing their severity.\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions low-dose hormone replacement therapy, which is one option for particularly bothersome hot flashes. It could have also\u00a0mentioned\u00a0lifestyle changes such as keeping cool and avoiding dietary triggers, which are useful approaches for some\u00a0women. The story also notes that almost half the women in the placebo arm of one of the trials reported improvement. It would have been helpful to readers to highlight that fact and put the drug results in context with the fact that women feel better after a few weeks even without any treatment. On balance, the story does enough to fulfill the criterion.", "answer": 1}, {"article": "\u201cOur lab is on an island in the South.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nA new school of thought in the beauty world is pushing the idea that what you put on your skin after a day at the beach could play a part in reducing sun damage.\nNot everyone is convinced of the effectiveness of after-sun care.\nThis information is in the early stages of transforming the category of after-sun care\u2014a category traditionally limited to aloe vera-laden moisturizers and gels that lowered the temperature of sun-parched skin but not much else.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Though the alternative \u2014 staying out of the sun \u2014 is mentioned, it is dismissed as unrealistic. \u201cI\u2019m on the phone with you from Hawaii and can see at least 40 people on the beach, soaking in the rays,\u201d says the founder of True Nature Botanicals. \u201cMy kids are outside playing. I know that it\u2019s not realistic to say \u2018no sun.\u2019 \u201d\nIt would have been interesting to have heard whether cancer researchers feel the same way about the futility of trying to limit their own children\u2019s sun exposure.\nThe story could have at least made some reference to evidence about the reduction in cancer risk for people who consistently use sun block, limit their time in the sun, and use hats and other clothing that blocks UV light. Without that perspective, readers may be misled into believing that apr\u00e8s sun treatments may offer comparable protection.", "answer": 0}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nWhile the medication remains the single most effective agent in the management of PD symptoms, long-term use causes its own side effects, among them abnormal involuntary movements or AIMS.\nPlans for a clinical trial of low-dose lithium for PD patients are in early stages.\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although levodopa/carbidopa is the main approach to treatment, other drugs are available that are not mentioned. In addition to medical therapy, deep brain stimulation is also available at most academic medical centers.", "answer": 0}, {"article": "We did not come across a single study where there was a coordinated effort done by some large agency to really conduct a large national study,\u201d says Doraiswamy.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\n\u201cMost individuals already know that yoga produces some kind of a calming effect.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0suggests that yoga would be an attractive alternative to psychiatric medications, but it doesn\u2019t mention that psychotherapy is a well-validated and effective\u00a0nonpharmacologic treatment for many of the disorders discussed in the story. And other major categories of treatment for people with some of the disorders discussed include a range of medications, a range of self-help strategies, and for some conditions, somatic treatments such as transcranial magnetic stimulation.", "answer": 0}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the study mentions glimepiride as an alternative to Actos, it does not mention other options nor does it discuss the pros and cons of the alternatives. In particular, it would have been nice to know if any of the other classes of medications used to control glycemia are associated with reductions in plaque formation.\u00a0 ", "answer": 0}, {"article": "It is known as BMS-790052.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the new drug with intravenously administered peg-interferon and ribavirin \u2014 the current\u00a0standard of care\u00a0for hepatitis C. \u00a0", "answer": 1}, {"article": "\"Our finding is so exciting because there is already an approved drug against RANKL called \u201eDenosumab\u201d.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nThe second group received RANKL blockade treatment for prevention with the result that virtually no malignant changes in breast tissue could be observed even over a longer period of observation.\nA multinational research effort now made the discovery that RANKL is also the main driver of BRCA1 mutation-driven breast cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions prophylactic surgery as the only current method for reducing breast cancer risk. It doesn\u2019t compare denosumab to mastectomy nor to bisphosphonates, which are other drugs that interfere with RANKL proteins and RANK receptors.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Mentions other \nadjuvant drug treatment, tamoxifen, as well as some side effects of both of the aromatase inhibitor drugs (Femara and \nArimide) studied as well as Tamoxifen.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nOther available topical treatments must be used for several weeks, and often irritate the skin.\nThe new gel, Picato (ingenol mebutate), is applied once daily for two or three days, depending on the area being treated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted above, no data were provided comparing the performance of the new gel and previously available topical treatments.", "answer": 0}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\nThey also plan to look at how the video game can be integrated into a rehabilitation program together with other rehabilitative techniques.\nOAK BROOK, Ill. - Playing \"brain-training\" video games may help improve some cognitive abilities of people with multiple sclerosis (MS) by strengthening neural connections in an important part of their brains, according to a new study published online in the journal Radiology.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release fails to mention any alternatives to the use of the video game/training program which might produce equivalent improvement in connectivity within this region of the brain. As previously mentioned, there are other forms of therapy for patients with MS and it isn\u2019t clear how this new therapy compares. At least a mention of this would have been appropriate. The last line of the release says this new treatment could be combined with existing rehabilitation therapy, but we think this is too little, too late.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The relevant research is based on evaluating the use of beta blockers in conjunction with conventional chemotherapy, not as an alternative to chemotherapy or other courses of treatment. As such, we\u2019ll rate \u201cCompare Alternatives\u201d as Not Applicable.", "answer": 2}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions no alternatives to the use of these devices.\u00a0 It does mention in passing that touching contaminated surfaces is an alternative route of infection to that of inhalation. But what about frequent hand washing? And in a story focusing on the lengths people will go to in order to lower their risk of catching the flu, it\u2019d be nice to see some acknowledgment of the value of the flu vaccine.", "answer": 0}, {"article": "It defines low birthweight as being when a baby is born weighing less than 5 pounds, 8 ounces.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nBut overall, the findings support the benefits of kangaroo mother care, the team concluded.\nKangaroo mother care was first described in Colombia, and the team of experts there who first showed it was safe did a 20-year follow-up to see how the babies fared as they grew up.\n\u201cAlmost two decades of implementation and research have made it clear that kangaroo mother care is more than an alternative to incubator care.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The purpose of the study was to compare the KMC approach with a neonatal intensive care. There are no other viable alternatives to infant care that we know of.", "answer": 1}, {"article": ".\nA free abstract of this article will be available via the Cancer News Room upon online publication.\nPublished early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.\n\"Because of this disparity, it remains unknown whether isoflavone consumption should be encouraged or avoided for breast cancer patients.\"\nCANCER; Published Online: March 6, 2017 (DOI: 10.1002/cncr.30615).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There other dietary and lifestyle factors that affect cancer risk and survival. The release doesn\u2019t mention any of them.", "answer": 0}, {"article": "Leukemia is the most common childhood cancer and accounts for about 30 percent of all childhood cancers.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Perhaps it goes without saying that the alternative to breast milk is infant formula, but the release could have stated this explicitly, which would have provided an opportunity to point out the other potential health advantages of breastmilk as well as the financial advantages. Not doing so provides a rather incomplete narrative.", "answer": 0}, {"article": ".\nStill, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\nThe authors say capsaicin also possesses antimicrobial properties that \u201cmay indirectly affect the host by altering the gut microbiota.\u201d\n\nThe research corroborates a 2015 study conducted in China and published in the BMJ that found regular consumption of spicy food is associated with a lower risk of death.\nFor the study, researchers at the Larner College of Medicine at the University of Vermont analyzed data on more than 16,000 Americans using the National Health and Nutritional Examination Survey (NHANES).\n\u201cSuch evidence may lead to new insights into the relationships between diet and health, updated dietary recommendations, and the development of new therapies,\u201d they write.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Of all the things people might do to live a longer, healthier, life, how does eating red hot chili peppers stack up? The reader of this story has no help evaluating how\u00a013% decrease risk of death compares to other dietary factors, such as the fruit and vegetable recommendations included in USDA dietary guidelines.", "answer": 0}, {"article": "Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nA limitation of the study was the modest number of participants.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The entire release is about an alternative\u00a0comparison, which is refreshing. On the other hand,\u00a0it is hard to compare alternatives in highly controlled settings. Real life is a lot different.", "answer": 1}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nThe UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\nThe UroLift System's permanent implants, delivered during a minimally-invasive procedure, act like window curtain tie-backs to hold the lobes of an enlarged prostate open.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We learn that there are some alternatives (drugs and surgery), but we aren\u2019t told that there are numerous other minimally invasive procedures available\u2013laser treatments, microwave thermotherapy, radiofrequency ablation, vaporization, etc. \u00a0The release is overly dismissive of drug therapy, which has been shown to be effective, well tolerated, and safe. Pushing this treatment as a first line treatment is inappropriate\u2013and the absence of data from head-to-head trials with either other minimally invasive procedures or the gold standard (transurethral resection of the prostate or TURP) means that the relative value of the new technology is quite uncertain.", "answer": 0}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\nTreatment effectively reduced the viral load of the pregnant women, says Pan.\nPan and colleagues enrolled 200 pregnant women with a high \u201cviral load,\u201d defined as one million copies of the virus per milliliter in a blood sample.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention other ways to reduce lung cancer risk, such as quitting smoking.", "answer": 0}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was not adequate mention of what has been demonstrated to reduce the chance of developing type II diabetes.", "answer": 0}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\nEven after the Women\u2019s Health Initiative news broke, some women couldn\u2019t face the changes without hormone treatment.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article was only focused on HRT and did not discuss any alternatives.", "answer": 0}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of articulating how the social media model might differ from conventional depression diagnostic tools, as well as how these approaches could potentially be used to support each other (rather than using one in place of the other).", "answer": 1}, {"article": "on Sept. 2.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nIn the prospectus for that offering, the company said that one of the risks for investors was \u201cthe relative price of Folotyn as compared to alternate treatment options.\u201d It said there was a risk it might have to lower the price or offer discounts to successfully market Folotyn.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly states that there are no alternatives to Folotyn for this particular indications, but compares the price of the drug to several other expensive cancer drugs. The story should have emphasized that Folotyn was studied in patients who have relapsed and a comparison with currently used regimens is not available.", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nHebrew SeniorLife, an affiliate of Harvard Medical School, is a national senior services leader uniquely dedicated to rethinking, researching and redefining the possibilities of aging.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\nThe Musculoskeletal Center within IFAR studies conditions affecting bone, muscle, and joint health with aging.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As we noted previously, the Framingham Cardiovascular Risk Calculator is commonly used to assess the 10-year risk of a cardiovascular event and guide related treatment. The release does not mention this tool or how the results of bone density scanning would compare or improve upon it.", "answer": 0}, {"article": "Forty-nine of the deep brain stimulation patients, or 40%, had 82 serious adverse events, compared with 11% of the drug patients, who had 19 serious adverse events.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nBeyond that, doctors need to do a better job of optimizing drug therapy, he said, noting that there are thousands of potential combinations of drugs that can be used to control symptoms.\nShe said she worried about having the surgery, but it got to the point where she felt as though she had run out of options.\nSome neurologists remain unconvinced about the benefits of the therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that the alternative to surgery is a cocktail of medications, which have their limitations.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are numerous other minimally invasive treatments (laser, thermotherapy, radio frequency ablation) that are not mentioned.", "answer": 0}, {"article": "; Walter Rocca, M.D.\nIn the study, women with APOE e4 \u2014 one form of the most common gene associated with late-onset Alzheimer's disease \u2014 had lower levels of amyloid deposits.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.\n\n\u201cIf our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer\u2019s disease field today,\u201d Dr. Kantarci says.\n\u201cIt also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.\u201d\n\nStudy co-authors are Val Lowe, M.D.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers no other approaches available to postmenopausal women for reducing Alzheimer\u2019s disease risk and that\u2019s appropriate in this case. It would be an over-reach to try and name the many other Alzheimer\u2019s disease prevention options being studied.\nIn addition, the findings\u00a0address an intermediate endpoint, i.e. amyloid deposition as a disease marker, not the disease itself.", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"I personally think foods [containing soy] are better.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story only stated, \u201cSoy has been touted as an alternative treatment to hormone replacement therapy after HRT was linked to an increased risk of breast cancer.\u201d\nBut there\u2019s still a decision to be made by women \u2013 taking both harms and benefits into account.\u00a0 As already noted in the \u201cBenefits\u201d criterion comment above, the story never delivers specific data on the absolute benefit seen in the soy vs. placebo meta-analysis. So it paints HRT as risky, and then promotes soy\u2019s benefits with its definitive headline \u201cSoy supplements can cool hot flashes\u201d and other language in the story \u2013 without ever clearly defining the scope of the benefit.\nWhat was the size of the benefit?\u00a0 What was the size of the tradeoff of potential harms?\u00a0 The story didn\u2019t deliver that information \u2013 so a meaningful discussion of alternatives was not provided.\u00a0 One could imagine a very helpful infographic being created to explain this.\nTo make matters worse, both the subhead and the body copy allow a researcher to go beyond the evidence of the study \u2013 which was about soy supplements \u2013 and to offer her opinion, \u201cI personally think foods containing soy are better.\u201d", "answer": 0}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nPatients in the study had minimally-invasive surgery that fixes the problem by inserting a replacement valve to send blood around the damaged valve while leaving it in place.\nThe results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses alternatives this way:\nPeople who don\u2019t get this type of minimally invasive surgery may instead get a more invasive procedure that involves surgeons cutting open the chest to repair a damaged valve.\nSurgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nWhile this is an attempt to explain the other type of surgery, it uses terms that apply to heart vessel surgery, not valve surgery (\u201cangioplasty,\u201d and \u201ckeep the artery propped open.\u201d)", "answer": 0}, {"article": "Other sources include pink grapefruit, watermelon, and guava.\n\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nTomatoes are not the only food that is rich in this antioxidant.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio.\nResearchers measured the level of lycopene in their blood when the study began and followed the men for about 12 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that tomatoes aren\u2019t the only sources of lycopene. It also included a recommendation for a diet rich in fruits and vegetables, adequate exercise, and quitting smoking, as steps that may be beneficial for stroke prevention.", "answer": 1}, {"article": "A role for dietary macroalgae in the ameliorating ration of certainement Risk Factors Associated with cardiovascular disease.\nBy adding seaweed to processed foods we can make food healthier.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\nBut the responsibility should also be shared by society, argues University of Southern Denmark professor of biophysics, Ole G. Mouritsen, who has authored several books on seaweed as food.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are discussed. In fact, why not simply talk about less salt instead of salt substitutes. The seaweed being added is at such a marginal percentage as to beg the question: why bother?", "answer": 0}, {"article": ".\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nAlthough the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population.\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Again, the release explains a trial which presumably used different medications and/or different doses to reach the targeted systolic blood pressure levels (although none are identified). It offers no information on alternative mechanisms for reaching those goals and without more information on what approaches were used, it would be hard to cite alternatives.", "answer": 0}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nUltimately, a candidate molecule called ICEC0942 suppressed tumour growth in a wide range of cancer types in lab tests.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nResearchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.\nIn a bid to come up with new forms of treatment that work in a distinct way from established ones, chemists, biologists and clinicians at Imperial College London collaborated on creating a new drug, the properties of which are reported in the journal Molecular Cancer Therapeutics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of competing projects to develop better therapies for hard-to-treat cancers.", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe NeuroStar system resembles a dentist's chair.\nThe cost, however, is less than an extended hospital stay.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does provide some insight into the alternative approaches including drug therapy and electroconvulsive therapy. No useful information is provided about ECT, Vagal nerve stimulation or magnetic seizure therapy. \u00a0 The comparisons however are provided by devotees of the technology and no references are provided.", "answer": 0}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions\u00a0estrogen in the form of pills, patches, rings and gels. ", "answer": 1}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nNicolaides said the aspirin may help improve blood flow from the mother to the placenta.\nACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nLow-dose aspirin can also help reduce the chances of eclampsia, which is seizures due to preeclampsia for high-risk women, Kramer noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no known treatment alternatives to preventing preeclampsia.", "answer": 2}, {"article": "The oldest cyclists had less muscular power and mass than those in their 50s and early 60s and considerably lower overall aerobic capacities.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nAge does seem to reduce our endurance and strength to some extent, Dr. Harridge said, even if we exercise.\nAll in all, the numbers suggest that aging is simply different in the active.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story implies that the fountain of youth may be vigorous exercise in the amount described. But there is no attempt to say whether lesser amounts, or other types of physical activity, may have similar results or not. A reader may then say, \u201cWhat\u2019s the point? If I can\u2019t do that much, I shouldn\u2019t bother to get off the couch at all.\u201d Exercise is not an all-or-nothing activity. The authors could have provided a brief statement that it isn\u2019t clear whether lesser amounts of exercise may have similar or different results.", "answer": 0}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nThe study wasn't really designed to answer the question of which screening regimen is best, study researcher Rebecca Hubbard, PhD, says.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did an adequate job comparing \u2013 at a very high level \u2013 annual screening versus biennial screening.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nDupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release gets a borderline satisfactory for mentioning topical corticosteroids as an alternative treatment for eczema but neglects to mention that other pharmaceuticals are also now available for treating it.", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story appears to imply that standard treatments don\u2019t work for patients with tumors that have this specific gene variant. However, cancer treatment statistics indicate that these patients are just as likely as other patients to respond to first-line treatment. The new drug is intended to be used when those standard treatments aren\u2019t enough. Then the tumor gene test is needed, because giving this new drug does not appear to do any good for the overwhelming majority of patients, it is to be used only in that subset of patients with tumors that might be susceptible. Also, the story should have been clearer about explaining that neither of the preliminary trials included any comparison to standard treatment.\n", "answer": 0}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t discuss any other research in the field of colon polyp risk reduction \u2013 or even what other observational studies may have suggested about other strong associations.\u00a0 And there was nothing on whether these results apply to fish oil supplements, which is how many people get their omega-3s instead of eating fish.\n ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provides an excellent overview of some of the newer procedures and techniques for laser eye surgery to correct\u00a0 vision problems related to the size and shape of the cornea. The story mentions the potential pros and cons of LASIK and PRK surgery, and how a surgeon and a patient might decide which procedure is right, if appropriate at all. \nThe story provides an excellent service by encouraging people to be educated consumers when making a decision about this heavily promoted eye surgery", "answer": 1}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\nEdge was a panel representative from the American Society of Clinical Oncology, which created the guidelines along with the American Society for Radiation Oncology and the Society of Surgical Oncology.\nEdge said that doctors need to consider patients individually.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story essentially compares getting radiation therapy to not getting radiation therapy (but, as noted above, doesn\u2019t really offer much detail on the benefits of radiation therapy).\nDepending on the\u00a0circumstances, patients who receive post-mastectomy radiation may also be treated with chemotherapy, and we wished that had been discussed, too, since the combination can potentially increase health risks.\n\u00a0", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that \u201cIn recent years, the use of computed tomographic colonography\u2014known as CT or \u201cvirtual\u201d colonoscopy\u2014has eliminated the need for the most invasive part of the procedure.\u201d That\u2019s not entirely true. As the Boston Globe points out, 1 in 5 patients who have a virtual colonscopy still have to undergo a traditional scope procedure. Also, the story makes no mention of the other alternatives to colonscopy, most of which are discussed in the Boston Globe piece.", "answer": 0}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin.\nOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nThe study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story basically talks about three drugs. The main drug, metformin; the supplementary class of drugs known as sulphonylureas; and the new drug being studied. But it does not talk more broadly about other approaches to\u00a0diabetes management, which could have been accomplished with a few more sentences.\nThe article is set up, as the study is, to give a comparison between two specific drug types for second-line therapy along with metformin (a sulphonylurea and DPP-IV inhibitor, linagliptin).\u00a0 However, there are several other \u201csecond-line therapy\u201d drug classes out there that are used for the same purpose, including meglitinides such as repaglinide that may cause less hypoglycemia than sulphonylureas but are less expensive than DPP-IV inhibitors, and therefore may be a better option for patients than either of the drugs in this study.\u00a0 So one or two sentences that place this study in the larger perspective of second-line therapy for diabetes, acknowledging other possible alternatives, would have been helpful for readers.", "answer": 0}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion about alternative sources for the problems reportedly resolved by B12 nor was there any information about other options for managing problems such as depression, loss of appetite, or lethargy.", "answer": 0}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nThey point to several study limitations, such as the potential for confounding and difficulty assessing type, timing and dose of supplements.\nBut results from previous studies have been inconsistent, suggesting that other unmeasured factors (confounding), such as a mother\u2019s overall health and lifestyle, could also play a role.\nThe researchers stress that their findings cannot establish cause and effect, but say they raise questions about a possible association that warrant further investigation.\n\u201cTogether, the three analyses appear to point toward a potential inverse association between multivitamin use with ASD with intellectual disability,\u201d say the authors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not discuss that pregnant woman might achieve recommended vitamin intake via the food they eat.", "answer": 0}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nU.S. researchers say the technique certainly shows promise.\nNov. 28, 2011 (Chicago) -- Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story spells out both the current treatment options and potential new therapies. It says, \u201cStandard treatment options include surgery, chemotherapy, and radiation. Researchers are looking at a number of ways of destroying tumors with heat from radiofrequency waves or by freezing it, for example.\u201d But the story could have given even a little information about how the tumor reduction rates in this preliminary study stack up against chemotherapy and radiation.", "answer": 1}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nOne of medicine\u2019s greatest villains: HIV.\nThey usually die within five years of diagnosis.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a good job of describing other treatment options \u2014 including bone marrow and cord blood transplants \u2014 as well as the associated risks.", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nIn clinical trials, the pioneering diagnostic -- developed by researchers at University College London (UCL) and the Western Eye Hospital -- allowed doctors to see individual nerve cell death in the back of the eye.\nAlthough detection has been improving, most patients have lost a third of vision by the time they are diagnosed.\nA SIMPLE eye test could help solve the biggest global cause of irreversible blindness, glaucoma.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no mentions of alternative methods to screen for early signs of glaucoma.\nAccording to the American Academy of Ophthalmology, the test for glaucoma is not one test but several including measuring eye pressure and cornea thickness, examining the optic nerve and testing peripheral vision, among other steps.", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\nThis research was supported by the National Institute on Deafness and Other Communication Disorders the National Center for Advanced Translational Sciences.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a variety of ways to treat hearing loss besides cochlear implants but, outside of the mention of oral steroids (with no detail given), none are mentioned.", "answer": 0}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nFiguring out if this biomarker would also work in people is challenging.\nThat got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\nPlus, the treatment seemed specific to the food addiction.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are treatments for addictive or impulsive behaviors, although arguably they all have less than stellar records of success, and many that involve medications come with a host of side effects. Some mention of these should have been made, though.", "answer": 0}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nWe can now see with much greater accuracy what tissue is cancerous, where it is and what level of treatment it needs.\nThe new method aims to get round the problems by targeting the prostate with ultrasound.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention several current methods of detecting and diagnosing prostate cancer \u2014 the PSA (prostate-specific antigen) test, a digital rectal exam (DRE),\u00a0the use of MRI imaging, and an invasive biopsy, which are all alternatives to this new test.\u00a0 The story also points out the shortcomings of each of those approaches. However, this is a just-passing Satisfactory, since all of this information was taken directly from the university\u2019s news release (see below).", "answer": 1}, {"article": "\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release mentions the weakness of corticosteroids in uveitis treatment, it doesn\u2019t go far enough in explaining how steroids compare with adalimumab, even though steroids were given to the patients concurrently with adalimumab in \u201cdiminishing doses\u201d throughout the trial.\nIt\u2019s worth noting, especially for comparison with adalimumab, how the long-term use of corticosteroid drugs work against uveitis symptoms by suppressing the body\u2019s entire immune system \u2014 and, as a side effect, metabolism \u2014 not just one specific target of inflammation. Humira also suppresses the body\u2019s immune system although through a different mechanism.", "answer": 0}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nNaltrexone is certainly not a cure-all, researchers say.\nAnd it won't help everyone who has a drinking problem \u2014 especially if the disorder is severe.\nA Medicine That Blunts The Buzz Of Alcohol Can Help Drinkers Cut Back\n\nIf you drink more alcohol than you want to or should, you're not alone.\nIt's now been about five months since he started taking the medication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was a tricky one\u2013the story briefly\u00a0discusses a variety of other methods that can help treat alcohol dependence, but it doesn\u2019t compare them head-to-head. That said, we do get a sense of the options available.", "answer": 1}, {"article": "\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nAfter her surgery the difference was dramatic.\nShe was optimistic, but nervous, about the surgery.\nTwo months later, it was time for follow-up assessments.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of treatment options for leber congenital amaurosis, though presumably there are no other treatment options.", "answer": 2}, {"article": ".\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nSupporters such as those at TMS NeuroHealth say they are seeing better results than that among their patients, who can continue taking antidepressants along with their treatment.\nLinda Carpenter, an associate professor of psychiatry and human behavior at Brown University, who has conducted medical studies using rTMS for depressed patients, says the treatment is effective for some patients, possibly even better than simply trying another medication.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job comparing rTMS with the major treatment alternative for patients who do not respond to antidepressant medication: electroconvulsive therapy. ECT has a much longer track record of use and is more effective, but has more risks and side effects and may not be feasible for patients who are not good candidates for anesthesia.\nThe story could have compared rTMS to FDA approved vagal nerve stimulation (also evaluated in the AHRQ report) \u2013 which has even weaker evidence for benefit.", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nAn earlier analysis of the study concluded that women who ate five servings of fruit and vegetables and exercised 30 minutes a day had significantly improved cancer-free survival.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to mention other breast cancer recurrence strategies (avoiding weight gain, medications, etc.).\u00a0 Especially as the outcome of the study reported on was to show no benefit, other options that have demonstrated efficacy for decreasing risk recurrence could have been mentioned.", "answer": 0}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll rate this Not Applicable. The story does not say whether alternatives to the DXA test exist (e.g. ultrasound) or how these methods stack up against each other. But DXA is well established as the evidence-based choice for bone scanning \u2014 so we\u2019re not sure it would\u2019ve helped much to get into these other methods.", "answer": 2}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\nThe findings were reported Monday in an American Heart Association online conference.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main PLATO study was a comparison of an experimental drug (ticagrelor) to an approved one (clopidogrel).", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is passing mention of chemotherapy, as well as stem cell transplant, and the story does note that these patients have exhausted all other available options. However, there is no mention of what the current accepted treatments for these specific lymphomas are. Furthermore, a clear understanding of treatment alternatives is compromised because\u00a0the story\u00a0does not clearly state that CAR-T therapy is currently only being tested for Acute Lymphocytic Leukemia (ALL) in children and young adults, as well as some B-cell lymphomas and leukemias. Without knowing this the reader can not answer\u00a0the obvious: \u201cwhat exactly does CAR-T treat and what are the alternatives?\u201d", "answer": 0}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nOther healthy people interested in taking aspirin to prevent cancer should consult their doctors, experts say, and possibly await further evidence.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not present alternative ways of reducing cancer risk. Some other news reports specifically noted that avoiding smoking and obesity are both known to reduce cancer risk.", "answer": 0}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nAfter three months the results were promising, the company said.\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\nRogers said it could be several years before Medtronic undertakes a much larger late-stage trial.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Some comparison was made with drug therapy for erectile dysfunction.\u00a0 But there was no mention of a very safe and often effective alternative \u2013 the penile vacuum pump. Penile implants are also effective, though require surgical procedures. It would have required only an additional line to give this backgrounding context.\u00a0 Even business story readers and investors would want this reminder.", "answer": 0}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that the person undergoing the new immunotherapy failed to improve with chemotherapy, though it does not mention tumor excision or radiation as other potential therapies. And one wonders whether the prior chemotherapy played a role in the one Seattle patient\u2019s remission.\u00a0 ", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news-release-driven info dances around the edges of what we want to hear, but never really delivers.\nExcerpts:\nBut we\u2019re not given any meaningful, substantive, data-backed comparison.\u00a0 It wouldn\u2019t take much space to do so.\u00a0 How often do other treatments fail?\u00a0 How often do debilitating side effects occur from surgery, radiation, chemotherapy?", "answer": 0}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nEarlier studies had shown this effect in primates, but this new study, published Wednesday in the New England Journal of Medicine, provides the first clinical trial data for testing the drug on humans.\nIf these initial results pan out in larger trials, the drug could prove to be more effective than statins, the widely prescribed drugs which have been very successful in lowering levels of LDL - or bad cholesterol.\nTwo arms used 72 healthy volunteers who were either injected with a single dose of the drug in increasing amounts to test for side effects, which is the purpose of a phase one clinical trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Superficial comparisons were included:\nAgain, we\u2019ll give the story the benefit of the doubt on this but it is too early to even suggest that the antibody won\u2019t have any side effects.", "answer": 1}, {"article": "PSA is a protein produced by cells of the prostate gland.\nIn the study, researchers used data on more than 5,500 men in their 60s and 70s who took part in a drug trial for a prostate cancer prevention drug.\nThe whole issue of prostate cancer screening -- including the PSA test, the digital rectal exam and PSA velocity -- has been controversial, said Dr. Otis Brawley, chief medical officer of the American Cancer Society (ACS).\nTHURSDAY, Feb. 24, 2011 (HealthDay News) -- Blood tests that indicate prostate-specific antigen (PSA) levels are rising rapidly over time are of little use in detecting aggressive prostate cancer and should not be done, a new study indicates.\nHigh levels of PSA can be a marker for prostate cancer, although it's far from a perfect screening tool, experts say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story contrasted using change in PSA level versus simply the PSA level for their impact on prostate biopsy recommendations and subsequent diagnosis of prostate cancer.\nMore importantly, much more explicity than the competing AP story, this story (through the words of Dr. Otis Brawley of the American Cancer Society) addressed the option of not being screened at all.\u00a0 Excerpts:\n", "answer": 1}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\n\u201cTelephone-delivered psychotherapy is one way to overcome some barriers to mental health treatment that rural older adults face,\u201d the study concludes.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\nAt four months\u2019 follow-up there also was greater decline in self-reported GAD symptoms and depressive symptoms among participants in the telephone CBT, according to the results.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release points out that the study focuses on older adults living in rural settings where psychotherapy may be unavailable.\u00a0 It also points out that older adults may prefer psychotherapy over medications. \u00a0We wonder about other approaches to address loneliness in the elderly, especially in rural areas, that could improve a person\u2019s quality of life.\n\u00a0", "answer": 1}, {"article": "Some teens didn\u2019t know how to use the pumps correctly, dropped them or didn\u2019t take good care of them.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Multiple daily insulin injections, the standard most widely used treatment option for Type I diabetes, is appropriately referenced. ", "answer": 1}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are at least other 6 drugs under development for gout at the moment. The story didn\u2019t mention anything about any of them.", "answer": 0}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not a word about any other research on acupuncture for menopausal symptoms and no comparison with any other methods used to relieve symptoms.", "answer": 0}, {"article": "Enrollment ran from 1993 to 1998.\nWomen with the least-inflammatory diets had lower bone mineral density overall at the start of the study, but lost less bone than their high-inflammation peers, the researchers found.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\n\"This suggests that a high-quality, less-inflammatory diet may be especially important in reducing hip fracture risk in younger women,\" the researchers wrote.\nRebecca Jackson, the study's senior author and director of Ohio State's Center for Clinical and Translational Science, said the new findings support a growing body of evidence that factors that increase inflammation can increase osteoporosis risk.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not go into any depth about the different diets being studied, but it does explain that different diets with different levels of inflammatory components had different degrees of impacts on bone density.\nIt states early in the release that \u201cvegetables, fruits, fish and whole grains\u201d are beneficial but it would be nice to see more focus on specific foods and even specific diets considered to be pro- or anti-inflammatory so that readers could compare and contrast different diet patterns.\nThese different food types were not described in the research publication either, but in these cases, we encourage PR staff to seek clarification from the investigators.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\nTrials directly provided nuts to the intervention group rather than relying solely on dietary advice to consume nuts.\nThis study was supported in part by funds from The International Tree Nut Council Nutrition Research and Education Foundation.\nOf 1,301 articles surveyed, 61 trials met eligibility criteria for this systematic review and meta-analysis, totaling 2,582 unique participants.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned such as exercise, medications, lifestyle changes and so on. In fact, other research points to olive oil, for example, as being helpful in modifying cholesterol and risk for cardiovascular disease. A brief mention of this would have been appropriate.", "answer": 0}, {"article": "\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\nAn international team of researchers has developed a simple laboratory score that is safer and faster at diagnosing patients who visit the emergency department with heart attack symptoms.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nAccording to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text mentions two alternatives: a single blood test, called a cardiac troponin test, and \u201cmultiple blood tests over several hours.\u201d\u00a0 It makes the case that the proposed laboratory score is superior to both.\nThe release omits discussion of other strategies such as electrocardiograms, exams and patient history typically used in acute treatment facilities. Stress tests are not as readily available. It does raise the question of the timing of the troponin test that was used to calculate the score \u2014 ideally, we\u2019d like to know that results were quickly available if we\u2019re seeing this as a way to shorten emergency room stays.", "answer": 1}, {"article": "Weight gain is a common side effect of Zyprexa.\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nFrom 20 to 45 percent of people who score high on the scale go on to develop full-blown psychosis, in which these symptoms become extreme, researchers have found.\nThe scale rates severity of more than a dozen symptoms, including suspiciousness, grandiosity and bizarre thoughts.\nThose on medication gained an average of 20 pounds during the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of other treatment options for patients who show signs of psychosis or who develop schizophrenia. Psychotherapy (including cognitive behavioral therapy) in conjunction with medication has been tried with some success in other studies to help patients manage symptoms (i.e. delusions, hallucinations) and improving functioning. ", "answer": 0}, {"article": "I will say it\u2019s an effective method of controlling pain.\u201d\n\nDr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\n\u201cI was like, \u2018Well, O.K., I\u2019ll get to meet some people, it will get me out of the house.\u2019 I didn\u2019t believe any of it.\nThe fibromyalgia study involved the yang style of tai chi, taught by a Boston tai chi master, Ramel Rones.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story talks about how the study compared different alternatives, and it mentions, at least in passing, several other therapies.", "answer": 1}, {"article": ".\nCanha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nOpen windows and doors helped reduce carbon dioxide levels and improve ventilation and air flow, which was related to better sleep quality for the healthy young adults in the study.\n\u201cSleep quality is affected by many factors, such as health and emotional states, bedding conditions and different environmental conditions, including noise levels and temperature,\u201d said Dr. Nuno Canha of the University of Lisbon in Portugal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t provide alternative treatments known to improve sleep quality, such as establishing good sleep hygiene.", "answer": 0}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nThe new study seems to make a powerful argument in favor of PSA testing.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nThat kind of prostate cancer -- metastatic prostate cancer, in which the cancer spreads to the bone or other parts of the body -- is rapidly fatal, usually within two years or less.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to PSA screening is the choice to decline screening, which is implicit in the discussion about the tradeoffs.", "answer": 1}, {"article": "SOURCE: bit.ly/AhalBY\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nThe results suggest that people eat a healthy diet with \u201cmagnesium-rich foods such as green leafy vegetables, nuts, beans and whole grains,\u201d she added.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story a satisfactory grade for emphasizing that this study could not address whether other aspects of peoples\u2019 diets affected the findings \u2013 and that the results were consistent with dietary recommendations.\nThe story would have been stronger if it had mentioned the importance of hypertension control in stroke reduction \u2013 and that it may be the favorable dietary pattern that is working with these people through improved blood pressure control.", "answer": 1}, {"article": "Media campaigns, increased tobacco and tightening of smoking laws have all had an effect as well.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\nDr. Hurt said products like nicotine gum and patches \u201care absolutely essential, but we use them in combinations and doses that match treatment to what the individual patient needs,\u201d unlike smokers who are self-treating.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nAt each stage, about one-third of the people trying to quit had relapsed, the study found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story lists a range of alternative factors for successful smoking cessation at the end of the piece: \u201cMotivation matters a lot; so does a person\u2019s social environment, the amount of support from friends and family, and the rules enforced at the workplace. Media campaigns, increased tobacco taxes and tightening of smoking laws have all had an effect as well.\u201d This isn\u2019t quite a comparison with nicotine products, but we give the story credit for covering some of this territory.", "answer": 1}, {"article": "Vemurafenib, approved in 2011, can cause non-lethal skin cancers.\nFor the first time, however, patients such as Herry have options.\nPatients with a limited time to live may not be so positive, Turnham says.\nAll improve survival by a few months.\nDoctors now dare to hope that giving these new drugs in sequence, or in combination, will help people with melanoma live for years while feeling relatively good.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was an overview of competing alternative therapies.", "answer": 1}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\nIn addition to enhancing the patient\u2019s surgical experience, the more precise localization of the surgical site enable surgeons to plan the procedure better.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does provide comments on the current standard of care and places the Savi Scout in a positive light in comparison.\u00a0 But since no clinical trials have been conducted comparing the two,\u00a0 readers should be reminded that the advantages stated are theoretical.", "answer": 1}, {"article": "Read all the details of this study, the full list of contributors and their financial support in Clinical Cancer Research.\nFurthermore, these tumor cells were sensitive to an experimental drug, neratinib.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\nTo identify the patients in this study who carried the new HER2 mutation, the researchers required tissue from the tumor, a biopsy, from which they could extract and sequence the genetic material to determine the presence of the HER2 mutation.\n\"This is the first time we had a reasonable number of patients treated for HER2 mutations in whom we could estimate the response rate.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives were compared in this study although the study authors mentioned that this drug was aimed at those women who did not respond to conventional therapies to treat HER2+ cancers.", "answer": 0}, {"article": "(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nThe diagnostic could prove particularly useful in infants and young children.\nAdditionally, within the patients identified with central nervous system infections, the CSF cytokine fingerprint was different in cases of viral infection compared to those with non-viral pathogens, such as bacteria or fungi.\nRather than testing for the presence of bacteria or virus, the researchers looked at the first tell-tale signs of infection: the cytokines produced by the patient\u2019s immune system in response to pathogens and other injury processes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This was perhaps the weakest points of the release, since many alternatives do exist and which also use CNF.\u00a0 For example, the color and clarity of CNF can indicate an infection, and the presence of free-floating cancer cells typically indicate some kind of tumor.\nThe release would have been stronger had it brought up these and other standard-of-care procedures, noted how they work, and explained how this particular test may be better or cover a blind spot.", "answer": 0}, {"article": "For more information on biopsies, visit the U.S. National Library of Medicine.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\nIn addition, image-guided biopsies are more accurate, Quencer said.\n\"Doing image-guided biopsy allows more definitive diagnosis and shorter hospital stays,\" said Dr. Robert Quencer, chair of radiology at the University of Miami Miller School of Medicine, who was not involved on the study.\nMoreover, by 2008, 67 percent of these biopsies were being done through the skin with the help of CT scans, ultrasound and MRI, Kwan's group found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No evidence-based comparison of biopsy techniques was provided \u2013 only the vague testimonials on behalf of the less invasive approach mentioned above.\u00a0 ", "answer": 0}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nSince the study was limited to young children with mild persistent asthma receiving asthma controller therapy, the authors also note that their findings may not apply to other age groups or children with more severe asthma.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study was designed to compare the safety of two drugs \u2013 acetaminophen and ibuprofen \u2013 in children with mild, persistent asthma, since previous observational studies had correlated acetaminophen with increased asthma symptoms.\nSince the drugs themselves are already alternatives in treating pain and fever, we rate this one Not Applicable.", "answer": 2}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the nature of this follow-up story, a discussion on the existing alternatives to HIV prevention may not be warranted.\u00a0 \u00a0\u00a0", "answer": 2}, {"article": "The median age was 75 years (range 41to 94).\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\nTheir collective experience is among the largest multinational series of patients treated with image-guided SBRT to date.\nTo date, they have accumulated data on close to 1,200 such patients and identified medical and technical factors that affect tumor control and toxicity.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no meaningful comparison to alternatives. The closest the release comes to mentioning any alternative is in a quote by the lead author, \u201cThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options.\u201d However, this is not sufficient to give them credit here.", "answer": 0}, {"article": "While other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThe new Swedish study echoes previous research in men and women.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nThe research is published in the Journal of the American College of Cardiology.\nIt also adds new information.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have included a line about other, more established methods of preventing cardiovascular disease, but didn\u2019t.", "answer": 0}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\nDr. Jacob Lalezari, director of Quest Clinical Research of San Francisco, led the first test of this with the company and colleagues at the University of California in San Francisco and Los Angeles.\nThe gene-snipping compound was added in the lab, and about one-fourth of the cells were successfully modified.\nThree months later, five men had three times the number of modified cells expected.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Within the realm of other gene therapy attempts, the story explained, \u201cThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients. Other gene therapy attempts tried to add a gene or muffle the activity of one, and have not worked against HIV\u201d", "answer": 1}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story focuses on a comparison of IVF v. IVM.\u00a0 Other methods to increase fertility are not discussed.\u00a0 Women with subfertility and PCO may try less dramatic means to enhance their likelihood of conceiving with modest weight loss and conventional medications as needed.\u00a0 ", "answer": 0}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe present study is also the first to test its clinical utility in a U.S. population.\nOverall, 5.1 percent of patients had a major cardiovascular event each year.\nPatients were grouped into four risk categories according to their ceramide levels: low (0\u20132), intermediate (3\u20136), moderate (7\u20139) and high (10\u201312).\nMayo Medical Laboratories collaborated with some of the original researchers who established the role of ceramides in cardiovascular disease and Zora Biosciences Oy, a diagnostics discovery company based in Finland, to develop and refine the test.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release doesn\u2019t mention that over the past few years many new blood tests for refining cardiac risk have been researched. Independent expert guidelines do not endorse their use. How well ceramides compare to these blood tests will have to be determined by future studies.", "answer": 0}, {"article": "Several companies, including one owned by Koniver, make herbal combinations.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\nOne of Blakeway's patients wrote an article for the magazine, Cookie, about her experience with acupuncture for her flagging sex life.\nShocked and not quite sure what to do, she turned to medical doctors, and found there wasn't much they could offer, as there's no prescription medicine like Viagra to help a woman when her sex life gets stuck.\n(CNN) -- Losing interest in sex would be unfortunate for most people, but for Linda Poelzl it was a professional hazard.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Before rushing out to try maca root supplements or herbal combinations, women might want to\u00a0explore whether\u00a0there\u2019s an alternate explanation for their\u00a0symptoms, whether it\u2019s a relationship problem, a physical health issue\u00a0(e.g. thyroid disorder, depression, sleep deprivation), or perhaps\u00a0the side effect from a\u00a0medication. This story didn\u2019t mention any of these possibilities or how they might be treated. \u00a0\u00a0\u00a0", "answer": 0}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\nThe patches also deliver their medicine directly to the site of a person's pain.\nFuture over-the-counter options, they predicted, could include reduced-dosage versions of the NSAID-delivering patches now available through prescription.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives are barely mentioned, and no non-pharmaceutical alternatives are mentioned. \u201cBoth doctors said that they expect more over-the-counter pain patches to hit the market if the popularity of Salonpas continues to grow. Future over-the-counter options, they predicted, could include reduced-dosage versions of the NSAID-delivering patches now available through prescription.\u00a0\u201cSuccess begets success,\u201d Dombrowski said. \u201cIf this does very well, other drug companies will say, \u2018I want a piece of this action.'\u201d\u201d\u00a0\u00a0Readers are left with the message that people are running out to buy these pain patches because they work, and that more companies are going to be making these patches because they are so beneficial. But there is no proof provided in this story of their success or their benefits.\u00a0There is no evidence conveyed that the patch is better than nothing, let alone existing, accepted treatments.\u00a0From a business story standpoint, this story fails. From a medical story standpoint, the story is incredibly misleading.", "answer": 0}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nDr. Michele Tagliati, an associate professor of neurology and director of the Parkinson's Disease Center at the Mount Sinai School of Medicine in New York City, described the results as somewhat surprising and said they emphasized the need for further study.\nStudy author Dr. Xiang Gao, an instructor and epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston, said the findings are important for anyone at increased risk for Parkinson's because most people with the disease eventually become severely disabled.\nGao said that though the drug levodopa is the current standard treatment for Parkinson's, much more is needed.\nThe findings came from an analysis of data on 136,474 people who did not have Parkinson's at the start of the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentioned that levodopa is the current standard treatment for Parkinson\u2019s, there was no discussion of any other research into prevention of Parkinson\u2019s Disease. ", "answer": 0}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\nSymptoms include sad, hopeless feelings that persist, generally for more than two weeks, Lusskin said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story appropriately discusses antidepressant medication and psychotherapy, two very important and helpful treatments for partum depression.", "answer": 1}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\nGontero noted that cognitive behavioral therapy might help build confidence in some men.\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\nDr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said functional issues resulting from conditions such as birth defects or prostate cancer surgery may warrant penile surgery, but such cases are unusual.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given that so much of the story comes back to the idea that men don\u2019t really \u201cneed\u201d these procedures, it would have been worth discussing whether there are any other ways to help men feel better about their body type or their perceived sexual inadequacy. Obviously people seek therapy for sexual disorders, but that was addressed only briefly:\u00a0\u201cGontero noted that cognitive behavioral therapy might help build confidence in some men.\u201d\u00a0 After all of the attention the story gave to medical/physical interventions, the cognitive behavioral work seemed to deserve more attention.", "answer": 0}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nAnd, as the debate over PSA testing shows us, early diagnosis is only useful if early treatment can help patients live longer and healthier lives, preventing progression to advanced-stage cancer down the line, but without increasing the risks of other health problems too much in the process.\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nBut a new study this week reflects the continued view of many physicians \u2014 that screening does help to catch tumors earlier.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to PSA screening is the choice to decline screening, which is implicit in the discussion.", "answer": 1}, {"article": "More adults and kids taking Prozac, known generically as fluoxetine, had at least a 50 percent improvement in scores on depression tests after six weeks compared to those assigned to take a placebo pill.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\nIrving Kirsch, who studies antidepressants and placebos at Harvard Medical School in Boston, said the new report didn\u2019t make him more optimistic about the drugs.\n\u201cThere are alternative treatments for depression that also produce about the same symptom reduction as the drugs do, but without the risk of side effects,\u201d Kirsch added, including psychotherapy and exercise.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least noted alternatives including psychotherapy and exercise, but didn\u2019t give information about the effects, pros/cons of these options.", "answer": 0}, {"article": "According to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nHaddleton says the technology has exciting potential for other medications, such as opioid painkillers.\nAn ibuprofen patch that delivers the painkiller directly through the skin to the site of pain, at a consistent dose for up to 24 hours, has been developed by UK researchers.\nThe team says that popular ibuprofen gels make it difficult to control dosage and can be easily rubbed off.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was a decent amount of discussion about alternatives like ibuprofen administered orally or topically as a gel.", "answer": 1}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nMost participants were able to stay on both diets.\nThe association has strict policies to prevent these relationships from influencing the science content.\nAfter three months, the participants switched diets.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This study was designed to strictly compare just two types of diets. So not bringing up other dietary options seems appropriate.", "answer": 1}, {"article": "\"The work by [first author] Price et al.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nThe study is in the May 1 issue of Cell Metabolism.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have included even a line about other research in the prevention of cell aging.", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explored alternatives.", "answer": 1}, {"article": "\"It's a really interesting paper,\" said Dr. Nicholas D. Schiff, director of the Laboratory of Cognitive Neuromodulation at New York-Presbyterian Hospital/Weill Cornell Medical Center.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions that multiple drugs may be needed to control blood pressure in individuals with treatment-resistant hypertension, it never mentions the lifestyle factors that contribute to the problem and can help alleviate it if addressed. These include\u00a0obesity, high sodium intake, and heavy alcohol use.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains how, in theory, real-time imaging could significantly improve surgical outcomes. But the story does not actually offer any comparison of the outcomes of surgical procedures that use real-time imaging techniques versus surgical procedures that do not.", "answer": 0}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states through a quote from the lead author of the study that the lap band procedure \u201cis a good result when compared to BMI reduction using the few medications available or lifestyle measures,\u201d but offers no actual comparisons with any non-surgical approaches to weight loss.", "answer": 0}, {"article": "Sept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nResearchers then analyzed health status information collected after the women turned 70.\nAfter taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, an expert could have put these results in perspective with other factors known to promote healthy aging, such as a healthy diet and regular physical activity,\u00a0which were not mentioned in the story.", "answer": 0}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Like the AP competition, the story fails to mention\u00a0the availability of\u00a0options to reduce vaccine pain. These include\u00a0the Flumist nasal spray and topical creams that can be used to anesthetize the site of the needle stick.", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\nBut, as the current authors point out, more than half of the women in that study were already taking their own calcium supplements on top of what they had been prescribed for the trial, which may have clouded the results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not provide readers with any information about possible alternatives, saying only that women should be making sure that they get a maximum of 1,500 milligrams of calcium from both their diets and supplements combined. This isn\u2019t a very good guidepost for readers. We would have liked to have seen at least a sentence or two indicating what patients might be able to do for bone strength, if anything, were they to avoid calcium supplementation.\n", "answer": 0}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\nThe study included 520 youngsters with ear infections.\nThese infections are the most common reason why children are given antibiotics, the University of Pittsburgh researchers noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This rates not satisfactory by virtue of the fact it didn\u2019t mention the one alternative that the evidence suggests might be best, at least for older kids: Doing nothing except treating the pain.", "answer": 0}, {"article": "While 2 percent of adults aged 45 to 54 have disabling hearing loss, the rate increases to 8.5 percent for adults aged 55 to 64.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\nThe EAS System FDA approval is for candidates who are 18 years old and older who have normal to moderate sensorineural hearing loss in the low frequencies, sloping to a severe-to-profound hearing loss in the high frequencies.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\nThe SYNCHRONY EAS implant best assists people whose hearing loss is referred to as \u201cski-slope\u201d hearing loss, based on the steeply sloping image that appears on an audiogram when a patient has more trouble hearing higher-frequency sounds.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release makes some distinction between the type of hearing loss most likely to benefit from this FDA approved device; and it explains in some detail how the device is an improvement over other cochlear implants, it isn\u2019t clear about the overlapping benefits of newer digital hearing aids and the implants for people in the \u201cmoderate\u201d sensorineural hearing loss category.", "answer": 0}, {"article": "\"Obviously that's very exciting,\" Spira said.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nThe study findings were published in the April 7 issue of the journal Science Translational Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not only was the other genetic signature research not mentioned, there was no discussion of other means of detecting early lung cancer such as chest CT \u2013 albeit controversial. ", "answer": 0}, {"article": ".\nThe problem was to find a way to get more insulin to the brain but not to the body.\nThe solution was a special device made by Kurve Technology that delivers a spray of insulin deep into the nose.\nBut Dr. Martha Daviglus of Northwestern University, who led a panel last year that assessed published papers on preventing and treating Alzheimer\u2019s, urged caution.\nIn addition, she said, beta amyloid, a toxic protein that accumulates in the brain of Alzheimer\u2019s patients, seems to tie up insulin in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there are no effective ways to prevent or delay the progress of Alzheimer\u2019s.\u00a0However, it should have mentioned that the\u00a0FDA has approved some medications for the treatment of individuals with Alzheimer\u2019s disease. Although these drugs do not affect the course of the disease, they may have a small effect on preserving the functioning of patients in the early stages of the disease.\u00a0 It also could have noted that there are other drugs in late-stage testing for Alzheimer\u2019s disease.", "answer": 0}, {"article": "In addition to Chang, other authors on the all-MD Anderson study include: Stephen Hahn, M.D., Ritsuko Komaki, M.D., Pamela K. Allen, Ph.D., Zhongxing Liao, M.D., Steven H. Lin, M.D., Ph.D., Daniel Gomez, M.D., James Welsh, M.D., Melenda Jeter M.D., James Cox, M.D., Michael O'Reilly, M.D., Ming Li, M.D.\nIn contrast, the historical OS rate with standard of care concurrent chemotherapy and traditional radiation was 16 months at the time when the study was designed.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nThe researchers hypothesized that the median OS would increase from historical data of 16 months on standard therapy to 24 months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that results were compared to historical controls, but then goes on to detail all of the limitations with this comparison. The release does mention\u00a0intensity-modulated radiation therapy (IMRT) at the end and states the historical control was chemotherapy with conventional radiation.\nThe alternatives could have been presented in a more straight-forward way.  ", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions another drug that has a similar mechanism of action, and is approved for BRCA-mutated breast cancer and ovarian cancer.\nThere is no discussion of how the drugs may differ with regard to harms or benefits\u2013which we\u2019ll address in novelty, below.", "answer": 1}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nThat can call into question the ultimate relevance of the findings.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nWell, the study's lead author tells Shots that it might be enough to \"tip the balance a little bit, but not overwhelmingly so.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself was a comparison between two treatment paths, and the story explains that. A mention of drug treatment as an option would have been welcome.", "answer": 1}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nHe points out that psychedelics should never be used carelessly, and that the \u201cset and setting\u201d (meaning the dose, mood, environment, company and surroundings) where a person takes them are of paramount importance.\nAll of which adds up to a compelling argument that psychedelics \u201cshould be the focus of intensive study for treating mental illness,\u201d Wood says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although it mentions that mental health problems are often treated with\u00a0drugs like serotonin-specific reuptake inhibitors, it doesn\u2019t discuss how the psychedelic drugs compare to those drugs or each other, or other types of non-drug therapy. We\u2019ll give the benefit of the doubt here, though we wished for more detail.", "answer": 1}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nThe researchers pointed out traditional bone scans are unable to differentiate between malignant and nonmalignant lesions.\nBut a team from Memorial Sloan-Kettering Cancer Center in New York City said the technology could help identify cases where prostate cancer has spread to the bone.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Existing methods of looking for prostate cancer spread were waved off with a few words \u2013 \u201cboth methods have their limits.\u201d\u00a0 In readers\u2019 minds, that may automatically set up the newer idea as having the inside track on being better.\u00a0 Yet existing methods \u2013 by default \u2013 at least have proven track records.\u00a0 Such framing is imbalanced.\nBone scans are actually considered quite sensitive for metastatic disease.\u00a0 The pattern of abnormalities in combination with clinical data is often sufficient to make the diagnosis. The combination of bone scans and PSA already provides considerable information about tumor progression and hormone resistance.\u00a0 Biopsies are usually not necessary in the presence of suspicious bone scan abnormalities.\u00a0 It\u2019s a huge leap to assume that using this test in humans would lead to improved outcomes (the goal of \u201cpersonalized medicine\u201d).", "answer": 0}, {"article": "\"It just blows it up.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\nGregory Chinchar, a professor in the University of Mississippi Medical Center's department of microbiology and immunology, said that he was surprised that the peptide targeted the hemagglutinin on the flu virus.\n\"The peptide described in the Immunity report is somewhat unusual because of the apparent specificity,\" Rollins-Smith said about how urumin specifically targets H1 viruses.\nFerrets are next, then possibly humans\n\nA challenge to possibly using frog mucus as a flu-fighting treatment in humans is figuring out how to get the urumin peptide to attach to flu virus cells in the human body, Jacob said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story would have benefited from information about how this possible antiviral treatment might fit in with other types of treatment. For example, the researchers note in the abstract of their report that vaccines may take too long to produce in pandemic situations, making antiviral treatments relevant.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of other options for reducing coronary heart disease risk or of\u00a0other treatments for menopausal symptoms, since no one is proposing that HRT be used for reducing coronary disease risk.", "answer": 0}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\nPlus, the research needs to be expanded to many more study participants and tried on younger people with autism and those who are not as high-functioning as the subjects in this first trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Unlike the Reuters story, this one actually pointed out that there are other ways to detect autism beyond brain scans. \u201cCurrently there\u2019s no biologic test for autism, so pediatricians look to see if a child is meeting certain developmental\u00a0milestones as well as\u00a0signs and symptoms of autism. (The advocacy group Autism Speaks has posted\u00a0videos to help parents see the signs of autism)\u201d\u00a0We would have liked to have seen a couple of additional comments about the current testing modes, their limitations and the degree of accuracy provided by them.", "answer": 1}, {"article": "Bernard M.Y.\nThis trial looked at the benefits of statin therapy with 80 milligrams (mg) versus 20 mg simvastatin (Zocor) among 12,000 heart attack survivors.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nThis applied even if the patients already had low levels of low-density lipoprotein (LDL, or \"bad\") cholesterol, he noted.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main comparison with the higher doses of statins studied is to lower doses of this class of medication, and this was covered in this story. We would have liked to have seen at least some discussion of how statin use compared to diet and exercise in reducing risk for heart attacks and stroke.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\nThe new results were similar to those previously published on the more intense cognitive behavioral therapy.\nThese improvements were sustained for at least 6 months, and were backed up by data from a sleep monitor worn on the wrist or ankle.\nBuysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nWe will credit this story for discussing the alternatives of sleeping pills and cognitive behavioral therapy. Although there was no reference to other less-intense non-drug approaches that clinicians may recommend for dealing with insomnia, there was a comment at the end of the story that offered some basic advice that readers could use on their own.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In a practice that is far too common in such stories, this one mentioned alternatives but waved them off as ineffective without citing any data.\nUntil recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and massage devices. The creams are largely ineffective and the devices have a modest effect that typically lasts about six months, doctors say.\nMeantime, this entire story was based on two company-funded studies \u2013 one tiny and one unpublished!!!", "answer": 0}, {"article": "Coronary heart disease, which causes heart attacks and angina -- chest pain resulting from the heart not getting enough blood -- is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares this process, which involves infusing the patient with a donor\u2019s bone marrow stem cells, with both use of the patient\u2019s own stem cells and with surgical introduction of the cells. \nThe story does not specify conventional treatments for heart failure, which would have provided useful context. Still, the story earns a satsifactory rating. ", "answer": 1}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\nIt can't tell us whether text messaging could eventually lead to fewer subsequent heart attacks among the patients receiving those messages or whether the positive health outcomes would continue past the six-month study window.\nYet patients in Chow's study resoundingly said that the text messaging helped them make the necessary changes \u2013 more than 90 percent of the participants found the program useful.\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story is not so much on how the text message intervention directly reduced heart disease risk, but on the extent to which it resulted in patients taking steps to reduce their own risk \u2014 such as by exercising more, smoking less, making dietary changes, or taking prescription drugs on a regular basis. The story does discuss other \u201cmobile health interventions,\u201d such as smartphone apps \u2014 but notes that there don\u2019t appear to be many mobile health projects that rely simply on text messages. The story also looks at how the text messages helped patients pursue lifestyle changes \u2014 like exercising more and smoking less \u2014 that reduced their risk.", "answer": 1}, {"article": "When the lights went up, Nadella welcomed both Lawton and engineer Zhang on stage, thanking them for showing that thanks \"developers can have impact.\"\nMicrosoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nEmma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson's sufferers.\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nThe watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The Microsoft video embedded in the story states that there is no cure, and the story notes how the watch is not a cure. However, there\u2019s no mention of any alternative treatments, and many exist. Some of the first-line medications (levodopa, dopamine agonists, anticholinergics) are very effective in controlling tremor. For patients with\u00a0resistant symptoms, treatment with second-line medications (clozapine, amantadine, clonazepam, propranolol, neurontin) can be used. In patients with disabling\u00a0refractory\u00a0tremor, neurosurgical treatments including thermocoagulation and deep brain stimulation offer tremor control.", "answer": 0}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nBut for many women, being told they need a C-section is unpleasant news.\nBy late evening she was told she'd need a C-section to deliver her son, Avery.\nAnd there were a bunch of little adjustments, such as moving the EKG monitors from their usual location on top of the mother's chest to her side.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece compared other alternatives to the family-centered cesarean \u2014 mainly, the vaginal delivery and the traditional C-section. It mentioned that in a typical C-section, a closed curtain shields the operating field and the baby is quickly whisked away after birth.", "answer": 1}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nNot every Omada Health participant makes the progress they're aiming for.\nThere is some evidence that these kinds of programs are working.\nAnd he says he's pleased with the results of the pilot study of Omada's program.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article very briefly mentions that other technology-based programs for improving diet and exercise exist, but does not go into much detail, especially on outcomes. We think it would be useful to have included outcomes from a well-studied program, such as Weight Watchers, or even Virta Health, which recently published some (more) impressive one year results with a similar sounding app.", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nThat is, each year, coffee would be keeping 1 person in 1,000 from dying.\nBut given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nIf you do want to infer causation from this latest study, know that drinking coffee reduced the absolute mortality risk from 6.8 deaths a year per 1,000 people to, at best, 5.8.\nthat causes the observed benefit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We thought that a comparison of alternatives to coffee was beyond the scope of the story.", "answer": 2}, {"article": "L-Nutra, to sell products that serve this purpose, which may be seen as a conflict of interest.\nThis activation, or reduction, of pathways is why the components of the diet, such a proteins, must also be controlled.\nTo him, diet underpins longevity.\n(CNN) How much -- or how little -- you eat could influence how long you live.\nHe also believes the benefits are down to improved efficiency on a cellular level.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story makes no mention of other ways to achieve similar benefits. How does this dieting approach compare, for example, to regular exercise as a means to age healthier?", "answer": 0}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nScientists working to develop a 'game-changing' new antibiotic have made a significant advance towards creating commercially viable drug treatments by producing two simplified synthetic versions of the substance which are just as potent at killing superbugs like MRSA as its natural form.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It appears that the release compares teixobactin to existing antibiotics, but it does not tell readers that the comparison is laboratory studies versus real world experience, which is not a fair comparison.", "answer": 0}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nEfforts are already underway in Europe to develop guidelines for how ketamine should be used and prescribed to treat bipolar illness and depression, the researcher said.\nBy developing more specifically targeted drugs, Zarate noted, it may be possible to treat patients effectively while avoiding these symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly conveys that these patients had tried many treatments. What is unclear is at least 2 things: 1) although these patients had tried many treatments over their lifetime history of bipolar disease, to enter this study they need to fail 1 adequate course of an antidepressant and 1 trial of a mood stabilizer \u2013 so while they appear to have recently failed on average 7 drugs, this is not true and the story is misleading in this respect. \nNonetheless because of the mention that was made of alternative approaches, we\u2019ll give the story the benefit of the doubt. ", "answer": 1}, {"article": "This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nNor does it lead to cancer.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\nUrological experts are beginning to rethink treatments, too, based on symptoms and how much a man is bothered by them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided a pretty extensive laundry list of approaches that can be taken to manage benign prostatic hyperplasia from not doing anything to surgery.\u00a0", "answer": 1}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\n\"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\nFor the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.\nIn the randomized phase III clinical trial, patients whose disease progressed on antiangiogenic therapies were treated with either nivolumab or everolimus.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although not named specifically, other therapies are mentioned: \u201d\u00a0A number of targeted therapies have been approved in recent years for the treatment of advanced RCC, with five antiangiogenic and two mTOR inhibitors (including everolimus; these drugs block a protein that regulates cell growth, proliferation, survival, etc.), showing benefits in pivotal phase III trials\u201d\nTo be sure, this is not really a true comparison of options, just a listing. But since the main alternative is the treatment used in the trial, this may be a moot point. We\u2019ll give the benefit of the doubt on the rating.", "answer": 1}, {"article": "I weigh 160 pounds, and when I do this I put about half my weight into it,\" he said.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\nThe bystander who needs to provide those chest compressions is often a loved one of the victim.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article discusses hands-only and mouth-to-mouth resuscitation, and explains that these are used while bystanders await other options\u2014usually treatment by emergency medical personnel and/or automated external defibrillator and, ultimately, hospital medical staff.", "answer": 1}, {"article": "\u201cBut this is a small study, a proof of concept.\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\n\u201cWe must bear in mind that this is a pilot study with a small sample,\u201d Anna Fenton, co-editor of Climacteric, said in commentary on the work.\nBut they stressed that the trial was small, so far larger studies are needed to confirm the results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several alternative treatments to hormones. It says, \u201cAmerican researchers said in January that the antidepressant Lexapro, made by drugmaker Forest Laboratories, significantly cut the number and severity of hot flushes in menopausal women, and other antidepressants including GlaxoSmithKline\u2019s Paxil and the Pfizer drugs Prozac and Effexor also have been found to be effective.\u201d\nBut it seems strange that the story refers only to these brand name products and does not mention any of the generic medications such as fluoxetine and citalopram that have also been proven to reduce hot flashes.\nThis issue, and the lack of cost information, make this story less helpful to consumers than it might have been.", "answer": 0}, {"article": "Learn more about psoriasis treatments from the National Psoriasis Foundation.\nThe current study included 317 people with moderate to severe psoriasis.\nThe study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\n\"Very high levels of response\" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As with the \u201cnovelty\u201d criterion above, on this point, WebMD\u2019s version of the story was better because it at least reminded readers that \u201ca similar drug, Stelara\u2026was approved by the FDA in 2009.\u201d Neither story wrapped this research into the broader context of other approaches to psoriasis \u2013 including non-drug therapies.", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nThat would look for known genetic factors linked to Alzheimer\u2019s, including the presence of certain versions of the ApoE gene.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out that other methods of testing are available for Alzheimer\u2019s disease including sophisticated scanning and genetic testing. We\u2019ll award a satisfactory rating on that basis. However, we\u2019d note that the story does not point out that many of the tests used in the study are currently used to diagnose mild cognitive impairment and are already used by primary care physicians and others.", "answer": 1}, {"article": "Of those 40 women, 26 had mutations carrying low to moderate risk of breast or ovarian cancer, eight had mutations associated with Lynch syndrome, which increases colon and ovarian cancer risk, and three had high-risk breast cancer genes.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nThough these results indicate that additional genetic screening is clinically useful, some genetic test results will be uncertain, and it can be psychologically difficult for patients to deal with this uncertainty, Ellisen said.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece in itself is about an investigation of the clinical usefulness of additional (alternative) genetic panels to the \u201croutine\u201d BRCA1/2 tests. So the story meets our standard here. But as mentioned before, there are serious concerns about the use and availability of genetic test panels and it would have been great to add some context.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nOver the next six weeks of testing, I came down to earth as I realized that while the sensor enabled me to drastically cut my usual number of lows, it did not eliminate them.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nI kept following the recommendations of the embedded calculator, taking only very small amounts of insulin to bring my sugar level down.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes alternative options, including traditional blood glucose monitoring devices and insulin pumps (minus the glucose sensors). The story also describes other similar devices that may be on the market soon. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss alternatives to oophorectomy.", "answer": 0}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story only gave half of the picture of alternative approaches; it mentions other supplements that have been studied for PMS, but fails to note that there are also prescription medications for PMS such as SSRIs.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note other UC treatment options, and notes that the patients in the study had not responded to those treatments.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the story\u2019s focus on blood pressure, it\u00a0should have mentioned how the results of this study might compare to treatment with blood pressure medication.", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nThere are about 150 U.S. ketamine clinics, compared with about 20 three years ago, said society co-founder Dr. Megan Oxley.\nKetamine\u2019s potential for almost immediate if temporary relief is what makes it so exciting, said Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist who has used ketamine to treat depression patients since February.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned conventional antidepressants that \u201ctarget serotonin, a different chemical messenger, and typically take weeks to months to kick in \u2014 a lag that can cause severely depressed patients to sink deeper into despair.\u201d\nIt also quoted an expert who said \u201cketamine should be a last-resort treatment for depression after other methods have failed.\u201d\nThe story could have mentioned other medications to treat depression as well as psychotherapy.", "answer": 1}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nAll content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\n\u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d\n\nDisclosures: The authors reported no financial disclosures.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release alludes to the standard dietary recommendations for people with chronic kidney disease and how hard those recommendations are to follow. But it does not provide us enough information to feel like a true comparison, nor does it discuss the controversies surrounding those recommendations.", "answer": 0}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story briefly mentions chemotherapy, surgery and radiation as treatment options for cancer.\u00a0 ", "answer": 1}, {"article": "We need to assess these options before jumping to possible universal screening.\"\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nExperts believe using family history is a good way to identify children who may be at greatest risk of high cholesterol \u0097 and therefore of future heart disease.\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes comments from an independent expert suggesting alternatives to universal cholesterol testing to identify children who may have elevated cholesterol levels. For children who are found to have high cholesterol, the story says doctors may advise lifestyle changes or drug treatment. However, the story fails to mention the lack of evidence that identifying elevated cholesterol in children is more effective at preventing the development of heart disease or other health problems than helping all children to maintain a healthy lifestyle and then waiting until adulthood to test cholesterol levels.", "answer": 0}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternatives, which is why we give it credit here. It could have done a better job explaining why all other treatment methods should be exhausted, short of surgery, before turning to plasma injections.", "answer": 1}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\nAs biochip tests allow clinicians and researchers to quickly run multiple tests on one sample of blood, this new test is also faster and more affordable than the standard DNA test, producing results in only three hours.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes it very clear that the new test was being compared with standard DNA testing.", "answer": 1}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\n\u201cWith current anti-depressant SSRIs (selective serotonin reuptake inhibitors) it could take four to six weeks to get a treatment response.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that women currently can receive antidepressants for postpartum depression, but that the new drug being studied goes to work relieving symptoms faster than traditional antidepressants \u2014 days rather than weeks.", "answer": 1}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\nThe hemophilia gene therapy is one of several being tested for conditions including sickle cell anemia and Huntington's disease.\nThe one-time treatments seek to fight the disease by adding correct copies of a patient's defective genes.\nAnd its effects lasted; after a year and a half, the longest patient follow-up, the therapy was continuing to work.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Individuals coping with hemophilia B have few options, and the story describes the main one: injections of blood-clotting factor to stem runaway bleeding.", "answer": 1}, {"article": "\u201cI was actually able to forgive myself,\u201d said Nigel McCourry, 36 a Marine veteran who was deployed in 2004 to Falluja, Iraq, whose experiences mirrored those of three other patients interviewed.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nA handful of medications meant to help left him feeling like a zombie, and he gave them up.\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nHe struggled to sleep.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The answer is revealing; essentially current interventions \u2014 mostly psychotherapy and/or drugs \u2014 have been mostly ineffective.", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\nOverall, the MRI detected 25 of 27 cancers, DeMartini said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough the story does say that MRI scanning would be used in conjunction with conventional mammography, it does not include any discussion of the relative merits. Indeed, the study did not appear to include any comparison of MRI scans to conventional mammography that would provide any insight to whether the combination of scanning methods might be superior to conventional mammography alone.\n", "answer": 0}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe study was presented at the Genitourinary Cancers Symposium.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have at least included a line about other research exploring other ways to prevent prostate cancer or slow its progression. It also could have provided information about active surveillance.", "answer": 0}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nAnd the women who were screened earlier had smaller tumors.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\nBut only 29 women fell into the \"never had a mammogram\" group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that different advisory groups have differing guidelines for what age to start getting mammograms (40 or 50 years old).\nIt would have been nice if the story had included examples of what makes someone higher risk or not (personal cancer history, family history, history of radiation), but we think this was satisfactory.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does mention Fosomax and Actonel, this is not sufficient information on the alternatives and the advantages and disadvantages of the different approaches. The story should have also mentioned calcium supplements, physical activity, estrogens, and smoking and alcohol cessation as alternatives.", "answer": 0}, {"article": "These new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nOthers have such high cholesterol that taking statins alone is not enough.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that millions of people take statins in order to lower their levels of a certain cholesterol. It positions these new drugs as alternatives to statins. While that\u2019s enough for a Satisfactory rating, the story does not point out that exercise and changes in diet are also known to lower levels of harmful cholesterol. There are also a number of other therapies available for patients with elevated lipids.", "answer": 1}, {"article": "January 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\nThe researchers identified women over age 65 who underwent DTI reconstruction at the Cleveland Clinic between 2012 and 2015.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The point of the study was comparing two options for breast reconstruction.", "answer": 1}, {"article": "It's a success story you might dream of when you start, but it actually seeing to happen is a great feeling.\"\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nOf the 406 participants that began the study, 335 completed the telephone follow-up at the end of 12 months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared online self-help interventions to an online education course about depression, and the story reflects that. The story doesn\u2019t discuss the use of in-person therapy for preventing the onset of MDD, nor does it discuss the use of pharmaceutical interventions.", "answer": 0}, {"article": "Most clinics just draw the cells from bone marrow or fat and inject them back into the patient without checking for stem cells, hoping that patients get better,\u201d he says.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nFunding for this study was from Mayo Clinic\u2019s Center for Regenerative Medicine.\nNone of these techniques have been studied because clinics maintain that use of a patient\u2019s own cells is not a drug.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted earlier in this review, other treatments \u2014 tested and untested \u2014 exist, including Platelet\u00a0Rich Plasma presumed to carry biological growth factors to arthritic joints; steroid injections; exercise; surgery; and analgesics. None were mentioned.", "answer": 0}, {"article": "It\u2019s possible that the immune cells had destroyed most of the cancer cells expressing the original protein, so other cancer cells with other proteins began to proliferate and survive.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\nDespite these treatments, his cancer had returned and also spread to other parts of his brain and spinal cord.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a pretty good job of describing the standard therapies available and, in this case, delivered to the patient. \u00a0\u00a0", "answer": 1}, {"article": "\u201cIt\u2019s a tricky thing to get your mind around,\u201d Whitlock said.\nIn general, Whitlock\u2019s team found, HPV tests were more sensitive than conventional Pap tests, but they were less specific, meaning they had a higher false-positive rate.\nBut the false-positive rate was 15 percent, compared with two percent with Pap testing.\nYou\u2019re trying to make a tradeoff between sensitivity and specificity.\u201d\n\nSince cervical cancer screening is repeated over time, what\u2019s needed is evidence of the longer-term effects of different tests, according to Whitlock.\nSeveral other clinical trials in the review looked at HPV testing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was great detail in comparing the liquid test and HPV testing with traditional cervical cancer screening.", "answer": 1}, {"article": "Overweight or obese people, however, exist in a state of chronic inflammation.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\nBiomarkers of inflammation were measured at the beginning and end of the study.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n\"If ensuring that vitamin D levels are replete, or at an optimum level, can decrease inflammation over and above that of weight loss alone, that can be an important addition to the tools people can use to reduce their cancer risk.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study didn\u2019t discuss alternative preventive measures or genetic causes of increased cancer risks. But this is such a broad and expansive topic that we don\u2019t think the release should have been expected to address those myriad issues. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "That\u2019s the good news.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nWomen who took a combination of estrogen and progestin face increased risk for breast cancer, previous studies have shown, Chlebowski said.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although not as thorough as the NY Times on this point, the story at least stated:\n\n\u201cIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms \u2026 this role may be vanishing as existing and emerging data continue to be better understood.\u201d\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone. Women who took a combination of estrogen and progestin face increased risk for breast cancer, previous studies have shown, Chlebowski said.\u201d\nWe\u2019ll give it a satisfactory score on this, but for reader comprehension, we think the Times piece was much better.\n\u00a0", "answer": 1}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not present a meaningful comparison of alternative treatments to surgery. But it does list a variety of treatments. \u201cThe first line of treatment is an ever-growing arsenal of pharmaceuticals \u2013 most not approved for migraine \u2013 including over-the-counter and prescription analgesics, triptans, ergotamines, antiseizure drugs, antidepressants, cardiovascular drugs, and opioid painkillers.\u00a0For migraines that are focused at the back of the head, newer treatments include shots to numb the occipital nerves at the nape of the neck, or an implantable device that stimulates those nerves.\u00a0Botox, given every three months, is injected into neck and forehead muscles.\u201d We wish that the story had helped readers sort through this list to understand which treatments tend to provide the biggest relief. Instead, it goes straight to another patient whose only credentials appear to be a \u201cmigraine odyssey\u201d that \u201cinspired an educational book and her website, helpforheadaches.com.\u201d\nJust listing the alternatives isn\u2019t the same thing as comparing them. This treatment hasn\u2019t been adequately compared to others that are listed as being used in these patients.", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story highlights two other drugs that were recently approved to treat patients similar to those included in this trial.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nCephalon soldiered on, giving FDA more data.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable.\u00a0 There was no discussion of other approaches to jet lag.\u00a0 But we acknowledge that this short blog piece was written to address the news of the day \u2013 the new regulatory review.\u00a0 So this news \u2013 in this news format \u2013 need not try to do it all. As stated above, we appreciate how it gave context and history even with its tight 250-word space.", "answer": 2}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThe pets provided more than just emotional support and companionship, participants said.\nSixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nBrooks says, \"Many felt deep emotional connections with their pet that weren't available from friends and family.\"\nThe interviews with participants are poignant, and reveal the struggle and isolation that can come with mental illness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention other elements of treatment for schizophrenia or bipolar disorder, such as therapy groups that encourage peer support, pharmaceutical or psychosocial interventions.", "answer": 0}, {"article": "\"I could ride a bike!\nThey gave it to Alex for free.\nIn truth, she had been more concerned about getting him therapy for his autism-related delays -- the limb difference was secondary.\nThere were other things the 12-year-old boy said he would do if he had two hands.\nEach electronic limb takes about 30 to 50 hours to make and assemble.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than the appearance, there are no comparisons with other types of prosthetic arms.", "answer": 0}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThese imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The main premise of the news release is that MRI imaging can help people lower their risks for cognitive decline by encouraging them to make lifestyle and behavioral changes. It states that risk factors include obesity, diet, sleep, hypertension, diabetes, depression and smoking. However, the release does not address any alternatives \u2014 besides brain imaging \u2014 that might help people make the desired changes. Behavioral change counseling, which is an established approach to reducing problematic behaviors, is not discussed.", "answer": 0}, {"article": "EMF runs two research grant programs - a national Rural and Remote program and a highly successful Queensland program - as well as a Research Support Network.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the study leader states that patients using this drug \u201cmight not need more complicated treatments including surgeries,\u201d that doesn\u2019t meet our criteria for comparing alternatives. Are there other drugs similar in function to tamsulosin that might also benefit patients?\u00a0 Alpha blockers which relax the ureter muscles have helped some pass stones with less pain. Some patients with larger stones are treated with lithotripsy which employs sound waves that break stones into smaller pieces.", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThe treatment works well for many kinds of tumors, including those found in the brain, esophagus, lung, head and neck, prostate, liver, spinal cord and gastrointestinal system.\nThe center will provide one of the newest and highly precise forms of radiation therapy available, pencil beam scanning (PBS), which targets tumors while significantly decreasing radiation doses to healthy tissue.\nProton therapy is just one of several new methods for treating cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does discuss alternative cancer therapies, such as Gammapod and selective internal radiation therapy \u2014 but neither of those therapies is used on esophageal cancer. In fact, the list of therapies included in the release muddies the water for readers: it\u2019s not clear why it\u2019s there. However, the release does not discuss longstanding treatment options for esophageal cancer, such as surgery and chemotherapy. This is particularly problematic because esophageal cancer treatment often involves chemotherapy and radiation therapy, or chemotherapy, radiation therapy and surgery. Discussing radiation therapy in isolation may give readers a skewed picture of treatment options \u2014 particularly for Stage II, III, and IV esophageal cancer.", "answer": 0}, {"article": "But they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\n\u201cThe vast majority of our patients are happier having them than not,\u201d he said about orthotics that are inserted in shoes.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\nThat\u2019s why Dr. Nigg says for now it is difficult to figure out which orthotic will help an individual.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did not discuss alternatives to orthotics for athletes. Yet there are many other preventive and therapeutic strategies such as flexibility and strength training, proprioceptive work, and attention to technique which may offer superior benefits to simple insoles and inserts.\nThe article focused mainly on orthotics compared to no intervention. This might be appropriate for prevention, but a symptomatic patient would also be considering other physical treatments and interventions.\n", "answer": 0}, {"article": "\"This is very encouraging work.\"\nThe experimental therapy eliminated the need for insulin injections for months or even years in 14 of 15 patients who were recently diagnosed with the disease.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\nThe study suggests a new avenue for treating the intractable disease, in which the immune system destroys insulin-producing beta cells in the pancreas.\nThe strategy is similar to an approach showing some success in treating other immune-system disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article discusses the alternate, standard thereapy for type 1 diabetics, which is insulin injections.\u00a0 ", "answer": 1}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\nAlso of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were company comments about qualitative differences among alternative approaches, but no real substantive discussion about comparative outcomes.", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nPeople who have a gastric bypass often have nutritional and vitamin deficiencies, Lenhard said.\nBefore undergoing bariatric surgery, teens and their families receive extensive counseling, Michalsky says.\n\"One of the surprises was that almost all patients benefited as a result of the surgery,\" says M. James Lenhard, the medical director of Christiana Care Health System's Diabetes & Metabolic Diseases Center in Wilmington, Del., who was not involved in the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job here, quoting Geetha Raghuveer, a pediatric cardiologist at Children\u2019s Mercy Kansas City in Missouri who, it reports, was not involved in the study. Raghuveer is quoted saying surgery \u201cwould be considered for the highly obese and those not responding to any behavioral modifications, physical activity or calorie restriction.\u201d Further, the story says, Raghuveer endorses public health efforts that \u201caim for better obesity prevention, including parent education and interventions when children are toddlers and preschoolers.\u201d\n\u201cThe big question is, how do we prevent obese kids from getting to this point where they would need an invasive surgical procedure?\u201d Raghuveer says in the story.", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nZaidi said that both vitamin D and calcium are extremely important for human health, so people should follow the previous vitamin D and calcium recommendations.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story gave some broad contex about other approaches to prevent bone-thinning:\n\u201cTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\nTo reduce the risk of bone weakening, the NIH recommends not smoking, drinking less alcohol and exercising more.\nZaidi said that both vitamin D and calcium are extremely important for human health, so people should follow the previous vitamin D and calcium recommendations.\u201d", "answer": 1}, {"article": "The company\u2019s shares were up 22.6 percent at $4.28 in mid-morning trade after touching a high of $4.90.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\nEvofem is also testing Amphora as a preventive treatment for chlamydia and gonorrhea - two of the world\u2019s most common sexually transmitted infections.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other birth control products, such as male condoms and birth control pills.\nHowever, the story sharply misleads readers by claiming that the positive results with the gel brings: \u201cthe first hormone-free contraceptive close to approval.\u201d That\u2019s simply wrong. Current hormone-free products include male condoms, copper IUDs, diaphragms, and cervical caps.", "answer": 0}, {"article": "# # #\nSCS is reversible and is an important option for chronic pain sufferers who otherwise would rely on opioids or back surgery for relief.\nIdentifying a new intervention that does not rely on paresthesia to mask pain is novel to SCS and has the potential to improve pain relief and quality of life for these complex patients.\nHF10 therapy also provides pain relief without paresthesia \u2013 a stimulation-induced sensation commonly perceived as tingling or buzzing, which masks a patient\u2019s perception of pain \u2013 typical of traditional SCS.\nGiven the prevalence of chronic pain, high frequency SCS is an exciting advance for our patients.\u201d\n\n\n\nSCS is an increasingly common therapy that delivers electric pulses to the spinal cord, through a small device implanted under the skin, for difficult to treat chronic pain in the trunk and limbs.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions traditional SCS, opioids, and back surgery as other approaches to back pain, and notes that they have \u201climited effectiveness and\u00a0commonly known side effects.\u201d But we don\u2019t think this is enough for a Satisfactory grade here. The options for treatment of back pain are much more diverse than just surgery, narcotics, and an implanted spinal cord stimulator, and so in a sense the release is offering a false choice. Other less invasive components of multimodal pain management strategy include exercise, physical therapy, yoga, NSAIDS (e.g. ibuprofen), and behavioral counseling.", "answer": 0}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nIn a series of tests, the Brigham and Women's Hospital researchers also found that the memory of T-cells -- the cells that mount an immune response against invading viruses -- may be more important than the antibodies generated by injected vaccines.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no meaningful, data-driven comparison of scarification delivery of vaccine versus injection. ", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\nThe drug also met all its secondary goals, such as improving symptoms and lung function and reducing the need for standard drugs called beta agonists.\nWenzel, director of the Asthma Institute at the University of Pittsburgh, said other drugmakers have tested medicines that block one or both of the proteins, but without success.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not attempt to compare this drug to other drugs or treatments for asthma. (Olamizumab [Xolair], for example, has been available for a number of years to treat severe allergy and asthma.) Instead, it made glancing references to other drugs, always disparagingly. For example, it quotes the lead researcher saying, \u201cWe have been treating asthma with sort of Band-Aid therapies that didn\u2019t get at the underlying causes.\u201d", "answer": 0}, {"article": "It does lots of testing and flaunts products with scientific terms like microbeads, enzymes and rejuvenating serums.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\nAnd what if the company selling the product did the tests?\nWhile some people will want to see and feel an impact, he said, for many the clinical claim alone suffices.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No need to compare this with other alternatives.\u00a0 This story was all about unsubstantiated claims made for one product.\u00a0 ", "answer": 2}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states that Biaxin is the current standard of treatment for community acquired pneumonia; in fact, there are many others. ", "answer": 0}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nResearchers say current guidelines should be updated to incorporate the scans into routine care.\nHalf of the patients were given a scan called a computed tomography angiogram, or CTA, in addition to standard diagnostic tests.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No mention is made of other non-invasive tests used to screen for coronary artery disease, such as calcium scans, exercise ECG\u2019s, echocardiography, and nuclear heart scans to name a few.\u00a0 These alternatives are named in the published study.", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The research is already comparing two alternatives to babies born prematurely: either administer aggressive, intensive-care treatments or palliative care to keep them comfortable. The story states this fact in the first paragraph.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not explicitly describe whether there are other methods of detecting AR-V7, though it is implicit that AR-V7 has not been used clinically as a biomarker before, and two other companies developing a similar test are mentioned. The\u00a0story is based around whether using AR-V7 as a biomarker could lead to better outcomes than\u00a0current clinical standards, so the comparison to the \u201cstatus-quo\u201d alternative is thoroughly explored.", "answer": 1}, {"article": "Coronary angioplasty is a procedure in which arteries are opened to increase blood flow to the heart.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\n\u201cWe have unequivocal evidence and data that show better outcomes when we access the heart\u2019s coronary arteries and perform angioplasty through a blood vessel in the wrist rather than through the femoral artery in the groin,\u201d said first author Amit P. Amin, MD, an assistant professor of medicine.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The point of the study was to compare variants on angioplasty method, and the release does that clearly.", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In addition to vitamin D supplements, the story mentioned food, supplemented foods, and functional foods (cod liver oil) as well as sun light exposure as options for obtaining vitamin D.\nThe story would have been improved with some explanation of why sunlight exposure is most often inadequate due to latitude and cloud cover in addition to the discussion in this piece about the impact of sunscreen use.\u00a0\n\u00a0", "answer": 1}, {"article": "The Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\nThis study, as well as another published earlier this year, were both conducted by Columbia University Medical Center and sponsored by the National Institution of Health (NIH).\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is not advocating a treatment, per se, but a change in diet aimed at prevention of disease. Other prevention options for those at risk for Alzheimer\u2019s were not discussed. ", "answer": 0}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nThe volunteers took pills once a day for six weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since the story framed this primarily as an anti-aging therapy \u2013 with possible impact on heart disease, stroke and type 2 diabetes thrown in \u2013 it would have been helpful for readers to be reminded about proven approaches to any of these conditions.\u00a0 But the story gave no such comparisons. ", "answer": 0}, {"article": "Special software monitors the electrical activity in your brain.\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nAnd one chapter of the book is devoted to neurofeedback.\nBut other children got a placebo -- a race car that paid no attention to their brain waves.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quotes a researcher who says that two other approaches \u2014 medication and behavior therapy \u2014 have a more extensive research base supporting their use for ADHD compared with neurofeedback.", "answer": 1}, {"article": "It's a substantial number of women,\" Lyman said.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The less extensive sentinel lymph node dissection surgery is clearly compared with the currently recommended axillary lymph node surgery.\u00a0 The article points out that the more extensive surgery did not have a mortality or disease-free survival benefit.", "answer": 1}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes standard Pap smear tests, adding that they do a \u201cpoor job\u201d of detecting endometrial and ovarian cancer. Blood testing for cancer-related biomarkers, such as CA-125, is also noted as well as ultrasound tests of the uterus. The story also notes these are most commonly late-stage tests.", "answer": 1}, {"article": "First published on July 1, 2008 at 12:00 am\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story sketched out two modes of treatment for acute kidney injury which did not appear to differ from one another in terms of outcomes. It was not clear from the story whether one represented standard care or not. \u00a0In addition, there was no discussion of whether there are choices to be made by patients who experience acute kidney injury.", "answer": 0}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nBeing able to identify this lung cancer \u201csignature\u201d through a simple breath test has emerged as one of the most promising ways to diagnose the disease.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release effectively points out that current practice uses periodic CT scans as the method of monitoring the potential recurrence of lung cancer in patients. It states that the breath analysis might be a substitute for the more expensive imaging procedure.", "answer": 1}, {"article": "It develops in four stages.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nWe currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\nThe test detects chemical changes on tiny amounts of \"cell-free\" DNA that are released into the blood when liver cells are injured.\nIn this first stage of research the team developed the blood analysis in 26 patients with NAFLD.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses the new technique and liver biopsies. It doesn\u2019t discuss other techniques, such as the use of MREs or other noninvasive diagnostics (like those discussed here or here or here). How does the proof-of-concept approach discussed in this news release compare to any of these other techniques? It\u2019s not clear.\nImaging tests including ultrasound, CT and MRI can detect fatty changes in the liver, although not necessarily fibrosis. The NAFLD fibrosis score used by the investigators as a comparison test is probably the most useful for detecting fibrosis.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In just an additional line or so, the story could have included something about alternatives for inflammatory osteoarthritis. It also could have mentioned other foods that are rich in anti-inflammatory and anti-oxidant compounds.", "answer": 0}, {"article": "Airways became less likely to close off after exposure to an allergen.\n\"By doing that, we hoped to produce improvements beyond the maximal therapy that these patients with severe asthma are on.\"\n\"Further studies will be needed to assess its utility in moderate asthma.\"\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\n\"It will take years of study to determine the usefulness of this drug in treatment.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We would have liked to see more discussion of the options for treating severe asthma besides the story\u2019s fleeting mention of \u201cnew-wave asthma drugs headed for the market.\u201d", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\nStandard practice is to offer children with autism two tests as a first-line genetic work-up: karyotype and fragile X testing, the researchers said.\nBut that leaves 85 percent or more families with little explanation for the disorder, Marion said.\nCMA detected chromosomal abnormalities in slightly more than 7 percent of patients, making it the best available genetic test for autism spectrum disorders, the study authors said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided data comparing the two standard genetic tests to the newer CMA test. ", "answer": 1}, {"article": "But what about Alzheimer\u2019s?\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of any other approaches under investigation for prevention or delay of Alzheimer\u2019s disease.", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nEven with surgery, there was a high risk of recurrence.\nHe learned surgery is the most common treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses, in brief terms, the risks and challenges associated with surgical treatment options and with other forms of radiation therapy but it makes no effort to compare treatment outcomes.\u00a0The release could have been much more clear that treatment options are surgery vs. \u201ctraditional radiation\u201d vs. proton beam radiation.", "answer": 0}, {"article": "Children with ADHD have trouble paying attention, focusing and can be hyperactive.\nNineteen of those children had a relapse in symptoms on the challenge test.\n\"Measuring IgG levels in kids doesn't seem helpful,\" Ghuman said, but it does look as if the elimination diet may help some children.\nGhuman said that this study doesn't answer a number of questions, such as whether or not the elimination diet reduces symptoms long-term.\nThe researchers selected foods that were considered both low- and high-IgG foods.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Neither story we reviewed (neither this one nor WebMD) did a good job in this area. Some discussion of the success rate of the two standards\u00a0of care \u00a0\u2014 behavioral therapy and medication \u2014 would have strengthened the story.", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is, by its nature, about comparing alternatives. The story looks explicitly at home births compared to births in medical centers; and, among medical centers, the story explains the difference between hospitals and birth centers.", "answer": 1}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\nNewswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\nThe Agency for Healthcare Research andQuality (AHRQ) reported significant improvements in the safety ofmetabolic/bariatric surgery due in large part to improvedlaparoscopic techniques.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes several mentions of alternative therapies including traditional gastric balloon surgery, other newly approved gastric balloon devices, bariatric surgery, weight-loss drugs and diet and exercise.\nThe release also suggests the gastric balloon pill would be an option filling a treatment gap between weight-loss drugs and surgery.\nWhile the release doesn\u2019t offer data on how the gastric balloon pill compared with all these alternative methods, we\u2019ll give it a pass for the frequent mentions of alternatives.", "answer": 1}, {"article": "Recently, he says, urologists \"have begun to realize these criteria are not adequate.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nBut even when researchers allowed for these errors, they found the test doesn't predict how patients ultimately do.\nStill, both study author Reese and Andriole say the new study may serve as a wakeup call to those who are over-relying on the clinical staging system.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included one expert\u2019s perspective that the new study questioning the value of clinical staging \u201cmay not make much difference in the real world\u201d because other tests are used like the Gleason score and the percentage of biopsies that are positive for cancer cells.\u00a0 So some attempt was made to put this into the context of other tests that are used.", "answer": 1}, {"article": ".\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\n\"Depression is common in older adults and more frequent in people with memory problems, vascular risk factors such as high blood pressure or high cholesterol, or people who have had a stroke,\" said study author Laurel Cherian, MD, of Rush University Medical Center in Chicago and a member of the American Academy of Neurology.\nPeople in the two groups that followed the DASH diet most closely were less likely to develop depression than people in the group that did not follow the diet closely.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "One alternative raised in the release is the Mediterranean diet. But the release doesn\u2019t describe the Mediterranean diet or quantify how adherence to that diet was associated with a decreased risk of depression symptoms. Other factors that can contribute to reduced risk of depression aren\u2019t discussed.", "answer": 0}, {"article": "Whole plasma must be matched to blood type.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nResearchers trying to answer the question say they found the treatments are at least safe.\nThe study is a very long way from showing that.\nThere was no measurable effect on memory or thinking, the team told the Clinical Trials on Alzheimer\u2019s Disease conference in Boston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does state flatly that, \u201cThere\u2019s no cure (for Alzheimer\u2019s), and treatments that have looked promising have flopped in big trials.\u201d", "answer": 1}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 There may be significant religious and ethical advantages to freezing eggs as opposed to embryos.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable. The story didn\u2019t really compare egg freezing with other fertility approaches, but that\u2019s OK because it really focused on questions about the egg freezing trend. The story did touch on several advances \"nudging the use of egg-freezing forward\" and on several methods to test the genetic viability of both eggs and embryos. ", "answer": 2}, {"article": "\u201cRemember this day.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nKeytruda, as a sole agent, was targeted only at patients with high PD-L1, making them more receptive to immunotherapy.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\nRival drugmaker Bristol-Myers Squibb had tried a catch-all approach with its Opdivo drug but it failed to help previously untreated patients when given on its own in a trial that included people with low levels of a protein called PD-L1.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The primary message of this story is that Keytruda is superior to standard chemotherapy, as well as to another immunotherapy drug, marketed by Bristol-Myers Squibb, which was also approved by the FDA in 2015.", "answer": 1}, {"article": "\"However, if your child is overweight or obese I recommend that you consult your primary care physician for advice, and consider having their vitamin D levels tested.\"\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\nEarlier this year, researchers in the Netherlands published a study indicating higher levels of belly fat are linked to lower vitamin D levels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives to taking vitamin D to head off some of the symptoms of obesity are noticeably absent. Why aren\u2019t diet or exercise mentioned, at a minimum?", "answer": 0}, {"article": "Visit sirweb.org.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nResearchers found that talimogene laherparepvec (T-VEC)--a genetically modified version of the herpes virus--can be safely administered into active cancer in the liver and stimulate the immune system to destroy cancer cells throughout the body.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\nUsing image-guided needle injections, researchers at centers in the United States, Switzerland and Spain, treated 14 advanced-stage cancer patients with liver metastases, including those with cirrhosis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release rightly quotes the study\u2019s lead author saying that there are \u201climited treatment options\u201d for patients with advanced liver cancer. It notes researcher\u2019s future plans to combine the\u00a0 therapy with a checkpoint inhibitor to activate a stronger immune response.\nThere\u2019s no cure for advanced liver cancer, although chemotherapy and low-dose radiation may be used to slow its spread and relieve pain. The drug sorafenib (Nexavaris) has been shown to improve survival.\nRadiofrequency ablation (RFA), transarterial chemoembolization (TACE), and the targeted therapy sorafenib (Nexavar) may be other options for select patients with liver cancer. For patients whose cancer originated elsewhere and spread to the liver, chemotherapy specific to the primary cancer may be appropriate.", "answer": 1}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\nOne of the patients texted the program 1,217 times.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned a control group that received pamphlets about chemotherapy. It wasn\u2019t clear if that was the current standard method of helping women cope. Also, the story could have explored existing options such as such as online support groups or regular check-ins with a doctor\u2019s office, or\u00a0already existing ask-a-nurse lines that are open all the time for patients.", "answer": 0}, {"article": "For more on losing weight, visit the U.S. National Library of Medicine.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\nIt helped patients in clinical trials lose as much as 13 percent to 15 percent of body weight.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nAfter one year, 47.5 percent of those taking lorcaserin had lost 5 percent or more of their body weight.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Like the other two pieces, it ignores the idea that drugs might not work better than exercise or diet. It took one year on a drug for people to lose 13 pounds on average. That\u2019s a little more than 1 pound a month, and that number dropped considerably the second year. As Katz points out, \"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug\u2026This close look at lorcaserin reaffirms that better daily use of feet and forks holds far greater promise for meaningful, sustainable and affordable weight control than pharmacotherapy.\" That is something that merited more than just a comment from Katz.", "answer": 0}, {"article": "\"It's all these other components,\" Eckel said.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not include information about how this dietary approach to cardiovascular disease and diabetes risk management compared with the use of medication or other dietary approaches. Other studies have compared the Mediterranean diet with a lower carb diet and others, and looked at intermediate endpoints that go along with the metabolic syndrome. This could have been addressed easily in just another line or two.", "answer": 0}, {"article": "\"Many labs are looking at this.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe research results on the new test are published online in PLoS ONE.\nThe only definitive way to diagnose the disease is by direct examination of brain tissue after the patient dies.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nA strength of this story is that it prominently points out that many other potential tests for Alzheimer\u2019s Disease are being developed. The story would have been better if it had explained why some people might choose not to be tested.", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\nThe study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not acknowledge that another shingles vaccine has been in use in the United States since 2006. Although the study results do suggest that GSK\u2019s vaccine is likely to be more effective than the currently used vaccine, the release could easily give a casual reader the impression that no other vaccine exists.", "answer": 0}, {"article": "Dr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nParkinson's is a degenerative neurological condition, for which there currently is no cure.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\nDr Henderson and her team at the University of Bristol studied 130 people with Parkinson's who had fallen in the past year.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While there do not appear to be any pharmacological treatments specifically for preventing falls in Parkinson\u2019s patients, there are non-pharmacological approaches to fall prevention including certain exercises, making adjustments to home environments, modification of medications and multi-pharmacy, walking aids, and more. The release does not mention these. In addition, the drug amantadine (aka Symmetrel) has been used to address muscle rigidity (which can lead to falls) in Parkinson\u2019s disease patients.", "answer": 0}, {"article": "Calcineurin is an enzyme that regulates communication between brain cells and memory formation.\nA new study from The University of Texas Medical Branch at Galveston has revealed that a treatment taken daily by people who have had organ transplants to prevent organ rejection protects against Alzheimer's disease.\nCompelling evidence shows that toxic protein aggregates called A\u03b2 oligomers selectively target and disrupt the points of communication between brain cells, impairing memory in people suffering from the disease.\nHowever, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\nUsing a mouse model of Alzheimer's, the researchers earlier showed that blocking calcineurin restored memory function.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The Alzheimer\u2019s association lists a host of strategies that may lower risk of developing dementia. \u00a0These include exercise, socialization, blood pressure control and the like. In addition, there is an ongoing randomized clinical trial of anti-amyloid drugs in high risk patients.", "answer": 0}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nThe trial's researchers were careful to list indications of possible harmful side effects, such as a reduction in levels of HDL (\"good\") cholesterol, Califf said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since results were not quantified in the story, we really don\u2019t even learn how the drug compared with statins alone. ", "answer": 0}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nLange said the findings should help make the process of diagnosing autism more scientific because it would rely on a test rather than a subjective assessment.\nThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At the present time there are no biologically based tests for autism. The diagnosis is made on the basis of subjective signs and symptoms. Unlike the CNN story we reviewed, this story makes no attempts to provide information on existing diagnostic testing.", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nAn international team of researchers from University Hospitals Leuven (Belgium), Sophia Children's Hospital Rotterdam (The Netherlands), and Stollery Children's Hospital Edmonton (Canada) has now challenged the validity of this common practice.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release is about a comparative study between early and late parenteral feeding upon admittance to an ICU.", "answer": 1}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe drug is associated with some serious side effects.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The company president may say that \"Krystexxa is the first-ever and only treatment approved by the FDA for adult patients who suffer with chronic gout that is refractory to conventional therapy\" but a good news story would explain:\u00a0", "answer": 0}, {"article": "Type 2 diabetes, which is often tied to obesity, affects about 8 percent of the U.S. population, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0While the last line of the story mentioned exercise and diet, there was no context for readers to evaluate how coffee and tea consumption compared to these strategies for reducing the chance of developing type II diabetes.", "answer": 0}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned means, other than the featured products, for obtaining recommended levels of vitamin B-6 and B-12.", "answer": 1}, {"article": "\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nIt could be several more years before the patch will be available for consumers.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\nFor those plagued with peanut allergies, protection may eventually come in the form of a patch worn on the skin, a new study suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story makes no overt effort to compare this intervention with alternatives, it does allude to such strategies as \u201coral or under-the-tongue therapy.\u201d We\u2019ll call this a borderline satisfactory.", "answer": 1}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nIt showed that patients with recurrent ovarian cancer treated with the drug got an extra 15 months without their disease getting worse, compared to a control group.\nA small pilot study on a drug called talazoparib, which is now owned by Pfizer, recently showed similarly compelling results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that an existing drug of this type, Lynparza, is being used to treat advanced ovarian cancer in women who have undergone chemo. The story attempts to compare the three drugs under development, but we do wish more data and commentary had been included so readers get a better sense of where each drug stands, and what makes them unique (or not).", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no comparison of the circumference reduction obtained with the devices either to each other or to other protocols.", "answer": 0}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned other therapies in passing. \u201cBesides dietary restriction, medication and behavior therapy are used to treat children with ADHD.\u201d But, given that existing therapies have been around for decades, we think the story does not meet our bar, which requires \u201csome assessment of their relative performance.\u201d", "answer": 0}, {"article": "Nonetheless, the doctors were pleased when M.R.I.\nBut a scan found a brain tumor nearly the size of a golf ball.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\nDr. Boockvar said microcatheters should increase the odds of success by delivering a high dose of the drug directly to where it was needed most.\nEach patient would receive just one treatment directed into the brain, followed weeks later by a series of intravenous treatments with Avastin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the conventional treatments for glioblastoma\u2013surgery, radiation and/or chemotherapy via pill or IV. ", "answer": 1}, {"article": "www.petermunkcardiaccentre.ca\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThe system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient.\nThis technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Heart failure is treated in a variety of ways and depends on the type and severity. Clinicians first treat its underlying cause, whether it be high blood pressure, coronary heart disease or diabetes. This may include lifestyle changes, such as increasing physical activity, reducing weight, quitting smoking and eating more heart-healthy foods.\nPhysicians may prescribe medications, such as ACE inhibitors, beta blockers and diuretics, so that the heart won\u2019t work as hard and that fluid won\u2019t build up in the lungs.\nIn severe cases, heart failure is treated with surgery, such as a heart transplant, or with the implantation of a device, such as a pacemaker, a left ventricular assist device or an implantable cardioverter defibrillator.\nSince the news release doesn\u2019t touch upon any of these alternatives, we give it a Not Satisfactory here.", "answer": 0}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nIn addition, the long-term effectiveness of the grass-pollen tablets is not yet fully clear.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\nNo sublingual immunotherapy products have yet been approved in the United States, however.\nStill, Nelson said that if sublingual products do win approval in the U.S., they will likely boost the number of hay fever sufferers who want to use under-the-tongue immunotherapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story discusses alternative approaches for treating grass-pollen allergies, specifically antihistamines and allergy shots.\u00a0 \n", "answer": 1}, {"article": "HIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nThe article recently appeared in the Journal of Controlled Release.\nThe implants were tested in an animal model and the team observed a significant reduction in T cell activation, meaning that the vaginal tract was demonstrating an immune quiescent state.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release briefly mentions \u201cconventional methods of HIV prevention, such as condoms or anti-HIV drugs.\u201d\nGiven the preliminary nature of this experimental device it\u2019s unlikely the authors can conclude how effective this vaginal implant is in comparison to these well-studied, conventional approaches. But mentioning how effective condoms and anti-HIV medications are might have been helpful context.", "answer": 1}, {"article": "They were then randomized to receive either Forteo or a placebo.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\nThe second paper involved 40 patients with severe gum disease that had affected their jaws, all of whom first underwent surgery on their jaw.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article notes that bone grafts are the most common treatment for the form of gum disease-related bone loss assessed in the small study. That, however, does not constitute a comparison or an acknowledgement that the pros and cons of Forteo relative to this existing treatment are unknown. Nor does it provide information about other alternatives, such as the existing therapies for osteonecrosis.", "answer": 0}, {"article": "Feifel charges about $500 for each injection and $1,000 for an intravenous infusion, which takes effect more quickly.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nIt found that current antidepressants really aren't much better than a placebo.\nThen one day, while investigating depression on the Internet, Paul discovered the research on ketamine.\nAnd Paul has spent much of his adult life searching for a treatment that would give him some relief.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story seems to have two different standards for summarizing study evidence. Even as the story highlights the potential benefits and minimizes harms of ketamine, it dismisses conventional treatments saying a major study concluded \u201ccurrent antidepressants really aren\u2019t much better than a placebo.\u201d\u00a0For the severe depression mentioned in the story, there is evidence that antidepressants are quite a bit better than placebo.", "answer": 0}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\nAfter several years of testing in her lab, Griffith began collaborating with Swedish eye surgeon Per Fagerholm of Linkoping University, who implanted the engineered collagen corneas into the 10 patients in Sweden.\nIt has been 10 years since Griffith and colleagues first reported the development of a material with the potential to grow healthy new tissue in people with damaged corneas.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the biosynthetic corneas both to human corneas and to plastic corneas. It is the only story of the three to even mention plastic corneas. Other alternatives could have been explored.", "answer": 1}, {"article": "AMD, the No.\n\"Showing that L-DOPA causes this protective effect will require further investigation, but if confirmed, could lead to new drugs or combination therapies for AMD that target DOPA-responsive cells in the retina.\"\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\nMARSHFIELD - A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned. While there is no known effective cure for AMD, there are treatments available to slow the progression of the disease or prevent severe vision loss including drug injection, laser therapy and vitamin supplementation.", "answer": 0}, {"article": "Another approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nThe revised guidelines are expected to reduce the cost of screening, the cost per life saved and overall deaths from prostate cancer.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not describe the option of no screening, nor does it describe all treatment options if prostate cancer is diagnosed, such as watchful waiting or radiation (in addition to surgery that it does breifly mention).\u00a0 ", "answer": 0}, {"article": "\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nIn its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of explaining how lung cancer is detected by existing CT scan and bronchoscopy, and discusses the exposure of the patients to some risk during these procedures.\u00a0Where it fails is in giving us numbers for how the earlier detection might show an increase in survival for patients.", "answer": 1}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nAfter six months, patients with the Obalon balloons had them removed.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\nThe balloons made patients feel full, the researchers explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes discussion of weight loss surgery and lifestyle interventions. It includes a quote noting that the Obalon device does not require patients to be sedated during insertion, which implies there are other similar balloon devices, though the story would have been better if it specifically noted that there are already two very similar devices available in the U.S. as well as other balloon devices that are for sale in other countries. It also could have pointed out that these results don\u2019t appear more effective than an intensive\u00a0behavioral program.", "answer": 1}, {"article": "For further information, please visit www.nucleix.com.\nTo date, there is no adequate screening process for the early detection of lung cancer, bringing 5-year survival rate to approximately 15%.\nTherefore, a screening test aimed at the entire risk group to assist in the early detection of the disease is highly needed and can dramatically increase lung cancer survival.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\nThe Lung EpiCheck blood test is based on a proprietary molecular biomarker technology, which combines new biochemical assays and sophisticated algorithms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes alternatives to the blood test include the standard CT scan.\nCurrently, early stage lung cancer can be detected either accidentally, when testing for other conditions, or by using low-dose CT scans, which are costly, carry associated risks such as high radiation, and are employed only for a very high-risk population.", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nIt\u2019s hard to test for gluten sensitivities.\nIf you think avoiding gluten will make you feel better, there is a reasonable chance that it will \u2014 even if gluten is irrelevant.\nFor those of you keeping track at home, that means that while 30 percent of Americans are trying to cut gluten from their diet, probably at most only 1 percent of Americans may have NCGS.\nBut let\u2019s say you take heart in the first of these studies and now believe that avoiding gluten will make some people feel better even though they don\u2019t have an allergy or celiac disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main options here seem to be a diet with or without gluten. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Dr.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\nDr. Ahlquist said he was very pleased with the new results, especially the 64 percent detection rate for precancerous polyps, since these are best targets for intervention.\nThe practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\n\u201cWith stool tests, you need a 90 percent specificity,\u201d said Dr. Bert Vogelstein, a cancer expert at Johns Hopkins University who is also an adviser to the company.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted in the \u201cbenefits\u201d criterion above, this story did not even discuss other stool tests like fecal immunochemical testing or other fecal occult blood tests that are currently available and have been shown to perform well in appropriate samples.\u00a0 It did a decent job in comparing two new technologies, but got hung up on this comparison while forgetting existing tests.\u00a0 In so doing, the end of the story devolves a bit into a \u201cmy product is better than your product\u201d tit for tat. Which is what can happen when your only quoted sources all have connections to the companies involved.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were no options presented for either maintaining bone mineral density or for treating low bone density. The only treatment recommendation within the story was for balancing phosphoric acid consumption with calcium rich foods; it would be more useful to present this in a more readily understandable format for readers to act upon if they so desired.", "answer": 0}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nIt could be that the whipworm larvae weren't prepared correctly.\nIt may depend on a person's genes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention how parasites compare to existing treatments for autoimmune diseases in terms of safety, efficacy or cost.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nRight now, Scharre noted, medications for Alzheimer's target brain chemicals involved in memory.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nAll three patients were in the earlier stages of Alzheimer's and were on standard medications.\n\"It's not something patients can ask their neurologist for.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that \u201cmedications for Alzheimer\u2019s target brain chemicals involved in memory.\u201d", "answer": 1}, {"article": "That accounts for a small percentage of people.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\nThe test detects only three out of more than 1,000 known BRCA mutations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story may actually confuse readers on this count. The story says: \u201cThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\u201d That\u2019s awkwardly phrased. It would be more accurate to say that this is the first test you can get without a prescription that reports on these three mutations. 23andMe is not the only company that provides genetic testing for BRCA mutations, and the story does not make sufficiently clear to readers that there are other genetic tests available that evaluate a broader range of potential mutations. It\u2019s just that these other tests aren\u2019t made available directly to consumers.", "answer": 0}, {"article": "\u201cI used to be so irritable because I was so uncomfortable,\u201d Joyce said.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nVolunteers using the toothpaste were also required to log their usage in a journal.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nBoth groups reported a significant decrease in their symptoms, including Joyce, who was in the toothpaste group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that normal treatments incorporate shots or drops of allergen extracts as a way of sensitizing patients.It also mentions medications.\nWe\u2019ll award a minimal Satisfactory on that basis, but we\u2019d note that it\u2019s not clear how long the participants used the toothpaste before they started to see a decrease in their symptoms. Usually allergy medication works anywhere from 30 minutes to a few hours to a few days. We saw no comparison on this factor between the toothpaste and regular allergy medication.", "answer": 1}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\n\u201cIt will be important to let patients know that fertility will have declined greatly in the years preceding the final ovulation.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no mention of any existing alternatives, of which there are several.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nTumor growth rate was also significantly slower in the walnut group compared to the control group.\nAs this study was conducted on animals, results cannot yet be implied for humans.\nAfter 25 days, researchers found that in walnut-fed mice, key miRNA that may affect cancer cell inflammation, vascularization (blood supply) and proliferation were positively engaged.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses the chemistry of inflammation and the growth of tumors in the mice. It briefly mentions \u201cdiet and lifestyle changes\u201d as means to reduce risk, but does not discuss what specific changes are shown to be helpful. It also does not discuss screening and polyp removal, arguably the best-supported intervention for catching colon cancer before it spreads.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story offered good comparisons in its broad-ranging discussion of treatment options.\u00a0 We only wish there had been a more direct discussion of not being treated, perhaps profiling someone who chose to forego treatment. And it did not mention the host of topical and oral drug treatments currently under study.", "answer": 1}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nThe skin still has to be able to breathe through this stuff.\nWe saw that as a very high bar.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story credit in this rating\u00a0since it mentioned current practices in treating dry skin, one of the touted uses of this new product, and explains how those current practices are less than optimum. It doesn\u2019t however mention that surgery is the common approach to addressing undereye bags.", "answer": 1}, {"article": "\u201cIt felt as though my head was a cement block,\u201d Kaufman told NBC News.\nThe aim of the medication is to stop a migraine before it even starts.\nAccording to UCSF Medical Center, more than 35 million Americans suffer from migraine attacks.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nMost migraines are benign, although they can be disabling.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions some alternatives, but only to discuss how they don\u2019t work and/or carry side effects. This is a particularly important shortcoming. There are several medications that can be used effectively for patients with chronic migraine to prevent their occurrence, including beta blockers, calcium channel blockers, and some medications used in seizure disorder. \u00a0Some patients are also able to prevent migraine by careful lifestyle changes, like avoiding changes in caffeine consumption, alcohol (particularly wines), foods, and irregular sleeping habits.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nOf that group, 85 percent had small tumors that had not spread.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\nIn the ensuing years, about 27,000 more scans were done, with some people having them annually.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions x-rays and no screening as alternatives to CT scanning.", "answer": 1}, {"article": "Right now, the work done by Topakian's group is still \"experimental,\" he said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nNonetheless, some experts said that research suggests that patients with no symptoms are better off without the surgery.\nIn addition, over the two years of the study, 10 people had TIAs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Sorting throught the quotes from experts, it would seem that the combination of ultrasound tests could be used to better predict those individuals at lower risk who would be best off managed with medical therapy; and to better predict which individuals stand to benefit the most from surgery because their risk was higher.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story takes a broad view, and looks at the evidence for using testosterone for a number of conditions. Given that, it would be tedious to try and discuss all the alternatives.", "answer": 2}, {"article": "\"This is really the gold standard.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nAccording to data submitted to the FDA, the test detects each virus 78% to 100% of the time, depending on the type, and has few false positives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article covers all of the bases on treatment diagnosis and treatment option.\u00a0 The flu can be diagnosed based upon clinical observations of signs and symptoms or by other available\u00a0flu tests.\u00a0 Treatment options, flu medicine, antibiotics or no treatment, are clearly indicated.\n\u00a0", "answer": 1}, {"article": "The American Heart Association has more on heart failure.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nThe enzyme regulates calcium cycling, which, in turn, is involved in how well the heart contracts, the researchers said.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than saying that one goal of this line of research is to provide an alternative to heart transplants, the story does not describe the alternative treatments available to people with heart failure. For example, even when drug therapy loses its effectiveness, some heart failure patients are receiving heart assist pumps for long-term use\u2026 so there are approved alternatives to a heart transplant for some patients like those in this trial. The story should have included that fact. ", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although quantification is mostly missing, the article properly points out that clinical judgment-based treatment alone misses the mark a lot of the time, and is essentially educated guesswork. The article might have been strengthened even more had it given information about alternatives or adjuncts to drugs, such as behavioral therapy and electroshock therapy.", "answer": 1}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions a grab-bag of \"lifestyle changes\" but does not do anything to describe what they involve (do you have to do them all?)\u00a0or the pros and cons of the different options.", "answer": 0}, {"article": "But Johannesdottir added that \"we hope that our finding will inspire more research on skin cancer prevention.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\nMeanwhile, Dr. William Ting, a private practice dermatologist in San Ramon, Calif., praised the study despite agreeing that many factors are at play when it comes to skin cancer formation.\nThe authors noted that prior work supported the notion that NSAIDs may offer some measure of protection against cancer (most notably colorectal cancer), by specifically impeding the cancer-causing activities of COX-2 (cyclooxygenase) enzymes.\nThe study appears in the May 29 online issue of the journal Cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions sun protection as a key method of preventing skin cancer.", "answer": 1}, {"article": "Most of the time, concussion testing in youth sports falls to volunteer coaches or parents with little if any medical experience.\nThe pace-along-the-tape test was also relatively accurate.\nBut it had not been evaluated for use in young athletes.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nEye tests can tell evaluators a great deal about how well someone\u2019s brain is working.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The most commonly used testing method \u2014 the\u00a0Standardized Assessment of Concussion \u2014 which measures cognition and a timed tandem gait test of balance were part of the research being reported and were described in the story.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a real strong point for the story. The story not only describes multiple other surgical options, as well as hormone treatments, but notes that many patients can wait until menopause, when changing hormone levels can mitigate problems associated with fibroids.", "answer": 1}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\nXeljanz targets certain proteins involved in the body's inflammatory and immune responses that other so-called biologic drugs don't, the researchers said.\nIn the first trial, nearly 19 percent of the patients taking Xeljanz experienced a remission of their condition in eight weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This one is a close call. The story makes clear that Xeljanz is given in pill form, as opposed to infusion or injection, which is a point worth making. It also notes that the trials only involved patients for whom existing pharmaceutical treatments had failed. In addition, the story tells readers that patients don\u2019t develop antibodies to Xeljanz, as they do with other pharmaceuticals in the same class of so-called \u201cbiologic\u201d drugs.\nThe story does not, however, explain to readers why antibodies are important or relevant to the treatment process. The story\u00a0also doesn\u2019t mention surgical treatment options, which involve removing the colon and rectum. Ultimately, however, the story does a very good job of placing the drug\u2019s potential use in context. One source, for example, notes that there is still far too much uncertainty to recommend making Xeljanz the first line of treatment, while another describes it as a potential \u201crescue therapy\u201d when other options fail. Altogether, the story is more good than bad on addressing alternatives.", "answer": 1}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story is about screening for Alzheimer\u2019s, so it would have been useful to talk about other efforts to develop screening tools (and the lack of effective ones) or methods currently used to diagnose the condition.", "answer": 0}, {"article": "Fibromyalgia is a syndrome marked by widespread pain \u2014 including discomfort at specific \u201ctender points\u201d in the body \u2014 along with symptoms such as fatigue, irritable bowel and sleep problems.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\nThe therapy involves an educational component where patients learn about the emotion-pain connection.\nIn addition, the control group received no active therapy to serve as a comparison.\nSchubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other common approaches to treatment, including painkillers, antidepressants, CBT and exercise therapy. It also provides some discussion of the overlap between CBT\u00a0and affective self-awareness, both of which focus on recognizing and modifying\u00a0maladaptive responses to emotions and thoughts.\u00a0For comparison purposes, we think it would have been interesting to hear how these other therapies have performed in similarly designed studies of fibromyalgia pain. Nevertheless, the story does enough to earn a satisfactory.", "answer": 1}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nThe incidence has more than doubled in developed countries in recent decades.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Aside from avoidance of maternal smoking, there are no known ways to reduce the risk of developing asthma in childhood. The story explains this is why doctors are testing this method, and excited by the findings.", "answer": 1}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\nThe infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares a range of methods for alleviating vaccination pain in infants \u2014 training parents on how to soothe a child, giving the child sugar water, and applying lidocaine cream. We\u2019re not told the contents of the training video but presumably it focused on holding, verbal soothing and nursing. In its practice guidelines, the CMAJ recommends breastfeeding during a vaccine injection to mitigate pain in infants.", "answer": 1}, {"article": "\"Men need to learn as much as they can about the possible outcomes and benefits of the various treatments and the potential side effects, and choose which direction they are most comfortable with,\" Brooks said.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\nBrooks said more comparative effectiveness research, which compares different kinds of treatments, is needed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was about a systematic review of studies comparing different doses of radiation and different types of radiation therapy \u2013 and whether any has been shown to be a better option than \u201cwatchful waiting.\u201d", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Many alternatives are mentioned, and that\u2019s enough to skirt by as Satisfactory.\nHowever, the discussion of alternatives (such as antiperspirants and Botox injections) seems mostly to revolve around pointing out how problematic they are, without any discussion of actual comparative effectiveness, which is a disservice to readers.", "answer": 1}, {"article": "Dr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\n\"These results represent an important step toward a new treatment option for patients with ADHD.\nThe CGI-I is a standardized assessment tool that allows clinicians to rate the severity of ADHD illness, change over time and efficacy of medication.\nOnce the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.\nIncluding study 305 and previous studies, Shire now has a robust database of 15 clinical studies evaluating SHP465 in more than 1,100 subjects.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the news release mentions the existence of other drugs, this new drug is not compared to any of them but to placebo and a symptoms standardization tool.", "answer": 0}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story simply stated that \u201cKeytruda, when compared to chemotherapy, enabled certain patients to live longer.\u201d \u00a0No basis for that comparison was provided.\nA review of this class of drugs pointed out that another PD-1 inhibitor, Bristol-Myers Squibb\u2019s Opdivo (nivolumab), has also shown to improve survival (albeit marginally) in gastric cancers.\nIn addition, Endpoints News noted that another PD-1 drug is being tested by Celgene and BeiGene to treat esophageal and esophagogastric cancers.", "answer": 0}, {"article": "Dr. Andrew Adesman is chief of developmental and behavioral pediatrics at Cohen Children's Medical Center of New York, in New Hyde Park, N.Y.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n\"Children with autism typically receive treatment beginning at 3 to 4 years old,\" he explained.\nThe research involved 54 families of babies who were at increased risk for autism because they had an older sibling with the condition.\nUsing the therapy during the baby's first year of life may \"modify the emergence of autism-related behaviors and symptoms,\" lead author Jonathan Green, a professor of child and adolescent psychiatry at the University of Manchester in England, said in a journal news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any of the other therapies for treating children with ASD, which include behavioral modification therapies and medications, or the pros and cons or costs of these different therapies.", "answer": 0}, {"article": ".\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\nAccording to the authors, scientists and practitioners continue to explore the use of alternative therapies in the prevention of common infections as part of the global movement to reduce antibiotic use and resistance.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a number of lifestyle changes, in addition to modifying one\u2019s cranberry consumption, that can reduce the risk of UTIs. For example, increasing one\u2019s water intake or changing one\u2019s form of birth control.\nIn addition, there are medical interventions such as use of vaginal estrogen preparations (for post-menopausal women) and taking an antibiotic preventively after intercourse.", "answer": 0}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does suggest in the first paragraph other approaches to improving semen quality.\u00a0 \u201cAmong the most (advice) dispensed: eat a healthy diet, keep a healthy weight, avoid alcohol and tobacco and stay away from certain medications, such as blood pressure and depression drugs.\u201d", "answer": 1}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nBut no matter where you live, surgery is not necessarily the best or only option.\nHe says his intent was not to put some orthopedic surgeons out of business.\nWhether you have surgery often depends on where you live and what doctor you see.\n\"It was just to find the truth for patients.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions various kinds of non-operative care, including physical therapy, medications and steroid injections, as the alternative to surgery.", "answer": 1}, {"article": "de Rooij, PhD, Patricia J.F.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nHowever, prior to this study there has been a lack of randomized controlled trials with a long-term follow-up that compare the effectiveness of noninvasive treatments.\nConsequently, there is no consensus in international BCC guidelines on the first choice of noninvasive therapy for superficial BCC.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study notes that several topical agents are available in addition to surgery. It might also have mentioned that surgery can be done as a one time thing and probably has better outcomes.", "answer": 1}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story indicated that the CCTA was a possible non-invasive alternative to a cardiac catheterization. \u00a0While this may be true in certain circumstances, neither test is recommended for the population of individuals who were in the study. That point could have been emphasized more clearly.\nThe story could have reported on the fact that the researchers did not report the effect of coronary calcium scores (information that the researchers collected but did not feed back to patients and providers); that is the test most often touted for coronary heart disease screening in asymptomatic people.", "answer": 0}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nThe Hopkins work was described as \"outstanding\" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.\nIt is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.\nCurrently, identifying the dangerous tumors in that group is no better than \"a coin-flip,\" Veltri said, and, as a result, many men and their doctors choose treatment that might be unnecessary and can cause impotence and other major problems.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The existing alternative is to use the PSA test, digital exam, and biopsy results to determine whether a man should consider aggressive treatment. The story does not indicate how much more accurate the new test was compared to PSA. The glib comment about a coin flip does not necessarily accurately characterize the study results.\nPerhaps the story also should have told readers that there are other companies with similar sorts of tests in development.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story, in describing the study, makes clear that management of angina pain with medication is equally effective in these kinds of patients.", "answer": 1}, {"article": "The American Heart Association reports that more than 80 percent of smokers say they want to quit.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\nTherefore, quitting leads to a quick drop in endorphin levels, he said.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\nBut the government organization had only dealt with drugs - not new technology - for smoking cessation, which has slowed down the process, Camera said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job placing the therapy into the larger context of interventions to help people quit smoking, particularly acupuncture.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nThat study found a benefit when 5-Hour Energy was compared to a placebo like flavored water, she said.\nThat mark, which also appears on the back label, explains in fine print that \u201cno crash means no sugar crash.\u201d\n\nThat is hardly surprising, because 5-Hour Energy does not contain sugar.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Aside from caffeine, we\u2019re not sure that there are any other legal means of increasing alertness. We\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\"They take them because they have a disease that impacts their daily life,\" Economy says.\n\"So for women with severe debilitating depression that is not responsive to other non-pharmacological treatments, this should be reassuring information.\"\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Two\u00a0choices are presented in this story for pregnant women who suffer from\u00a0depression:\u00a0take SSRIs or don\u2019t. But that leaves out a third possible choice, mentioned in the study, which is to take a non-SSRI antidepressant. The story could have earned a Satisfactory by mentioning that alternative, or at least providing more information about the complications pregnant women might face if they\u2019re depressed and not taking an antidepressant.", "answer": 0}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis new approach places them right on the scalp.\nWhen Detective Thomas Tobin was busting bad guys for the New York City Police, he never imagined that his toughest adversary would turn out to be \u2026 pain.\nNow he's trying something that might seem shocking: an electrical current applied to his head - part of a clinical trial at Beth Israel Medical Center in New York.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reporter does an excellent job at the end of the piece describing the wide range of treatments used for serious chronic pain\u2013and that multiple approaches are often required. \nHe also makes clear that TDCS would be one treatment to add to the arsenal, not a breakthrough that would make other options obsolete. ", "answer": 1}, {"article": "\u201cAnd it might be of some help.\u201d\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nBut the new study, which mainly assessed full-term babies, found no cognitive difference at 18 months whether mothers received DHA supplements or placebos.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was only a brief mention of alternatives on the postpartum depression issue \u2013 and that in the very last line: \"\u201cThere\u2019s no harm that we know of at all, in contrast to many antidepressants\"\u00a0\u2013 according to one doctor.\u00a0 But that is insufficient context and comparison. \nDitto for this issue:\u00a0 \"Some studies, including the new report, suggest DHA supplementation in pregnancy reduces the likelihood of premature birth.\"\u00a0 But how does this evidence (no data given in the story) compare with other attemtps to do the same thing?\u00a0", "answer": 0}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\nHoney may suppress cough because its sweetness causes salivation that coats the throat, authors of the study suggested.\n\"I would be reluctant to routinely recommend to all parents that they give honey, because in some rare cases children can have reactions to honey.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions cough medicine as the alternative.", "answer": 1}, {"article": "But the evidence that pot smoking actually helps with spasticity has been anecdotal.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\n\u201cI think this study shows that yes, (marijuana) may help with spasticity, but at a cost,\u201d said Corey-Bloom, of the University of California, San Diego.\n\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that the marijuana was used in subjects who had failed to get better with standard medication.", "answer": 1}, {"article": "\u201cThere is a lot more to be done to fill in the research on the biological mechanism,\u2019\u2019 Dr. Horne said.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nBecause about 90 percent of the patients were Mormons, a faith that encourages its members to fast for one day a month, the doctors expected to find a relatively high rate of regular fasting among the study participants.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Another mixed bag, but with a confusing message that warrants an unsatisfactory grade.\nThe story points out that one of the limitations in the study may have been that its subjects \u2013 Mormons \u2013 abstain from alcohol, smoking and caffeine \u2013 all factors that could affect heart health.\nBut later in the story it allows the researcher to say \u201cwhat it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\u201d\nHuh?\u00a0 That seems to convey some independent protective effect that the study simply can\u2019t prove.\u00a0 And it seems to minimize the other confounding factors acknowledged earlier in the story.", "answer": 0}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\n\"The results are very encouraging, given the great need for additional treatment options for depression, and our finding that magnesium supplementation provides a safe, fast and inexpensive approach to controlling depressive symptoms.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release makes some statements suggesting magnesium supplements are as effective as SSRI anti-depressants and offer lower cost and fewer side effects. No evidence is offered for this and the study was far too small and too brief to demonstrate magnesium effectiveness.\u00a0\nThe release should have delved into this area more,\u00a0especially\u00a0because there are so many current treatments for depression. For example, the release offered no mention of other classes of anti-depressant medications or non-drug interventions like cognitive behavioral therapy.\u00a0\u00a0", "answer": 0}, {"article": "Other Northwestern authors are senior author Dr. Ronald Ackermann and co-authors Mercedes Carnethon and Dr. Namratha Kandula.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nBy following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened.\nBut there has been little attention focused on this group's most recent diabetes screening guideline.\nBy following the limited guidelines and only screening patients who are overweight or obese, approximately 30 percent of Asians with prediabetes or type 2 diabetes would be identified.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Are there alternatives to \u201cscreening?\u201d That might be a philosophical question, but one has to ask if there is an overall health benefit to more intensive screening. We\u2019re told that \u201clifestyle programs and some medications have been proven to prevent or delay type 2 diabetes among adults with prediabetes,\u201d though that\u2019s a topic under debate by experts. We also learn that \u201ca large volume of research over the last three decades has demonstrated that treating type 2 diabetes prevents life-threatening complications such as heart attacks, strokes and kidney failure.\u201d But some experts argue that the only proven action that prevents complications are lifestyle changes. The majority of drug and insulin interventions come from trials showing that they can alter sugar levels, but there is very little evidence they prevent complications in type 2 diabetics.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\nAnd I do a little twitch with my muscle in here.\n\"I've always compared it to being like a toddler learning how to, you know, walk, write, eat.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternative treatment options, such as physical and occupational therapy. It isn\u2019t clear what additional benefit the device has provided beyond standard physical and occupational therapy. Time also can have a helpful effect. It isn\u2019t clear what is the relative contribution of this new device versus standard care. ", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nThe potential market is huge: It\u2019s estimated that 50 million Americans have allergies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is acknowledgment of the possibility that the new treatments may not work any better than older ones for many patients. The story would have been stronger if it had done more head-to-head comparisons of effectiveness.", "answer": 1}, {"article": "Keytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\nUsually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway.\nThe researchers wanted to see how it worked against the standard chemotherapy cocktails.\nIt helped patients live longer overall and helped them live longer without their tumors growing or spreading, Merck said.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does talk about the alternatives to this drug, and the \u201cso-called standard of care.\u201d But it does not provide any numbers to back these comparisons up. There\u2019s a dilemma here because Merck did not release the details of the study. We would have been happy, though, even if the story made mention of some of the comparison findings from other studies. The drug is approved for treatment in lung cancer, so there must have been previous trials that could be referenced.", "answer": 0}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nTamoxifen is the only hormonal option for women before menopause, Litton says.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\nStudies show that only 80% of women take tamoxifen for five years, Litton says.\nGray noted that tamoxifen has risks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The two women with breast cancer who reviewed this story found one good point, one weak point in the story on this criterion:", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The clinical trial trial itself involved multiple alternatives: yoga, aerobic exercise and stretching, and a self-care educational intervention involving activity and lifetyle modification.\nSo that probably fulfills this criterion.\n \n", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\nA five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release correctly states that behavioral therapies, the standard treatment for autism, are time-intensive, costly and sometimes offer minimal benefits.", "answer": 1}, {"article": ".\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nThe association makes no representation or warranty as to their accuracy or reliability.\nThe Dallas-based association officially launched in 1998 as a division of the American Heart Association.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does a good job of explaining the comparison of doing the procedure between 6 and 24 hours after a stroke and not doing it. Theoretically, they could have compared the procedure to clot-busting medication which is sometimes used in these settings, but that would have been a different study altogether.", "answer": 1}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nSince mindfulness meditation may have different effects on different mental struggles, the challenge for its proponents will be to specify where it is most effective \u2014 and soon, given how popular the practice is becoming.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does an excellent job describing the practice of mindfulness mediation, as well as the utility and purpose of mindfulness therapies in a clinical setting. The notes that mindfulness is typically compared with\u00a0 traditional cognitive therapy, another treatment option. The sidebar listing meditative therapies and evidence of their relative benefit is an excellent addition to the article. ", "answer": 1}, {"article": "John Farrell, 70, of Valparaiso, Ind., had severe back pain and needed surgery this summer, but his cardiologist said that blockage of his coronary arteries need to be fixed before he could undergo the back operation.\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article indicates that conventional bypass and stenting are alternatives to the robot-assisted surgery. ", "answer": 1}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nTraining deep-learning models on data from more than a quarter of a million patients, the scientists were able to predict the cardiovascular risk factors that were not previously thought to be present in retinal fundus images.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions cardiovascular risk calculators, which use parameters such as a person\u2019s gender, smoking status, blood pressure, and age.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the  paper states.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Most doctors opt for screening women for cervical cancer more often than guidelines suggest, according to a new study.\n\u201cThere\u2019s really no advantage to annual screening compared to screening every two or three years,\u201d lead author Katherine Roland told Reuters Health.\nWomen should talk to their doctors about screening, especially if they think they are being screened too often, researchers added.\nIn addition, Roland added, some doctors might be afraid of missing very early cervical cancer and getting sued if they screen less frequently.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Comparison of screening intervals was at the heart of the story: \u201cThere\u2019s really no advantage to annual screening compared to screening every two or three years,\u201d lead author Katherine Roland told Reuters Health.", "answer": 1}, {"article": "As rates of sugar-related disorders such as diabetes, obesity and heart disease climb, many experts believe that when Americans rid themselves of fat, they simply replaced it with sugar in all its forms.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nBut that the rise of the chronic diseases was actually linked to higher sugar consumption is a challenge.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did a fairly good job of describing the limitations of previous dietary studies, compared to this one, especially as it relates to the effects of cutting sugar vs. losing weight.\u00a0It would have also been helpful to mention the role of exercise in controlling metabolic disease.", "answer": 1}, {"article": "Among the 620 adults (average age, 71 years; 74 percent women) who were randomized, 96 percent completed the study.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nFurther studies are needed to help identify which patients will not benefit from casting.\nCasting required less operating room time compared with surgery.\nAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release aptly compares this new treatment with traditional surgery, which has largely been abandoned due to high rates of malunion resulting in functional deficits in displaced ankle fractures. The release also briefly mentions traditional \u201chard\u201d casting.", "answer": 1}, {"article": "\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\nThe main side effect from the device is that people can wake up with a sore tongue.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We are only told that the usual alternative\u2013an external continuous positive airway pressure (CPAP) machine\u2013\u201cproved too cumbersome\u201d for this one patient\u2019s continued use. Also, according to a NEJM study, we are told that CPAP machines don\u2019t \u201chelp prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\u201d How does the implantable device fare in terms of heart attacks or stroke? The story doesn\u2019t tell us.\nBottom line:\u00a0There is much more evidence showing CPAP is proven to improve the very same outcomes for which the new device is touted. This point should have been included.", "answer": 0}, {"article": "Since the 1990s, Japan has been an active center of research into the study of electrical motor cortex stimulation (EMCS) to treat post-stroke pain using surgically implanted devices.\nSince pain relief from rTMS increases a few days after treatment, weekly treatment sessions were selected to try to sustain pain relief at treatment intervals that could be maintained on an outpatient basis.\nOf 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nIn 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nThe study participants had all been treated medically after a blood clot or bleed in one side of the brain (unilateral ischemic or hemorrhagic stroke).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although a similar but more invasive therapy (electrical motor cortex stimulation) was noted in passing, we think that some additional comments should have been included about alternative treatments, Stroke.org list a host of therapies for post-stroke pain including physical therapy, NSAIDs, narcotics, and antiepilesy drugs.", "answer": 0}, {"article": "And finally, this is a very real world study.\u201d\n\nThe study was received well by the audience.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nEngaging patients in such a way could be a very powerful tool in promoting behavioral change, Nolan said.\n\u201cThe electronic counseling (e-Counseling) intervention had an effect similar to that of adding an additional blood-pressure-lowering medication,\u201d said Robert P. Nolan, the lead author of the study, a senior scientist at the Peter Munk Cardiac Center at the University Health Network and an associate professor at the University of Toronto.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because the participants were already taking high blood pressure medication, which would be the typical alternative to compare this non-drug intervention against, we\u2019ll rate this N/A.", "answer": 2}, {"article": "They are most commonly treated with regular infusions of clotting factor.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\nBased on previous work by Margaritis, the UNC team identified dogs for this gene therapy study.\nThe current study sets the stage for clinical trials in humans.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release tells us that this rare clotting disorder is currently treated by infusions of clotting factors. The release could have done a better job of explaining how difficult that therapy is for patients. Is the disorder regulated well by that method? We aren\u2019t given any information or what those costs are vs. what a one-time gene therapy might cost.", "answer": 1}, {"article": "Their average age was 69.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\nAbaloparatide and Forteo are synthetic peptides that help grow and strengthen bone, Miller said.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes Forteo, the current dominant drug on the market for treating low bone mineral density. But see Quality of Evidence section above for how this could have been done better.", "answer": 1}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nAbout 27 million surgeries are done just in the United States each year, and in as many as half a million cases, infections occur at the site of surgery.\nHospital-acquired infections are a major problem in medicine, so doctors are always looking for the best way to reduce the risk.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This question was not addressed in the story. The reality is that there is no routinely applied standard of practice related to routine surgery. While antibiotics are routinely administered early during a surgical procedure, patient preparation is not standardized.\u00a0 ", "answer": 0}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\nBefore having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nThe type of sugar you eat may affect your cravings for high-calorie foods, researchers report.\n\u201cInsulin is released when we consume glucose,\u201d she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address any other techniques for controlling food cravings.\u00a0It also doesn\u2019t talk about other treatments for obesity such as nutritional education, behavioral support, group work, etc", "answer": 0}, {"article": ".\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\nAn advantage of small-molecule PPF -- which has been previously used in clinical trials in an attempt to treat Alzheimer's disease and dementia -- is that it can penetrate the blood-brain barrier and reach the tumor.\nSince then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While there are no truly effective treatments for glioblastoma multiforme, in this case it would have been helpful to compare this experimental approach to others being studied. In particular, the release could have noted that gene therapy, therapeutic vaccines, radio-labeled drugs and antibodies are also being tested, including tests in patients, an important contrast to this study, which was just a cell culture test.", "answer": 0}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nGeneral support for Marb\u00e1n's laboratory is provided by the National Institutes of Health.\nThe study was published today by the European Heart Journal.\nCapricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development.\nThe team is studying the use of stem cells to treat patients with Duchenne muscular dystrophy as well as patients with heart failure with preserved ejection fraction, a condition that affects more than 50 percent of all heart failure patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Who\u2019s to say that lifestyle factors such as a good diet and robust exercise wouldn\u2019t do a good job of staving off the harms of aging more reliably than a costly stem cell procedure? That\u2019s not mentioned.", "answer": 0}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nAnother concern was that doctors could misinterpret the device's feedback, particularly error messages when a mole cannot be scanned.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nThe agency also worried about its use by general doctors not accustomed to identifying suspicious skin moles.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the device to clinicians throughout, and shows clearly that dermatologists are still the ones with the best authority in this area.", "answer": 1}, {"article": "National Jewish Health is the leading respiratory hospital in the nation.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\nPeople suffering from it often deal with a lifetime of painful symptoms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The article does well in mentioning two alternative treatments for eczema that can often prove problematic: antibiotics and corticosteroids.\nThere are a host of other treatment options as listed here.", "answer": 1}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\nIn previous studies, folic acid levels have been linked to mental ability; however, until now this had not been linked with improved school performance, the study authors said.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did a very nice job of indicating food sources of folic acid as well as those foods that are good sources of folic acid by virtue of food supply supplementation.", "answer": 1}, {"article": "The non-contact sports included were cheerleading, cross country, cycling, tennis and track.\n\"This research suggests that this advanced form of ultrasound may provide a more accurate diagnosis of concussion,\" said Hamilton.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nTesting of the TCD technique at the sideline at the time of injury will be an important next step to determine its ultimate utility,\" said Randolph S. Marshall, MD, MS, with Columbia Presbyterian Medical Center in New York and a member of the American Academy of Neurology's Science Committee.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Existing strategies to detect changes in blood flow in the brain\u2014magnetic resonance imaging (MRI) and \u201ctraditional\u201d transcranial Doppler devices\u2014are compared to the advanced version of TCD ultrasound tested here.\nHowever, we think the criteria here was just marginally met. An alternative for diagnosing concussion not discussed is evaluating clinical signs and symptoms, the typical method for classifying a head trauma as a concussion or not. We do not know whether doppler ultrasound is a better predictor of long-term problems than clinical signs and symptoms.", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nHis physical therapist quickly diagnosed it as tennis elbow.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nA study by researchers at the Nicholas Institute of Sports Medicine and Athletic Trauma, Lenox Hill Hospital in New York demonstrated this benefit.\nAnd the FlexBar makes it simple to do this kind of stretch.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other treatment approaches to tennis elbow, including ultrasound, strengthening and stretching exercises, cross-friction massage, heat and ice.", "answer": 1}, {"article": "Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\nThe results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.\nPerhaps the most important question is what the results mean for postmenopausal women.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This comparison was brief but adequate.", "answer": 1}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n(Mr. Skjoth, who has a master\u2019s degree in nutrition and chemistry but is not a doctor, said this is because other products may clog the scalp, causing hair loss.)\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t directly compare this product with other hair loss treatments such as minoxidil, laser treatments, and finasteride, a prescription-only medication marketed as Propecia. It mentions Rogaine (minoxidil) and a hair thickening shampoo as things one woman tried without success before turning to Harklinikken. The story does mention that for many women the hair will regrow on its own, which is a strength of the piece.", "answer": 0}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nMost doctors say meditation can\u2019t hurt you, but now there\u2019s reassuring evidence that it may help you as well when it comes to warding off disease.\nMost doctors say meditation can't hurt you, but now there's reassuring evidence that it may help you as well when it comes to warding off disease.\n\u201cIt\u2019s like discovering a whole new class of medications,\u201d Schneider says of the power of meditation in improving the patients\u2019 health.\nIn the latest trial to address those limitations, however, meditation does appear to have an effect on reducing heart attack, stroke and even early death from heart disease, at least among African-Americans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions \u201cheart-friendly diet and exercise\u201d and \u201cmedication\u201d as elements of cardiovascular care. We\u2019ll call it good enough.", "answer": 1}, {"article": "Still, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nAnd for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease.\nPrevious research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story alludes to other treatment options, including medications and electroconvulsive therapy, and it quotes an outside expert saying that these are preferable.", "answer": 1}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\n\u201cThese are patients who knew they were out of options,\u201d he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.\nBecause of the side effects, the treatment will carry a boxed warning, the FDA's most serious.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses other drugs on the market. The implication is that the patient has failed all other available treatments. For insurers this will be a major point. Given the cost of the treatment, insurers may require additional standard therapies that may be less effective but significantly less costly. Moreover, how this new therapy compares to others has not been directly tested. It doesn\u2019t appear that any such head to head comparisons are in the near-term future.", "answer": 1}, {"article": "\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\nThe task force advises that men age 45 to 79 take aspirin to stave off heart attacks, as long as the benefit outweighs the risk of bleeding.\nLeFevre added that while the new study did add extra evidence compared with earlier work, it failed to analyze the effects on men and women separately.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Embedded in the analysis was at least a nod to other approaches.\u00a0 For example, the story stated:\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health. \u201cIn my mind, if you have diabetes or multiple risk factors for heart disease \u2014 such as smoking or obesity \u2014 it is reasonable to take aspirin.\u201d In addition, working to eliminate those risk factors by other means will not only slash the risk of heart disease, but also a host of other health problems.\u201d", "answer": 1}, {"article": "But how?\nIf you're squeamish about vitamin A, there are a number of alternatives.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nWe've long assumed sunscreens will do the trick, but then came reports that the vitamin-A compound (retinyl palmitate) integral to many of them could actually be making us more melanoma-prone.\nYour skin vs. the sun: A sunscreen pill?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story tells us that Fernblock is an alternative to sunscreens (with vitamin A). But it also says Fernblock should be taken with sunscreen. So it is unclear what Fernblock\u2019s role is and how it would compare to any real alternative. How does it compare to sunscreen alone, to sitting under an umbrella or to staying indoors entirely?", "answer": 0}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nA new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects.\nIn this small trial of 79 Iranian women aged 45 to 60 years, soft capsules containing 100 mg of fennel were administered twice daily for eight weeks.\nImprovements were compared between the intervention and placebo groups at four, eight, and 10 weeks, with a significant statistical difference documented.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release cites hormone therapy (HT) as the most effective treatment for symptoms, while noting concerns about HT\u2019s potential side effects.\nA broader discussion about managing hot flashes (the most bothersome symptom for most women) by avoiding alcohol and spicy foods, wearing layers, and other interventions would have been helpful.", "answer": 1}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nJust because the system produced strong results in mice does not mean people will respond the same way.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\nPlus, donors are in short supply and can\u2019t yield enough cells to treat the millions of people with type 1 diabetes around the world.\nVegas said that if the primate studies are successful, the next step will be developing a therapy to be used in people.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does contrast this research with other research into treating diabetes. The story might have provided\u00a0a bit of context about other work on developing an artificial pancreas for Type 1 Diabetes patients (there\u2019s a lot on this).", "answer": 1}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nAnd all of the people in this study are white, so that's a limitation.\nSo being fatter, at least a bit, may be healthier.\nThe most relevant was the decline in smoking since the 1970s.\nBut this does raise the prospect of whether it may soon be time to tweak the official definition of normal, healthy weight.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 2}, {"article": "\u201cShe sent me a picture of Giovanni playing in his front yard,\u201d Kefalis said.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nAnd it runs in families.\nBut that\u2019s about all.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss if there are alternatives under development.", "answer": 0}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\nIt focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Chemotherapy also is sometimes used presurgically to\u00a0shrink tumors and allow\u00a0for\u00a0less invasive surgery instead of mastectomy. The story should at least have pointed this out and could have attempted to provide some comparison of the two approaches.", "answer": 0}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\nHad the screening continued for 10 years, as many as 80 percent of lung cancer deaths could have been averted, she said.\nBut one-quarter of those given CT scans were found to have anomalies, nearly all of which were benign.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story reports that no other screening method (including chest x-rays) has been shown to reduce lung cancer death rates among current and former smokers. However, many health experts are concerned that lung cancer screening could lull smokers into a false sense of safety. This story fails to mention quitting smoking as a way to reduce the risk of death. Nonethless, we\u2019ll give the story the benefit of the doubt on this criterion.\n", "answer": 1}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\nThe findings may be applicable to other countries, too, according to senior author Dr. Susan R. Davis from Monash University in Melbourne.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the benefit of the doubt here. The story mentions systemic estrogen therapies, topical creams, and non-hormonal treatments. As noted above, we wish there had been more detailed comparisons of these treatments. Even some links telling people where to get more information would have been helpful.", "answer": 1}, {"article": "In 2015, he was ranked the No.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nAmong elder women, the American Cancer Society and the United States Preventive Services Task Force recommend regular mammography for ages 65 to 74.\nThese linked files also permitted them to explore breast cancer mortality differences between elderly black or white women who self-selected for regular annual or biennial mammography screening.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The main alternatives to extending mammograms to this age group are: 1) no mammogram after age 74 or 2) patients/physicians deciding together to have mammograms based on the patient\u2019s history and risk factors.\u00a0The release should have urged women older than 74 to talk with their healthcare provider about continuing or ending screening. Instead, the first paragraph seems likely to frighten older readers into thinking they definitely need to continue mammograms.", "answer": 0}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nThe study was funded by Dynavax Technologies Corp., which provided SD-101.\nThe other 13 people in the study had previously received a type of immunotherapy before the study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release describes a phase Ib study using a combination of Keytruda an experimental agent. The presumed alternative is Keytruda alone, and that\u2019s made relatively clear in the release. However, this was not a head-to-head trial of the two.", "answer": 1}, {"article": "The print edition is scheduled to be published in August.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release focuses on only one technique \u2014 the Kriya Kirtan. However, the news release could have provided more context, as given in the article, on the importance of other lifestyle factors including diet, physical activity, cognitive training, and social engagement. The combination of these lifestyle factors actually does have some randomized controlled trial evidence supporting it now, with recent publication of the FINGER study.", "answer": 0}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nThe average weight loss seen with either gastric bypass or duodenal switch will improve or reverse obesity-related ills like diabetes, sleep apnea and knee arthritis, according to Livingston, who wrote an editorial published with the study.\nIn the U.S., he said, about one in three weight-loss surgery candidates have a BMI of 50 or higher.\nTwo years after surgery, duodenal switch patients had lost more weight: about 50 pounds more, on average.\nHe pointed out, though, that larger, longer-term studies are still needed to show whether the extra weight loss with duodenal switch ultimately improves severely obese patients\u2019 health and extends their lives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story concentrates on patients receiving weight-loss surgery, and does not discuss non-surgical alternatives at much length. It does mention the study by Livingston questioning the value of surgery over medical management. Behavior coaching, diet and exercise are all potential treatments for obesity.", "answer": 1}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\nWhen it launches nationally in March, Snooz'n will be available in grocery and convenience stores and pharmacies, like most of these drinks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is the most important shortcoming of the story. While prescription sleep aids are mentioned briefly, the story really should have delved deeper into discussion of\u00a0the effectiveness of sleep medications. It also didn\u2019t mention behavioral treatments for insomnia, which may be just as effective as drugs and produce a more enduring benefit.\u00a0The public should\u00a0understand that behavior change will nearly always trump a pill (or supplement, etc.) for long-term efficacy and health effects.", "answer": 0}, {"article": "America\u2019s ongoing battle with weight-loss that has led to fad diets and invasive surgeries like gastric bypass and stomach stapling.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only time alternative treatments are mentioned is when the story refers to gastric bypass and stomach stapling as \u201cinvasive surgeries\u201d in the first sentence. There is no discussion of exercise and diet, other than in conjunction with Orbera. There is no discussion of how Orbera\u2019s benefits compare to gastric bypass or stomach stapling. There is also no discussion of how Orbera differs from other gastric balloon procedures (more on that under \u201cNovelty\u201d).\nAlso, the way these other surgical alternatives are characterized in the story is misleading. Yes, they\u2019re \u201cinvasive,\u201d but they\u2019re also clinically proven to help obese patients lose weight, keep it off, and live longer. We\u2019re not sure if the same is true for Obrera, because this piece includes no discussion of clinically tested benefits. And, it should be noted that Obrera is invasive, too \u2014 after all, it involves placing a large foreign body in a person\u2019s stomach.", "answer": 0}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\nA spokesman for NexBio, David Wurtman, said the company would seek Food and Drug Administration approval to test Fludase in people with parainfluenza.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "       \n \nThe story points out that there are no existing alternatives for preventing parainfluenza virus infections. In addition, the story briefly mentions other vaccines that have developed resistance to the flu virus.\n ", "answer": 1}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\nAfter the 12-week experiment, Cotton and his colleagues found mindfulness therapy increased neural activity in a part of the brain that plays in a role in processing cognitive and emotion information known as the cingulate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions pharmaceutical interventions, but doesn\u2019t actually offer a comparison. How might mindfulness-based cognitive therapy be better or worse? And how does mindfulness-based cognitive therapy compare to (or differ from) other forms of cognitive therapy for children with anxiety disorders?", "answer": 0}, {"article": "The world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story contains some information about the nature of the new clinical trial and that it was designed to compare the \u201cnewer\u201d cocktail to older ones, including one with a drug made by Roche. It\u2019s also open that this is meant to boost sales of a drug to help offset the loss associated with other drugs going generic or facing biosimilar competition.\nThat wasn\u2019t enough, though. Readers are not given enough information to know if this cocktail is better than cheaper and more tested alternatives. For example: What about the outcomes of lung cancer patients treated with the combination of drugs without immunotherapy?", "answer": 0}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes a glancing reference to \u201cother methods.\u201d It says, \u201cThe single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays. The main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\u201d This is not an adequate comparison.\nIt would have been helpful to mention specific blood tests for the tumor types looked at even in this small sample size\u2013this would have given context and why this work is important.", "answer": 0}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\nThen the monkeys were exposed to active forms of the virus.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of noting other vaccine types and the clinical testing of a competing vaccine.", "answer": 0}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\nLine Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison was (or perhaps could be) given between this experiment in 9 lenses and lens replacement surgery or any other experimental approach to cataracts. ", "answer": 0}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions interventions that are commonly recommended for low back pain, including waiting it out. Generally speaking, there\u2019s no standard treatment for most back pain, and often no treatment is recommended.", "answer": 1}, {"article": "\"And for those people, medication can help.\"\nThey concluded that the higher-dose zonisamide showed promise as a weight-loss aid, but advised clinicians to carefully weigh the pros and cons on a patient-by-patient basis.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nThe authors said such side effects were typically \"mild.\"\nBut they also suffered more side effects than patients not taking the medication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the other drugs offered to treat obesity, but it does not make a clear comparison. It says, \u201cJust a few prescription medications are approved in the United States for long-term treatment of obesity, including orlistat (brand name Xenical) and lorcaserin hydrochloride (Belviq).\u201d It does, though, explain how the drug stacked up against diet alone, saying, \u201cPatients who took 400 milligrams of the anti-seizure drug zonisamide daily for a year lost nearly 7.5 pounds more on average than those assigned to dietary and lifestyle changes alone, the new study found.\u201d\nThe story could have discussed costs and compared side effects and weight loss to the other two drugs. It wouldn\u2019t take much time, space, or words to do so.", "answer": 0}, {"article": "For more on stroke, visit the National Stroke Association.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nArora explained that tenecteplase is not widely used in the United States for heart attack patients because these patients are typically treated with angioplasty or heart bypass surgery.\n\"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients,\" said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville.\nThe researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story said tenecteplase is \u201ceasier to give, requiring only a single injection, while alteplase requires an injection and an IV drip.\u201d\nThat\u2019s sufficient but the story would have been stronger had it mentioned the option of simply proceeding with surgical removal of a clot, called a thrombectomy, without first giving either medication. All patients in this trial went on to receive mechanical thrombectomy regardless of which medication they received.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.\nPatients should not receive Ilaris if they are allergic to canakinumab or any of the ingredients in Ilaris.\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nPatients should not get live vaccines if receiving Ilaris.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Even if there are no approved drugs for these indications, surely there is some sort of therapy that patients suffering from them are prescribed, even if it\u2019s limited to palliative care. To leave out details on how patients with these rare disorders are currently treated does a disservice to the readers.", "answer": 0}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\nThis cancer trap can be used for early diagnosis and treatment of metastasized cancer.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers only the broadest possible language regarding diagnosis and treatment of metastasizing cancers. We appreciate that it would be impossible to provide a detailed overview of the existing diagnosis and treatment options in a news release. However, we would expect some discussion of how the \u201ccancer trap\u201d would compare to existing techniques and technologies. This is missing.", "answer": 0}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nExisting treatment options -- diet and lifestyle modification, psychological therapy, and other drugs -- do not help all people with the condition.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare the antibiotic approach to existing alternatives. It says only, \u201cExisting treatment options \u2014 diet and lifestyle modification, psychological therapy, and other drugs \u2014 do not help all people with the condition.\u201d Well, neither did the drug being studied!\u00a0 And the story didn\u2019t give any details about past research into antibiotic therapy for IBS.", "answer": 0}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\nBut none of these works for everybody, and the immune suppressant drugs can raise the risk of cancers such as lymphoma.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\nThe drug, called Dupixent, is a twice-a-month injection under the skin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states:\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus. But none of these works for everybody, and the immune suppressant drugs can raise the risk of cancers such as lymphoma.", "answer": 1}, {"article": "There are some caveats to the study.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nStill, it\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The headline states that reducing simultaneous opioid/benzodiazepine use is \u201cnot the only answer\u201d to opioid overdoses. But the story doesn\u2019t provide discussion of other strategies, such as social services and behavioral healthcare to assist recovering addicts, regulation of pain management clinics, prescription drug monitoring laws, access to naloxone, and a host of others.\nThe article also does not address a critical point: That benzodiazepines are not\u00a0the right treatment for chronic anxiety and there is little reason to prescribe them long-term (one issue is that patients may have been started\u00a0on them years or decades ago and it\u2019s very hard to get them off of them despite what we know now).\nOther treatments such as antidepressants (eg. sertraline, fluoxetine) and therapy are much more effective and safer for chronic anxiety. The article does mention that opioids are, similarly, not the right treatment for most chronic pain, but this was buried toward the end of the article and should have been given more prominence.", "answer": 0}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\n\"This may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE,\" said McKee.\nAlthough there are different stages of the disease that indicate how far it has progressed, this study was unable to determine any connections between levels of CCL11 and severity of CTE.\nBut one of the biggest obstacles in understanding CTE has been the inability to diagnose it in the living.\nIn this new study, researchers found an increased amount of the protein CCL11 in patients previously diagnosed with CTE.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that there is no method for diagnosing this brain disorder in living people, and it mentions that other biomarkers are being tested.\nHowever, the information was relayed in a somewhat confusing way. The story notes that a diagnostic approach focusing on CCL11 may only be \u201cone part of a larger process.\u201d It then quotes a researcher from the study as saying: \u201cThis may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE.\u201d The story then refers to other studies that have attempted to identify other means of diagnosing CTE in living patients. However, it offers little information on those other diagnostic tools. Presumably, they have significant limitations since we are still unable to diagnose CTE in the living. But perhaps other biomarkers have been found, but not yet incorporated into a reliable diagnostic tool. Either way, we wish that had been more clear \u2014 as well as the relevance of these previous studies to the CCL11 research.", "answer": 1}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nSuch fatty, low-carbohydrate Atkins-type diets are well established as a means of successful weight reduction, Dr. Stewart said.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\n\u201cThose on the high-fat diets showed no harmful impacts\u201d after 45 days or so, she said.\nWith the memory of Memorial Day cheeseburgers and bratwursts still lingering, many of us may be relieved to hear that a new study suggests that a meaty, high-fat, Atkins-style diet can do more than contribute to rapid weight loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We learn from this story that soon to be presented results suggest that overweight individuals with seemingly healthy blood vessels lose an initial 10 pounds of weight faster on a low-carbohydrate diet than a low-fat diet.\u00a0 So, while the story is about comparing two alternatives, it could have at least mentioned other diets and drug approaches.", "answer": 0}, {"article": "For more information on stents, visit the U.S. National Library of Medicine.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\nFor the study, a team led by Dr. Duk-Woo Park from the University of Ulsan College of Medicine and Asan Medical Center in Seoul randomly assigned 2,645 patients undergoing angioplasty, a procedure to restore blood flow through the artery, to one of the three stents.\nFonarow said the study results can help cardiologists arrive at treatment decisions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Taking into account that the article implies availability of the 3 stent types, the study itself was comparing a newer approach with the \u201cold standby.\u201d", "answer": 1}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\nThe results are encouraging, allowing the children who were treated to eat peanuts without fear of an allergic reaction.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nIt makes sense that the probiotics may enhance the immunotherapy\u2019s effect, since probiotics are beneficial bacteria in the gut, where food allergens are processed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted above, the story notes that it is not clear whether the combination therapy works better than treatment that uses only immunotherapy. And the story does refer, briefly, to earlier immunotherapy studies. That\u2019s enough to earn a satisfactory rating here. However, a little more information on standard treatments and up-and-coming immunotherapy research would have made the story much stronger.", "answer": 1}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story fails to mention the existence of the many other moisturizing creams that purport to treat stretch marks. It also did not mention that plastic surgery is sometimes used to treat stretch marks.", "answer": 0}, {"article": "He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nIn people with osteoarthritis, the cartilage in a joint wears away in some areas.\nThe wearing away of cartilage leads to pain and other symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there are no\u00a0drugs currently available that can\u00a0delay the progression of knee osteoarthritis, and that current osteoarthritis treatments, such as medication and physical therapy, are aimed at improving symptoms.", "answer": 1}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nTwo of these drugs, in a category known as PCSK9 inhibitors, were approved by the Food and Drug Administration last summer for use by some individuals with extremely high cholesterol levels.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does mention three other drugs that are designed to reduce cholesterol levels. However, the release would have been stronger if it had also mentioned the importance of diet, exercise and other lifestyle factors that can significantly influence cholesterol levels.", "answer": 1}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternative therapies are discussed in the story. There is a lot of new drug development for melanoma; none mentioned.", "answer": 0}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\nStill, the PSA test remains \"a blunt instrument,\" when it comes to determining the aggressiveness of a particular tumor, Neal said.\nOf the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The entire story was about whether PSA screening is better than no screening. ", "answer": 1}, {"article": "\"It took quite a bit of time to get approval,\" Mithoefer says.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that \"MDMA is believed to raise levels of the feel-good brain chemical serotonin and the so-called \"bonding hormone,\" oxytocin.\" Existing anti-depressants and anti-anxiety drugs do the same thing, but none of these drugs are mentioned. Also, because these patients were talking to therapists, there should have been some control in the study design for the therapy itself. How do we know how much the drug was raising people\u2019s sense of euphoria and how much of the change was due to the therapy?", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a good job of comparing IUDs to vaccines and regular screening, even going into the details of when and how often each of those should occur, and making it clear that IUDs are not yet a proven option for cervical cancer prevention.", "answer": 1}, {"article": "Cancer is the No.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nResearchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up.\nThe blood test detected the majority of cancers in people with four of the biggest cancer killers: breast, colon, lung and ovarian cancer, the team at Johns Hopkins University said.\nWyndham said it will be important to study such tests in large groups of people who have not had cancer diagnosed, to see if it can truly be used to screen asymptomatic people for cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes the following: \u201cSeveral different liquid biopsies are already on the market, used to help track whether cancer treatments are working. But there\u2019s nothing yet that can detect cancer in someone who has not yet been diagnosed.\u201d\u00a0 It also includes the following:\n\u201cCurrently, colon cancer can be detected very early with colonoscopies, and even stopped before pre-cancerous growths get out of control. But colonoscopies are uncomfortable and carry a small risk of injury.\n\u201cMammograms can detect early breast cancer, Pap smears can detect cervical cancer or pre-cancerous changes and a type of specialized chest x-ray called a spiral CT can detect lung cancer. There\u2019s a debate over the usefulness of screening for prostate cancer but blood tests and physical exams can indicate some men at high risk.\u201d\nThis is sufficient to list early methods to find cancer, but the story could have also mentioned that early screening or testing doesn\u2019t always equate to saving lives, just more medical care. We just covered this issue as it relates to lung cancer, \u201cImbalanced \u2018Saved by the Scan\u2019 campaign neglects big concerns over lung cancer screening.\u201c", "answer": 1}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\nIn all patients, 14.8 percent of participants experienced at least a partial shrinkage of their tumors, an effect that lasted from more than 2.1 to more than 13.8 months at the time of the response analysis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not give us very much information about alternatives. These patients had already received other therapy and their cancer had recurred, so it is implied that they had no other alternatives. But this isn\u2019t stated very clearly. We can assume (and it seems evident) that the platinum-based therapy that the patients didn\u2019t respond to initially is the usual treatment.", "answer": 1}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nThat's why the device requires training every time Burkhart uses it.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\nThe injury in his spinal cord means he doesn't have any movement below his elbow, so he is missing the fine motor movement in his hands that would allow him to grasp or pick up objects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This experimental device does appear to allow this patient to do things that no other treatment can. However, the main achievement is a proof of concept. Unfortunately, the story makes the difference between his baseline function and his movements in the laboratory appear bigger than it is.", "answer": 2}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\nBasically, it would be pushing a \"reset\" button on the child's body, with the hope of wiping autistic symptoms away.\nBut a significant portion of parents will feel good about this and watch this with incredible interest.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article gives brief mention (one sentence) to traditional treatments\u00a0including educational, physical, speech, and behavioral therapies.\u00a0 There is no mention of psychotropic medications which are also commonly used.", "answer": 0}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide adequate information about treatment options.\u00a0 The story did not provide sufficient information about the risk of death from aortic aneurysms if left untreated in order for the reader to evaluate the relative benefit to be gained from the treatments discussed. Watchful waiting (or active monitoring) is an option, but it was not discussed. ", "answer": 0}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nAgitation is a frequent symptom of advanced Alzheimer's, Lanctot explained.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\n\"There's virtually no data on whole-plant marijuana, whether or not it's effective or safe in people with Alzheimer's disease.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s clearly explained that a major rationale for this study is that the existing pharmaceutical approaches in treating agitated Alzheimer\u2019s patients \u2013 mainly off label use of antipsychotics and anti-seizure meds \u2014 don\u2019t work very well and have significant side effects.\nThere are behavioral approaches to agitation but, given the topic of this article, not including them seems reasonable.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note that existing medications on the market \u201ccan alleviate symptoms but don\u2019t slow underlying disease progression.\u201d We\u2019ll rate this Satisfactory, although these medications are really only\u00a0marginally effective in a minority of patients.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states that six other drugs, all with shortcomings, are available to treat relapsing-remitting MS.", "answer": 1}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\nThe same is true for 88 percent of CRT-D patients, they noted.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to provide the reader with sufficient information on the differences between the devices in the study and the rationale for one over another in patients with heart failure. The study sought to answer 4 questions, only one of which was highlighted in the story. As a result a comparison between the various devices and remote monitoring is muddled to say the least.", "answer": 0}, {"article": "Being around for my daughter, my son, my wife.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not report anything about existing treatment alternatives, such as various types of chemotherapy and stem cell transplants, including typical outcomes for lymphoma patients.", "answer": 0}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article notes some of the common alternatives to surgery\u2014drugs and physical therapy\u2014although it does not mention another very common treatment, epidural steroid injections. ", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Did not mention other options for \nreducing cancer risks. ", "answer": 0}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nResearchers stress the findings are preliminary and that men with the cancer should not reach for the aspirin bottle in an attempt to improve their health.\nAlso, lab and animal studies suggest drugs that anticlotting drugs like aspirin may interfere with cancer growth and spread.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe researchers say it would be premature to recommend the use of anticoagulants in prostate cancer patients, because the benefits and risks have yet to be clearly identified\u2026 and so it is also premature to expect comparisons to alternatives.", "answer": 2}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor Siravo, she said her memory is back to 100 percent.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\n\"And then that didn't work.\nShe said on a night, she could be up four hours and sleep two.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does tell readers that CPAP, a widely used treatment for sleep apnea, did not work for the patient being profiled. However, the story doesn\u2019t let us know how often CPAP is ineffective, whether there is any difference in effectiveness between CPAP and Inspire for most patients, or what other treatment options are available.", "answer": 0}, {"article": "Thirty women each received real acupuncture that also included a bit of an electric buzz or the inactive placebo pill, 32 women got sham acupuncture, and 28 women received gabapentin (Neurontin).\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\nThe study was published Aug. 24 in the Journal of Clinical Oncology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study was all about comparing alternatives so by that means, rates a satisfactory score.", "answer": 1}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nIn the paper, \u201cThe Effect of Body Posture on Brain Glymphatic Transport,\u201d Dr. Benveniste and colleagues used a dynamic contrast MRI method along with kinetic modeling to quantify the CSF-ISF exchange rates in anesthetized rodents\u2019 brains in three positions \u2013 lateral (side), prone (down), and supine (up).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compared the potential benefit of sleeping on one\u2019s side and on the stomach or back. But there are many other potentially modifiable risk factors for Alzheimer\u2019s and other neurodegenerative diseases that weren\u2019t mentioned. Things like exercise, a healthy diet. maintaining social connections, etc have been more thoroughly studied than sleep positions.", "answer": 0}, {"article": "Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternatives in a story like this one are the recommendations from other organizations, and the story does a good job of explaining the varying recommendations from the USPSTF and three other groups: the National Comprehensive Cancer Network, the American College of Obstetricians and Gynecologists, and the American Cancer Society. Well done.", "answer": 1}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nA mere sip would leave her vomiting and gasping for breath.\nNo one should try the approach on his own, because the treatments themselves can trigger potentially life-threatening reactions.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\n\"The side effects were so great that they were as bad if not worse than the disease itself,\" Burks said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story touched on avoidance of allergens and the use of desensitization shots as two alternatives to the treatment under study as well as the use of rescue medication such as epinephrine after unintended exposure for the management of allergic reactions.\n\u00a0", "answer": 1}, {"article": "Lung cancer is the No.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As the study didn\u2019t evaluate a particular approach for treatment or prevention \u2014 e.g., \u201cmetformin used twice-daily in people without diabetes who are at high risk for developing lung cancer\u201d \u2014 the approach is somewhat hypothetical, and alternatives not quite as relevant at this stage.\u00a0While\u00a0we did appreciate the references to other, recent research on iloprost and myo-inositol in lung cancer, the brief summary of the latter research may have gone a bit too far; in April 2010 we addressed the early nature of myo-inositol research.\nEmbedded in the grim statistics on mortality, and the partial attribution of high mortality to progression, there is acknowledgement that our available alternatives for preventing, treating, and halting the progression of lung cancer need improvement.", "answer": 2}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention other approaches, besides eating eggs for breakfast, that are helpful for weight loss.\u00a0 Even one additional line could have addressed this idea.", "answer": 0}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\nTo assess the impact of fish on cognitive health, the authors focused on 260 mentally healthy elderly individuals drawn from the Cardiovascular Health Study, sponsored by the U.S. National Heart, Lung, and Blood Institute.\nThe team further observed that people who ate baked or broiled fish weekly displayed better so-called \"working memory,\" enabling them to more effectively execute routine tasks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The competing WebMD story much more explicitly stated \u201cother risk factors for memory loss.\u201d\n ", "answer": 0}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\nThe new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\nSince the kidney did not \u201cstruggle\u201d after transplant, there is a greater likelihood that its long-term outcome will be better, he adds.\nSince 2012, there has been an unprecedented 63 per cent increase in lung transplants at TG as a result of this system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Here\u2019s how the release handles the issue: \u201cThis technology has advantages over the usual cold storage method in which a deceased donor kidney is cooled on ice to about four degrees Celsius, with no oxygen, slowing down its metabolism, and inhibiting the repair process. The kidney cannot survive longer than 30 hours in cold preservation. The new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\u201d\nThis is a direct comparison, which is good, but raises some questions. For example, how long can a kidney survive using the new technique? More than 30 hours? There\u2019s a reference to \u201cthe damage of cold storage,\u201d but it doesn\u2019t tell readers what that damage is \u2014 or what it means when they say a kidney can \u201cimprove and repair itself.\u201d", "answer": 1}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nIts efforts have helped produce a 20-fold increase in government funding for prostate cancer.\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nThe trial, called TOPARP-A, received support from a wide range of funders including Cancer Research UK, the Prostate Cancer Foundation, Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.\nThe next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This criteria doesn\u2019t apply since all the gene-specified patients were given the same treatment. The release implies that the study enrolled patients whose alternative treatments had failed, but it doesn\u2019t say what those treatments were. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nMarijuana appears to improve the memory and learning abilities of old mice.\n\u201cThey have an excellent safety record and do not produce adverse side-effects when administered at a low dose to older individuals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives were not discussed. There are prescription medications for memory decline, as well as exercise and stimulation (eg, games).", "answer": 0}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nResearch published today in Scientific Reports shows that light from RayVio's 293nm ultraviolet (UV) LED is more efficient than sunlight at producing vitamin D3 in skin samples.\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Natural sunlight is the main alternative discussed in the news release, since skin samples exposed to sunlight needed much more time to produce comparable levels of vitamin D3 than those exposed to RayVio\u2019s UV LED. The news release also mentions diet, pointing out that vitamin D is also found in plants, yeast and mushrooms. Other foods containing vitamin D include oily fish \u2014 like salmon, mackerel, and blue fish \u2014 as well as fortified milk and other dairy products.\nAnother alternative to treat vitamin D deficiency is oral supplementation.\nWe feel the news release\u2019s comparison to natural sunlight is enough for a Satisfactory rating here.", "answer": 1}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\n\"I'm hoping that these results will lead to a change in the clinical guidelines when they are revised in early 2019, which could make identifying diabetes a lot more efficient in many cases,\" Selvin said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made it clear that doing tests one at a time is called for in the current guideline.\nBut the story doesn\u2019t mention the fasting plasma glucose test and the oral glucose tolerance test, which along with the glucose blood test, can be used if A1C test results aren\u2019t consistent, the A1C test isn\u2019t available, or you have a condition such as pregnancy that might render the A1C test inaccurate.", "answer": 0}, {"article": "It will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nThis study builds on previous research published in 2014, which found that light therapy works best at night because the body's circadian rhythms are more sensitive to light at night, even through closed eyelids.\nThis time around, researchers tried to further optimize the process.\nIn this latest study, Zeitzer and Raymond Najjar, a former postdoctoral scholar at Stanford now at Singapore Eye Research Institute, found that short flashes of light at night are more effective than continuous light exposure and could speed up the process of adjusting to a different time zone before a trip.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Jet lag has been studied with other therapies, most notably with caffeine and melatonin. Neither of these other therapies are mentioned in the context of describing this study. Cochrane systematic reviews on jet lag therapies can be found here and here.\nThis report doesn\u2019t suggest any comparison between the light therapy and these other therapies.", "answer": 0}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nTo Learn More: The full study is available on the For The Media website.\nEvery article is free online from the day of publication.\nThe absolute risk reduction was 0.27 percent, making it necessary to treat 370 women to save one life.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release let readers down in providing the broader context about controversies over appropriate treatment \u2014 if any \u2014 for women diagnosed with DCIS.", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nBut Keith-Thomas Ayoob, an associate professor at Albert Einstein College of Medicine in New York City who studies nutrition, said chocolate does have its benefits.\nSaposnik said more studies will help clarify the association between chocolate and stroke risk.\nStill, two of the three studies analyzed in the review provide yet another suggestion that health benefits lurk in chocolate, dark chocolate in particular, said review co-author Dr. Gustavo Saposnik.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No explanation was given for the researcher\u2019s recommendation of dark chocolate over milk or white chocolate, and no reasons were given for why \"dark chocolate in particular\" \u2013 as the story states \u2013 may have health benefits. ", "answer": 0}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nThey have been able to show in a controlled trial that targeting this area with magnetic pulses can improve the condition in some patients.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nTMS uses magnetic pulses to the brain, and has been shown to be effective in several psychiatric conditions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is a close one. The release includes a quote from an independent researcher who was not associated with the study. In that quote, the researcher says, \u201cWhile response rates were moderate, TMS is a welcome addition to the therapeutic repertoire especially for patients who do not respond to medication.\u201d That\u2019s useful information. However, the release would have been far stronger if it had offered even one or two sentences about other treatment options, including medication. For example, do AVHs persist for many patients on medication for schizophrenia?\nOther non-drug techniques such as cognitive behavioral techniques are being used for auditory hallucinations as well.  ", "answer": 0}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nThe study did not look at whether eating soy in food has the same effect on hot flashes as supplements, Bolanos-Diaz said.\nWomen typically suffer between 30 and 150 hot flashes a month, said Dr. Rafael Bolanos-Diaz, professor of health economics at San Marcos University in Lima, Peru, who co-authored the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We suppose that in an ideal world. the story could have at least commented on other alternative options that have been explored for hot flashes. But the story adequately discussed the comparison results from the study, and we appreciate that it ended with a comment about \u201cwatchful waiting\u201d as well \u2013 reminding readers that not everyone chooses to take something for hot flashes.", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does cite a physical therapy expert about steps that can be taken to prevent or minimize neck pain. For example, the story says, \u201cWhen you\u2019re working on a computer or using a device, try to take a break every 15 or 20 minutes and stretch or change position.\u201d That\u2019s good, but for many people experiencing neck pain, it may not be enough. There are a wide array of treatment options for neck pain, depending on the diagnosis of what is causing the pain, including medication (such as NSAIDs like ibuprofen) and physical therapy.", "answer": 1}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nIn an article on Popular Science\u2019s website, Jay writes about her experience with pain and the next-generation way she\u2019s finding relief.\nJay lays out the hows and whys of spinal stimulation, and she paints a vivid picture of a life in agony, a journey that has included skeptical doctors, plenty of painkillers and unanswered questions about the future.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story referenced Jay\u2019s use of \u201cpainkillers\u201d and states that spinal stimulation \u201cmay become more popular\u201d due to the opioid crisis. But it didn\u2019t compare the effectiveness, safety, or cost of spinal stimulation with the array of treatments available for back pain. Those treatments include not just opioids but over-the-counter medications, movement, cognitive behavioral therapy, acupuncture, spinal manipulation, and steroid injections.\nIn general, patients contemplating this procedure have already undergone many other treatments. Moreover, there as other treatments that could be done as alternatives. These would include non-invasive treatments such as interdisciplinary rehab, yoga, non-opioid pain meds and invasive treatments such as surgery and injections. More on the range of treatment Jay tried and other she considered would have been helpful.", "answer": 0}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nThe researchers randomly assigned nearly 600 women with heavy menstrual bleeding to receive either the IUD or standard medical care.\nThey assessed improvement using a patient-reported score on a scale designed to measure severity of symptoms.\nWomen in the IUD group reported much greater improvement -- 32.7 points on the symptom scale versus 21.4 points in the standard treatment group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study discussed the usual treatment for heavy menstrual bleeding, but what is not clear is if the side effects from using Mirena are different from the current medications. Inadequate discussion of alternatives and comparisons overall.", "answer": 0}, {"article": ".\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nHowever, the study did not compare patients with unknown stroke onset who received tPA to those who did not, Oppenheim said.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided insight about a couple of situations in which it wasn\u2019t possible to determine the time of stroke onset. \u00a0The study reported on whether MRI could be used in these sorts of situations when the patient isn\u2019t able to provide information about the time of stroke onset.", "answer": 1}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\nDr. Bryan Becker, president of the National Kidney Foundation in the U.S., said about half of kidney patients could benefit from these vessels if further tests confirm they work.\nThe study was was paid for by Cytograft Tissue Engineering.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story makes clear that tissue-engineered blood vessel grafts are still far from clinical use, it says that at least for some patients in this study, the experimental grafts performed better than standard approaches. However, the study did not make any direct comparisons to standard approaches, so there is no evidence to support claims of superiority.", "answer": 0}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\n\"And other similar studies have looked at omega-3 and muscle preservation and have also suggested that fish oil can act to prevent inflammation caused by both disease and hardcore medications, like chemotherapy agents.\"\n\"Fish oil may prevent loss of weight and muscle by interfering with some of the pathways that are altered in advanced cancer,\" study author Dr. Vera Mazurak, of the University of Alberta in Edmonton, Canada, said in a news release.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quoted the researcher from a news release saying \u201cThis holds great promise, because currently there is no effective treatment for cancer-related malnutrition.\u201d\u00a0 But there was no discussion of any other research or any other approaches to cancer-related malnutrition.\u00a0 So this claim of novelty by the researcher was never explored or substantiated. This is NOT the only research in this field, and the story could have included at least a line about other work.", "answer": 0}, {"article": "\"The Suboxone got me far enough away to look and say 'wow, look at your life.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\nIt's an orange pill that's dissolved under the tongue.\nFor Brian, life now involves not only counseling and but a personal inventory as well.\n\"I didn't know how bad being on opiates affected me,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment refers to methadone early on. But it does not mention counseling as a stand-alone option for addiction to painkillers, or other drug- or non-drug options. ", "answer": 0}, {"article": "In the study, 15 men and 15 women drank either 17.6 ounces of a beet juice beverage consisting of about three-fourths beet juice and one-fourth apple juice, or a placebo juice.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the \u201cDASH (Dietary Approaches to Stop Hypertension)\u201d diet, which has been proven to lower blood pressure. It could also have mentioned that there are effective blood pressure medications available.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that this procedure is largely for cosmetic purposes, but it has been used as a reconstructive technique. Fat transfer has been used without stem cells for reconstruction for about 10 years.\u00a0 The story also notes the more common silicone and saline implants as options for breast reconstrution and augmentation. ", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison with other approaches, except the implication that behavioral approaches like exercise are not necessarily easily followed,\u00a0and so taking a pill is an easier choice. Granted, when you depend on human compliance and behavior change for public health benefits, the results will be limited. But, the story overlooks the fact that taking a pill every day also requires long-term compliance, limiting the results, too.", "answer": 0}, {"article": "The number of hot flashes also fell from about 20 a week to less than 10.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\nThe new study, published in the journal Menopause, is based on 90 Chinese women.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that \u201cThe standard drug treatment for stubborn menopause symptoms is hormone replacement therapy. But doctors and women have become increasingly wary of that option because of serious side effects such as increased risk for heart attack, stroke and breast cancer.\u201d", "answer": 1}, {"article": "Chemotherapy before surgery might provide a false assurance that there's no more residual cancer, whereas microscopic tumour may remain after the surgery, leading to cancer recurrence and possibly, death.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses several other conventional treatment options for advanced-stage ovarian cancer.", "answer": 1}, {"article": "For further information or interview requests contact Sandy Fleming at the University of Kent Press Office.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nAn eight week return to running programme using the anti-gravity treadmill was individually designed by Dr Hambly.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any alternatives to the treadmill for people needing rehabilitation after knee surgery. \nThe release is about a study of a single patient who pursued a single rehab journey following surgery. Besides that limitation, the news release also missed an opportunity to mention that there are non-surgical approaches to treating cartilage damage in the knee.", "answer": 0}, {"article": "Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\nThis data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\nFurthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not list other flu vaccines by name, but does clearly describe the conventional vaccine that was compared to Flublok Quadrivalent in this study. The release also articulates what distinguishes Flublok from conventional vaccines in terms of its manufacturing and components (e.g., Flublok is made without using eggs, etc.).", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does well to provide relevant historical and cultural context; namely, that the traditional approach to labor pain in the US is biased toward epidural anesthesia, despite the fact that nitrous oxide is a common alternative in other countries.\nGiven the current opioid epidemic in this country, it may have been timely to mention the extensive use of narcotics in managing labor pain in the US.", "answer": 1}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nAn experimental vaccine that could hold off Alzheimer's disease showed promising results in animal testing, according to researchers at the University of Texas Southwestern Medical Center.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nThe vaccine is one of several promising treatments aimed at reducing the buildup of those substances before they become deadly plaques and tangles in the brain.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the vaccine is among \u201cseveral promising treatments\u201d aimed at reducing the buildup of proteins associated with Alzheimer\u2019s. It could have also mentioned that another Alzheimer\u2019s vaccine is undergoing clinical trials.\nIt could have also mentioned current available medicines that have a very modest, short-term effect. Drugs called cholinesterase inhibitors have been approved by the FDA to lessen symptoms from Alzheimer\u2019s, but none is curative.", "answer": 1}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\nA message left for the AAC Consulting Group, a Rockville, Md., company that filed the petition, also was not immediately returned.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of lifestyle or dietary approaches or drugs for decreasing heart disease risk.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided an overview (albeit sometimes brief) of dietary changes, Kegel exercises, biofeedback, surgery to repair the sphincter, Solesta and InterStim.\nOur non-journalist reviewer (HD) thought this should be graded unsatisfactory.\u00a0 He wrote: \u201cWhile the story did a reasonable job in providing the reader with treatment options, it really centered on a Medtronic device that is only useful in certain types of patients.\u00a0 There are other forms of the disorder and other more effective treatment options for select patients.\u00a0 Readers are provided with a limited view of the disorder and its many treatments.\u201d\nThe journalist reviewer (GS), while acknowledging that the discussion of treatment options was limited, still felt it was more inclusive than many such stories we review.\n\u00a0", "answer": 1}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nThe device \u2014 known as a sub-retinal implant \u2014 sits underneath the retina and works by directly replacing light receptors that are lost as a result of the disease.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are other implants, saying, \u201cOther types of retinal implants, known as epiretinal implants, sit outside the retina and because they bypass the intact light-sensitive structures in the eyes they require the patient to wear an external camera and processor unit.\u201d But that\u2019s not a true comparison, nor does it provide readers with the true picture of how much R&D is happening right now in this field. As is often the case in medicine, surgical options and devices are not the only solution. Lowly old Vitamin A is often the first step for treating retinitis pigmentosa.", "answer": 0}, {"article": "BLOOMINGTON, Ind.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\nThis research was supported in part by the National Institutes of Health's National Institute of Mental Health and National Institute on Drug Abuse.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release did not mention any alternatives for treating ADHD such as non-stimulant medications or cognitive behavioral therapy.", "answer": 0}, {"article": "Several studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nHowever, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThey did not study actual people eating actual chocolate.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story quoted the Harvard expert:\nThose at risk of heart attack and stroke should first focus on lifestyle, Ding says. That includes weight loss if needed, exercising regularly, and not smoking.", "answer": 1}, {"article": "63 senior respondents of a mean age of 80 were studied during 3 consecutive weeks.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nIncreased blood pressure and reduced robustness of circadian rhythms are frequently reported in elderly subjects.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The only mention of alternatives occurs in the last sentence, which mentions \u201cbasic medication\u201d for hypertension sufferers and offers up circadian pacemakers as \u201ca new strategy in the treatment of hypertension.\u201d\nThere are established treatments for people with hypertension and for those with insomnia.  The former may range from changes in diet and the addition of exercise to a variety of medications to manage blood pressure. When insomnia becomes a regular occurrence, some people get help from behavioral changes (including diet, exercise and stress reduction) or a variety of prescription or over-the-counter sleep aids that are available.\u00a0", "answer": 0}, {"article": "CHICAGO --- Soon you can seek mental health advice on your smartphone as quickly as finding a good restaurant.\nBut Northwestern researchers hope participants will provide confidential feedback, via four weekly questions, that will be used to further develop the system.\nBut participants robustly used the IntelliCare interactive apps as many as four times daily -- or an average of 195 times -- for eight weeks of the study.\nThe data will help the system make even better recommendations and provide more personalized treatment.\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that over the course of 8 weeks, participants experienced improvements similar to what people with depression or anxiety would find through psychotherapy or medication. But again,how can such a comparison be made when\u00a064% of participants were already taking antidepressant medication, and 22% were receiving psychotherapy, when they enrolled in the study?", "answer": 0}, {"article": "\u201cBut with these foods you do not consume the minerals, fluid and carbohydrates,\u201d he said, \u201cso nonalcoholic beer seems to be optimal\u201d for everything, perhaps, apart from your well-deserved celebratory carouse after the race.\nThe men drinking the nonalcoholic beer reported far fewer illnesses than the runners swallowing the placebo beverage.\nBut the supplement has largely failed to show benefits in human athletes.\nIt began with human marathoners completing a punishing, unsimulated race, and showed demonstrable benefits, in terms of minimizing postrace damage.\nJust how nonalcoholic beer eases the ravages of strenuous marathon training and racing is still being investigated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not mention potential alternatives that might aid marathon recovery, including any other dietary alterations, and does not discuss the advantages and disadvantages compared with any other approaches.", "answer": 0}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut patients treated with fake or \u201csham\u201d acupuncture - using retracting needles that don\u2019t stick in the skin, for example - estimated their pain at somewhere in between the other two groups, suggesting that they also got some benefit from the procedure.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nPark, who was not involved in the new study, said acupuncture focuses on healing the underlying tissue injury that is causing pain, rather than treating the pain itself as medications would.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions medications, physical, and talk therapy as potential options for chronic pain.\u00a0 A complete story however might also have included some information about the standard treatments and how they compare to placebo.\u00a0 When you look at physical therapy for chronic low back and NSAIDs the results are not all that impressive", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Ideally, we\u2019d like to see some mention here of the option not to perform BMD testing, since there is no real evidence supporting this recommendation. But the story gets high marks for talking about a range of treatment options for osteoporosis and general bone health, and we applaud that. It\u2019s rare to see a story try to pack in so much treatment information into one story, which is why we often ding stories in this part of the review.", "answer": 1}, {"article": "About the American College of Radiology\n\nThe American College of Radiology (ACR), founded in 1924, is a professional medical society dedicated to serving patients and society by empowering radiology professionals to advance the practice, science, and professions of radiological care.\nSeventy-five percent of women diagnosed with breast cancer have no family history or other factors that place them at high risk for the disease.\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nTo mark National Breast Cancer Awareness Month, women are encouraged to ask their health care providers about scheduling an annual mammogram.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A few options are mentioned, i.e. mammography screening only for high-risk groups, later-age screening, and less-than-annual mammograms. Other approaches that could have been discussed include regular physical exams of the breast by a clinician (without mammography) as well as breast self-exams.\u00a0", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no comparisons with alternatives. It mentions chemotherapy and radiotherapy in passing. Reading the story carefully, one might believe that any treatment developed from this finding would work only in conjunction with these other treatments. But we can\u2019t be sure.\u00a0The story should have mentioned other proposed interventions intended to disrupt the spread of cancer cells, including some drugs that are already in clinical trials.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story just briefly mentions the alternatives\u2013chemotherapy.", "answer": 1}, {"article": "\"That time frame is not anything to write home about,\" Gulley says.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\nFor them, the median time before the cancer progressed was about two months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison in the story to existing alternatives. The median survival, for example, is presented without the context of how long these patients might have lived had they been undergoing standard chemotherapy and radiation treatments.", "answer": 0}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The report describes laboratory testing on animal models, like mice and monkeys, and says chemicals are metabolized at a different rate in animals. We think that\u2019s enough for a Satisfactory rating here.", "answer": 1}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\nYou can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was mostly about gut bacteria, but it does discuss the potential impact of A. muciniphila on cholesterol, glycemia (i.e., blood sugar levels), and other risk factors for cardiovascular disease. It would have been useful here to discuss other interventions, such as exercise, that can influence these risk factors.", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\nPrevious surgical treatment was performed on 31 of 38 knees in the study group and 37 of the 42 knees in the control group.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other techniques for addressing knee pain, including oral medications, injectable medications, physical therapy, and other surgical treatment options, are not mentioned. It is not clear from the release how or why osteochondral allograft transplantation may be more advantageous than other options.", "answer": 0}, {"article": "\"We've got a lot of repeat customers, unfortunately,\" Shah said.\nShe and others say they know of no other physician in the Washington area who favors the radial approach.\n\"There's no data out there to suggest it is worse and growing evidence that it may be better,\" said Shah, an assistant professor of medicine at Harvard Medical School, who performs 60 to 70 percent of procedures through the wrist.\nSome senior interventional cardiologists say they worry that the method may be hyped.\n\"I think there is a reluctance among physicians who are used to doing procedures a certain way\" to change, said Mazhari, who learned to do the procedure last year and uses it about 80 percent of the time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While there was no discussion about the appropriate use of cardiac catheterization in general, the story included information about the two arterial routes that may be used for the procedure.", "answer": 1}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story mentioned knee replacement in the body of the piece and listed non-surgical approaches to the management of knee osteoarthritis at the end.\u00a0 But there was no meaningful comparison of outcomes.", "answer": 0}, {"article": "The question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nThe all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention several drug regimens that are available for treatment of hepatitis C and notes that they appear to take longer to achieve a response than the new drug. We\u2019ll call this good enough for a satisfactory, but we\u2019d note that there are other treatments for hepatitis C that have a long and detailed history in the medical literature. A good hepatitis C expert could have provided a nice summary for readers.", "answer": 1}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\nLoyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo robotic surgery or open surgery to remove cancerous bladders.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nMAYWOOD, IL - Robotic surgery is as effective as traditional open surgery in treating bladder cancer, according to a landmark study published in the journal Lancet.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The comparison of robot-assisted to open surgery was the main point of the release.", "answer": 1}, {"article": "\u201cThus, development of an effective therapy to kill glioblastoma stem cells is urgently needed,\u201d Dr. Pei-Yong Shi, professor of genetics at the University of Texas Medical Branch and author of the study published in the journal mBio told Newsweek.\nA vaccine against the Zika virus could one day be used to fight the deadly brain cancer that claimed the life of Senator John McCain, according to a study in mice.\nCurrently, most people diagnosed with the condition die within two years.\nThe animals dosed only with the stem cells developed tumors.\nResearchers used a vaccine against the mosquito-borne virus to kill human glioblastoma brain cells which had been implanted into rodents.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Normal cancer treatments such as radiation, surgery, and chemotherapy are mentioned, and described as not successful in the long run against\u00a0human glioblastoma brain cancer.", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly discusses treatments that are supported by clinical studies and professional societies.\nWe do wish the evidence for and\u00a0success rates of the alternatives were described much more thoroughly.", "answer": 1}, {"article": "Brown rice is a whole grain \u2014 white rice before it has been refined and polished and stripped of the bran covering, which is high in fiber and nutrients.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\nJust replacing a third of a serving of white rice with brown each day could reduce one\u2019s risk of Type 2 diabetes by 16 percent, a statistical analysis showed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0Although the study came up with a suggestion derived from a statistical analysis about replacing some of one\u2019s white rice with brown rice, there was no discussion of other methods (i.e. maintaining adult body weight within the normal range or engaging in aerobic exercise) for reducing one\u2019s risk of type II diabetes. Even a short line could have been dedicated to this important context. ", "answer": 0}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\nThe review, by Shaheen Lakhan, PhD, and Marie Rowland, PhD, of the Global Neuroscience Initiative Foundation in Los Angeles, found that five of six published studies they analyzed reported a reduction in spasticity and an improvement in mobility in MS patients treated with marijuana extracts.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated that \"many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\u00a0 But we are not told anything about what these therapies are \u2013 nor are we given any details about all of these suggested shortcomings.\u00a0 So readers are not able to make any meaningful comparison based on the story. ", "answer": 0}, {"article": "\"We want to take the focus off pain and put it onto functioning, and finding pleasurable ways to spend time,\" Ilgen says.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nAddiction treatment programs often have patients who suffer from chronic pain, but offer few options to treat them, Ilgen says.\nIlgen and his colleagues hope their results will help bring the techniques into addiction treatment settings, where the cognitive behavioral therapy approach is often used.\nIn the meantime, he notes, people struggling with addiction who want to seek relief from pain should explore the full range of treatment options that have been shown to work in non-addicted patients, including physical therapy, exercise and psychotherapy as well as antidepressant medications.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release both addresses why some alternative treatment options are not available for chronic pain patients who suffer from addiction, and explicitly states that \u201cpeople struggling with addiction who want to seek relief from pain should explore the full range of treatment options that have been shown to work in non-addicted patients, including physical therapy, exercise and psychotherapy as well as antidepressant medications.\u201d", "answer": 1}, {"article": "However, he said, \"I think it is becoming more popular, both from a physician perspective but also from a patient perspective.\nCancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nThe shorter treatment duration encouraged McCartney to have brachytherapy.\nHer first oncologist suggested the traditional approach.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article describes the most common alternative, external beam radiation. \n\u00a0", "answer": 1}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\nOne doctor said screening isn\u2019t enough; patients need close monitoring to make sure they get help.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\n\u201cA lot of patients with depression don\u2019t follow up on it,\u201d said Dr. Mary Whooley, a professor of medicine at the University of California, San Francisco, who was not on the panel.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions antidepressants, psychotherapy and excercise as possible treatments for depression.", "answer": 1}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\nThis new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.\nAuthors analyzed 53 randomized controlled trials that examined knee OA treatments for at least 28 days and included a minimum of 30 participants per study group.\n\"While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.\"\n\"Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A comparison of existing alternatives is the point of the journal article. The news release highlights the comparisons in clear language.", "answer": 1}, {"article": "\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nConducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, this study found that incorporating pecans into a typical American diet significantly improved insulin sensitivity and had a significant effect on markers of cardiometabolic disease in otherwise healthy overweight and obese adults with excess belly fat.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many different dietary recommendations that could lower a person\u2019s risk of heart disease and type 2 diabetes. This release does not discuss any other strategies for lowering the risk of type 2 diabetes or heart disease.", "answer": 0}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\nData on aspirin and other NSAID usage came from the women\u2019s responses on questionnaires.\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a host of things that women can do to reduce their risk of breast cancer, though all of it\u2019s based on observational data, and aren\u2019t powered to prove that reducing the behavior actually reduces breast cancer.\u00a0There should have been at least some discussion about these factors.", "answer": 0}, {"article": "\"He grew up around athletics, so I'm sure it was a culture shock for him,\" says his grandfather, Lacey Calloway.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\nVictims often show no earlier symptoms, looking the picture of health.\nApproval is generally granted to teens with little to no family history of heart problems and a physical exam devoid of medical red flags.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of the relative value or effectiveness of standard physical examinations and health histories for identifying potential risks of sports participation.", "answer": 0}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\nFollowing numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\nFor thousands of women, this may soon replace surgery as a treatment for breast cancer.\nThe ongoing refinement of the technology makes treatment more precise and extremely reliable.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "ICE3 is compared extensively to surgery, which is the leading treatment for breast cancer. However, it would have helped to put the treatment into context with preceding and follow-up treatments, including radiation and chemotherapy.", "answer": 1}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nNot surprisingly, these \"preclinical tests\" (that is, those performed before testing on humans) were especially rigorous for botulinum.\nBotox's manufacturer, Allergan, thinks those older studies are more credible.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story really did not provide much insight into the uses of this compound other than its use with wrinkles. It did not include any information about treatment options for wrinkle management or treatment options for the other conditions which botulinum toxin is used to treat.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article fails to mention that the pain and functional limitations caused by knee osteoarthritis occasionally improve on their own or often respond to nonsurgical treatments (e.g. strengthening and exercise, weight loss, medications, injections, bracing, in-shoe orthotics) and smaller operations (e.g. osteotomy). (A sidebar on a motion analysis laboratory mentions braces and physical therapy). For younger surgical candidates, this is important information, because knee replacements have a limited life and young patients concerned about the need for a second operation later in life often prefer to wait as long as possible before having their first.", "answer": 0}, {"article": "Weight training or cardio?\nIn this 18-month study of 249 adults in their 60s who were overweight or obese, restricting calories plus resistance training in the form of weight-machine workouts resulted in less muscle loss, but significant fat loss, when compared to weight loss plus walking or weight loss alone.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\n+ Total fat loss was much greater when participants combined diet plus walking (about 16 pounds) and diet plus weight training (about 17 pounds).\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The way that this study was designed compared the intervention of weight training and a weight loss diet (calorie-restricted dieting), diet and walking, and diet alone. Both walking and weight training were much more successful for weight loss than dieting alone. However, the release could have made the distinction in benefits a bit more clear. While seniors lost similar amounts of weight when walking and participating in weight training, the study showed that much of the weight lost from walking was coming from muscle mass, while the weight loss from lifting was from fat.", "answer": 1}, {"article": "Fluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\nThe long-acting therapy is taken once-daily at bedtime.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nAdamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that deep brain stimulation is a treatment option for those with severe symptoms.", "answer": 1}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nInfants who have a genetic profile linked with asthma risk could be protected against respiratory symptoms if they are breastfeed, according to a new study.\nWhen infants were not breastfed, those carriers exhibited a trend towards an increased risk of respiratory symptoms.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There was no information provided pertaining to possible alternatives to breastfeeding that also might lead to a reduced risk of asthma among infants, even though there is a wealth of information linking numerous environmental factors to the exacerbation of asthma. A recent review article names more than 100 genetic variants have been associated with the development of asthma along with a host of environmental factors.", "answer": 0}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nWalnuts are the only nuts with appreciable levels of omega-3 fatty acids, which some studies of male infertility have linked to better sperm quality, says researcher Wendie Robbins, PhD, of the UCLA Fielding School of Public Health.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\nTheir study is part of a growing body of evidence that men\u2019s dietary and lifestyle choices might affect their fertility.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that fish oil is also a source of omega-3 fats that are thought to be beneficial for fertility. It could have mentioned that the\u00a0major omega-3 found in walnuts is\u00a0alpha-linolenic acid (ALA), which is\u00a0a precursor\u00a0to the two long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), that\u00a0are most consistently associated with health benefits. Only a small amount of ALA gets converted by the human body to these\u00a0beneficial forms, whereas fatty fish is naturally rich in the active long-chain\u00a0fatty\u00a0acids. Therefore, eating fish might theoretically be as good or a better choice for improving fertility.", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nLomaira should be used together with regular exercise and a reduced-calorie diet.\nPhentermine is not recommended for use in pediatric patients 16 years of age or younger.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nDosage should be individualized to obtain an adequate response with the lowest effective dose.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of other drugs or methods of weight control. Nor does it compare its efficacy with the multitude of dietary approaches available today. It does say that Lomaira \u201cshould be used together with regular exercise and a reduced-calorie diet.\u201d", "answer": 0}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\nCapsule co-inventor, RMIT's Dr Kyle Berean, said the second human trials have revealed information about gas production in the gut previously masked when measured indirectly through the breath.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release makes it clear that the capsule is being developed as (hopefully) a more sensitive measure of intestinal gases than currently used breath tests. It\u2019s also made clear such testing is used to diagnose conditions like small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nIn this study, researchers found that patients who received a single fraction of 19 Gy HDR brachytherapy experienced similar clinical outcomes as with LDR brachytherapy, but with the convenience of a single visit.\n\u201cGiving the entire dose in a single treatment theoretically could have had a greater negative impact on the normal tissues in close proximity to the prostate\u2014meaning the bladder, urethra and rectum\u2014but this was not found to be the case.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\nAt an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says the study compared safety and effectiveness of single high-dose-rate (HDR) brachytherapy to longer courses of HDR treatment and that this alternative \u201cmay or may not be sufficient to result in cure rates comparable to historical standards.\u201d\nThis sounds inconclusive. Just what are the \u201chistorical standards?\u201d And why talk about \u201ccure\u201d rates?\nA recently published randomized trial (PROTECT, Hamdy et al. NEJM, September 2016) of active monitoring, radiotherapy, and surgery for men with localized cancer found a 99% prostate-cancer specific survival for all treatment arms through 10 years of follow up. \u00a0Speaking of a \u201ccure\u201d rate for low-risk\u00a0disease that does not need to be cured is very misleading. H. Gilbert Welch, MD, MPH. professor of medicine at the Dartmouth Institute, has described these low risk diseases as \u201cpseudo disease.\u201d", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Very few details of conventional alternative treatments are included, but the story points out that glioblastoma is resistant to most treatment options. Still, the story should have noted that alternatives include surgery, radiation and chemotherapy.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0notes that\u00a0other asthma treatments aren\u2019t \"game-changers\" for patients who aren\u2019t responding to medical therapy, the implication being that thermoplasty is. But we don\u2019t really know whether thermoplasty represents a big improvement over medical therapy just yet. \nThat being said, the story did emphasize that this treatment is only being considered for patients whose asthma isn\u2019t being controlled by existing treatments. By providing this important context, the story\u00a0does enough to satisfy the criteria.", "answer": 1}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\nClearPop for Rapid Earache Relief has been shelved by Raley's (CA, NV) select RiteAid locations, and is available at boutique drugstores and Amazon.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release\u00a0makes no comparisons between this product and the efficacy of antibiotics or other pain relief drugs such as Tylenol, Motrin, aspirin and others that come in pediatric formulations.", "answer": 0}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nAt the heart of the paramount discovery is the dietary supplement vitamin B3, also known as niacin.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\nThis breakthrough, led by Professor Sally Dunwoodie from the Victor Chang Institute, has identified a cause of recurrent miscarriages as well as heart, spinal, kidney and cleft palate problems in newborn babies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any other strategies for preventing miscarriage beyond vitamin B3 supplements.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention another chemoprevention hormone drug, tamoxifen. It also mentioned aromatase inhibitors as options being investigated for chemoprevention. Does not mention need for mammograms (screening as early detection shown to improve outcomes) in post-menopausal women at a higher risk of breast cancer. It should be noted that the results presented in this story are initial findings after 4 years of raloxifene. Tamoxifen is usually taken for 5 years and there is much more long-term clinical data on safety and efficacy for this drug. The study was unblinded early due to the improved side effect profile for raloxifene, which was not statistically significant. ", "answer": 1}, {"article": "reflect problems that cause squeaking, which it contends occurs in less than 1 percent of implants.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nBeyond annoyance and embarrassment, many patients and their surgeons fear that the squeaky ceramic hips may signal that the joints are wearing out prematurely.\nBut Dr. Fabio Orozco, a surgeon at the Rothman Institute, a major orthopedics group in Philadelphia, said that a recently completed review of about 1,500 Rothman patients with ceramic hips had found that the squeaking condition occurred in 49 of them, or about 3 percent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out that the alternatives to a ceramic total hip replacement include hip replacements with implants made from metal and plastic. It doesn\u2019t mention whether there are nonsurgical alternatives to hip replacement, but this is beyond the scope of the story.", "answer": 1}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the importance of eating right, exercising, and taking medication to treat heart risk factors for improving heart health \u2014 which is important to reiterate. However, treatment of heart disease was not the primary point of the study. One of the main reasons for doing this study was to compare the predictive power of CAC tests to some other risk factor assessments, and the story does not mention those other methods.", "answer": 0}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\nThe study appears in the September issue of the journal PLoS Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story does not mention any alternative approaches to reducing the risk of rheumatoid arthritis. There are a number of risks factors associated with the development of rheumatoid arthritis. Of the four, only smoking is modifiable. The others are female gender (women get RA about twice as often as men), family history and age (most people with RA develop it between 40 and 50 years of age). A complete story would have provided a bit more background for the reader.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t explain how someone with serious chronic back pain becomes a candidate for surgery, and then how he or she becomes a candidate for BMP. \nA paragraph that explains the available treatment options at various stages of the condition would have been very useful. \nThis is particularly true since a long-standing question about spinal fusion surgery, regardless of technique, is whether it is overused and potentially harmful.\u00a0\u00a0 ", "answer": 0}, {"article": "Find her on Twitter at @maiasz.\nHowever, patients on nicotine did lose a few pounds, which is a known side effect.\nPeople with Alzheimer\u2019s disease have reduced numbers of nicotine receptors in their brains\u2014 and while the research is conflicting, some evidence suggests that the drug could protect these neurons.\nIntriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternative strategies to either improve or slow down the degradation of cognitive function in people with mild cognitive impairment.", "answer": 0}, {"article": "When a person has diabetes, their body either doesn't produce enough insulin or doesn't process blood sugar properly.\nThis research was funded, in part, thanks to grants from the Diabetes Action Research and Education Foundation and the American Diabetes Association.\nAt the root of that is the failure of beta cells, whose job it is to produce insulin.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not put this potential treatment into context with available treatments. However, the research is far too preliminary to even begin making comparisons to alternatives.", "answer": 2}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe results are \"provocative,\" but this type of study can't prove that screening prevents deaths, said Dr. Matthew R. Smith of the Massachusetts General Hospital Cancer Center.\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternative screening strategies for cervical cancer were discussed. \nThe option of not being screened for prostate cancer came through in this quote:\u201dThey\u2019re identifying a group of guys who don\u2019t need to be screened, or need to be screened less often,\u201d said Dr. Otis Brawley, the cancer society\u2019s chief medical officer.\nFor ovarian cancer the story emphasized that the study in question was \u201ca warning to people who get screening tests that aren\u2019t recommended, or who question whether screening can ever hurt.\u201d", "answer": 1}, {"article": "While the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\nIt is not a diagnostic test for Down syndrome, she says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\n\u201cFor women who are concerned about losing a pregnancy as a result of an invasive test, this is an excellent addition to our armamentarium of screening,\u201d she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story tries to do a good thing by explaining at the very end that the new test is not a diagnostic test, as amniocentesis and chorionic villus sampling are.\u00a0 Rather, it\u2019s a screening test.\u00a0 The distinction \u2013 and the significance of that \u2013 could have been made more clearly, but we give the story the benefit of the doubt.", "answer": 1}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\n[1]\n\nThe vaccine, called rVSV-ZEBOV [2], was studied in a trial involving 11,841 people in Guinea during 2015.\nAfter interim results were published showing the vaccine's efficacy, all rings were offered the vaccine immediately and the trial was also opened to children older than 6 years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release also briefly summarizes a study of a different Ebola vaccine candidate being developed by a Chinese organization. This study, also published in the same issue of The Lancet, was much smaller, involving only 500 participants, and suggested that the effectiveness of this vaccine declined during the first six months after the initial injection.\nTo be even more thorough, the release\u00a0might have\u00a0acknowledged that still other vaccines are under development by GlaxoSmithKline, Johnson & Johnson and at least one other pharmaceutical company.", "answer": 1}, {"article": "For more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nThe Scottish study took advantage of the small country\u2019s rich trove of linked birth and medical databases to track the long-term health of 321,287 babies.\nHowever, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a careful job of comparing the different delivery methods.\u00a0There could have been perhaps a little exploration about recovery time and adverse events in the moms who have c-section.", "answer": 1}, {"article": "The 54-year-old said: \"I knew straight away that I had been given the drug.\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of alternative treatments for asthma. There is no comparison with current approaches such as inhalers and corticosteroids or any other approaches regarding this illness.\nThere are a variety of established treatments that are used according to standard protocols depending on asthma severity.  ", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are currently ways to detect colon, lung, breast and ovarian cancers, all with some major benefits and some troublesome harms. \u00a0If this odor-sensing\u00a0technology is to succeed, we need to know if it is able to detect early signs of the disease\u00a0more accurately than current technologies\u00a0that are in use. The story should have discussed that.", "answer": 0}, {"article": "\"It might be tens or hundreds of dollars, rather than thousands,\" he said.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\nThe researchers also found a similar type of blood test could determine gestational age, which is used to calculate the due date of the baby.\nIn a test of 31 healthy pregnant women, testing for nine cfRNAs seemed roughly as accurate as an ultrasound at measuring gestational age.\nThe test, if it does turn out to work in clinical trials, would be cheaper than ultrasound, said Quake.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "BuzzFeed\u2019s story establishes early on that ultrasound tests are the go-to method for determining pregnancies that are at-risk for preterm delivery, among other complications. It also gives the accuracy of that test as a measure (48%) and compares it to the experimental test\u2019s accuracy (45%).", "answer": 1}, {"article": "Stay out of the sun, or utilize a proper sunscreen.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nBut a new study published Monday in Cancer suggests that at least one decision our parents make FOR us may have an impact on our predisposition to certain types of cancer.\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll rule this one Not Applicable.\u00a0 It didn\u2019t discuss alternative ways to reduce the risk of prostate cancer and that is understandable.\nThe story didn\u2019t discuss any alternative ways to reduce the risk of prostate cancer.\u00a0 Studies have suggested that chemoprevention with drugs such as finasteride or dutasteride can reduce the risk of prostate cancer by about 25%.\u00a0 Though the benefits of this are controversial, it would provide a ballpark comparison.", "answer": 2}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the new drugs to the standard therapy for chronic hepatitis C. \n", "answer": 1}, {"article": "The women were then followed for an average of three years.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nThe authors say that improving doing more light and moderate physical activity could be almost as effective as rigorous exercise at preventing disease and prolonging life.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\nIn a study of women age 65 and older, just 30 minutes a day of light exercise\u2014like running errands and cleaning the house\u2014was linked to a lower risk of death.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared different levels of physical activity. As such, it was comparative. However, there are other important lifestyle habits that affect mortality (cigarette smoking or drinking alcohol, for instance), and it would be interesting to know how helpful light activity is compared to these other lifestyle modifications.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes the question of whether the lice control products are any more effective than regular shampoos and conditioners. It also mentions that girls can keep wear their hair \u201cup and tight.\u201d", "answer": 1}, {"article": "\"Now they tell me, 'You never say 'What?'\nThe implant is permanent.\nMerlo had Esteem implanted in her left ear in September.\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\n\"That helps my speech,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly mentions hearing aids, but the article does not go into detail about other alternatives to surgery.", "answer": 0}, {"article": ".\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nTheir study showed that small molecule analogs that target the functions of SecA, a central part of the general bacterial secretion system required for viability and virulence, have potent antimicrobial activities, reduce the secretion of toxins and can overcome the effect of efflux pumps, which are responsible for multi-drug resistance.\nThe inhibitors also reduced the secretion of three toxins from S. aureus and stopped three MRSA strains of bacteria from reproducing.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that there are antibiotics currently used to treat MRSA infections. More detail regarding the effectiveness of these antibiotics and rates of antibiotic resistance would have been welcome.", "answer": 1}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nBecause of the widespread impact of high blood pressure, researchers are likely to investigate in some depth any simple dietary interventions that could potentially benefit the wider population.\nThe authors note that the reduction achieved in the active supplement group is close to that achieved by medication.\nResearchers have concluded that one glass of beetroot juice a day is enough to significantly reduce blood pressure in people with high blood pressure.\nThis is the first study that shows evidence of dietary nitrate supplementation's long-lasting benefit in a group of patients with high blood pressure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make\u00a0the\u00a0point (through a quote borrowed directly from a news release) that for some high blood pressure patients, complying with daily doses of drugs to combat their condition, \u201cwhen they feel ok,\u201d presents a major problem, and therefore, obtaining the same therapeutic outcome though eating specific foods would be \u201chugely beneficial.\u201d The story also notes that there are other sources of dietary nitrate other than beet juice, including leafy greens\u00a0such as lettuce and cabbage.\nWe\u2019ll award a satisfactory here, but we note that the story could have mentioned several other dietary approaches that are also associated with lowering of blood pressure. The best known are lowering sodium intake and the related \u201cDASH diet.\u201d Weight loss and exercise are also among the range of blood pressure-lowering alternatives.", "answer": 1}, {"article": "\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\nMoon and colleagues studied these responses in 10 athletes who had experienced the condition while exercising or competing in triathlons.\nOne study participant, triathlete Katherine Calder-Becker, said her bouts with SIPE threatened to end her competitive career.\nMoon said larger studies are needed to replicate the results and learn more about possible adverse side effects of the drug.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Information about possible treatment alternatives (for example, diuretics or oxygen) is not provided.", "answer": 0}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nIt revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens.\nGrob\u2019s study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "Caused by defective genes, cystic fibrosis affects multiple organs.\nAlthough HGH not a cure for the disease, which afflicts 30,000 people in the U.S., the researchers found that it reduced the number of hospitalizations among those who have the disease.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\n\"Hopefully, this is going to encourage cystic fibrosis care providers to use it more frequently in patients at the lower end of weight and of short stature,\" Lapin said of the findings.\nHuman growth hormone is a promising tool in treating cystic fibrosis, a new University of Connecticut study suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\nBesides certain foods containing EPA and DHA, supplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects, he added.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release doesn\u2019t mention evidence-backed strategies to reduce breast cancer risk such as limiting alcohol consumption and getting exercise.", "answer": 0}, {"article": "For more information, see www.scripps.edu.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe original form of vancomycin is an ideal starting place for developing better antibiotics.\nEven if the process isn\u2019t streamlined, Boger believes the new vancomycin\u2019s lifesaving powers make its production valuable.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t discuss the other areas of research into developing new drugs that may be useful in addressing antibiotic resistance \u2014 and it\u2019s a large field. We would not expect a news release to provide an exhaustive overview of other approaches being taken, but providing a sentence or two about other approaches would be extremely valuable in helping readers to place the new work in context.", "answer": 0}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nLike many patients his age, he didn't expect there would be any effective treatment.\nOne year after surgery, more people had died from other causes than died from lung cancer.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "For early stage lung cancer elderly patients who may be presented with a spectrum of choices from surgery to hospice, the article provides little evidence-based advice.", "answer": 0}, {"article": "HDL cholesterol is not fully understood, but essentially sucks cholesterol out of cells, to be flushed from the body through the liver.\nThe study was sponsored by Merck, the drug\u2019s manufacturer.\nPeople who can\u2019t control cholesterol with diet, exercise and statin drugs could soon have a new option.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\nThe first patients will be enrolled in April, according to Dr. Rory Collins of Oxford University, where the research will be overseen.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The lead sentence of this story portrays the experimental drug as a potential complement to lifestyle changes and statin treatment. ", "answer": 1}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nIn two trials of 484 patients in total, people were given either OraVerse or a sham injection.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not seriously explore the treatment \"option\" of not having the injection. ", "answer": 0}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\nThough they may suffer from physical and emotional pain as a result of VVA, women may not feel comfortable discussing these symptoms with a healthcare professional, may not recognize the symptoms as treatable, may not fully understand the treatment options available, or if they did receive treatment, found the current prescription treatment options inconvenient, messy, or uncomfortable to use.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions several other over-the-counter and prescription products used to treat symptoms of VVA, including creams, moisturizers, tablets, vaginal rings and oral drugs. However, it does not explicitly compare the softgels to these products but mentions that women preferred the softgels to them. The only reference to this comparison comes in a quote from the first author, who described the softgels as \u201ca more elegant delivery system that is easier to use and not messy.\u201d\nIt would have been nice to see the data on how those women who had previously used another product felt the softgels compared.", "answer": 0}, {"article": "\u201cThis is an important finding,\u201d said co-lead researcher Prof David Murray.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\nResearchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) publishing in the BMJ Open journal found that the less invasive procedure was being used less than it could be.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "If, as we noted under \u201cDisease Mongering,\u201d the story is focused only on patients that require either partial or total knee replacement, then the only alternatives are, well, partial or total knee replacement. And the story refers explicitly to both.\nBut there are nuances missing. The partial procedure is thought to be a simpler one. As such, it may lead patients to undergo surgery at an earlier stage than they may otherwise have if they had the full replacement. As such, an alternative of waiting would be reasonable. This really is the challenge. There are few things between conservative measures and surgery for patients with knee arthritis.", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nThe patients who received AMG145 had 41 percent to 63 percent reductions in \"bad\" (LDL) cholesterol and did not experience significant muscle-related side effects, said study leader Dr. David Sullivan, of the Royal Prince Alfred Hospital in Australia, and colleagues.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"For those patients with elevated LDL who are intolerant to statins, this provides a viable option,\" said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make clear that this drug is intended to offer an alternative to patients who have problems with standard statin drug treatment. It also reports that reductions in LDL cholesterol levels were comparable to those seen with statin treatment. However, as noted above, the story fails to point out that while statin treatment has been shown to reduce health risks for patients with heart disease neither this trial nor any others have yet shown meaningful health benefits for these patients.", "answer": 1}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\nHe added that creating an actual test for use by doctors will require collaboration on the part of researchers.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted earlier, the story explicitly compared accuracy rates for the saliva test versus the survey tool doctors currently use. In addition, the story mentioned that researchers also are testing for concussion-related biomarkers in blood, using EEG records and \u201cexploring functional MRI techniques to look at the metabolic function of different areas of the brain.\u201d The story discusses all of these approaches as preliminary investigations.", "answer": 1}, {"article": "Professor Roy Taylor said: \"What we have shown is that it is possible to reverse your diabetes, even if you have had the condition for a long time, up to around 10 years.\nThe group included many people with longer duration diabetes, defined as more than 8 years and ranging up to 23 years.\nIn fact, after 6 months a thirteenth patient had reversed their diabetes.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\nParticipants in this study had Type 2 diabetes for between six months and 23 years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are alternatives to this diet that have been shown to correct blood sugar results in large studies \u2014 specifically weight loss surgery. This should have been mentioned.", "answer": 0}, {"article": "Also, there was increased expression of an enzyme involved in blood vessel formation and a protein involved in nerve cell survival and growth.\nThe mice with a condition simulating Alzheimer's disease in humans received 11 LIPUS treatments over a period of three months.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\nThis limits the types of drugs and cell therapies that could be made available to treat dementia.\nThe mice with vascular dementia received the treatment on the first, third and fifth days following a surgical procedure that limited the brain's blood supply.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that \u201cthere are currently no curative treatments available for vascular dementia or Alzheimer\u2019s disease, the most common causes of dementia.\u201d", "answer": 1}, {"article": "The FDA needs good data to make their decision, because when the agency approves a drug is sends a signal to the world.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nIf they do say no, the Vertins could lose access to the drug that has stabilized their condition.\nThe Vertin brothers are not among them; the drug shouldn\u2019t help them at all.\nBut the family\u2019s struggles with DMD were just beginning.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no known cure for Duchenne muscular dystrophy.\u00a0 The story does devote some space to another drug, Exondys 51, which has been approved by the FDA, but the text is clear that the type of DMD that afflicts the three boys is not responsive to that drug.", "answer": 1}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job here. It mentions that pills were standard treatment for asthma decades ago, but were replaced with inhalers that deliver drugs directly into the lungs. It also mentions that drugmakers recently launched injectable drugs for severe asthma that also target eosinophils and \u201care developing improved asthma inhalers, including \u2018smart\u2019 devices with sensors that monitor use.\u201d The story could have elaborated on how inhalers might compare to pills in terms of safety and efficacy, and mentioned there are other\u00a0new drugs (known as leukotrene receptor antagonists) that are also available as pills.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0As noted in the competing reviews, the point of the study was to compare early palliative care with existing standard cancer treatment. We\u00a0wish, however,\u00a0that the story had spent more time discussing what standard\u00a0oncology care (the current \"existing\u00a0alternative\") entails. \u00a0\u00a0\u00a0\u00a0\u00a0", "answer": 1}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nTheir approach detects micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nDr. Lu\u2019s team used a biochemical approach combined with MRI to detect molecular changes that signal micrometastases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted earlier, the release had some information about alternatives, but it was somewhat disjointed and the reader would have a hard time understanding that there are indeed alternatives to this approach without reading the original paper.", "answer": 0}, {"article": "No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.\nThe SelectMDx test can help predict the likelihood that clinically significant prostate cancer will be found by a biopsy.\nThe test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the text does a good job of explaining the risks of a prostate biopsy, it does not make clear that the gains found in the study stem from a comparison of employing the SelectMDx test to determine if a particular prostate cancer warrants further diagnostic efforts versus using a PSA test or ultrasound to make such a judgment.\nThe traditional alternative is actually to make biopsy decisions based on PSA alone\u2013not ultrasound (which is used for the biopsy). \u00a0However, MRI is increasingly being used to identify potential high-risk tumors and guide guide biopsy decisions: MRI-targeted or standard biopsy for prostate-cancer diagnosis. \u00a0Kasivsisvanathan V, et al. N Engl J Med 2018; 378:1767.", "answer": 0}, {"article": "Check it out if you're interested in finding a trial for yourself or someone you care about.\nKnowing which patient with mild cognitive impairment patients may go on to develop Alzheimer's is vital information for researchers, who are looking for treatments for the fatal brain disease.\nThat suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer's disease, researchers say.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\n\"The way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "That independent expert added this important reminder:\n\u201cWhat I tell people is: If they\u2019re worried about their thinking abilities, that they should make an appointment with a neuropsychology or a neurologist to get an evaluation,\u201d Brinkman says. \u201cThe way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\u201d", "answer": 1}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release lists alternative therapies for SJD which include \u201cphysical therapy, steroid injections and/or radiofrequency ablation of sacral nerve root lateral branches\u201d as well as the therapy compared in the trial.", "answer": 1}, {"article": "I couldn't get anything done,\" Ham said.\nCannabis could have limited benefits as a treatment alternative, said Harvard Medical School's Dr. Kevin Hill, who last year authored the JAMA study that found benefits in using medical marijuana to treat chronic pain, neuropathic pain and spasticity related to multiple sclerosis.\nAdvocates argue a growing body of scientific literature supports the idea, pointing to a study in the Journal of Pain this year that found that chronic pain sufferers significantly reduced their opioid use when taking medical cannabis.\nAnother study, published last year in the Journal of the American Medical Association, found cannabis can be effective in treating chronic pain and other ailments.\nSubstance abuse experts argue there are already approved medications.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives were not adequately discussed. There are a wide range of alternatives for pain control other than\u00a0opioids and marijuana treatment options, such as\u00a0non-opioid analgesics and physical therapy. Also, the prescription drug\u00a0Marinol is a medicine with the active ingredient of marijuana (THC) that\u2019s approved to treat the nausea of chemotherapy and for appetite stimulation in HIV patients, and the dosing can be better controlled.", "answer": 0}, {"article": "However, \"I don't want women who chose mastectomy to think they did the wrong thing,\" Hwang said.\nThe findings may reverse the mastectomy trend, said Dr. Laura Kruper, co-director of the breast oncology program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., who was not involved in the study.\nHwang believes the study does arm women with valuable information.\nHwang and others suspect that women told they could safely opt for lumpectomy were still afraid to try it.\nThe study is scientifically sound in many ways, Kruper said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t say anything about adjuvant chemotherapy or hormone therapy.", "answer": 0}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nTrulance should be avoided in patients six years of age to 18 years of age.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should not be used in patients with known or suspected mechanical gastrointestinal obstruction.\nTrulance should not be used in children less than six years of age due to the risk of serious dehydration.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A mention that there are numerous other prescription medications, over-the-counter drugs and lifestyle treatments available for this condition would have been beneficial here.", "answer": 0}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\nBut it did reveal it was important to further study hormones and the body\u2019s endocrine system, and how they relate to mental illnesses like anxiety and depression, he said.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives to testing cortisol levels in hair were mentioned \u2014 as in saliva and blood.\u00a0Alternatives regarding ways to identify children at risk would seem to abound and likely explain much more than any lab test ever will. For example,\u00a0kids who come from homes where they aren\u2019t provided with adequate food, from parents with mental health problems, etc. (sociological/environmental variables). We\u2019ll give the benefit of the doubt here but it\u2019s really only a partial Satisfactory.", "answer": 1}, {"article": "\"The challenge now is to determine if humans benefit the same way,\" said Gerdes.\nImportantly, there are currently no effective treatments for diastolic heart failure.\nAbout half of the human patients with heart failure suffer from this particular condition, known as diastolic heart failure.\nA 2013 study in The Journal of Translational Medicine showed thyroid hormone treatment administered to rats at the time of a heart attack led to a significant reduction in the loss of heart muscle cells and improvement in heart function.\nEarlier, a study in the Journal of Cardiac Failure found that thyroid hormone replacement therapy in rats significantly reduced the incidence of atrial fibrillation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many heart failure treatment options, from surgery to drugs. But most of those treatment options, such as angiotensin-converting enzyme (ACE) inhibitors, target systolic heart failure specifically. There are currently no effective treatments for diastolic heart failure, and the release tells readers this.(Diastolic heart failure happens when the left ventricle doesn\u2019t let in enough blood; systolic heart failure occurs when the left ventricle doesn\u2019t squeeze hard enough to push out sufficient blood.)", "answer": 1}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\nBut many tumors do not significantly differ from surrounding healthy tissues with contrast enhanced MRI and so evade easy detection.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We don\u2019t think the story discusses the relevant comparison techniques. It talks mainly about the new technique\u2019s performance compared with other types of MRI. But as noted above, many prostatic cancers, especially those with low PSA and Gleason scores, are not imaged at all (other than by ultrasound during biopsy). For us, the meaningful comparison of the new MRI technology would be with clinical staging, not another MRI technology. Unfortunately, such a comparison is never made or discussed.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story skates very quickly by the notion that diet and exercise are alternatives to the ReShape device, as well as alternatives to bariatric surgery.\u00a0 It would have helped to quote a psychologist or other expert on behavior change about what permanent value may or may not come from such a short-term weight loss.\nTo have a medical device, with very real risks, temporarily placed in someone\u2019s stomach in the name of temporarily losing 7 more pounds than matched controls (whose weight losses may well be longer lived given they were fueled by behavior change) is not good medicine. \u00a0The story \u2013 perhaps through the input of an independent expert \u2013 could have made the point that\u00a0well-supported behavior modification may have achieved the same result as the balloon intervention did.", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although competitors\u2019 drugs were mentioned, the context in which they are used was neglected.\u00a0 The majority of people with psoriasis use topical products (never mentioned) to manage their skin disorder.\u00a0 The focus on very expensive biologic treatments without noting the drugs are used in patients with moderate to severe disease is a skewed picture.\u00a0 ", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An independent source is included who mentions transcranial magnetic stimulation (TMS) and electroconvulsivetherapy (ECT)\u00a0as alternatives to antidepressants in the treatment of resistant depression.\nOne alternative that is not mentioned is cognitive behavioral therapy.", "answer": 1}, {"article": "Moffitt is the No.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release briefly referenced chemotherapy and endocrine therapy as alternatives to pre- and post-surgical radiation but offered no comparison data.", "answer": 0}, {"article": "DOI: 10.1371/journal.pone.0177782\nWhile the Pap smear can be performed by a non-specialist, colposcopy requires visualization of the cervix, relying on highly trained professionals and expensive equipment that is not easily accessible to underserved populations.\nCurrent standard practices for cervical cancer screening require three things: a speculum, a colposcope and a trained professional to administer the test.\nHealth providers -- or even women themselves -- are able to capture images of the cervix using the rounded tip of the device to manipulate its position if necessary.\nThat is in part because women do not receive screening or do not follow up on a positive screening to have colposcopy performed at a referral clinic.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is some description of current standard screening practices, and several failed attempts at lower-cost alternatives to traditional practice are briefly mentioned.\u00a0However, we are rating this Not Satisfactory for several reasons. First, there is confusion about the role of colposcopy; it is not a primary screening tool, but rather a method for further evaluation of women with an abnormal screening test for cervical cancer. Colposcopy is an essential part of any screening program, to be sure, but it is not generally seen as feasible or effective as a primary screening test. Second, cervical cancer screening methods in resource-poor settings have been actively studied and several alternatives to standard Pap smears exist. These include HPV testing (a rapid HPV test is under development using a self-collected sample) and visual inspection after acetic acid application.", "answer": 0}, {"article": ".\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nDespite the adverse effects, more than 75 percent of participants reported being willing to use this method of contraception at the conclusion of the trial.\nOnly four pregnancies occurred among the men's partners during the efficacy phase of the study.\nDuring this period known as the efficacy phase of the study, the men continued to receive injections every eight weeks for up to 56 weeks.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions other available birth control methods for men including condoms, vasectomies and withdrawal. However, it should have given readers an idea of how the efficacy rate of injectable hormones compares with other available methods of birth control. According to the study, the efficacy of male injectible hormones is high when compared with other reversible methods available for men, and is comparable with the efficacy of female oral contraceptives.\nAlso, the news release did not mention other approaches to male birth control under study, which include hormone-containing gels applied to the skin and the synthetic hormones that could be formulated into a pill as well as non-hormonal mechanisms to prevent sperm development, according to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.", "answer": 0}, {"article": "Dr. Carroll's co-authors are Eric C. Larsen at Maine Children's Cancer Program, Scarborough, ME; Meenakshi Devidas and Si Chen at the University of Florida; Wanda L. Salzer at the U.S. Army Medical Research and Materiel Command, Fort Detrick, MD; James B. Nachman at the University of Chicago; Elizabeth A. Raetz at the University of Utah; Mignon L. Loh at the Benioff Children's Hospital and the University of California, San Francisco; Leonard A. Mattano Jr. at HARP Pharma Consulting; Catherine Cole at Princess Margaret Hospital for Children and University of Western Australia; Alisa Eicher at Doernbecher Children's Hospital, Portland, OR; Maureen Haugan at Ann and Robert H. Lurie Children's Hospital of Chicago; Mark Sorenson at University of Iowa Hospitals and Clinics; Nyla A. Heerema and Julie M. Gastier-Foster at The Ohio State University School of Medicine; Andrew A. Carroll at the University of Alabama at Birmingham; Michael J. Borowitz at Johns Hopkins Medical Institutions; Brent L. Wood at University of Washington; Cheryl L. Willman at University of New Mexico; Naomi J. Winick at University of Texas Southwestern Medical Center, Dallas; and Stephen P. Hunger at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania.\nThe clinical protocol also examined how to best use a steroid formulation called decadron to treat high-risk ALL patients.\nThis was a large-scale study involving pediatric cancer centers across the country.\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is comparing the efficacy of treatment regimens using different drugs so alternative treatments\u00a0for B-acute lymphoblastic leukemia are noted.", "answer": 1}, {"article": "The editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0did not make any reference to dietary changes, lifestyle changes, or exercise.", "answer": 0}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nAn international team of scientists found that Montmorency tart cherries helped to positively impact the gut microbiome - a collection of trillions of bacteria and other microbes that live in the intestinal tract.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "What\u2019s not made clear to readers is that dozens (perhaps hundreds) of foods and beverages are rich sources of polyphenols.", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll rate this Not Applicable. The story deals entirely with focused vs. whole-brain radiation and doesn\u2019t discuss other approaches to brain cancer such as surgery or chemotherapy. But radiation is the standard of care for brain metastases (the main focus of the story), so we don\u2019t feel that the story should be expected to discuss those other treatments. Had the story mentioned the fact that radiation is the standard of care in this situation, we would award a Satisfactory. But since no mention is made either way, the best the story can do is Not Applicable.", "answer": 2}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nBriana enrolled in the phase 1 clinical trial of larotrectinib and began taking the drug twice a day.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The case study of the responsive patient includes mention of surgical management of her tumor prior to larotrectinib. The release does not include mention of the chemotherapy agents that are considered first-line therapy for many pediatric cancers.", "answer": 0}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nFourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.\nThis poor prognosis is partially due to the fact that most patients are not diagnosed until they are already at a late stage of the disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that chemotherapy is a first-line treatment for these types of mesotheliomas and it alludes to other standard therapies without naming them. We are not told of the potential of other therapies to treat this disease and the prognosis of those patients, nor the effectiveness or safety of competing therapies. We\u2019ll give the benefit of the doubt but that additional information would have been helpful.", "answer": 1}, {"article": "(Reuters) - U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbbott said it expects the risks to lessen as surgeons gain experience with it.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAnalysts have predicted Absorb will gain a market niche but not surpass drug-dispensing metal stents such as Xience in share until longer-term data show more favorable clinical results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The clinical trial summarized in the story compared the dissolvable stent with a metal stent coated with a drug to minimize future blood clots.\nThe story would have been stronger if it also had\u00a0mentioned traditional metal stents (with no drug coating) and the use of drugs to manage heart disease.", "answer": 1}, {"article": "Before cimaglermin could be used to treat patients, it must prove its worth in a series of progressively larger and challenging trials and then be approved by the U.S. Food and Drug Administration.\nPeople with heart failure often take a combination of drugs, Lenihan said.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nOne patient who received the highest dose of cimaglermin developed abnormal liver function, which cleared up over a two-week period, Lenihan said.\nEvery drug currently used to treat heart failure has to be given daily or several times a day to get it to work, Bishopric said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention alternatives for dealing with weakened left ventricular function, primarily through this paragraph:\n\u201cPeople with heart failure often take a combination of drugs, Lenihan said. These include medications to lower blood pressure and diuretics to help remove excess fluid that builds up as a result of the heart\u2019s labored pumping ability. In addition, some people have implanted defibrillators or pacemakers.\u201d", "answer": 1}, {"article": "After 78 weeks, they found that patients given bapineuzumab had about a 25 percent reduction in plaque compared with those on placebo.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nThe treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling.\nThe drug\u2019s developers have since dropped the top dose from large ongoing Phase III trials.\nThe new study, which only involved 28 patients, is modest fillip.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of other approaches to treating Alzheimer\u2019s disease.", "answer": 0}, {"article": "But don't rush out to adopt a furry friend just yet.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nThe latest findings from Kozyrskyj and her team's work on fecal samples collected from infants registered in the Canadian Healthy Infant Longitudinal Development study build on two decades of research that show children who grow up with dogs have lower rates of asthma.\nHer team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This study is focused on describing the association between allergies and pets that were observed over a long-term study. But since the ultimate goal seems to be reducing allergies and asthma there are alternatives to exposing your baby to a dog to prevent them, such as incremental exposure and allergy screening tests. These alternatives were worth a brief mention.  ", "answer": 0}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is effectively a comparison between the use of SDF and the use of drilling and filling to treat cavities. The story does not address the use of laser technology, in lieu of drilling, but that technique still requires the use of fillings \u2014 and would still require the patient to be still during potentially lengthy treatment (which is one reason for the use of general anesthesia in young patients).\u00a0 Alternatives of using nitrous oxide in the office or procedural sedation with the proper safeguards were not\u00a0discussed, either.", "answer": 1}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\nThe use of concomitant cisplatin and radiotherapy resulted in a statistically significant improvement in laryngeal preservation compared with radiotherapy alone, with a hazard ratio of 0.46.\nPatients who entered the trial had stage III or IV nonmetastatic squamous cell carcinoma of the oropharynx, hypopharynx, or larynx (Figure 1 and Table 1).\nPatients received weekly cetuximab infusions during the radiotherapy treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The focus here is on laryngeal cancer treatments that don\u2019t require surgical intervention, so we can leave surgical interventions out of the picture. However, there are a range of other chemotherapy treatments that can be used in conjunction with radiation therapy, such as cisplatin. The release doesn\u2019t mention these \u201cchemoradiation\u201d options, much less offer any sort of comparison.", "answer": 0}, {"article": "It seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story the benefit of the doubt on this criterion. The story indicated that a regular diet supplemented with probiotics was not better for relief of constipation in children than supplementation with dairy products.\nAt the end of the piece, there was mention of treatment which consists of education, dietary advice, behavioral modification and then if these were unsuccessful, the use of laxatives. Because in this context \u2018dietary advice\u2019 often refers to fiber content and fluid consumption in the diet, it is not clear how probiotics compared to these other approaches.", "answer": 1}, {"article": "Co-authors are Evgeny Pokushalov, M.D.\nAbout half of those patients will develop AF after surgery.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\nIf confirmed in heart bypass patients, Botox injections could also help prevent AF in people undergoing valve repair or replacement.\nBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Given the impact of post-operative atrial fibrillation, it is reasonable to assume that other attempts have been made to reduce its incidence in this population.\u00a0 A variety of antiarrhythmic drugs and beta adrenergic blockers have been studied with variable results. It would have been very helpful to add a few words about the alternative pharmalogical agents.", "answer": 0}, {"article": ".\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nThis data highlighted compelling early results using the company's MRIdian system for the treatment of inoperable, locally advanced pancreatic cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This study was all about comparing alternatives, so it scores Satisfactory on that criterion. It would have helped readers if alternatives would have been described more in laymen\u2019s terms.", "answer": 1}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\nThe women in the study had to suffer at least six episodes of incontinence over three days.\nThis study covered urge incontinence, but there\u2019s also stress incontinence, which is caused by pressure on the bladder.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We not only see a comparison to the medical device that the study focused on, but also methods that require no overt treatment, \u201csuch as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\u201d The story also notes that \u201c[e]xercises to strengthen the pelvic floor muscles can help, as can \u2018bladder training\u2019 to accustom the body to urinating at regular times.\u201d\nThe story could have been more clear that these treatments aren\u2019t likely to work for the women in this study who had a specific type of severe urge incontinence that is usually not responsive to exercise and other less invasive measures.", "answer": 1}, {"article": "Rates are rising, in part because tanning became fashionable.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\nNew data about to be released to a meeting of cancer specialists shows that 40 percent of the patients who have been taking the drug are still alive three years later.\nAbout 15 percent of these patients have what\u2019s called a complete remission, meaning there is no trace of their tumors.\nThe drug, called Keytruda, takes a new approach to treating cancer by stopping tumor cells from cloaking themselves against the normal, healthy immune system response.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the\u00a0majority of participants in the study had Stage IV disease and had limited treatment options. It also briefly discusses the other alternative treatment, i.e. ipilimumab.\nWhile this is Satisfactory for this criterion, we would have liked to see more general information about how melanoma is treated,\u00a0including surgery, chemotherapy, and radiation therapy.", "answer": 1}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nResearchers have developed a prototype male pill that appears to be safe in a month-long trial.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\nResearchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does refer to other medical treatments aimed at male birth control that are under development, namely \u201ca long-lasting injection or topical gel.\u201d So we\u2019ll give it credit here. We wish it had offered slightly more information here (e.g., are both of those technologies also hormone-based?).", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nThe drugmaker is testing other CBD treatments for glioblastoma and schizophrenia.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nThe drug is the first treatment approved for Dravet syndrome.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does note that parents are giving their affected children \u201cunregulated\u201d CBD formulations, and although there are also other drug treatments and (although of unproven value) some efforts at surgery to abate the seizures, these offer less than good solutions, as the article notes.", "answer": 1}, {"article": "Taken together, the risk of suicidal thoughts and behavior was 0.43 percent for those on drug therapy and 0.22 percent for those given placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes some pharmacological treatments available for patients with epilepsy.\u00a0 No other treatments are discussed.\u00a0 The story\u00a0might have been enhanced by giving more info on alternative treatments along with some pros/cons.\u00a0\u00a0 \nOther available drug treaments include: phenobarbital, phenytoin, carbamazepine, valproate, gabapentin, lamotrigine, topiramate, levetriacetam, oxcarbazepine, zonisamide, felbamate. ", "answer": 0}, {"article": ".\nThis expanded cord-blood technique has been a \u201chuge home run\u201d for patients, said Colleen Delaney of the Fred Hutchinson Cancer Research Center in Seattle, who helped create it.\nBut she has been free of cancer for five years.\nQuinn, Gordon and 11 other participants in Delaney\u2019s clinical trial \u201care all alive, in remission, at a median age of about 4.7 years,\u201d the researcher said, but two patients died when the disease relapsed.\nWhat eventually saved her, though, was an experimental transplant using stem cells from the blood of a baby\u2019s umbilical cord, an approach that can be used without perfectly matching blood types.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and radiation but no true comparison to standard cancer therapies or even emerging cancer therapies \u2014 like immunotherapy \u2014 is done in the piece.", "answer": 0}, {"article": "\u201cMy first reaction to this study, because it came as a bit of a surprise, was, \u2018Oh, are we doing our job explaining that point to patients?\u2019\u201d Dr. Gralow said.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nDoctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes surgical treatment options for women with early stage breast cancer. However, the story does not mention radiation with lumpectomy. Forgoing radiation due to preferences to avoid side effects\u00a0 may play into a woman\u2019s decision to undergo a mastectomy or bilateral mastectomy. The story cites breast cancer experts who note that there is little difference between these surgical treatments in terms of dying from breast cancer.\u00a0 The story lists other non-surgical options for prevention for women at high risk of developing breast cancer, or having a recurrence. The story also didn\u2019t mention that some reconstruction procedures (e.g. tram flaps) can only be done once, so women considering those may have double and do both at once. \n\n", "answer": 0}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\n\"This important study demonstrates that many men with high-risk prostate cancer derive a survival advantage through a multi-modality approach to their disease.\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\nHowever, this may be an option for some patients to reconsider.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The point of the study was to compare two common treatment options, and both are adequately described in the release.", "answer": 1}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nAs for Cooke, she said she noticed a change in her depression almost immediately.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article\u00a0makes no comparison between botox and\u00a0current treatments for depression so we\u2019re left wondering: what does botox bring to the table? How do its benefits compare with medication? Does botox have fewer side effects?\u00a0Does it cost less than other therapies? All we get is anecdotal evidence from the one patient who had unsuccessfully \u201ctried alternative therapies and medication to cope with her symptoms.\u201d", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u2019s second paragraph briefly mentions some options:\n\u201cAvoiding germs entirely would require something like solitary confinement or a head-to-toe application of Purell. As an alternative, many people try to do what they can to strengthen their immune systems. Vitamin C is old news, and echinacea and other herbs haven\u2019t really panned out. \u201c", "answer": 1}, {"article": "After an average follow-up of almost six years, 149 of the 359 women, or 41.5 percent, had become pregnant one or more times, and 131 gave birth to a total of 150 babies.\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\nDespite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with symptomatic fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses the different alternatives for treating uterine fibroids. It at first leads the reader to anticipate a study comparing UFE to myomectomy, but it turns out that the study is\u00a0much more about comparing conventional UFE to\u00a0partial UFE. The hypothesis that partial UFE may help reduce the risks of infertility compared to conventional UFE could have been given\u00a0more discussion.\nIt is not clear why the lack of difference between conventional and partial UFE is not highlighted in the study abstract or the release.", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nBoth drugs increase the risk of dangerous bleeding.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story indicated that the drug reported on was more effective than the currently available treatments at reducing death, heart attack, and stent clotting. \u00a0The story would have been greatly improved had it provided absolute data on the occurrence of these events.", "answer": 1}, {"article": "The women were followed for an average of about 3.5 years.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAlthough the story says the decision to undergo preventive surgery is complex, it does not describe the alternative approaches that women may choose.", "answer": 0}, {"article": "Alcohol consumption may also protect people who already have the autoimmune disease from developing a more debilitating form.\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\n\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\n\"There are limitations to any research which asks patients to report their exposure to something (such as alcohol) over a period of time,\" Maxwell added.\n\"What's been reported is that people who drink excessive alcohol actually have higher levels of the cytokines that lead to the inflammation and moderate amounts of alcohol actually may lower these levels.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not even a word about other approaches to treating rheumatoid arthritis.\u00a0 Even a line may have satisfied this criterion. ", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\nOne year after starting treatment, all participants had improved vision.\nPhysicians now have robust data to help them counsel patients and make informed decisions regarding treatment options,\u201d says study co-author Lloyd P. Aiello, M.D., Ph.D., Professor of Ophthalmology at Harvard Medical School, Director of Joslin\u2019s Beetham Eye Institute, co-head of Joslin's Section of Vascular Cell Biology, and founding chair of the DRCR Network.\nAt the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses three competing drug therapies, but there should have been some mention of the alternative to drugs \u2014 laser treatment. How do these results compare with laser outcomes?", "answer": 0}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\nThe website includes detailed assistance developed by the National Cancer Institute to support smokers trying to quit.\nMore than 1.8 million smokers attempted to quit smoking because of the nine-week-long 2014 Tips From Former Smokers ( Tips ) campaign.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a number of other campaigns out there that aim to help smokers kick the habit, such as the FDA\u2019s \u201cThe Real Cost\u201d campaign. How effective have those other campaigns been? How does that compare to the 2014 Tips campaign? The release offers no information related to those questions.", "answer": 0}, {"article": "Newswise \u2014 Bethesda, Md.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other than the mention of organ transplantation, there was no mention of other treatments or preventative measures to prevent liver failure.\nFor a number of liver conditions, there are specific treatments. Whether statins are effective and how they compare to existing treatments is an unanswered question.", "answer": 0}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nA new procedure used by Phark and other doctors claims to stop the progress of cavities without drills or Novocain.\nThe new treatment uses a coating of mild acid that is applied to the decay to open up a route to the pores and clear out decayed enamel.\nThe treatment, called Icon, is one of several new cavity treatments that avoid drilling.\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story points out that fluoride treatment and other methods are less expensive, less invasive and have a longer track record than the featured product. However, the headline and lead anecdote portray the product as an alternative to traditional fillings, which is not an approved use of the product.", "answer": 0}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternative treatment options. Deep breathing exercises are mentioned, but what other options are available? What are the advantages and disadvantages of this approach by comparison?", "answer": 0}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\nBut recent work by one of Baker\u2019s co-authors hints that nasal sprays with the hormone insulin may have a positive impact on memory in people with Alzheimer\u2019s disease - although that\u2019s far from conclusive yet.\nBaker said researchers have failed so far to come up with effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\nBaker added that it\u2019s too early to say whether the hormone could play a role in thwarting the development of Alzheimer\u2019s, which may affect as many as five million Americans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Here\u2019s the relevant adequate section of the story:\n\u201cBaker said researchers have failed so far to come up with effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\nBut recent work by one of Baker\u2019s co-authors hints that nasal sprays with the hormone insulin may have a positive impact on memory in people with Alzheimer\u2019s disease \u2013 although that\u2019s far from conclusive yet.\u201d", "answer": 1}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\nIn addition, the Zika virus was much less efficient at attacking the differentiated, healthy brain cells.\nMice that got the ZIKV-LAV injected as well saw a significant delay in tumor development.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that normal cancer treatments such as radiation, surgery, and chemotherapy are not successful in the long run against\u00a0human glioblastoma brain cancer.", "answer": 1}, {"article": "TMS works by producing an electrical current that can pass through the skull and into the target area of the brain.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nIn a second phase of the study, all patients were given the real TMS treatment.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story doesn\u2019t do enough to describe the\u00a0treatment options for a patient with major depression who fails the first treatment: These options include a\u00a0change in medication or combinations of medication, psychotherapy with or without medication, and neurostimulation such as TMS or ECT. \u00a0This type of information could have been obtained from an independent expert. ", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\nOverall, the drug\u2019s benefits are particularly clear for people with both PDR and DME.\nThe results, published by the Journal of the American Medical Association, demonstrate the first major therapy advance for the condition in nearly 40 years.\nAbout 6 percent of eyes in the Lucentis group received laser therapy, mostly for issues other than DME.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does a good job of comparing Lucentis to conventional laser treatment for PDR and we\u2019ll award a Satisfactory rating on that basis.\nHowever, we\u2019d note that these are not necessarily the only two options. Lucentis is classed as an \u201canti-VEGF\u201d (anti- vascular endothelial growth factor) drug \u2014 by blocking a protein called VEGF, the drug can reverse abnormal blood vessel growth and decrease fluid in the retina. Other drugs in this category include Avastin and Eylea. Are those drugs under consideration for trials related to PDR treatment? If so, it\u2019s worth mentioning \u2014 particularly since Avastin costs around $60 per dose, as compared to Lucentis\u2019s $2,000 per dose.", "answer": 1}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\nThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\nEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\nOverall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release describes the results of comparing the diagnostic accuracy of regular CT or MRI scans alone or with the addition of sestamibi SPECT/CT\u00a0imaging. The release also states that the alternative to diagnostic certainty is surgery, even when it is unknown whether the tumor is malignant or non-cancerous.", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the context of the research, this is not relevant.", "answer": 2}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says \u201cthe ability of the test to correctly diagnose normal moles was 36 percent, approaching the levels achieved by expert dermatologists performing visual examinations of suspect moles under the microscope.\u201d\nThat differs from what\u2019s in the study, which reports \u201cthe visual examination of pigmented lesions by expert dermatologists using dermoscopy and following criteria such as the Menzies (or CASH[3]) method has yielded diagnostic accuracy as high as 98% sensitivity and 68% specificity in some studies.\u201d\nSixty-eight percent specificity is much more accurate than 36%, so we\u2019re not sure how that can be defined as \u201capproaching the levels\u201d of accuracy of visual exams by expert dermatologist.", "answer": 0}, {"article": "The study comes a month after Gov.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThe Texas law will require insurance companies pay $200 of the bill for patients to get the test every five years.\nIt eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough this story points out that alternative screening techniques are available and it makes reference to cholesterol, it does not include any details about the alternatives.", "answer": 0}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story introduces two approaches to managing arthritic pain for patients: joint replacement surgery and the bone cement outpatient procedure. The story mentions that the procedure is not appropriate for people with severe (\u201cbone-on-bone\u201d)\u00a0arthritis, but is directed at people with thin cartilage and mild arthritis. In standard clinical practice, joint replacement surgery is reserved for end-stage, debilitating arthritis. More appropriate comparison treatments for mild arthritis would include physical therapy and over-the-counter medicines. We do not learn from this story how the pain relief or functional improvements of bone cement compare to these typical conservative therapies. It\u2019s unclear whether or not this procedure has any place compared to standard treatment.", "answer": 0}, {"article": "\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nResearchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not tell readers either that other researchers are working on similar tests that use spinal fluid or that brain scans are also being developed that may be able to detect changes associated with Alzheimer\u2019s Disease.", "answer": 0}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe new treatment, 'vascular-targeted photodynamic therapy' (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In some cases, the news release accurately compares VTP with the control, active surveillance. However, it also misleads readers by comparing VTP with aggressive treatment for higher-risk prostate cancer. For example, it states:\nRadical therapy causes lifelong erectile problems and around one in five patients also suffer from incontinence. By contrast, VTP only caused short-term urinary and erectile problems which resolved within three months, and no significant side-effects remained after two years.\nMoreover, the wording used by the release is misleading\u2013radical therapy does not always cause lifelong erectile problems as suggested. Nerve-sparing procedures can preserve potency for a substantial proportion of patients.\nBut with respect to VTP, even short-term problems are unacceptable if the treatment is not actually necessary.", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the rise of imaging technology in diagnosing Alzheimer\u2019s disease, which used to be only definitively diagnosed post-mortem. It also mentions another new experimental technique \u2014 transcranial magnetic stimulation. We think the story could have better discussed the\u00a0relative accuracy of each option, though.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nYet there was only a slight drop in deaths from the condition over the same period, suggesting many of the clots were too small to cause harm.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The dilemma was framed appropriately at the end:", "answer": 1}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nWHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of \"good\" cholesterol, despite being treated with statins.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of alternatives. Not only are there many statins on the market, but there are other approaches to managing high cholesterol levels and triglycerides. While statins are clearly the standard of care for patients with specific characteristics, the release should at least make mention of alternatives.There have been a number of medicines used in patients with diabetes to examine their role in decreasing cardiovascular events. The fact that there are many alternatives \u2014 from changes in diet and exercise to supplements (niacin) and medications (such as those derived from Omega-3 fish oils and fibrate drugs which lower triglycerides) \u2014 should have been mentioned.", "answer": 0}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions alternatives in two different contexts. Chest radiography was an alternative test to CT scans. The study set out to analyze the most beneficial frequency of screenings and concluded that less frequency is a better alternative for smokers with an initial negative screen.", "answer": 1}, {"article": "(H\u00f6gqvist Tabor says it's tricky because it depends on the individual, and can range from a few beats per minute to 10 beats per minute.)\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nSo a woman who saw a bump in her resting heart rate history could use that information to schedule intercourse with her partner, H\u00f6gqvist Tabor said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the use of the Fitbit to manually tracking one\u2019s cycle (i.e. taking daily temperature and tracking consistency of cervical mucus). It also mentions some other gadgets that track body temperature. We\u2019ll award a Satisfactory on that basis, but there are a host of other options available for women who are seeking help in becoming pregnant. The story doesn\u2019t address any of them.", "answer": 1}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nMONDAY, April 25, 2011 (HealthDay News) -- Acupuncture might help reduce the hot flashes that frequently affect prostate cancer patients while they're on hormone therapy, a small study suggests.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There wasn\u2019t any comparison given between what acupuncture did in this tiny study and what else is now done or is being investigated for hot flashes in such men.\nOther hormone therapies and antidepressants are currently used.", "answer": 0}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\nAbout one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story mentioned opioids, laxatives, and\u00a0the drug\u00a0Amitiza as other potential treatments for IBS with constipation. But the story didn\u2019t discuss the mainstays of treatment for IBS \u2014 exercise and dietary changes (along w/ stress management).\u00a0It also didn\u2019t mention many other treatments that have at least some evidence to support their use, including\u00a0antidepressant drugs, fiber supplements, probiotics, anti-spasmodic drugs, and peppermint oil. In addition, there was also no discussion of how the benefits of the new experimental drug stack up against any of these alternatives. \u00a0", "answer": 0}, {"article": "Professor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\n\"Whilst we know a low-dose of aspirin has been shown to reduce the incidence of cancer, its role in the treatment of cancer remains uncertain.\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\n\"There is a growing body of evidence that taking aspirin is of significant benefit in reducing some cancers,\" said Professor Peter Elwood who led the research published in the journal PLOS ONE.\n\"The results from six studies of other cancers also suggest a reduction, but the numbers of patients were too few to enable confident interpretation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternative approach to going on a low-dose regimen of aspirin \u2014 i.e. not doing so \u2014 is assumed but not made clear. But we\u2019ll award points to the release for smartly quoting one of the study authors on seeking out the advice of a doctor before taking aspirin regularly.", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of how the effects seen in this study compare with other methods of improving cardiac health, managing cholesterol or sleeping better, including lifestyle or medications.\nModerate exercise, for example, also raises HDL levels, lowers blood pressure, and reduces waist circumference. \u00a0And yes, it also improves sleep and mood, and reduces fall risk.", "answer": 0}, {"article": "The FASEB Journal, April 2017, vol.\nMore research is needed to determine if compounds in red raspberries play a role in human cardiometabolic pathways.\nFollow-up research explored the potential relationship between feeding freeze-dried whole raspberry powder and cardiometabolic risk in obesity prone rats.\nA research team from the University of Michigan studied the potential biologically active properties of red raspberries with in vitro assays including antioxidant and anti-inflammatory capacities.\nAdditionally, a type of bacteria called Akkermansia that has been associated with metabolic health was increased during red raspberry intake only.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release was focused on raspberries, and raspberries alone. It would have been useful to know if other related berries (maybe blackberries, elderberries or lingonberries) have been found to have similar benefits.\u00a0", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\nGuss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\nAll patients in the study \u2014 mostly women age 22 to 75 who are or were patients at the Perlmutter Cancer Center of NYU Langone \u2014 had either advanced breast, gastrointestinal, or blood cancers and had been diagnosed as suffering from serious psychological distress related to their disease.\nStudy results were also endorsed in 11 accompanying editorials from leading experts in psychiatry, addiction, and palliative care.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that study participants received counseling in addition to the psilocybin treatment \u2014 which is an important point to make. However, the release doesn\u2019t discuss the use of counseling as a stand-alone treatment option for anxiety or depression, nor does the release address other pharmaceutical treatment options that can be used to treat mental health problems. The release would have been much stronger if it had compared the pros and cons of this treatment method with other treatment methods.", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nAnd that could explain why patients like James usually stop overheating once they are taking ketamine.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\nKetamine \"helped me get my life back,\" says James, who asked that we not use his last name to protect his career.\nThe fear was \"overwhelming,\" he says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes numerous claims about ketamine helping people when other treatments did not, but it does not provide specific comparisons about the pros and cons of ketamine compared to approved treatments.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a range of treatment options for lymphedema. The article mentions a few:\nThe main treatment consists of wearing compression bandages and massage to bring down swelling. A lymphedema specialist initially prescribed a large pump that massaged (patient) Wolfe-Tank\u2019s arm for an hour a night, temporarily relieving some of the pain.\nIt also says lymph node transfer is \u201cnot the only option. A technique called lymphovenous bypass reroutes lymph-carrying channels, going around damaged or missing nodes to drain into veins instead.\u201d\nThe story laudably conveys a recommendation that patients be \u201cevaluated in a comprehensive lymphedema program to determine their best options.\u201d Information on what a \u201ccomprehensive lymphedema program\u201d is and how to find one would have been useful.", "answer": 1}, {"article": "A study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nThe latest results, however, raise questions about that advice.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\nThe AHA further breaks down the unsaturated-fat advice by suggesting that people devote about 5% to 10% of their daily calories to foods containing linoleic acid.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even a brief mention of other approaches to reduce cardiovascular risk, such as other lifestyle changes (e.g. quitting smoking), drug therapy, and surgery, would have earned a satisfactory here.\u00a0 It would have required only a few more words to do so.", "answer": 0}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\nIt was 85 percent accurate in detecting these cancers in more than 300 patients, the new study found.\n\"At present the only way to diagnose esophageal cancer or stomach cancer is with endoscopy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made it clear that this test is to help improve upon the current method of endoscopy:\u00a0\u201cA breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\u201d It could have been clearer that finding cancers \u201cearlier\u201d \u2014 especially in healthy-seeming people \u2014 would be a huge leap from what is demonstrated here.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the continued benefit of mammography for early detection of breast cancer. The story highlights that computer-assisted screening does not replace human judgment in interpretation of radiological films. ", "answer": 1}, {"article": "Common symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nThe rate of infections and other serious side effects was similar in the Stelara and placebo groups, researchers said.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\nPatients in the study on average started at 320 or 325 on the CDAI scale, researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gets a check here for telling us that subjects in this study had tried TNF antagonists but didn\u2019t benefit or couldn\u2019t tolerate them. It gets another check when it mentions that when medicines for Crohn\u2019s disease stop working, many patients require surgery.\nThere was room for more details here, too, or an outline of what\u2019s unknown. The article states the trial was placebo-controlled in individuals who \u201cfailed\u201d other approved meds, but that doesn\u2019t mean we know how it compares to other meds commonly used, like prednisone.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nThis trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.\nThe trial was led in the UK by Professor Kevin Harrington of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 20 research organisations from around the world.\nNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.\nNivolumab will still have to go through approval by the European Medicines Agency and NICE before it is available for head and neck cancer patients on the NHS.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study at issue was for patients who were seeing cancer progression despite the use of conventional chemotherapy treatments. In other words, as the release makes clear, the alternatives had been tried already.", "answer": 1}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nThis combination of treatments, however, was not effective in men with either low-risk prostate cancer or advanced disease, the researchers said.\nFor patients with high-risk prostate cancer, using hormone therapy for just a short while is not effective, he added.\nOverall, hormone therapy reduced the risk of dying from prostate cancer over 10 years from 8 percent to 4 percent, Jones said.\nBut when the researchers looked closely at those findings, they found that patients with low-risk prostate cancer did not need hormone therapy because the chance they would survive with radiation alone was already almost 99 percent, Jones said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was some discussion about how current radiation therapy differs from that received by the men in the study reported on. \u00a0However there was no mention of some of the other forms of radiation therapy that are often used for men with low-risk prostate cancer such as brachytherapy.\nThere was no discussion of alternative approaches to prostate cancer such as surgery or delay of invasive treatment called active surveillance.", "answer": 0}, {"article": "GAITHERSBURG, Md.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that this drug would be taken in combination with current antiretroviral therapies. The story places this new drug in the context of a discussion of new drugs that interrupt the replication of HIV; however, bevirimat is still in the midst of clinical trials. ", "answer": 1}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nTraining with the system improved McGlynn's speed when it was turned off to 23 yards per minute, indicating therapeutic benefit.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\nNathan Makowski, an investigator at the Cleveland FES Center, created by Case Western Reserve and the Cleveland VA, said that FES technology has been used primarily for therapy in stroke patients in the past.\nBoth men gained strength and endurance through repeated use of the systems and fine-tuning by the researchers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s scant reference to existing treatments, with just one quote that briefly mentions physical therapy:\nIn each patient, \u201cthe pulses are sent in a pattern that is close to how normal muscles work,\u201d said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center. \u201cWe try to time the pattern to stimulation so that it\u2019s integrated with their ability. Similar to regular physical therapy, we can see results.\u201d", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that the current alternative option to the genetic test is to assess risk of recurrence based on a patient\u2019s age, other illnesses and tumor characteristics\u2013a method that results in a clear recommendation for or against chemo in only 30 percent of patients.\n\u00a0", "answer": 1}, {"article": "\u201cWe are not hopeful here.\u201d\nCanakinumab had stirred considerable scientific interest because it appears to finally deliver proof that fighting inflammation offers a promising new way to counter heart disease in patients who already get cholesterol-lowering treatment.\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\nNarasimhan, who said the company now plans to start separate cancer trials for canakinumab, said the drug could be particularly suitable for smokers with risks of both lung cancer and heart problems.\nWhile Narasimhan said it was too early to discuss pricing, he argued so-called PCSK9 cholesterol drugs that cost about $14,000 annually should not be relied on as a yardstick.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Both this story and the TIME story don\u2019t mention that there are\u00a0many effective and less expensive alternatives to secondary cardiac disease prevention, such as smoking cessation, aspirin, statins, blood pressure control, etc.", "answer": 0}, {"article": "On the other hand, longer treatment was tied to a 24-percent decrease in hip fractures, which along with wrist and spine fractures affect about half of all people with osteoporosis.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nAfter taking bone drugs for five years, about one in 1,000 women went on to suffer a thigh fracture over the next year.\nAnd one preliminary study, published along with the Canadian findings in JAMA, hints that the common heart medication nitroglycerin might also boost bone health.\nBut some experts worry that negative media coverage might have led to more fractures and possibly deaths by dissuading patients from taking the drugs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does briefly mention alternatives, including hormone therapy.", "answer": 1}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\nThe heart health benefits were even greater for men who sweated it out in a sauna more frequently.\nHe says there\u2019s evidence to support the use of infrared saunas for high blood pressure, congestive heart failure and chronic pain.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives are not discussed, especially for the health claims mentioned like sleep improvement or better heart health.\u00a0How do infrared saunas compare, for example, to exercise, diet modifications or other alternatives? Also, can the effects of a sauna be replicated by going out in hot weather and/or working up a sweat? What makes saunas unique and worth the time, effort and cost?", "answer": 0}, {"article": "Pneumonitis was more frequent among patients who were not actively using ace-inhibitors (Odds Ratio (OR) = 3.49, p = 0.02) and less frequent in smaller tumors (OR = 0.03, p < 0.01).\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nFor these patients, the best curative option is SBRT, a specialized type of external beam RT that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor.\nRecursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release claims that SBRT is effective, without mentioning other types of radiation therapy or other options for lung cancer patients who are not candidates for surgery. It is unclear to the reader what this \u201cnew\u201d treatment is meant to replace.", "answer": 0}, {"article": "\"Nobody wants to sedate a healthy infant,\" says Dawson.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nBosl says the first children enrolled in his study are now at 2 and 3 years old, which is the age when autism usually is diagnosed.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nDr. Max Wiznitzer says the researchers have found a \"really fascinating technique, that offers a different way to look at the brain.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to compare this diagnostic approach to existing approaches, saying only that \u201cBosl says the first children enrolled in his study are now at 2 and 3 years old, which is the age when\u00a0\u00a0autism usually is diagnosed. This will now allow the researchers to evaluate them for autism and then look back at the brain activity patterns of the children who do fit the clinical criteria for autism.\u201d How they are going to be evaluated for autism remains a big question. One presumes that they will be given a battery of behavioral tests, which, for now, are the gold standard. This should have been explained and the reasons why children younger than 2 cannot be accurately screened should have been explored.", "answer": 0}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\nStudy authors did point out that further clinical trials looking specifically at CHD outcomes may continue to provide a better understanding of the promising beneficial relationship between EPA/DHA and CHD risk.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many actions that invididuals can take to reduce their risk of coronary heart disease, including losing weight, exercising regularly, and managing stress. The release doesn\u2019t mention any of them. This is particularly problematic given that these are actions which are not mutually exclusive: one could lose weight, exercise regularly, manage stress and eat more fish (for example).", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nUnfortunately, the procedure provided no benefit to patients, though it caused substantial pain to two of the study participants.\nIn Pharr's father's case, the progress of disease was rapid.\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\nWhat he discovered during that experiment was that none of the patients suffered long-term effects (from either the surgical procedure or the implantation of stem cells), and no unusual acceleration of disease occurred.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are no effective treatments available.", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nDr. Biesecker acknowledged that there was no guarantee of success.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nStill, Mr. Del Sontro is preparing for the worst.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Dozens of novel\u00a0risk factors, such as C-reactive protein, have been\u00a0proposed to more accurately identify individuals\u00a0whose cardiovascular risk is not appropriately predicted\u00a0by traditional risk\u00a0factors.\u00a0The use of these novel risk factors\u00a0is controversial. The story should have addressed this evidence. What about the Framingham risk score?", "answer": 0}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\nBased on the current study and prior studies in acute migraine attack treatment, sTMS not only helps to stop a migraine attack, but it also helps prevent them.\"\nWhile there is no cure, a new study published in Cephalalgia in March shows single-pulse transcranial magnetic stimulation is a new way to prevent migraine attacks.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The lead author is quoted as saying:\nFor certain patients, treatment options for migraines, such as oral medications, are not effective, well-tolerated, or preferred.\nSome context would have been helpful here. It would help readers to know that the treatment of migraines is usually dictated by which of the several types of migraine the patient has (ie. episodic, chronic, environmentally triggered, and with or without an aura), and whether the goal is preventing an attack or treating an ongoing attack.\nTMS is a relative newcomer to a vast menu of treatment options for migraine.\nIt would have been helpful to state that there a large number of different treatments available for migraines including over-the-counter and prescription medications. Some are FDA approved and some are not. They include treatments for both acute symptoms of a migraine as well as preventing migraines from happening. There are also non-medication based treatments such as laying down in a darkened room and relaxation techniques. The use of preventive therapies for migraines is considered when the frequency is enough that focusing on the acute episode alone is not enough. This is something that patients decide, but is often considered if there are more than one attack per week. As noted, this study shows benefit, but it was not blinded and it doesn\u2019t compare itself to other available treatments.", "answer": 0}, {"article": "\"Additional research will be needed to fully answer this question in the future.\"\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThis suggests that the anti-inflammatory impact of routine exercise may minimize nocturia, he said.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\nThe study team said two of the higher-dose patients developed significantly low blood sodium levels (hyponatremia) as did one person taking the placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other treatments for nocturia are mentioned in the story, although it says there are no drugs approved for its treatment.\u00a0 However, there are a number of behavioral approaches to treating nocturia that are not considered at all in this story, except for a passing reference to another paper on exercise.", "answer": 0}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since the story involves the comparison of two classes of drugs for treating cardiovascular disease, there are obviously treatment options available.", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story ended with an important message about patient decision-making and with an expert quote that there are good alternatives to hysterectomy but many patients never hear about them.\u00a0 But then the story missed the golden opportunity of outlining what those alternatives are.", "answer": 0}, {"article": "\u201cThe findings were exciting,\u201d she said.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\nThe researchers found that the breathing exercise group\u2019s saliva had significantly lower levels of three cytokines that are associated with inflammation and stress.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention is made of other approaches to manage stress. Exercise, laughter, social support, meditation and mindful prayer, and stepping away from the problem have all been shown through research to reduce stress, according to the American Psychological Association, which notes that not every strategy works for every person.", "answer": 0}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nResults from the Phase 2 study, reported in the Journal of Neurosurgery on Dec. 18, 2015, demonstrated the safety of DBS in Alzheimer's patients.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\n\"Previous pilot studies researching the use of DBS in Alzheimer's have indicated the potential to slow cognitive decline in some patients, and have even shown metabolic changes in the brain that may slow the progression of the disease.\"\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release briefly mentions the fact that there are \u201cfew promising pharmacologic treatment options,\u201d but there is little discussion of their use or\u00a0efficacy. Except for that, there is no mention of other treatment. Based on growing\u00a0evidence, there\u2019s increasing support for the idea that prevention may be the best bet to impact Alzheimer\u2019s and other forms of dementia.", "answer": 0}, {"article": "Knee replacements were first offered in the 1960s, and hip replacements began in the 1940s, so many boomers are facing the same surgeries their fathers and mothers underwent.\nThe average age of patients listed in the American Joint Replacement Registry is about 66.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nAnd, he promised, \u201cI will get on the skates again.\u201d\n\nLike Smith, many boomers endured months or years of pain before surgery, pain caused by \u201cbone-on-bone\u201d friction when cartilage deterioration eroded their bone cushioning.\nBut having had the procedures, many say they wish they\u2019d done it sooner.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of alternatives such as cartilage restoration procedures to stabilize joints, losing weight to ease joint strain, and managing activity to avoid injury.\nTreatment of hip and knee osteoarthritis is a classic example of a \u201cshared decision\u201d that should be made based on patient preference because there is no \u201cright\u201d answer \u2013 joint replacement is often no better than physical therapy, for example, but this did not come across at all in the piece.\nHere\u2019s an example of a decision aid for hip and knee osteoarthritis.", "answer": 0}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\nIn fact, neither low doses of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, nor of alpha-linolenic acid (ALA), derived from nuts and several vegetable oils, provided any benefit to the vast majority of heart patients, the study showed.\nSo, the researchers theorized that the poor performance of the supplements may simply reflect the overwhelming power of the medications.\n\"It is possible that improvements in other treatments for heart attack patients have made fish oil supplementation less important for reducing cardiovascular risk,\" he acknowledged.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addressed some other approaches albeit indirectly: \"The scientists focused on patients who were already taking medications to control blood pressure, cholesterol and potential clotting. So, the researchers theorized that the poor performance of the supplements may simply reflect the overwhelming power of the medications.\"\nThere was no discussion of other things that have been shown to lower the risk of future coronary events in those who have had a heart attack beyond taking medications. Even one line offering such context would have been helpful. ", "answer": 1}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story discussed the use of probiotics for multiple conditions. We don\u2019t think the story could be expected to compare alternatives for all of these conditions, so we\u2019ll rate it not applicable.", "answer": 2}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nPigs fed PDX and GOS spent more time playing with new objects than pigs who didn't receive the prebiotic supplements.\nFortunately, modern infant formulas are getting closer to the real thing with the help of University of Illinois researchers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There was a clear need to discuss the alternative to infant formula which is, of course, breast milk of the mother mammal. It is curious to know if the control piglets were able to suckle with their mother, and thus gain other socio-emotional benefits of that bonding (plus probably other important developmental constituents of breast milk) denied to the formula-fed pigs.", "answer": 0}, {"article": "About 35% of U.S. adults take calcium supplements, alone or in multivitamins, according to a recent report in the medical journal JAMA.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\nSome people do need supplements.\n\u201cIf you look at the overall totality of the evidence, there\u2019s a lack of association between supplement use and heart attack and other cardiovascular events,\u201d says Manson, who co-wrote an editorial accompanying the review.\nThere are other reasons not to take calcium supplements.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "On its face, the story deals with two options: taking calcium supplements or not taking them. Both options are addressed here, so it earns a \u201csatisfactory\u201d rating. But this story also goes a step further, highlighting other factors in supporting bone health, including vitamin D consumption and exercise.", "answer": 1}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nAnd right now, HRT is the only treatment approved by the U.S. Food and Drug Administration for cooling hot flashes.\nAnd for now, he noted, it\u2019s also not clear why antidepressants would have effects on hot flashes.\nThose findings appear in a separate report in the journal Menopause.\nRight now, no antidepressant is specifically approved to treat hot flashes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions at the very end other remedies for treating hot flashes besides prescription drugs.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nRestaurants, office parties, potlucks, meals while traveling -- they're a minefield for people with celiac disease and gluten sensitivity who can suffer from stomach pain and upset, swollen joints, and other debilitating health problems when they ingest even a little bit of gluten.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article would be stronger if it mentioned not only the availability of other tests on the market, but also ways that those with celiac disease can reduce their risk of harm when they travel, eat out, or go to parties.\u00a0There is increasing availability of restaurants with the \u201cGF\u201d notation on the menu, indicating gluten free choices.", "answer": 0}, {"article": "\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nRight now, experts have little to go by in detecting autism other than carefully monitoring the regular developmental milestones in children, Young said.\nAbout 50 percent of kids with autism never develop language,\" she noted.\n\"We now feel pretty confident that, in many children with autism, there are alterations either in structure growth or connectivity of the brain, but we really don't understand the implications of that for core features of autism, one of which is problems with communication,\" Amaral said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reader would have benefited from a brief discussion on the current gold standard approach to the disgnosis of autism.\u00a0 While structural and functional diagnostic studies are used in research, they are not commonly applied in routine clinical care.\u00a0 The failure to compare existing methods to the study method does not allow the reader to appreciate how far from the norm the testing procedure is.\u00a0 There could have been more discussion of other diagnostic techniques that are in experimental trials or past techniques that have been tried and discarded.", "answer": 0}, {"article": "The National Institutes of Health, as well as the Michael J.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\nThis type of therapy increases levels of dopamine, a natural chemical in the body that sends signals to other nerve cells and can significantly decrease in cases of Parkinson's.\nCollier and collaborator Katrina Paumier, an assistant professor of molecular medicine, began looking at previous patient data to see if individuals who were on antidepressants experienced any delay in their need to go on a standard Parkinson's therapy called levodopa.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Parkinson\u2019s disease is complex, unfolds over many years, and has many dimensions. It is often misdiagnosed. The release should have included some description of treatments available. Besides the drug levadopa, surgery and other therapies have been used to ease symptoms.", "answer": 0}, {"article": "\"You don't get back the time you lost at work or the time you lost with your children.\"\nBut about 80% will get relief, he says \u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\nBut nearly 40% have headaches that are so frequent (at least once a week), severe or hard-to-treat that they qualify, Silberstein says.\nStill others try the treatments and decide they don't work or have unacceptable side effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is mainly about medications, but it does note that avoidable triggers can play a role in promoting migraines in some people.\u00a0 It also quotes a patient who says she\u2019s getting better results with diet, yoga and other lifestyle changes than with medications. We\u2019ll call it satisfactory.", "answer": 1}, {"article": "Their study was presented at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome, Italy.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nFibroids may cause severe abdominal pain, heavy bleeding, and interfere with fertility in some women.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Lupron and Uterine Artery Embolization as alternatives to EllaOne but fails to mention many other safe and effective options that are currently available. For example, oral contraceptives (which are not approved for fibroids but are commonly used for that indication) can help reduce bleeding and cramping associated with fibroids. Likewise, the Mirena IUD often stops bleeding altogether. NSAIDs can also be used for pain. Myomectomy, surgery to remove fibroids, preserves fertility. By not mentioning these options, the story leaves the reader with the impression that there are few viable alternatives.", "answer": 0}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\n\u201cPomegranate juice was shown in the last three years to contain the highest levels of polyphenols among a variety of products,\u201d Kristal said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, the Marion Nestle concluding quote was key:\u00a0 \u201cPomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity. Does this make pomegranates better than any other fruit? Investigators have yet to show this.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to note other measures sun-lovers can take to protect themselves from UV rays. These include the use of protective clothing and avoiding midday sun. (Dermatol Clin. 2002 Oct;20(4):601-6.)", "answer": 0}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "NIH lists a number of approaches to dealing with hot flashes in cancer patients, ranging from pharmaceutical interventions to hypnosis. The story mentions only those discussed in the study. We would like to see at least a mention of other techniques. And going a step further, it would be useful to compare the side effects of acupuncture to pharmaceutical solutions and other non-traditional approaches.", "answer": 0}, {"article": "The W.H.I.\n\u201cWomen today have so many options \u2014 a wide array of doses, from low to traditional, and ways to use them.\u201d In addition to pills, there are patches, gels and sprays applied to the skin.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\nMost of the 27,347 women entering the study were already in their 60s and 70s, already a decade or more past menopause.\nfindings, many new analyses and studies have prompted experts to rethink the wisdom of avoiding hormone replacement, especially for women within a few years of menopause whose personal and family history do not place them at high risk of breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story tried to cover so much ground in revisiting old ideas and explaining new ideas, it did not take the time to set up a comprehensive list of alternative ways for women to deal with menopausal symptoms. It listed the traditional hormone replacement and then discussed what it labeled \u201ccustom compounded\u201d products without much explaining of what they are.\nRegular exercise, for example, is among many non-drug approaches listed routinely for menopausal symptoms.", "answer": 0}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nThey used a statistical survival model to assess the probability that 655 specific demographic, lifestyle, and health measurements could predict death from any cause and six specific causes, in men and women separately.\nWe hope that our score might eventually enable doctors to quickly and easily identify their highest risk patients, although more research will be needed to determine whether it can be used in this way in a clinical setting.\nWhether this will help individuals improve self-awareness of their health status, however, or only lead to so-called cyberchondria, is a moot point.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study and its press release make much of the potential advantage of predicting death via self-report questions rather than biological tests. So the text makes an overt comparison, admittedly without data.\nThe release could also have included the comparison to doing nothing. Whether providing any risk information (this version or another) or no risk information makes a difference is a legitimate question.", "answer": 1}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that \"only an autopsy can establish for sure whether a patient had Alzheimer\u2019s. Brain scans and spinal taps are helpful, but they\u2019re not certain.\u00a0 But the story did not provide insight about treatment options and what one could and couldn\u2019t do with advance information about pending development of Alzheimer\u2019s disease.", "answer": 1}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nPatients with EGFR or ALK gene changes in the tumor received targeted treatments before starting therapy on this trial.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This trial is a direct comparison with existing treatment.\nAs it turns out, a similar trial involving squamous cell lung cancer patients, also presented at ASCO, that used a different immunotherapy drug, did report improved overall survival, but those results were not public when this release was written.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Herceptin (generic name trastuzumab) and chemotherapy (here, Xeloda) as other treatments for HER-2 positive breast cancer. ", "answer": 1}, {"article": "Please see paper for the complete list.\nOther collaborators on the study include Edwin C. Amos, Jonathan Canick, Mary Ackerley, Cyrus Raji, Milan Fiala, and Jamila Ahdidan.\n\u201cThe magnitude of improvement in these ten patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,\u201d Bredesen said.\nBredesen says decades of biomedical research, both in his and other labs, has revealed that an extensive network of molecular interactions is involved in AD pathogenesis, suggesting that a broader-based therapeutic approach may be more effective.\nDr. Bredesen hopes to eventually transform the perception and reality of Alzheimer\u2019s disease from a death sentence to a preventable reversible condition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release gives the briefest nod to an alternative, stating that the protocol to reverse memory loss \u201cfollows the abject failure\u201d of single-drug therapies for Alzheimer\u2019s. In reality, many interventions, not only drugs, have been tried and none have been found to work.", "answer": 1}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nWhat's new about the current treatment is the addition of a special signaling molecule called 4-1BB.\nThis may be why relatively small infusions of the CAR T cells had such a profound effect.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story talked about bone marrow transplants, while the Reuters story made no mention of them. This was an important comparison for readers. \u201cCure is possible, but it requires a risky bone marrow transplant. About 20% of patients don\u2019t survive this treatment \u2014 and even when they do, there\u2019s only a 50-50 chance of a cure.\u201d", "answer": 1}, {"article": "HIV, which stands for human immunodeficiency virus, infects and can destroy or change the functions of immune cells that defend the body.\nHis lab was the first to identify the proteins that can bind marijuana compounds on the surface of immune cells.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\n\u201cWe\u2019ll continue investigating these cells and how they interact and cause inflammation specifically in the brain,\u201d Rizzo said.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention of any alternatives in the release.", "answer": 0}, {"article": "\u201cA.A.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nThe review covered only carefully controlled trials.\nNone of the studies compared A.A. with no treatment at all, and the researchers said that made it more difficult to draw conclusions about effectiveness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several treatment options compared with, on in conjunction to 12-step groups.", "answer": 1}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\nAromatase inhibitors are not effective in this age group, the experts note.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\nYes, in two areas: preventing recurrent disease in other parts of the body and in preventing a second, separate breast cancer.\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\nBecause pediatricians can't offer parents much help with it -- for the most part, babies grow out of colic in time -- desperate parents often turn to alternative or complementary treatments, according to the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story compared all of the different therapies under review, unlike the MSNBC site\u2019s \u201cToday Moms\u201d story, which narrowly\u00a0focused on herbal tea. For example, the story quotes the paper saying, \u2018This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\u2019 according to the authors.\u201d", "answer": 1}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were a variety of ways that the story might have delved deeper here to earn a Satisfactory score. For instance, did the study consider masturbation and how that might affect cognitive functioning?\nBut mainly we were looking for some discussion of other healthy habits that are linked to better cognitive function with aging: healthy diet, exercise, continuing intellectual engagement, etc.", "answer": 0}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\nMerck officials stressed that the FDA's inquiry is based on reports, not clinical studies - which are the standard tool for evaluating drug safety.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The perspective of the clinician who prescribes Singulair and other drugs for asthma and allergies provides an adequate, if brief, discussion of treatment options. ", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addresses four other techniques used for assessing body fat: BMI, water weighing, bioimpedance and pinching folded skin with calipers. The story would\u2019ve been more useful had\u00a0it mentioned that there appear to be no comparative effectiveness studies on long term outcomes using these different methods.", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compared the study drug with the long time treatment, warfarin, as well as mentioning a newly approved medication and another medication in the approval process.", "answer": 1}, {"article": "For more information, visit https://www.nichd.nih.gov.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There currently is no standardized screening test for identifying gestational diabetes in the first trimester. Earlier research into the usefulness of HbA1c testing for gestational diabetes in early pregnancy have been limited to high risk groups.", "answer": 1}, {"article": "One therapy at M.D.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nThe treatment \u2014 shots that grab the immune system and jolt it to fight against rebel tumor cells \u2014 has been a dream for more than a century.\nThat's why immunotherapy's greatest successes will come when it can be used early in treatment, they say.\nSuch research already is under way \u2014 a potential antidote for people whose genetics seemingly fate them for cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and radiation as alternatives.", "answer": 1}, {"article": "Follow us at twitter.com/ClevelandClinic.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\nThe results show that if validated and adopted clinically, IsoPSA could significantly reduce the rate of unnecessary biopsies by almost 50 percent.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release compares IsoPSA to the current PSA blood test. IsoPSA detects molecular changes in the protein, it states. According to the journal article, IsoPSA is a structure-based assay encompassing the entire spectrum of the protein\u2019s structural changes.\nConventional tests are based on PSA concentrations in the blood or other bodily fluids.\nAlthough the news release doesn\u2019t go into much detail about current tests, we feel it does a good enough job for a Satisfactory rating here.\nHowever, it would have been good for the release to highlight that the current test is not uniformly recommended. No testing is a reasonable option according to the USPSTF\u2019s draft screening recommendations.", "answer": 1}, {"article": "Kisco, N.Y.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nMore people in the bypass group had complications right after the surgery.\nAnd certain procedures may still be preferable for certain patient populations, added Roslin, such as bands for patients with lower BMI who don't have so many metabolic challenges.\nAll patients were morbidly obese (with a body-mass index higher than 40), and 34 in each group had type 2 diabetes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As with the LA Times, there was no mention of the effectiveness of diet or lifestyle interventions for weight loss. Even a line would have helped.", "answer": 0}, {"article": "He walks about 50,000 steps a week, golfs, works out and tap dances and consumes about 1,800 daily calories.\nThat means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nThe study, known as DPPOS, puts science behind Mr. Held's success.\nThat was 10 years ago, when he joined the Diabetes Prevention Program Outcomes Study with the University of Pittsburgh Graduate School of Public Health, one of 27 institutions participating in the research.\nThat's to say, he's delayed the onset of type 2 diabetes and potentially can prevent the onset for the rest of his life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself implicitly lays out the options to preventing diabetes\u2013lifestyle changes, drugs or doing nothing. \nBut the story could have been improved significantly by indicating there are many different diet-and-exercise approaches beyond those used here, as well as numerous drug treatments and bariatric surgery.\u00a0 ", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\n\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\nNow, a study shows that a simple intervention conducted by staff in emergency departments can reduce the risk of future attempts.\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t adequately explain what the alternatives are\u2013if a hospital doesn\u2019t have this protocol in place, what normally happens with suicidal patients?\nThere\u2019s some history of alternative approaches that could have put this intervention into context. Up until 10 years ago \u201cno-suicide contracts\u201d were commonly used after emergency department visits, but they were repeatedly shown to be ineffective. Around that time, safety plans were recommended as an alternative, and clinical trials among active duty military found them to lower suicide risks. Post-discharge follow-up by in-person visit or phone calls was also shown to lower suicidal behavior by up to 30%. The authors of this study, then, developed and evaluated a combination of the two approaches.", "answer": 0}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nTUESDAY, Oct. 11, 2011 (HealthDay News) -- A small, preliminary study finds that ginger root supplements seem to reduce inflammation in the intestines -- a potential sign that the pills might reduce the risk of colon cancer.\nIt's already clear that people with inflammatory conditions such as inflammatory bowel disease are at higher risk of colon cancer, he noted.\nIf more funding becomes available, the researchers hope to launch a larger study, Zick said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No context was given about any other research in the field of the inflammation \u2013 colon cancer link.\nIs this the only research in the field?\nThe relevant comparison may be the relative reduction in colorectal cancer risk (or inflammatory markers) with aspirin, the most common anti-inflammatory product most people are exposed to.", "answer": 0}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\n\"And I said, 'There's gotta be a better way to treat cancer.'\"\nKanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\n\"She felt sorry for me,\" Kanzius added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment mentions other treatment options only in a glancing way and in the most negative light\u2013and without indicating that many cancers are treatable, and sent into remission, with current techniques. ", "answer": 0}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\nSpira and Bild put together results from two ongoing trials of smokers.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "       \n \nThe story did not mention alternative approaches for detecting early stages of lung cancer, including chest x-rays or CT scan screening.\u00a0 \n\u00a0\n ", "answer": 0}, {"article": "\"What we observed was a massive improvement in response,\" Baselga said.\nThey looked to see which drug was better at eliminating invasive cancer in the breast and metastatic cells in the lymph nodes.\nIn another study, published online Jan. 17 in The Lancet Oncology, researchers from Germany reported that Tykerb is less beneficial than Herceptin as a single-drug therapy.\nGlaxoSmithKline, the maker of Tykerb, helped fund the study.\nThose given Tykerb alone had a 25 percent response.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison given with past research about pre-operative chemotherapy attempts to alter the course of breast cancer outcomes.", "answer": 0}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no exact alternatives to bystander CPR, but the bystander use of AEDs has been shown to vastly improve survival rates after cardiac arrest if used quickly. Obviously they are not widely available outdoors, but they are increasingly placed in airports, office buildings, schools, recreational and sports venues, and even department stores. Some mention of AEDs would have been\u00a0welcome.", "answer": 0}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was at least the historical perspective on \u201cthe last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\u201d", "answer": 1}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nAndres Lozano, who led the study, said the results were encouraging because they pointed to a genuine therapeutic effect, rather than a placebo or hunger-increasing effect.\nImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated:\n\u201cTreatment usually focuses on changing behaviour, but experts say up to 20 percent of patients get no benefit from such treatments and are at risk of dying prematurely.\u201d", "answer": 1}, {"article": "\u201cThis is literally on the cutting edge of where the field is,\u201d Dr. DeKosky said.\nAnd when \u2014 researchers optimistically are saying \u201cwhen\u201d these days \u2014 drugs are shown to slow or prevent the disease, the thought is that people will start having brain scans or spinal taps for Alzheimer\u2019s as routinely as they might have colonoscopies or mammograms today.\nAnd they might want to offer the test to people with milder symptoms who want to know whether they are developing the devastating brain disease.\nDoctors might want to use the test in cases where they want to be sure of the diagnosis.\nHe suggested that, because most family doctors and internists are not experienced with the test, there could be special spinal tap centers where they could send patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story notes that brain scans are being developed that might also help confirm diagnoses of Alzheimer\u2019s Disease.", "answer": 1}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\nNor has \u201cconcentrating\u201d cells in fat been proved to make a difference in controlled studies, said Dr. Karol A. Gutowski, chairman of the plastic-surgery society\u2019s task force.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\nBut Dr. Stephen F. Sener, a professor of surgery at the Keck School of Medicine at the , wrote in an e-mail message: \u201cI\u2019ve seen enough injections of fat after mastectomies to tell you that fat necrosis is a real problem.\u201d It can result in a \u201cpalpable mass\u201d that needs to be biopsied to establish malignancy or infection, wrote Dr. Sener, the former president of the .\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe story mentions breast implants as an alternative to fat grafting. However, except for lower cost, implants are portrayed as inferior to fat grafting in all of the comparisons. Here again, the story should have noted that there are no published studies that directly compare the experiences of women who received fat grafts with those who got implants, so as the task force report noted, no one can yet say with any confidence how the options compare.\nAlso, the story did not mention other alternatives that were noted in the task force report: \u201cAlternative forms of nonsurgical and surgical management consist of injections of man-made substances to improve tissue volume (such as hyanuronic acid, polylactic acid, etc.), use of man-made implants, or other surgical procedures that transfer fat from the body (flaps).\u201d\n", "answer": 0}, {"article": "According to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\nWhen it comes to dosing, experts say sticking to a low-dose baby aspirin is best.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are other ways\u00a0to reduce cardiovascular risk, (exercise, diet modification, quitting smoking, other medications) and those would deserve at least a mention in a story like this, and how they compare in terms of benefits and harms.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The column does not compare Reiki to any other alternatives. It mentions one study that looked at other massage techniques, but doesn\u2019t explain how/if those approaches differ from Reiki. \u201cA 2004 study of 1,290 cancer patients at Memorial Sloan-Kettering found a light-touch massage, standard Swedish massage and foot massage all helped symptoms including pain, depression anxiety, nausea and fatigue; the study didn\u2019t have a control group.\u201d", "answer": 0}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\nBut it improves the ability to diagnose prostate cancer, Groskopf says.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of the myriad of molecules that are currently being investigated for their potential to provide better information for detecting the bad prostate cancers. ", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not even provide a clear picture of what would be involved in treatment using the medical device highlighted, let alone outline the other options available for those with cardiovascular disease.\u00a0 ", "answer": 0}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nHe points to other research under way with ivacaftor combined with another drug that could help people with the most common mutation of cystic fibrosis.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nAbout 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation, and the average person with the disease dies before age 40.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story should have noted that advances in managing cystic fibrosis have dramatically increased the life span of people with the disease. Indeed, the editorial accompanying the journal article notes that the health of CF patients declines so gradually now that it will require following many patients for many years to find out if this new drug actually helps them live longer than the treatments already available.", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story (and the study) suggest that medication can manage pain from blocked arteries.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In the last line, the story at least mentioned other approaches to colon cancer screening.", "answer": 1}, {"article": "He reviewed the findings for WebMD.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nA permanent artificial lens is then implanted to replace the natural lens and provide appropriate vision correction for each patient.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story suggests numerous times that laser surgery is likely to be safer and lead to better outcomes compared with traditional surgery. Again, these statements are based on very brief presentations and with limited information. While it may in fact be true, there is no reason to believe that the femtolaser is superior in any way to conventional surgery at this time. But it would have helped to have some idea of the outcomes currently seen with traditional surgery and how frequently complications occur. This information would have helped us judge how much we stand to gain from the new technology. Unfortunately, these details are not provided.", "answer": 0}, {"article": "When it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nLess than 1 percent of patients treated with cryoablation were hospitalized for a recurrence of the disease, compared with 6 percent in the drug group.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0While mentioning that Johnson and Johnson had an ablation device approved for use in the treatment of atrial fibrillation, there was no discussion about how the results obtained with the Medtronic device compared.", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention other approaches to dealing with female sexual satisfaction, which include treatment of underlying psychological and physical conditions, and individual or couples therapy. ", "answer": 0}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nThe research team, led by Dr. Nathan Hawkshaw at the University of Manchester, in the U.K., investigated whether CsA could provide some clues for treating baldness.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story said current treatments for hair loss \u201care limited to two FDA-approved drugs, mioxidil and finasteride, which have mixed results. The other option is minimally invasive hair transplant surgery.\u201d", "answer": 1}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nCaughey agreed with the researchers that any pregnancy occurring after weight-loss surgery merits a higher level of monitoring and should be considered high-risk.\nOnly 2 percent of women who had weight-loss surgery developed gestational diabetes, compared to 7 percent of the other group, the researchers said.\nThey recommended any pregnancy after weight-loss surgery be considered high-risk and receive stricter monitoring.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not mention alternative weight loss techniques (e.g. counseling on diet and exercise, medication, etc) for women prior to surgery, or the potential benefits for obese women of minimizing weight gain during pregnancy.", "answer": 0}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\nBelvin was the first recipient of the immunotherapy that Allison had ever met.\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nAn immunologist named Jim Allison, now at the University of Texas MD Anderson Cancer Center, had figured out that if the immune system was tweaked just right, it could do a better job of killing the cancer than the usual treatments.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story refers to other treatment options, including surgery, radiation and chemotherapy.", "answer": 1}, {"article": "Early iron deficiency can interfere with nerve development, biochemistry and metabolism, hampering both intellectual and fine motor development.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\nChristian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\nThe study was funded by the National Institutes of Health and the Bill & Melinda Gates Foundation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare the approach used in the study with any other approach.", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIn other words, it's not that the J-shaped spine is the ideal one \u2014 or the healthiest.\nMost Americans will at some point have a problem with their backs.\nNobody has done a study on traditional cultures to see why some have lower rates of back pain, he says.\nIn fact, Mummaneni says, stronger muscles might be the secret to Gokhale's success.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does stress that having good core muscle strength is important to reducing or preventing back pain, regardless of whether one uses the Gokhale Method. And it discusses approaches other than Gokhale to achieve that strength. However, it would have been good to note that there are multiple factors that can contribute significantly to back pain, including arthritis, osteoporosis, and injury. With any sort of nerve impingement (e.g. herniated disc pinching nerve), exercise alone will not work. And if there are degenerative changes, often more treatment is required, and that is very common. Finally, not all back pain is benign, and one would need to rule out things like metastatic cancer if pain is ongoing. The story would have been stronger if it had noted that sometimes exercise isn\u2019t enough \u2014 and sometimes other treatment options are required so that a patient can manage the pain well enough to begin an exercise regime.", "answer": 1}, {"article": "Dr. Eric A. Klein, chairman of the Cleveland Clinic Glickman Urological and Kidney Institute, said that the study \"is confirmatory of a lot of other, smaller studies.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nAnti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nHormone deprivation therapy is started, Keating said, when levels of cancer-associated prostate-specific antigen (PSA) increase after surgery or radiation therapy, but there are no other indicators of danger.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story was about the harms associated with the use of androgen deprivation therapy earlier in the course of prostate cancer treatment. \u00a0It mentioned several approaches (surgical removal of the testes, \u00a0multiple hormone blocking drugs, and drugs that target gonadotropin-releasing hormone) and provided several data points for each, though the information provided did not always allow comparison of the approaches to each other. \u00a0 Better organization of this information would have improved the readability of this story.", "answer": 1}, {"article": "\u201cFar too many cancers are picked up too late, when it is no longer possible to operate and the chances of survival are slim,\u201d he said.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\n\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\nA blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The current gold standard for confirming the diagnosis of most cancers is a tissue sample. This is not addressed in the article and should have been. It also could have been clearer that for some cancers there are no approved screening tests.", "answer": 0}, {"article": "CT scans, however, are considered overused - with more than 80 million performed in the U.S. during 2011.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused.\n\u201cWhat we found is that there is pretty good correlation,\u201d said the study\u2019s lead author Dr. Perry Pickhardt, professor of radiology at the University of Wisconsin School of Medicine and Public Health in Madison.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire frame of the story was a comparison of DXA tests to CT scans.", "answer": 1}, {"article": "\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nFurther testing showed the baby was healthy.\nMore testing showed she had anal cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives to the blood tests were mentioned in any context. The WSJ story, by contrast, notes that the blood tests are now used in place of more invasive amniocentesis or chorionic villus sampling to identify fetuses at risk. The WSJ also underscores the importance of having a positive blood test confirmed with one of these more invasive tests.\nNot undergoing testing at all might also be an option, but the story does not address this.", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gives an inaccurate portrait of how the\u00a0treatment approach with the new antiviral drugs will differ from the current standard regimen. The story suggests\u00a0that the new drugs will replace existing treatments, but\u00a0studies of newer antivirals have used the drugs\u00a0in combination with standard therapy not in replacement of it.\u00a0The story should have clarified that\u00a0the newer agents will, at least initially, be used\u00a0as an\u00a0adjunct to\u00a0existing therapies if and when they receive FDA approval.\u00a0\u00a0", "answer": 0}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nInstead, Kathiresan can calculate risk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe.\nEach variation alone would have only a tiny effect on health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does offer the following: \u201cOther scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \u201cpoly\u201d in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\u201d\u00a0 And there are multiple\u00a0other methods for assessing the risk of a person developing specific diseases, although the story doesn\u2019t offer any comparison between those methods and the new one it touts.", "answer": 1}, {"article": "The Lancet.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nThe magnitude of the total sleep time benefit of 85 minutes improvement over placebo is significant and clinically meaningful.\nThe pre-specified primary endpoint was the amount of sleep time in the first two thirds of the night.\nThis clinical design allowed for the study of HETLIOZ\u00ae without the confounding effects of sleep deprivation and variable light conditions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are lots of ways to deal with this problem beyond taking an expensive pill, none of which are mentioned.", "answer": 0}, {"article": "(Reuters) - Amgen Inc said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease, according to initial results of a large, eagerly-anticipated trial released on Thursday.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nRepatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no alternatives to the use of Repatha mentioned in the story although it does mention that patients in the clinical trial already were being treated with \u201coptimized statin therapy.\u201d \u00a0That\u2019s not enough to give readers any firm sense of what the alternatives are and how well they work. There is no mention of diet or exercise or any other treatment approach.", "answer": 0}, {"article": "In the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nThe Home Access HIV-1 Test System lets patients collect blood at home, but it must then be sent to a clinic for testing.\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\nIn a 2012 study, researchers estimated that in 2008, approximately 20 percent of all HIV-positive people in the United State were undiagnosed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This point is an important problem with the story. Without providing any evidence, the story pushes the assumption that self-testing at home offers the same benefits as testing that is coupled with counseling. While the story does provide some comparisons with at-home HIV tests currently available in the US, the comparisons are incomplete. It notes that users of one test have to send their blood sample to a lab and then call for results, without noting that this call provides an opportunity to explain the meaning of the test result and encourage follow-up counseling or treatment. The comparison with another test mentions only the false negative rate, without also reporting the false positive rates.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any discussion of other risk assessment tools, such as the PSA test, Gleason score, biopsy results, and sometimes MRI scans.\u00a0 It would be helpful to know the independent contribution of the expensive new test to decision making after adjusting for the other known risks.", "answer": 0}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nFor other patients, researchers expect other drugs will be needed, too.\nThe study, in 234 patients, was the largest trial of the drug in lung cancer.\nThe new trial looked at a type of lung cancer called squamous cell non-small cell lung cancer, which accounts for about 20%-30% of lung cancers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that \u201cchemotherapy, radiation, surgery and so-called targeted therapies \u2013 can help beat back tumors, but once cancer has spread, it almost always returns.\u201d We\u2019ll rate this sufficient for a satisfactory, although it would have been useful to have some actual data as to how\u00a0Opdivo compares to these other approaches.", "answer": 1}, {"article": "After the cap is placed on the patient's head, it is attached to a vacuum pump that sucks the air out of the cap, jamming the tiny grounds together to form a rigid layer that conforms closely to the shape of the patient's head.\nThey have designed a \"granular jamming cap\" filled with coffee grounds that does a better job of tracking patient head movements than current methods.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nOn the strength of these results, Vanderbilt University has applied for a patent on the design and the technology is available for licensing.\nThe researchers decided to see if this technique could be applied to the problem.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does discuss the use of stabilizing markers and points to their downside. Unfortunately, the release ignores the potential upside of the gold standard approach, greater precision in registration and greater precision of therapy.\nThe news release says researchers believe the cap will \u201ccontribute to improving the guidance system\u2019s accuracy\u201d by increasing the number of markers used to indicate head positioning as well as improving the stability of the markers. Currently, stabilizing markers would involve \u201cdrilling and attaching the markers directly to the skull\u2026which we don\u2019t like to do because it is painful and it\u2019s a step backwards from the majority of what we are doing,\u201d said assistant professor of otolaryngology Paul Russell, who is collaborating with the engineers on the project.", "answer": 1}, {"article": "But we don't know we're right yet.\"\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\nResults like those could also lead to the first approved drug to treat the underlying cause of Alzheimer's rather than just the symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is clear that there are no drugs that treat the underlying cause of Alzheimer\u2019s. It links to a story about a competing amyloid-reducing drug that failed to produce any benefit in a large clinical trial.\nWe did want to know: Are there any older drugs that have been tried for this? Were they equally optimistic when they were first introduced?\u00a0 Putting them into perspective would help as it seems there were prior drugs that were hyped to prevent or slow the progression of AD\u2013but subsequently didn\u2019t pan out.", "answer": 1}, {"article": ".\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\nThey then exposed the tissue to bitter substances.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nSubmit to The FASEB Journal by visiting http://fasebj.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release only makes passing reference to the bitter substances being better than other treatments. It does not name the bitter substance used in the study or any alternatives.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\nIt is designed for patients who have not had surgery.\n\u201cDecompression on the West Coast is a dime a dozen, but here in the Midwest, they are almost unaware of it.\nIt is less than half the cost of surgery but is rarely covered by insurance.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions surgery and painkillers, this is not sufficient information on alternative options.", "answer": 0}, {"article": "Co-authors include: Drs.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n\"While all sedation medications and combination of medications are effective and safe in the hands of experienced providers, ketamine-alone is associated with the fewest serious adverse events and significant interventions, making it a logical choice for providing procedural sedation for children in emergency departments.\"\nSignificant interventions in response to an adverse event were rare, occurring in only 1.4% of children.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release names propofol and fentanyl as two alternatives to ketamine, among the six medications evaluated. We give it credit for providing this general comparison of sedation drugs:\n\u201cThe incidence of serious adverse events was lowest among patients sedated with ketamine-alone and highest among patients sedated with combination drugs ketamine plus propofol or fentanyl.\u201d", "answer": 1}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nA new study finds hormone fluctuations that occur over the course of a woman's menstrual cycle may impact her ability to kick the cigarette habit.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\nNone of the study participants were enrolled in a smoking cessation program or were trying to quit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not mention other approaches to smoking cessation that have strong evidence to support them. Even though the value of timing smoking cessation efforts with a woman\u2019s menstrual cycle is unknown, the story could have done a service to readers by informing them of methods that have been rigorously tested.\u00a0This could have been done with just an additional sentence or two.\n\u00a0", "answer": 0}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nThat's called the relative risk, and it seems alarming.\nFor instance, they started out with a history of more fractures, so the comparison isn't valid.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "One strength of the story was its ending, with a discussion with a bone specialist about the option of taking a drug \u201choliday\u201d from time to time, and the question of whether women who stop taking it temporarily should start again.", "answer": 1}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t describe how type 1 diabetes is currently managed and why new automated systems might be an improvement.\u00a0An important benefit would be\u00a0the prevention of nighttime episodes of hypoglycemia. The\u00a0story doesn\u2019t\u00a0make this clear.\u00a0\u00a0", "answer": 0}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\nVericel last month reported that the study succeeded.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cIt\u2019s a little baffling that you\u2019re keeping patients alive, but not having any effect on those secondary endpoints,\u201d said Needham & Co analyst Chad Messer.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out alternatives by stating \u201cdespite all available medicinal and interventional therapies, the only options are heart transplant or a pumping assist device.\u201d", "answer": 1}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nThis is the second blinded, multi-center clinical utility validation study utilizing the nuclear-localized AR-V7 test.\nThis independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.\nIn March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not mention other ways to determine that hormone therapy isn\u2019t working. There may not be any comparable alternatives.\nThere are ways to assess prognosis and these could be considered alternatives. The paper states: \u201cTo investigate confounding factors that might influence the decision to administer an ARS inhibitor or taxane, a risk score was developed based on a prognostic model developed from our training cohort22\u00a0and applied to the current cohort.\u201d This suggests the authors developed a comparator to their test. As such, it would have been reasonable to comment that there may be other ways to assess risk. The advantage of this one is that it targets what treatment should be given beyond the overall risk itself.", "answer": 2}, {"article": "\"They are so good for you,\" Greene said.\nThis benefit was independent of other heart risk factors such as advancing age, high blood pressure, family history of heart attack, body mass index, exercise, smoking, and caffeine and alcohol intake.\nDuring the study period, 405 participants had heart attacks.\nMen are likely to benefit from eating berries as well, although this study included only women, said Cassidy, who is head of the department of nutrition at Norwich Medical School at the University of East Anglia, in England.\nAlthough more research is needed to confirm these benefits, \"these data are important from a public health perspective because these fruits can be readily incorporated into the habitual diet,\" the study concluded.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned. To prevent heart attacks, patients can either take medications, such as blood-thinning and cholesterol-lowering drugs, or make lifestyle changes, like maintaining a healthy weight, exercising and not smoking.", "answer": 0}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\n\u201cNature is a terrible obstetrician,\u201d he said, referring to the \u201ccontinuum\u201d of pregnancy and birth: the large number of zygotes that never implant, the 75 percent lost before 20 weeks, and stillbirth.\n\u201cIt\u2019s disheartening to see how hard that\u2019s going to be for some physicians to do.\u201d\n\nLockwood and Norwitz are aware that there is strong opposition to induction at 39 weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We will give the story a Satisfactory rating on this criterion because it clearly spells out that the subject is a debate between inducing labor 39 weeks into a normal pregnancy or waiting longer. However, the story mentions only one method of inducing labor.", "answer": 1}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As there is no cure for MS, treatment focuses on slowing its progression, managing its symptoms and speeding up recovery after attacks.\nThe release does note that current drugs work on the immune system, but there\u2019s more that could be said. To treat MS attacks, patients are given corticosteroids or plasma exchanges, in which their blood cells are mixed with a protein solution and put back into their bodies.\nDifferent drugs, such as beta interferons, are prescribed to delay MS progression and to alleviate symptoms. Patients may also undergo physical therapy and be given muscle relaxants to reduce muscle stiffness.\nThe news release doesn\u2019t mention any of these therapies, which is why we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThe study\u2019s five-day treatment sessions also leave questions about patients with chronic conditions who might need treatment for months or years.\nDuring each treatment, participants were asked about their pain, sleep patterns, mood, and overall quality of life.\nMost patients did not report feeling \u201chigh\u201d at any point during the study.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story talks about a range of treatment options and even has the study\u2019s lead author suggesting, that \"these patients should also be getting behavioral and physical therapy.\"", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does mention the obvious alternative \u2013 sunscreen, it does not mention protective clothing, umbrellas, hats, or just staying out of the sun period.", "answer": 0}, {"article": "This was not statistically different.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nThose reasons include shorter surgical times, less invasive procedures and use of regional anesthesia that allows early mobilization after surgery, Hallstrom says.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release highlights the comparison between alternatives for minimizing blood clot risk due to knee replacement surgery.", "answer": 1}, {"article": "For more information, visit www.camurus.com.\nThe CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamic properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage).\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\nCandidates include: Probuphine\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.\nAbout the Phase 2 Trial\n\nThe Phase 2 study was a three-center, randomized, double-blind, inpatient study to evaluate the degree of subjective opioid blocking efficacy of CAM2038 q1w in non-treatment-seeking participants with moderate-to-severe opioid use disorder.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The FDA approved buprenorphine in 2002. According to SAMHSA, medication-assisted treatments like buprenorphine should be given in combination with counseling and behavioral therapies. No mention is made of whether the subjects in the experiment were given those supplementary therapies. Nor was any mention made of alternative drug treatments to buprenorphine. One of the most common ones is methadone.", "answer": 0}, {"article": ".\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\nThese basic tenets of leading a healthy lifestyle have been shown to be important factors in breast cancer prevention.\nIn part this may be because many doctors are not even discussing this option with their patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story spends most of its time on drugs for prevention, but wisely does point out lifestyle alternative behaviors known to lower risk.\n\u201cMost important, become familiar with your family history, know your risk factors and discuss them with your primary-care physician. Age and family history cannot be controlled, but lifestyle changes \u2014 including eating a healthful diet, exercising, not smoking and not over consuming alcohol \u2014 are eminently doable and can reduce your risk. These basic tenets of\u00a0leading a healthy lifestyle\u00a0have been shown to be important factors in breast cancer prevention.\u201d\nIt would have been interesting to hear about the comparative effectiveness of instituting lifestyle changes vs. drugs for reducing cancer risk.", "answer": 1}, {"article": ".\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nUntil then, the patient must use another form of birth control.\nNow a procedure called Essure, recently approved by the Food and Drug Administration, gives women an alternative.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the Pill, the Ring, the Sponge, an IUD and tubal ligation as alternatives to Essure. The story could have provided more content for the reader about the pros and cons of the different approaches. ", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\nBut Freedland said that other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\nThe researchers also couldn\u2019t tell whether men started using statins before or after they were diagnosed with aggressive cancer.\nThe findings don\u2019t prove that the drugs, called statins, ward off aggressive cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Final line of the story quotes an independent expert saying \u201cthat other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\u201d", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned another class of medications, H2 inhibitors, that could be considered instead of proton pump inhibitors (PPI) for patients for whom guidelines strongly recommend the use of Plavix.\n\u00a0It is interesting to know that while several brand name PPI\u2019s were mentioned in the beginning of the story, omeprazole (Prilosec) was not listed. \u00a0And at the end of the story, only the brand names for H2 blockers were listed. \u00a0It would have been better to list both the brand and generic names.\u00a0\u00a0 We think that\u2019s a better practice in health journalism.\u00a0\u00a0 ", "answer": 1}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\n\"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although this study examines a novel approach, it is still necessary to compare it to existing protocols. At minimum, we would like to know how the booster strategy compared with the single vaccination. We\u2019re told the outcome is better with the novel strategy but we aren\u2019t provided any of the data.", "answer": 0}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nThe average number of CBT appointments required before a patient received dental treatment without sedation was five.\nCognitive behavioural therapy could help many people with a dental phobia overcome their fear of visiting the dentist and enable them to receive dental treatment without the need to be sedated, according to a new study by King's College London.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The primary alternative to CBT is sedation, which the release addresses.\nBut we expected the news release to go into more detail about the types of sedation and dental procedures the study authors were referring to. For example, prior to dental treatment \u2014 which can range from a basic cleaning or filling for a cavity, to more involved surgical procedures \u2014 patients might be given an anti-anxiety medication to make them more relaxed. In some cases, patients require intravenous sedation. Since the release doesn\u2019t describe what the authors mean by sedation, it\u2019s a very imprecise comparison.  ", "answer": 0}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\nThe inexpensive CRP test could identify those with higher inflammation, who might be candidates for taking a drug like canakinumab.\nSince statins lower both, it\u2019s hard to tell whether inflammation or cholesterol has the bigger impact on heart problems.\nThe bottom line is we now have clear evidence that lowering inflammation through this pathway lowers rates of heart attack and stroke with no change at all in cholesterol.\u201d\n\nAbout a quarter of people who have heart attacks will have another heart event even if they keep their cholesterol at recommended levels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does note that statin therapy also offers some anti-inflammatory effects that are possibly or probably responsible for prevention benefits in heart disease. But there are many effective and less expensive alternatives to secondary cardiac disease prevention that were not mentioned, such as smoking cessation, aspirin, statins, blood pressure control, etc.", "answer": 0}, {"article": "Their median age was 63.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\nStill there may be reasons to remove the cancer in the breast.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nA large, randomized, prospective study currently being conducted by the Eastern Clinical Oncology Group should produce the most reliable data on the subject to date, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article hints at \u201cmore sophisticated treatments and better imaging techniques\u201d that have developed over time, but it doesn\u2019t explicit state what those are. We would have liked to have seen a sentence or two describing some existing breast cancer treatments, in the case the patient chooses not to opt for surgery.\nHowever, since the story mentions radiation as a possible therapy, we give it a Satisfactory rating here.", "answer": 1}, {"article": "\"There was no significant difference,\" Boden said.\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\nAlthough about one-third of patients who initially got medical treatment later turned to angioplasty, the findings show how much medical treatment of heart disease has improved, Boden said.\nThe findings underscore the danger of rushing to adopt a procedure before careful studies have been conducted to fully determine its benefits, Boden and others said.\nThe researchers and others stressed that angioplasty clearly benefits patients who are in the throes of a heart attack or are at very high risk for one.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses lifestyle changes and medication as alternate treatment options, and these alternate options were directly compared to angioplasty in the study.\u00a0 ", "answer": 1}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because of the imbalance in its framing, the story doesn\u2019t even discuss the option of not having the test \u2013 which can be a rational choice.\u00a0 The framing \u2013 \u201csimple blood test\u2026easily done at the same time as a cholesterol screening, and covered by most insurance\u201d \u2013 is promotional.\u00a0 Why don\u2019t some experts think this test adds much?\u00a0 What is the evidence for that perspective?\u00a0 That alternative viewpoint is clearly downplayed.", "answer": 0}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\nIn 128 patients, the pRF treatment was delivered directly under CT guidance to the root of the nerve.\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\nThe one-year outcomes demonstrated that CT-guided pRF was superior to the injection-only strategy.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release defines what alternatives are available for acute back pain with sciatica, including pain medications, cortisteroids and surgery. It details outcomes in patients treated with steroid injections compared with\u00a0pRF.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "MRI was presented alongside the traditional echocardiography test. But there was no discussion of other methods of treating massive deep vein clots in the legs other than the Angiojet device.\u00a0 ", "answer": 0}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\nThe authors acknowledged certain weaknesses in their study.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article fails to mention other options for treating and preventing colds. Again, due to the disputed nature of the findings, this is a significant\u00a0oversight.\u00a0The reader will want to know: If echinacea doesn\u2019t work, what else can I try? ", "answer": 0}, {"article": "\u201cIt\u2019s a tough disease because we don\u2019t have a way to bring vision back once it\u2019s lost,\u201d he said.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\nIn this group, Coleman\u2019s team found that just over 5 percent, 82 people, had glaucoma.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\n\u201cGlaucoma can lead to blindness, and it would be great if it could be prevented because there is no cure,\u201d said lead author Dr. Anne Coleman of the University of California, Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make brief mention of lifestyle, environmental and diet interventions that may influence glaucoma, but could have made it more clear that none of these have been proven to prevent glaucoma.", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nThe 2009 H1N1 (\"swine flu\") pandemic sparked influenza cases around the globe, resulting in nearly 18,000 deaths, the authors said.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never mentions vaccines, which of course can prevent the H1N1\u00a0flu from developing in the first place. Also, existing medications such as acetaminophen and ibuprofen can ease fever and other flu symptoms.", "answer": 0}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story lists all the screening techniques the USPSTF looked at. It notes that the report intentionally did not rank the techniques and includes a dissenting opinion from a physician who was not part of the task force.\nIt was also worth mentioning that an average risk person who is informed about the screening may chose not to be screened as a reasonable choice, but only as part of a shared decision making process with her/his doctor.", "answer": 1}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\nThis is the first to correct an inherited genetic mutation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Effective alternative treatments for\u00a0RPE65 don\u2019t exist yet, and \u2014 while this may seem obvious to savvy readers who understand gene-editing technologies \u2014 the story should have clearly stated this for the vast majority of people who aren\u2019t familiar with the basics.", "answer": 0}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The researchers state that \u201climiting consumption of red meat, alcohol and refined grains while increasing plant-based foods\u201d reduce breast cancer risk, which is enough to earn the release a satisfactory rating. But we\u2019d note that obesity after menopause is another factor associated with increased risk, one that may be reduced through caloric moderation/restriction and maintenance of a healthy body weight. The release noted that participants who had longer fasting durations had a lower caloric intake, but it did not suggest that the lower calorie intake alone might be a factor in lowering breast cancer risk. That additional context would have been useful.", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the Heartmate II with earlier versions of the same device and with heart transplantation. \nBecause the story is about seriously ill patients for whom other treatments have failed, there is no need to describe the drug and lifestyle interventions used to manage heart failure. \nIt would have been useful, but not necessary, to mention other experimental surgeries and devices for advanced heart failure. ", "answer": 1}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nShe noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nThe trial, led by Dr. Charles Burant of the University of Michigan Medical School, included 426 patients with type 2 diabetes who were not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.\nDr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, \"given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents.\"\nOther diabetes experts had mixed views on the new findings.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not directly compare alternatives, but it puts the experimental drug in the right context through comments from Dr. Loren Wissner Greene. \u201cShe noted that glitazones \u2014 a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance \u2014 have all shown initial promise in clinical trials before worrisome side effects began to surface in users (Avandia was recently withdrawn from the U.S. market due to heart risks).\u201d", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned three anti-impotence drugs now on the market and talked about how the new cream might be better. But there is simply no evidence base upon which to compare three approved drugs with a cream that has only been tested in 10 rats.\u00a0", "answer": 0}, {"article": "Stroke.\nWhile there are therapies to help improve patients' mobility, they\u2019re only effective within the first few hours of an event.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nThey hypothesized that injecting stem cells into the brains of chronic stroke patients would increase their survival rates.\nAnd in a clinical trial testing the technique, researchers found injections can safely improve patients' motor function.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the article mentions there are \u201ctherapies\u201d that help\u00a0after a stroke, it does not mention what these are, how often they succeed, how often they fail, or their costs.", "answer": 0}, {"article": "Women are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nWe think about 40 [percent] to 50 percent of all endometrial cancer, which is in the lining of the uterus, is caused by obesity.\"\nA study looked at the effects of weight-loss surgery on obese women most at risk for cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is a nice admonition at the end of the release encouraging people to keep their eye on the main way to avoid complications from being overweight or obese: avoid eating too much and exercise more. The release says:\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery. \u201cWe really should be working on diet and exercise from the get-go in our entire society, starting with our children. And exercise does seem to be protective \u2014 even if you don\u2019t lose all the weight, it absolutely has beneficial effects,\u201d she said. \u201cThere are lots of studies showing if you exercise, it improves your insulin, your glucose, all of those sorts of things that go along with the cancer-causing effect. Almost everybody agrees adding exercise would be wonderful and improve health on many levels. But losing excess weight would also be good.\u201d", "answer": 1}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nEach test is non-invasive, requiring only the use of exhaled air.\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses current methods for diagnosing asthma including the physical exam, spirometry, and nitric oxide tests.", "answer": 1}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note the existence of at least one other drug: \u201cIn February, when results in mice were published suggesting that a skin-cancer drug, bexarotene, was beneficial for Alzheimer\u2019s, many patients started calling their doctors to find out more about the drug and whether they or a family member should use it off-label.\u201d\u00a0 But the story didn\u2019t provide details, nor compare those findings with the new ones.\nWe wish the story had included a simple line, as the Reuters story did:\u201dThere are no licensed drugs that can slow the progression of Alzheimer\u2019s, and currently approved medications only treat symptoms.\u201d\n\u00a0\n\u00a0\n\u00a0", "answer": 0}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nEven if the test is found to indicate that a birth will be premature, physicians would have limited options.\nThe test wasn't as effective at 24 weeks of gestation.\nPhysicians will \"be able to use a simple blood test and then know that this woman is at increased risk or reduced risk of a preterm birth,\" said Graves, whose laboratory performed the research in the study.\nWu said the study results are promising, but more research is needed to confirm that the test is reliable.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t comment on any other research in this field \u2013 nothing on any other investigations into what can be done to better predict prematurity.\u00a0 So this one study on this one approach is reported in isolation.\nThe big gap that is unaddressed is that we don\u2019t have any treatments even if we know someone is at high risk. In effect, we would be \u201calarming\u201d lots of patients to no particular end at this point; unless they have had a prior preterm birth and are eligible for progesterone treatment but use of that preventive intervention starts at 16 to 22 weeks and is not relevant to the new test.", "answer": 0}, {"article": "\"It's very exciting,\" Klein says.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\nMore than 100 studies involving some 30,000 patients have been conducted with Orlistat, according to GlaxoSmithKline (GSK) Consumer Healthcare, the maker of Orlistat, which has petitioned the FDA to permit OTC sales of the drug.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Article presents \ninformation on weight loss results from xenical, diet, and exercise (7% of body weight) compared with diet and exercise (4% \nof body weight) over a 4 year period. The story did not mention sibutramine, another prescription weight loss drug. ", "answer": 1}, {"article": "\"I'm like, well, I gotta do something, you know.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nWoodcock argues that the agency has to be extra-careful with weight-loss drugs, because chances are it won't just be obese people taking them.\nWoodcock says officials realize they may have to think about things differently.\nAnd the fact that there isn't ... medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "One source quoted captured some of the dilemma regarding alternatives:\u00a0 \u201c\u201dWe go from Weight Watchers to bariatric surgery. And the fact that there isn\u2019t \u2026 medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\u201d", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\nIf the drug could be \u201crepurposed\u201d and licensed for the treatment of bipolar disorder, it could reduce the unpleasant side effects of weight gain, thirst and potential kidney damage that patients risk when taking lithium.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\n\u201cEbselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side effects like lithium does,\u201d said Grant Churchill of the department of pharmacology at Britain\u2019s Oxford University.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes lithium as the dominant treatment for bipolar disorder. \u201cSome 60 years after it was first discovered, lithium \u2013 a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide \u2013 remains the most effective long-term treatment.\u201d", "answer": 1}, {"article": "Because about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\nIn the study, patients taking Jardiance had a 38 percent reduction in cardiovascular death, including from heart attacks and strokes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a novel preventative therapy and designated as an add-on, not a replacement, to standard therapy which include statins to lower cholesterol, and blood pressure drugs. The story mentions\u00a0Invokana, another drug in the same class as\u00a0empagliflozin, and it talks about\u00a0cholesterol-lowering drugs and blood pressure medication.", "answer": 1}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not talk about existing ways to reduce symptoms of allergies. One could argue that such discussion would be propagating the idea the study might apply to humans \u2014 not necessarily a good thing. But then again, the whole underlying point of the story is that there\u2019s some relevance here to people. On balance, we\u2019d rather see the story include this information, which might be more useful for readers than the sneezing rates of mice anyway.", "answer": 0}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\nLike in Lozano's study no serious side effects were seen.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Are there alternatives to deep brain stimulation for treating Alzheimer\u2019s? This story doesn\u2019t say.", "answer": 0}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nAnd any breast-feeding appeared to reduce the odds of the serious eye disease by 46 percent, the research showed.\nWhen they do, the screening and treatments are not as good, Chen said, so blindness may be more likely.\nHe added that in China, a previous study showed the incidence of ROP was 50 percent in infants with a birth weight under 1,000 grams (2.2 pounds).\nAnd the risk of severe ROP seemed to be reduced by 90 percent, the researchers added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not mention other preventative measures to take against ROP besides breast milk and formula. But neither does the original study, so we\u2019ll leave this criterion as not applicable.", "answer": 2}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nFor that reason, he and other experts say, most sufferers never even see an allergist.\nBecause they were not considered very sensitive, physicians were left with a lasting impression that blood testing was inferior to skin testing.\nDr. Mitchell, the Manhattan allergist, called that approach promising.\nThe blood test, which is not without its own ouch factor, measures levels of circulating IgE.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the skin testing and talking with their primary care doctors about their symptoms as alternatives to the blood test.", "answer": 1}, {"article": "\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\nWASHINGTON--A new dietary review of 49 observational and controlled studies finds plant-based vegetarian diets, especially vegan diets, are associated with lower levels of total cholesterol, including lower levels of HDL and LDL cholesterol, compared to omnivorous diets.\nTaking small steps, like those proposed by the National Cholesterol Education Program Adult Treatment Panel 3, which include assessing heart disease risk, making lifestyle and dietary recommendations, and assessing the need for future follow-up appointments and pharmaceutical interventions, could prevent approximately 20,000 heart attacks, 10,000 cases of coronary heart disease, and save almost $3 billion in medical costs each year.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release compares the effects of several other diet types on cholesterol levels to a plant-based vegetarian diet. Readers learned that a plant-based vegetarian diet is associated with greater reductions in total, HDL, and LDL cholesterol levels than omnivorous (diets based on both animals and plants), low-fat, calorie-restricted, or conventional diabetes diets. However, the release lumps most of these alternative diets into one group to arrive at a comparison between vegetarian diets and the others. Since there are large differences in cholesterol levels between the plant-based vegetarian diet and each alternative diet type it would have been helpful to readers to break these comparisons down by individual diet.\nMore importantly, it could be argued that these benefits may also apply to a \u201cplant-based\u201d diet that\u2019s not vegetarian. Strong clinical trial evidence supports a Mediterranean style of eating that doesn\u2019t require completely cutting out meat.", "answer": 1}, {"article": "Anderson Cancer Center.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article refers to \u201cvarious markers\u201d that are used to detect pancreatic cancer in a blood test but calls them too unreliable for widespread screening. The article is consistent with others in stating there currently is no reliable test available.", "answer": 1}, {"article": "\"But it does point the way to the possibility of raising oxytocin levels with other kinds of compounds to increase oxytocin levels more generally over a longer period of time.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\n\"It's not clear whether this would be effective at all in children or in young adults who had intellectual problems,\" warned Young.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nAlthough there are many kinks to be worked out, experts feel the strategy holds promise to treat one of the core symptoms of autism spectrum disorder.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does discuss the treatment of autism and that no drug therapies are currently available for the social dysfunction observed in people with Asperger syndrome and other forms of autism.", "answer": 1}, {"article": "Wu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\nCurrent mammography testing works well for detecting breast cancer in women over 50 with results of up to 95% accuracy.\nThe most effective screening tool for detecting breast cancer is mammography and for women of all ages to remain breast aware, reporting any changes to their [doctor].\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\n\"A statistically small reduction in risk may be very important to some women, while for others chemotherapy is not worth it.\"\nStill others, like Dr. Glick, are starting to tell women with estrogen-fed cancers that although they still need chemotherapy, they may not need the most intense treatment.\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Excellent discussion of chemotherapy treatment decision process, including discussion that no treatment is also an option. Certain chemotherapy treatments may carry serious risks and only small benefit for some women. For other women the benefit is greater, though this must still be weighed against the risks of treatment. ", "answer": 1}, {"article": "Eat as you dare.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\nEating more healthy foods was the key, even if some unhealthy foods were also consumed along the way.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did an adequate job of explaining the two diets, and it mentioned medication, which is another approach to preventing heart disease.", "answer": 1}, {"article": "\u201cBut it does give us hope.\u201d\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nChildren without autism were used as a control for the study, the news release reported.\nThe research team surmises the disparity is due to antibiotics prescribed within the first three years of life.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not include any information on other ways to manage gastrointestinal issues for children and teens with autism, which may include changes in diet. The story also does not mention cognitive behavioral therapies that are common for this diagnosis.\nJust to clarify, while some children with autism have gut problems, some do not. The diagnosis of autism may not include gut distress. Treating children for their gut symptoms may or may not have any influence on their behavior.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story balances the different approaches well. Again, we would have liked to have seen some numbers used in the comparisons, though.", "answer": 1}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nOther LA BioMed researchers who participated in the study were: Suguru Matsumoto, Rine Nakanishi, Dong Li, Anas Alani, Panteha Rezaeian, Jeby Abraham, Michael A. Fahmy, Christopher Dailing, Ferdinand Flores and Sajad Hamal.\nThe study involved 55 patients, aged 40 to 75 years, who had been diagnosed with metabolic syndrome.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release only discusses the impact of a single commercial product, Aged Garlic Extract, which is produced by the company funding the research and one of the\u00a0supporters of the conference at which the research was presented. It does not provide any information on other similar products although there are many available on the market. In addition, there are other ways to prevent or reduce the risk of cardiovascular disease including, but not limited to, avoiding smoking, controlling blood pressure, cholesterol and weight and taking daily aspirin.", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nThe research was funded in part by Cystic Fibrosis Canada.\nThe test is commonly used in universal newborn disease-screening programs and measures the concentrations of salt.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does a good job of explaining the sweat chloride test, which is widely used to make a final diagnosis of CF in infants and children.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that no effective early detection screening test exists. Existing strategies\u2014the CA125 blood test and vaginal ultrasound\u2014are mentioned and then discounted, in part via a personal narrative of a young woman who received a late diagnosis of cancer. While data-driven specifics aren\u2019t included on why standard methods aren\u2019t sufficient, this is enough to rate Satisfactory.\nA\u00a0direct comparison of\u00a0survival stemming from existing diagnostic tests relative to survival stemming from ROMA and OVA1 would have strengthened the story. If those numbers aren\u2019t available, that should have been pointed out.", "answer": 1}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nP-Cure is the innovative provider of image-guided solutions for better clinical effectiveness of proton therapy at a fraction of the current capital and operating costs.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nThe P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The device is being compared to existing devices used to deliver proton beam therapy. As such, there is a comparison. although it\u2019s a bit opaque. It points out that standard proton therapy may radiate healthy body parts inadvertently. It causes more discomfort. It costs too much. These statements could have been elucidated, preferably through quantification, to create a meaningful comparison for reporters and patients.", "answer": 1}, {"article": "\"What would you want for your wife, or your mom, or your sister, or your best friend?\"\nThe surgery she's upset about may be archaic - but it's very common.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\nAnd to get the word out she invites doctors to come to Baptist Hospital East in Louisville and learn the procedure.\nShe thinks hundreds of thousands of them are getting the wrong operation every year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any of the highly effective treatment\u00a0alternatives to hysterectomy. Fibroids and abnormal bleeding are the two most common reasons why women undergo elective hysterectomy. The story makes it seem as though the only option is between abdominal and laparoscopic hysterectomy, when in reality a woman has a choice among lots of options, such as vaginal hysterectomy, myomectomy, ablation, uterine artery embolization, and\u00a0medical management.", "answer": 0}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text offers an extended comparison of\u00a0the side effects of the current use of cortisol and those of the possible new treatment.", "answer": 1}, {"article": "\"I've been treating cocaine-addicted patients for something like 25 years, more, and I've never heard of anybody throwing away cocaine,\" says Dr. Charles Dackis of the University of Pennsylvania, who led a pilot study that suggested modafinil more than doubled addicts' chances of going cocaine-free for at least three weeks.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nBut for Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse, the narcolepsy medicine tops the list of promising potential therapies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention any other pharmacological, psychosocial or behavioral interventions, although cognitive behavioral therapy was part of the treatment for both the placebo and treatment groups in the pilot study conducted by Dr. Dackis and mentioned in the article. ", "answer": 0}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares red wine with the class of drugs called aromatase inhibitors.\nBut that class of drugs has a long track record.\nThis was a tiny, very short-term study of red wine.\nYet the story allowed the researchers to assert that \u201cthis this was the first rigorous study to find that red wine is a \u2018nutritional aromatase inhibitor in healthy premenopausal women.\u2019\u00a0 \u201d\nThat\u2019s a pretty bold comparison after such a preliminary finding.\u00a0 An independent expert probably would have challenged that, but the story didn\u2019t provide any such challenge.", "answer": 0}, {"article": "\"Our meta-analysis of RCTs characterizes how cocoa flavanols affect cardiometabolic biomarkers, providing guidance in designing large, definitive prevention trials against diabetes and cardiovascular disease in future work,\" said corresponding author Dr. Simin Liu, professor and director of the Center for Global Cardiometabolic Health at Brown University who worked with epidemiology graduate student and lead author Xiaochen Lin.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\nBut taking into account some of these heterogeneities across studies, the team's meta-analysis summarizing data from 19 trials found potential beneficial effects of flavanol-rich cocoa on cardiometabolic health.\nThe meta-analysis in the Journal of Nutrition, an assessment of the combined evidence from all 19 RCTs, focused on whether consumption of flavanol-rich cocoa products was associated with improvements in specific circulating biomarkers of cardiometabolic health as compared to consuming placebos with negligible cocoa flavanol content.\nThe greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no comparison of alternatives in the release. Are statins a much bigger factor, for example, in cardio health? What about omega-3 fatty acids? What about just eating a balanced diet overall?\nThe release would have been improved with a mention that modest weight loss and exercise are standard ways to improve metabolic markers for cardiovascular disease.", "answer": 0}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\nThe study is preliminary and doesn't prove cause and effect.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0This story was about the possibility that statin medications have a role for improving psoriasis. \u00a0The story did mention that examining whether statins improve psoriasis in the absence of high cholesterol was one area to be explored. \u00a0There was no discussion of other medications or medication combinations that may be under study to treat psoriasis and there was no mention of the lack of controls in the retrospective study reported on.", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nAt 14, MS-13 was his family.\nHere\u2019s how he got out.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Ideas about exercise modalities (dance, treadmills) are presented, but information about medications or devices used in the treatment of Parkinson\u2019s is lacking", "answer": 0}, {"article": "Dr Webster added: \"Patients are brought back at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nA new low dose three in one pill to treat hypertension could transform the way high blood pressure is treated around the world.\nWith high blood pressure the leading cause of disease burden worldwide, it's expected the findings published in JAMA will change guidelines globally.\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release calls the pill \u201cinnovative\u201d and says it \u201ccould transform the way blood pressure is treated around the world\u201d \u2026 but it fails to mention that combination blood pressure-lowering medications have been around for decades. And, as mentioned above, there are some once-daily \u201ctriple pills\u201d already on the market.", "answer": 0}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThis study published reports that topical curcumin gel applied soon after mild to moderate burns and scalds appears to be remarkably effective in relieving symptoms and improved healing of the affected skin.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\nDr. Heng uses curcumin gel for burns, scalds and other skin conditions as complementary treatment, in addition to standard treatment usually recommended for such conditions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the news release does mention the use of curcumin tablets, we wish it could have gone into depth about some conventional therapies used to minimize scarring after a burn.\nThere are various ways to treat burns, such as specialty wound dressings and antibiotics to prevent infection and to speed up healing. Careful monitoring for infection is critical. To minimize scarring, some doctors recommend wearing pressure garments, which are tight-fitting clothes to be worn over burned areas. These are worn 23 hours per day (taken off only for bathing) for up to\u00a02 years after the burn. If the burn area is very large, patients may undergo physical therapy. Deep burns could require plastic surgery or skin grafts.\nSince none of the more traditional burn treatments are discussed, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "\"I know scientists are supposed to be objective and dispassionate,\" Hendricks says.\nIn recent years, some scientists, such as this study\u2019s lead researcher, Peter S. Hendricks, have been pioneering innovative treatments to help decrease the suicide rate.\nPerhaps this study will be a turning point in how our culture regards psychedelics and mental health.\nAdditionally, the effects of psychedelics on the developing brain are still largely unknown, meaning they could pose a threat to people with a predisposition to schizophrenia.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have explained that antidepressant medicines and psychotherapy are effective for treatment of depression. Providing this context can help normalize and reduce stigma surrounding depression treatment.", "answer": 0}, {"article": "Previous studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nThen they were sent home with lunch, dinner, and snacks that conformed to their assigned diets.\nThe high-nitrate breakfast included 16 ounces of beet juice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison \u2013 not even a line \u2013 between what nitrites could do and what other approaches might do or have already been shown to do.", "answer": 0}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nNow, there's new information showing how important folic acid is.\nDr. Emily Senay discussed it on The Early Show Tuesday.\nFor safety tips from the CPSC on generators and carbon monoxide, click here.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Recommendations of adequate folic acid intake were presented.\u00a0 The treatment options, obtaining folic acid from dietary sources or from supplements were both presented.", "answer": 1}, {"article": "If the child said a word, the parent repeated it and added something.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article noted that there are no cures or predictably effective treatments for severe autism, and that even a modest improvement in symptoms would be a boon. The training intervention is compared adequately to the traditional \u201cdirect therapist-child\u201d type of treatment.", "answer": 1}, {"article": "Cancer cells are coated by platelets when they enter the bloodstream and are on their way to spreading.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\nA second study, conducted in the United States, Canada and Great Britain and also being presented at ASTRO, suggests that a combination of hormone therapy plus radiation may be the best treatment for men who have locally advanced prostate cancer with a high risk of returning.\n\"But we may expect to see this benefit in those who are taking aspirin for other [usually cardiovascular] reasons.\"\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe researchers say it would be premature to recommend the use of anticoagulants in prostate cancer patients, because the benefits and risks have yet to be clearly identified\u2026 and so it is also premature to expect comparisons to alternatives.", "answer": 2}, {"article": "Cytology-based screening, known as the Pap test or Pap smear, is used to detect abnormal cells.\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nThe analysis found that HPV testing identified more women subsequently diagnosed with cancer and precancer than the Pap test.\nResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is about comparing alternative screenings, either co-testing or HPV alone. The report does not address Pap alone (recommended for women under 30 years old).", "answer": 1}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\nThe new study grew out of efforts to discover whether different types of cancer are susceptible to Ezh2 inhibitors.\nEpizyme, a biopharmaceutical company based in Cambridge, MA, recently opened a pediatric trial of an Ezh2 inhibitor for children with rhabdoid and other tumors.\nIt offers a promising approach to shortening the duration of therapy in order to achieve a cure.\nJoining senior author Orkin, the study's lead author is Huafeng Xie, PhD, of Dana/Farber/Boston Children's.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Aside from\u00a0the current standard of care \u2014 imatinib-like drugs \u2014 the release only\u00a0vaguely references \u201csecond- and third-line targeted therapies\u201d that \u201ccan often return the disease to remission,\u201d yet doesn\u2019t name them.", "answer": 0}, {"article": "...\nShe says it can be hard to get the attention of teenagers about healthy eating.\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nThere's also a growing body of evidence linking fiber to weight management.\nMaryam Farvid, a fellow at the Harvard School of Public Health who is lead author of the study, says the influence of fiber on cancer risk may be time-sensitive.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t discuss other risk factors for breast cancer at all, much less other lifestyle choices that can reduce risk, such as maintaining a healthy weight, exercising, limiting alcohol consumption or getting enough sleep.\u00a0Perspective is needed about ways we can stay healthy overall and reduce later cancer risk.", "answer": 0}, {"article": "\"Those same benefits translate to people seeking to fight off the common cold, flu and other seasonal illnesses.\"\nRegular massages have been shown to make the immune system stronger, according to studies.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\nBreast Cancer Patients Have Improved Immune And Neuroendocrine Functions Following Massage Therapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release included no discussion of other alternatives to prevent the flu, common cold or other infectious diseases that are common in the fall and winter months. The Centers for Disease Control recommends an annual flu shot, washing hands and frequently cleaning touched surfaces and objects. England\u2019s National Health Service also recommends a healthy lifestyle, such as a wholesome diet, regular exercise and drinking plenty of warm fluids in the winter months.", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\nAdditionally, the scientists found that patients whose bone marrow before treatment contained a high number of certain immune cells, known as central memory cells, also had better response to MILs therapy.\nThree days before the injections of expanded MILs, patients received high doses of chemotherapy and a stem cell transplant, standard treatments for multiple myeloma.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does mention that other forms of this adoptive T cell therapy use different cells, suggesting that other approaches are possible. The release also notes, \u201cThree days before the injections of expanded MILs, patients received high doses of chemotherapy and a stem cell transplant, standard treatments for multiple myeloma.\u201d", "answer": 1}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\nDuring the course of the study, each person received annual, standardized testing for cognitive ability in five areas -- episodic memory, working memory, semantic memory, visuospatial ability and perceptual speed.\nFurther, the protective association of seafood was even stronger among individuals with a common genotype (APOE-\u03b54) that increases the risk of developing Alzheimer's disease.\nThe study group also completed annual food frequency questionnaires, allowing the researchers to compare participants' reported seafood intake with changes in their cognitive abilities as measured by the tests.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story says that \u201cresearchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\u201d It doesn\u2019t tell us which are potentially good (and which are bad), but it\u2019s sufficient for a Satisfactory rating.\nThe release would have been stronger if it had addressed the question (probably on some on readers\u2019 minds) about whether fatty acid supplements could possibly have the same effect that the researchers observed with seafood consumption. These supplements are widely used, not to mention costly, so this may have been worth including.", "answer": 1}, {"article": "Learn more at www.genomedx.com and follow us on Twitter at Twitter @GenomeDx, Facebook, LinkedIn and YouTube.\nAdding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors.\nUse of this test therefore has the potential to assist clinicians to better direct utilization of secondary therapy after surgery.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\n\"The Decipher test's tendency to make the two specialties more concordant in their treatment recommendations provides significant value toward standardizing care for patients.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019re not told if there are any alternatives. Even if Decipher stands alone as a post-operative\u00a0test, that\u2019s critical information.\nIn the study itself, the authors did provide clinicians with information about risk groups,\u00a0PSA, and extensive information about the pathology of the cancer. Studies (and guidelines) have used\u00a0these parameters to guide treatment\u2013it would be useful to know whether the initial decisions followed accepted practice. If not, then clinician education might be a more (cost) effective intervention than providing results from an expensive test.", "answer": 0}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article presents a truly novel technique and potential treatment.\u00a0 There\u00a0are no treatments options currently available for this condition.", "answer": 1}, {"article": "The findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nAll the participants reported eating about 2,000 calories a day when the study began.\nBut as researchers noted, if participants ate as little as they said, all the groups would have lost much more weight.\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reported on weight loss outcomes comparing four different methods for altering food consumption to result in weight loss.\u00a0 However additional treatment options were not even mentioned, such as balancing caloric intake with exercise, and weight loss surgery for the morbidly obese.", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Steroid treatments are mentioned and their numerous side effects emphasized.\nIt would have been helpful for the story to emphasize the role of non-medical treatment ( water avoidance, moisturizer, etc) since these are mainstays for many people.", "answer": 1}, {"article": "The F.D.A.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does explain that surgery is the alternative, but it would have been helpful to provide more concrete numbers (outcomes, cost) to show how patients fare with surgery vs TAVR. The story would have been better if also told readers about drug treatment for milder cases and that some valves can be repaired, rather than replaced.", "answer": 1}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nSuch research has become critically important as the number of children diagnosed with autism has soared in recent decades to 1 in 68.\nHundreds of millions of dollars of state and federal funding are being spent each year to provide help to children and adults with autism and being able to pinpoint children at risk in the early years could help direct those public resources to where they could do the most good.\nFiguring out a child's trajectory once he or she is diagnosed is just as challenging.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While noting that there are currently no blood tests or biological markers available to autism specialists, the story shares that specialists who treat children with autism currently rely on \u201cparent and teacher reports, observations and play assessment\u201d to make a diagnosis.", "answer": 1}, {"article": "FDNA scientists published a paper in January showing that their algorithm could better identify Down syndrome after being trained with a more diverse set of faces, and Muenke and Linguraru have also published papers this year demonstrating their algorithm\u2019s ability to identify genetic disorders correctly in children across a variety of ethnic backgrounds.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nBut there\u2019s one big stumbling block for both of them, a problem that has dogged medical genetics for decades: Data for non-white populations is sorely lacking.\nMeanwhile, Muenke and his colleagues at the NIH last month published an important advance: the ability to diagnose disease in a non-Caucasian face.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that there is physician experience, as well as genetic tests, as alternatives. Because the software-makers insist this new tool is not to be used for diagnoses, we\u2019re still not sure what the benefit of this new technology would be, and why it\u2019s needed, though.", "answer": 1}, {"article": "Friedman, who is now 70 and lives in Los Angeles, lost 175 pounds.\nIt's one of several procedures designed to help people maintain the benefits of bariatric surgery.\nSo Friedman opted for a less invasive procedure to make her stomach smaller again.\nAbout one in three patients regain significant amounts of weight a few years after surgery to reduce the size of the stomach pouch.\nFriedman kept the weight off for almost 10 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We are told the there are other procedures available to help maintain the benefits of bariatric surgery, but they are not described. \u00a0And while the story states that the patient is recommitting herself to lifestyle changes, exercise and diet after receiving the TORe procedure, it would have been useful to describe the role of these measures in preventing the initial weight regain. The authors of the research stated; \u201cTORe is one approach to avoid weight regain; a longitudinal multidisciplinary approach with dietary counseling and behavioral changes are required for long term results.\u201d", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire column was a comparison of methods.\u00a0 Very nice wrapup.", "answer": 1}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nPreviously there had been some concern that drugs needed to get the stem cells out of the bone marrow and into the bloodstream where they could be accessed might pose a risk of leukemia.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0discusses one of the primary\u00a0existing treatments for\u00a0Wiskott-Aldrich syndrome: bone marrow transplants.\u00a0The story\u2019s muddled overview\u00a0of this treatment is likely to leave readers confused, however. The story starts off its description by\u00a0saying that such\u00a0transplants, if they succeed, \u201cbasically cure the\u00a0disease.\u201d\u00a0It then goes on to list a number of\u00a0serious complications that can\u00a0plague even apparently successful\u00a0transplants. So the children\u00a0treated via transplant\u00a0sound like they probably aren\u2019t \u201ccured\u201d\u00a0as the story initially states. We\u2019ll call it satisfactory, but we wish the story was a bit clearer on this point.", "answer": 1}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\nThe trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\nBut with improved treatments, the typical life expectancy is now about 40 years, according to the Cystic Fibrosis Foundation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions existing therapies to target the genetic mutations of cystic fibrosis patients. There are other approaches under study such as such gene editing and stem cell replacement, but those have a ways to go scientifically.", "answer": 2}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\nThis project was funded in part by Shire Pharmaceuticals, the National Institute of Mental Health, the National Institute on Aging, and the National Institute on Drug Abuse.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers no mention or discussion of alternative treatments for menopause-related symptoms or cognitive dysfunction.", "answer": 0}, {"article": "According to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nExperts say the couples are not the only people who benefit from these tests.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nThese results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to screening before implantation is not screening before implantation. That\u2019s sufficiently clear that we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nProbiotics May Help Soothe The Stomach\n\nYogurts and supplements loaded with \"friendly\" bacteria may be able to fight the nefarious ones and soothe fickle bowels, according to a new study.\nAuthors of the review note that probiotics can work in several ways, including robbing the offending bacteria, viruses or parasites of nutrients.\nA Cochrane Library review of 63 studies found that probiotics can shorten the time a person has acute diarrhea -- with no negative side effects.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison with other treatments for acute diarrhea. A variety of over the counter medications are available to help improve symptoms, and simple dietary changes (avoiding dairy, for example) can also improve symptoms.", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\nWhen treatment was stopped, the benefits gradually tapered off, Baker said.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nDr. Joel Zonszein, an endocrinologist from Montefiore Medical Center, in New York City, praised the study but said some questions still remain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There wasn\u2019t the kind of clear context and background as provided in the Reuters story:\n\u201c\u2026researchers have failed so far to come up wiht effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\u201d", "answer": 0}, {"article": "ET.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The treatment of ED was not the focus of the research. Still, in a release suggesting the drug\u2019s safety and benefits in preventing future heart disease we\u2019d like to see some emphasis on how keeping a heart-healthy lifestyle through diet and exercise could be positive alternatives for risk reduction.", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nThat means for some low-risk individuals, taking daily aspirin could do more harm than good.\nThis information is essential for making rational guidelines for aspirin in primary prevention.\nThat\u2019s ironic because aspirin is ubiquitous and most patients perceive it to be safe and harmless.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives are mentioned (smoking cessation, eating a balanced diet, getting sufficient exercise), and that\u2019s sufficient to rate as Satisfactory. The piece would be strengthened by comparing the relative benefits of the other options.", "answer": 1}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\nMore than 80 percent still had a pain rating of at least 4, the findings showed.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nOne hour after treatment, less than 40 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that the study compared the result of using acupuncture versus the use of painkillers versus the use of both in tandem, so it is clear that there are alternatives available for analgesia.\nHowever, the three conditions\u2013acute low back pain, migraines or ankle sprains\u2013are all treated differently and have a host of known appropriate strategies. For example, rest for back pain, triptan medications for migraine, ice and elevation for sprain. We think this deserved a mention in the story.", "answer": 1}, {"article": "Jerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.\nThe demonstration of efficacy by Seciera\u2122 at 12 weeks is earlier than other drugs approved for dry eye in the same class.\nSun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera\u2122 (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does refer to \u201cother approved drugs in the category\u201d but it provides no information about what other approaches might be useful in dealing with dry eyes. The National Eye Institute, for example, offers several approaches to dealing with the problem including prescription and over-the-counter medications, as well as surgical procedures.", "answer": 0}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research.\n\u201cStatins are a vital medicine for people with \u2014 or at high risk of developing \u2014 heart disease,\u201d he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The first quote in the story says \"It\u2019s better to avoid fatty foods altogether.\" And the story goes on to make that point in several ways. The story quotes directly from the editorial, too, saying that there is \"no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation\".", "answer": 1}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe vaccines Gardasil and Cervarix were designed as a prevention for young women who have not yet been exposed to HPV.\nThis happens in anywhere from 10% to 25% of women infected with HPV, Kim said.\nThe vaccine trains T-cells in the body to go after cervical cells with potentially cancerous genes embedded in them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was some discussion of alternative approaches \u2013\u00a0 Gardasil and Cervarix.", "answer": 1}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We give the story credit for noting\u00a0that the \u201crates of quitting for smokers in this study who received the treatment and did not want to quit right away were about the same as those in previous studies of patients who wanted to quit abruptly.\u201d That\u2019s good context. However, the story does not mention that the competing drug bupropion (sold as Zyban and Wellbutrin) has also been shown to offer some benefit\u00a0in smokers who prefer to gradually reduce cigarette consumption over abrupt discontinuation. That\u2019s an important omission.", "answer": 0}, {"article": "\"My wife's family is from southern Illinois, too, so it's home,\" Reavill says.\nCalled the ReavillMED CV, the Food and Drug Administration-cleared device includes a catheter called a PICC line, IV tubing that sheathes it to provide sterility, and a transducer that can directly measure blood pressure to help determine needed fluid levels.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nDennis adds that the catheter could prove useful in patients with sepsis, or blood poisoning, which strikes about 750,000 Americans every year.\nIt reduces risks to an \"absolute minimum\" by moving the catheter insertion to the arm, the judges said, replacing a complex wire-guided procedure through the neck, which is typically used to monitor the heart during a hospital stay for very ill patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Venous heart catheters are mentioned \u2013 but no meaningful comparison was made with the new approach \u2013 again, because no evidence was provided. It is actually somewhat disingenuous to claim superiority of a new device that was approved by the FDA under a 510K premarket approval process \u2013 which is predicated on the assumption that the device is not significantly different than existing devices already on the market.", "answer": 0}, {"article": "Ishdori A, Capps O, Murano PS.\nThe supplement is the outcome of a November 2014 USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine roundtable on vegetable consumption in children.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nThe journal supplement features seven papers authored by leading nutrition scientists that explore the state of the science pertaining to vegetable consumption in children.\nThe forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato--a nutritious vegetable--in promoting health for all age groups.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many comparisons in the study but the release mentions none of the many other dietary sources of potassium and fiber.", "answer": 0}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nCollaboration with Ping Wang, associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, enabled the design and implementation of the key clinical validation study.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted above, this test was done by the device\u2019s developers under ideal lab conditions. The comparisons to existing devices and speculation about relative effectiveness should wait until field tests are done.", "answer": 0}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\nIt also didn't result in the blood pressure increases that helped doom torcetrapib.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\n\"Currently, we're not convinced that manipulation of HDL matters, though certainly it's promising,\" said Weintraub, who added that results should be available relatively soon from other trials exploring the issue.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does note that niacin (spelled incorrectly by the way) is the only drug that reliably increases HDL, we would have liked to have seen a bit more information about the role of diet and exercise and how researchers think a CETP inhibitor like anacetrapib (if approved) might fit into the context of other approaches. ", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\n\u201cThis therapy could be life-changing for men diagnosed with prostate cancer and I\u2019m honored to be among the first doctors the U.S. Food and Drug Administration approved to put it to the test,\u201d said Steven Canfield, M.D., chair of the division of urology at McGovern Medical School at UTHealth, who recognized the possibility of the nanoparticles to treat prostate cancer and helped developed the trial to test the theory.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We learn about other alternatives:\u00a0 \u201cTreatment options have traditionally included radical prostatectomy, which is the removal of the prostate gland and some of the tissue around it, radiation therapy and cryotherapy, among others. These methods carry the potential to have a negative impact on urinary function and sexual performance.\u201d\nand\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic. This new technology holds the potential to eliminate those life-altering effects, while still removing the cancer tissue and reducing hospital and recovery time.\u201d\nWhile this is useful information it is inadequate. Impotence and urinary incontinence are often the downstream consequences of prostate cancer treatment but how did the rates of these adverse effects compare to the gold nanoparticle treated group?\u00a0 We don\u2019t know.\nIn addition, the other treatment methods also carry the potential of curing cancers. We can\u2019t say the same for the new technology.", "answer": 0}, {"article": "Close to 800,000 people in the U.S. suffer a stroke each year, mostly older adults.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nBut researchers said it\u2019s still unclear what types of patients might benefit from the treatment and by how much.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that doctors typically prescribe cognitive rehabilitation for patients with post-stroke \u201cneglect\u201d symptoms, but that progress is often slow and the associated hospital stays costly.", "answer": 1}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\nMoreover, they warn that while regular screening might help doctors catch cancer earlier, it also comes with a high price tag and added risks to patients.\nWhile doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was a comparison of lung CT versus x-rays or physician followup of patient symptoms.", "answer": 1}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThose who took the highest doses saw their recurrence risk drop by half.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is a brief mention of radiation, but that is merely in passing. There really is nothing in the story about what a typical treatment regimen might be for these patients and what it might be like if statins became the go-to treatment. There also isn\u2019t anything in the story that offers any theory about what might be causing this. It seems as if the authors don\u2019t really know and are just excited about this potential connection that they have made. If they, or someone else in the field, were pressed to offer a theory, some of the holes in the evidence might begin to show.", "answer": 0}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nThe paper is currently available in Chronic Respiratory Disease.\nLow testosterone is common in men with COPD and may worsen their condition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a range of treatments for COPD, none of which are mentioned in this release.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nIt's only been implanted in a few dozen people who were studied for a matter of months, limiting information about its long-term use and safety.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nIt's also not clear when the pacemaker may be publicly available, and its cost is unknown.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are other wireless pacing devices being developed, yet the story offered no information about these alternatives, or how this new device might compare.\u00a0 What sets it apart?\u00a0 Why is this newsworthy?", "answer": 0}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\nDr. F. Xavier Castellanos, director of research at the New York University Child Study Center, called assertions that stimulants are neuroprotective \u201cexaggerated,\u201d adding: \u201cThe best inference is that there is no evidence of harm from medications \u2013 normalization is a possibility, but far from demonstrated.\u201d\n\nA.D.H.D.\nDr. Swanson, a co-author of a landmark federally funded study, the Multimodal Treatment of Attention Deficit Hyperactivity Disorder, said that follow-up research found overall improvement but no greater long-term benefits after three years for children who were treated with medication compared to those who weren\u2019t.\nSuch a practice has been deemed unethical due to the widespread belief that the medication can help struggling children, at least in the short-term.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story seems open to the possibility that ADHD can be treated without drugs, it doesn\u2019t specify any alternative approaches or how they compare with drug treatment.", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Neither this story nor the LA Times story compare this approach to existing alternatives, although this story does at least briefly mention medication as the first line of treatment for patients with newly diagnosed heart failure. But no meaningful comparison to other approaches was given.", "answer": 0}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nAll used the product for three months, for a total of 23,000 doses.\nThe rest of the men used a placebo spray.\nThe numbers aren't huge.\n1 sexual health problem in men.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t provide the context on other research in this area that the Wall Street Journal story provided: ", "answer": 0}, {"article": "Rectal cancer affects some 2,000 men and women in Sweden every year.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\nThe results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The purpose of this study was to compare the timing of existing standard\u00a0treatment modalities. Complementary and alternative treatments are beyond the scope of the news release.", "answer": 1}, {"article": "Almost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nThe trial of more than 53,000 current and former heavy smokers, aged 55 to 74, found the \u201cspiral\u201d CT scans apparently catch tumors before they have spread.\nDr. Bruce Johnson of the Dana Farber Cancer Institute in Boston, who is on the board of the American Society of Clinical Oncology, said he doubted most people would see the findings as a green light to smoke.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared spiral CT scanning to chest X-rays and did mention smoking cessation.", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDr. June knew that a drug could lower IL-6 \u2014 his daughter takes it for .\nSome patients have had the cells for years.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nHe hopes the new treatment will eventually replace bone-marrow transplantation, an even more arduous, risky and expensive procedure that is now the last hope when other treatments fail in leukemia and related diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and bone marrow transplants as other treatment options for leukemia.", "answer": 1}, {"article": "Feb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nThe study appears online in the Journal of Clinical Investigation.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss evidence-based strategies for weight loss, such as behavioral weight loss programs. It could also have mentioned other new research which shows, at least in mice, that exercise helps turn white fat brown.\n\u00a0", "answer": 0}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\nBut Dr. Carlson said that some of his colleagues, even after hearing the new study results, still thought the nodes should be removed.\nBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival.\nThe new research grew out of efforts in the 1990s to minimize lymph node surgery in the armpit, called axillary dissection.\n\u201cIt\u2019s a little frustrating.\u201d\n\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job explaining the history of this form of treatment and how it has evolved over time. \u201cBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival. And until recently, they counted cancerous lymph nodes to gauge the severity of the disease and choose chemotherapy. But now the number is not so often used to determine drug treatment, doctors say. What matters more is whether the disease has reached any nodes at all. If any are positive, the disease could become deadly. Chemotherapy is recommended, and the drugs are the same, no matter how many nodes are involved.\u201d The story goes on to do something that stories like this rarely do, it compares compares the harms from different forms of treatment, saying \u201cAfter armpit surgery, 20 percent to 30 percent of women develop lymphedema, Dr. Port said, and radiation may increase the rate to 40 percent to 50 percent. Physical therapy can help, but there is no cure.\u201d", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story references getting calcium from one\u2019s diet and getting vitamin D from sun exposure.", "answer": 1}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nThe two tests together appeared to generate both sensitive and specific results.\nNow that the researchers have validated the test, further studies in larger, more diverse populations will be important to understand how it is best used.\n\u201cThe real key is using this or any test to help drive decisions,\u201d says Jones, who was not involved in the research, \u201cIf it helps me to know who to biopsy or not biopsy, that\u2019s massively valuable information.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that \u201cwhen PSA levels are elevated, it\u2019s up to patients and their doctors to figure out what to do next\u201d and that \u201cThere really aren\u2019t very good tools to utilize to help make that decision.\u201d\n", "answer": 1}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nSo far, the treatment has restored immune systems in all 23 patients in the most recent clinical trials, including Evangelina.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Most children with SCID receive a bone marrow transplant or receive weekly injections of ADA. This fact was not noted in the story. In addition a quick check of ClinicalTrials.Gov uncovered several new approaches that are technically different from that of the story. In addition, drug companies are working on the development of other approaches to this form of SCID.", "answer": 0}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nIn low-risk patients, the cancer control rates was superior to historical controls.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\nAt five years following SBRT, 97 percent of patients were free from prostate cancer progression.\nActuarial five-year nadir+2 RFS was 97.1 percent for all patients, representing 97.3 percent of low-risk and 97.1 of intermediate-risk patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Some of the men in the study had a low-risk form of prostate cancer, which might have made them eligible for active surveillance rather than surgery. That option is not discussed in the news release. As mentioned in the quantifying benefits section, the news release does mention that this type of radiotherapy was compared with standard radiotherapy, although it was not directly studied.", "answer": 0}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nA new formulation currently being developed that contains half the amount of testosterone might decrease or eliminate that problem, Wang speculated.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nThe combination contraceptive needs to undergo further testing before it is commercially available.\nThere's more on contraception at the American College of Obstetricians and Gynecologists.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions condoms and vasectomy as the other contraception options for men. It would have been nice to see some data on how effective these are at preventing unwanted pregnancy and a comparison with the gel tested here.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\nIn the intent-to-treat population, Grade 3 or higher, non-hematologic adverse events were similar across all organ systems, including cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nThe trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.\nEven with current treatment, overall survival for AML is poor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release gets a satisfactory rating for devoting plenty of space to describing the new drug\u2019s advantages in terms of survival advantage over the comparator, or current standard of care. Are there other treatments that are useful in treating high risk AML? \u00a0We never get that information. This would have been much stronger if a statement about\u00a0the studies of the non-liposomal formulation of the drug was given.", "answer": 1}, {"article": "\"It's still new and it's quite different than previous genetic testing that's been available,\" says Norton.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\n\"Approximately 1 in 700 pregnancies there's an extra X or extra Y,\" she says, noting that these are mild conditions that would normally go undetected, unless a woman had an invasive test like an amnio.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\nSeitz, in Alabama, thought it was a bonus that getting this new blood test would tell her if she was having a boy or a girl.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did compare and contrast the new prenatal screening tests to traditional diagnostic tests like\u00a0amniocentesis and chorionic villus sampling, which are more invasive.", "answer": 1}, {"article": "JACC is ranked No.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\nResearchers used questionnaires to evaluate patients for depression and levels of physical activity.\nResearchers from Emory University Hospital in Atlanta set out to learn more about the relationship between depressive symptoms and heart disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study is not a traditional treatment-versus-control study, rather it studies possible interaction effects between physical activity and depression for different cardiovascular disease indicators. A discussion of alternative treatments is not particularly relevant.", "answer": 2}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention other treatment options, such as memantine. ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least gave a nod to Lactase and Beano products, but it doesn\u2019t address other common-sense approaches that may help treat gas and bloating: avoiding the foods that give you trouble, avoiding\u00a0fat-rich meals, eating smaller meals, etc.", "answer": 0}, {"article": "Studies conducted by the CDC through its Adult and Youth National Tobacco Surveys found increased experimentation by youth trying out e-cigarettes but not conventional cigarettes.\nThat's backed up by Etter's research as well as a recent study by researchers at Penn State College of Medicine, in which e-cigarettes were found to be less addictive than tobacco cigarettes.\nBut some critics argue these electronic nicotine delivery systems (ENDS) are fueling a new addiction to nicotine -- particularly among young people experimenting with them.\nBauld's research hasn't identified a dependence on nicotine with e-cigarettes in the same way as the addiction resulting from regular cigarettes.\n\"[They may] expand their market to other customers who didn't use cigarettes but might consider nicotine use.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not describe the efficacy of alternative smoking cessation methods (e.g. nicotine gum and patches), but it did at least mention some.", "answer": 1}, {"article": "AMHERST, Mass.\nParticipants in the study contributed more than 1 million person-years of follow-up, during which 2,041 women experienced early menopause.\nOthers on the study team were from Brigham and Women's Hospital and Harvard Medical School.\nThe study was supported by a grant from NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development.\nDiet was assessed five times over the 20-year study, allowing the researchers to capture within-person variation in changes in food and nutrient intake over times, Boutot explains.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There don\u2019t seem to be any common strategies to prevent early menopause, but the news release could have delved into alternative potential causes such as autoimmune disease, genetics and cancer treatment.", "answer": 2}, {"article": "HPV causes cervical cancer, which remains a significant health problem, particularly in less resource-rich areas of the world.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nNot all experts agree, though, that current practice would change based on the study's findings alone.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of describing the pros and cons of HPV DNA testing to pap smears, even indicating how HPV could be particularly useful in resource-poor countries.", "answer": 1}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nDr. Hochman emphasized that angioplasty was still the best treatment for many heart attack patients who go to the hospital early, within 12 hours of when the attack began.\nThe ones who might benefit, they say, are a small minority \u2014 perhaps 10 to 15 percent \u2014 who cannot take the class of heart medicines known as beta blockers, which have been proved to increase survival after a heart attack.\nHer report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThe new study tried to determine if late angioplasty could help them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story presented the treatment options following a heart attack as a balloon treatment (angioplasty) and stent along with optimal medical management OR optimal medical management alone that were discussed in the study outlined.", "answer": 1}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\n\u201cIt is a way for patients to treat their symptoms as often as they need to use the device.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did mention that there are \u201ccommonly prescribed treatments,\u201d and it named some of them.", "answer": 1}, {"article": "The F.D.A.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nBut with less than a third of the enrollment goal of 2,500 patients completed, doctors will have a long wait for esults.\nBy contrast, they say, carotid surgery -- called endarterectomy -- has no significant room for improvement.\nEven stenting proponents worry about overuse of the technology in challenging cases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Mentions endarterectomy having \ncomparable outcome; single mention of medical treatment with no mention of outcome; no data for watchful waiting. Therefore, \nincomplete.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\nEach person in the study was trained on how to find melanoma and attended booster sessions every four months.\nThe new results show people can ask friends or relatives to help examine their bodies for suspicious moles, said Robinson.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Early on in the news story, the writer mentions that without\u00a0a partner to assist in skin examinations, patients are told to use mirrors to check out hard-to-reach body parts.", "answer": 1}, {"article": "Drs.\nThese researchers also found that most antidepressant medications have been linked to weight gain.\n\"Our study suggests that bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese,\" said study leader David Arterburn, MD, MPH.\nSo for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In essence, the purpose of this study was to compare alternatives and report their effect on weight gain or loss. The news release notes that fluoxetine was chosen as the \u201creference\u201d drug to compare with buproprion. The study suggests that in addition to fluoxetine, the researchers looked at data from patients assigned to a number of other drugs, too, but their data sets were incomplete.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nOne reason for the euphoria surrounding the Novartis trial is that it was seen as an especially difficult test of the drug\u2019s effects.\n\u201cThis may be the key to solving the mystery of autism and other developmental disorders.\u201d\n\nGeraldine Dawson, chief science officer at Autism Speaks, the world\u2019s largest autism advocacy organization, said that a growing body of research suggests that the many genetic causes of autism all seem to affect synapses, suggesting that a treatment for one form of the disease might help others.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The treatment approach appears to be genuinely novel.\u00a0An expert source comments that\u00a0fragile X syndrome, up until recently, was viewed as \"disability needing rehab, not a disorder needing medication.\"", "answer": 1}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nPeople who have both Alzheimer's and vascular disease -- a condition called mixed dementia -- have a more rapid progression of Alzheimer's disease, Cole said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have at least briefly mentioned other approaches to risk reduction.\u00a0 For example, control of hypertension and use of daily aspirin to reduce risk of vascular disease in the brain.\u00a0 It doesn\u2019t require many words in a story to put one area of research into context of other research in the field. ", "answer": 0}, {"article": "(One British unit of alcohol equals a small glass of wine.)\nYet previous research in the area of maternal drinking has repeatedly found negative effects from even the lowest levels of alcohol consumption during pregnancy.\nThis data is notoriously hard to interpret, however, in part because it is based on women\u2019s self-reports: the public health message against drinking during pregnancy has been so widely adopted that women who do drink may significantly underreport their consumption to researchers.\nBut for those women who drink before finding out they\u2019re pregnant or who have an occasional glass of wine afterward, this study can provide reassurance that very low levels of alcohol consumption during pregnancy are unlikely to cause serious problems.\nWhen researchers controlled for factors like maternal education and income, which tend to be higher in light drinkers, it significantly reduced the positive effects associated with alcohol.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that some women who usually drink decide to abstain either when planning to become pregnant, while others stop drinking after they learn they are pregnant, and still others continue to drink during pregnancy.", "answer": 1}, {"article": "Lorch also pointed out that this study involved a mostly homogenous population in a country outside the U.S.\n\n\"We should see whether similar effects are seen in higher-risk populations, such as the low socioeconomic population, racial and ethnic minorities and those at higher risk for neurodevelopmental delay,\" Lorch said.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\nBut Rabe said these infants may actually benefit most from the practice.\nUntil recently, clinicians believed early clamping reduced the risk of hemorrhaging in the mother, but research hasn't borne that out.\nDelayed cord clamping has garnered more attention in the past few years for its potential benefits to the newborn.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s either early or late clamping, and the article describes both methods.", "answer": 1}, {"article": "The study is by Peter Rothwell, MD, PhD, FRCP, of John Radcliffe Hospital in Oxford, England, and colleagues, and has been published online by the journal the Lancet.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nThe fall in the risk of death broke down according to individual types of cancer: Reductions in pancreatic, stomach, and brain cancers were difficult to quantify because of smaller numbers of deaths, the authors say.\nThe latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not present alternative ways of reducing cancer risk. Some other news reports specifically noted that avoiding smoking and obesity are both known to reduce cancer risk.", "answer": 0}, {"article": "RELATED: What we know about how cancer starts could all be wrong\n\nIn January 2013, nearly four months after Landon\u2019s initial diagnosis, the two went from Utah to Colorado, where Riddle purchased an alternative treatment fraught with complicated politics and plenty of skepticism\u2014especially when it comes to saving the life of a preschooler with a potentially fatal disease.\nBut to do that, the family would need to leave Utah, where all cannabis is illegal.\nFirst, there would be several months of aggressive inpatient chemo and other therapies for what\u2019s known as \u201cremission reduction.\u201d After that, even when blood work showed the disease had entered remission, Landon would need years of chemo and monitoring\u2014called \u201cconsolidation\u201d\u2014to make sure his body wasn\u2019t harboring leukemia cells.\nFor most of the kids who go through the entire course of treatment, the illness turns out to be a mere blip on the screen of childhood.\nBut Landon appeared to be among a small percentage of children with leukemia for whom the treatment was unbearable, excruciating.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The problem here is that the story should have been more clear that one interpretation of the series of events is that the conventional treatment succeeded in putting the cancer into remission\u2026 and that the improvement in the patient\u2019s quality of life might be entirely due to the discontinuation of that treatment.\nBy repeatedly stating that the patient began to feel better after starting cannabis oil treatment, the story implies the oil caused the improvement and might be superior to the conventional treatment, rather than noting that the oil might not have anything to do with the patient feeling better, and that even in this single case, there cannot be any firm conclusions about the relative value of the treatment options.", "answer": 0}, {"article": "They were then followed till they were about 10 years old, according to the study.\n\"We observed that early dietary intervention [with extensively hydrolyzed formula] decreased the frequency of diabetes-associated autoantibodies, which are markers of an ongoing disease process, by about 50 percent by the age of 10 years,\" said the study's lead author, Dr. Michael Knip, a professor of pediatrics at the Hospital for Children and Adolescents in Helsinki, Finland.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\nAccording to Knip, the take-home message from the study is that \"it is possible to reduce considerably the initiation of the diabetes disease process in at-risk children in a simple and safe way: weaning to an extensively hydrolyzed formula.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are many options when weaning an infant from breast milk.\u00a0 The story discusses the NEJM study which compared extensively hydrolyzed formula with regular infant formula.\u00a0 While the more expensive hydrolyzed forumula was associated with fewer cases of Type 1 diabetes antibodies in at-risk children, the story notes that there is not definitive evidence that cow\u2019s milk formula will increase the risk of Type 1 Diabetes compared to other types of formular or breast feeding.", "answer": 1}, {"article": "HPV is the most common sexually transmitted disease.\nThe vaccine also protects against two other virus types that cause 90 percent of genital wart cases.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nAlso, the drug does not protect against infection from the many other virus strains not included in the vaccine.\nMerck said the vaccine could be used in females age 9 to 26, but would work best when given to girls before they begin having sex.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that the alternative is a pap smear and this vaccine is not a replacement for the pap smear. ", "answer": 1}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nBut drinking tequila won't help, the study authors noted.\n\"These results suggest that the supplementation of the standard diet with agave fructans prevented bone loss and improved bone formation, indicating the important role of agave fructans on the maintenance of healthy bone,\" Lopez said.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No such comparisons provided. ", "answer": 0}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThere were no significant changes in the placebo group.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We give the story credit for noting that the reductions in blood pressure were \u201cmodest\u201d compared with those achievable through drugs, and that \u00a0\u201cother fruits and plant extracts have not produced the same result.\u201d Nevertheless, the story\u00a0fails to consider the most obvious comparison: a diet high in fresh fruits and vegetables and low in processed foods and salt (such as DASH), which is associated with reductions in BP that were similar to those reported in the study. We\u2019ll call this a borderline satisfactory.", "answer": 1}, {"article": ".\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run.\nDriven to the Internet, he discovered a world of cognition-enhancing drugs known as nootropics \u2014 some prescription, some over-the-counter, others available on a worldwide gray market of private sellers \u2014 said to improve memory, attention, creativity and motivation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t address proven strategies to improve mental skills such as good nutrition, adequate sleep, social engagement, cognitively challenging activities, and exercise.", "answer": 0}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nAmong the antidepressants, Paxil seemed to have the strongest evidence of benefit.\nAll the nonhormonal drugs have side effects.\nThere were only two studies for Effexor, just one of which suggested it might help.\nIn the meantime, both Dr. Tice and Dr. Nelson said that for women who find their symptoms intolerable and want treatment, they would favor antidepressants over hormones.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Satisfactorily presents several non-hormonal options for treatment. However, lifestyle related non-hormonal treatment (e.g. cool, layered clothing, exercise, not smoking) is either not mentioned or presented as ineffective options for women with hot flashes. ", "answer": 1}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nThough the immunotherapy treatment is simply a matter of gradually increasing your tolerance to peanuts, you could have a severe reaction at home.\nThree-quarters of the study participants were given the treatment in increasing amounts every two weeks until reaching maintenance, when they received the equivalent of one peanut daily.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nGlover seized the opportunity to participate in a study on the safety and effectiveness of an experimental treatment that could give her daughter protection against accidental exposure to peanuts.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that there is currently no approved treatment for peanut allergy.\u00a0 \nIn addition, the profiled patient is described as having to eat her school lunch at a peanut-free table, showing reader the practice of avoiding exposure \u2014 currently the only way to manage a peanut allergy.\u00a0\u00a0\nHowever, the story doesn\u2019t mention that AR101 is among at least four peanut immunotherapy products potentially entering the market.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\nRebecca Branstetter, psychologist who blogs at Notes from the School Psychologist, says this dyslexia brain scan could provide useful information, but it doesn't highlight environmental factors -- such as the quality of instruction in the child's classroom -- that could contribute to reading problems.\nA study led by Fumiko Hoeft, psychiatry researcher at Stanford University School of Medicine, used brain imaging to answer this question.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nThe study authors wrote that although standardized tests did not accurately predict changes in reading ability during the study period, \u201cit is possible that there are behavioral measures not included here that may predict outcome.\u201d Indeed, their journal article specifically referred to other research into clinical testing that did appear to predict how children with poor reading skills responded to teaching. The story fails to make clear that the study reported here did not attempt to make a comprehensive comparison of the predictive power of scans and other methods of assessing children with reading problems. ", "answer": 0}, {"article": "A decision by the FDA is due by May 17.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nHe said previous studies excluded patients who had tried more than two other treatments.\nAmgen said Aimovig trial patients also had statistically and clinically meaningful improvements in secondary trial goals including fewer monthly migraine days and better physical function.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story alludes to the existence of other preventive therapies for migraines when it tells us that participants did not respond to other treatments. However, it doesn\u2019t say what those treatments are.", "answer": 0}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nResults show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\nThe improvements were more robust in those who were adherent to PAP therapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While CPAP is a widely used and effective treatment for sleep apnea, it is not the only solution. Other treatments include dental appliances, surgery, and nerve stimulation. The news release did not make any mentions of these alternate treatments.", "answer": 0}, {"article": "\"It's premature to make any conclusions,\" he said.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nD'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are options other than surgery or watchful waiting for prostate cancer (e.g. radiation). The story did not mention them.", "answer": 0}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nThe researchers cautioned that the drug was given in tightly controlled conditions in the presence of two clinically trained monitors and said they do not recommend use of the compound outside of such a research or patient care setting.\nTwo monitors aided participants during each session, encouraging them to lie down, wear an eye mask, listen to music through headphones and direct their attention on their inner experience.\nThe study was funded by grants from the Heffter Research Institute, the RiverStyx Foundation, William Linton, the Betsy Gordon Foundation, the McCormick family, the Fetzer Institute, George Goldsmith, Ekaterina Malievskaia and the National Institute on Drug Abuse (R01DA03889).\nSix months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Again, the release does a good job here. For example, the release cites a lead researcher from the Johns Hopkins team saying that \u201ctraditional psychotherapy offered to people with cancer, including behavioral therapy and antidepressants, can take weeks or even months, isn\u2019t always effective, and in the case of some drugs, such as benzodiazepines, may have addictive and other troubling side effects.\u201d Would a more detailed comparison be valuable? Yes. Do we think the language in the release is sufficiently meaningful to merit a satisfactory rating? Also yes.", "answer": 1}, {"article": "They included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\nFuture research might focus on interventions that could help diffuse these frustrations, the paper noted.\n\u201cAt the same time, people with Alzheimer\u2019s do have moments of clarity or show affection when it\u2019s unexpected.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There have been a number of studies on different approaches to enhancing communication for individuals who interact with dementia patients. The story does mention the fact that previous studies have been done, but it doesn\u2019t really describe them or their results in any meaningful way. We give credit for the mention of previous research below under the Novelty criterion, but we\u2019ll dock a point here for the lack of any real discussion of alternatives.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We rate this\nsatisfactory, although, in comparing treatment options, the possible harms of surgery could have been explored more fully.\nThe story does not mention specific potential surgical or post-operative complications. 22.3% of those who underwent surgery\n(this included those randomized to the surgery group or those from watchful waiting who crossed over into the surgery group)\nhad complications which included wound infections, urinary tract infections, and in a few cases, serious cardiovascular\nproblems requiring hospitalization.", "answer": 1}, {"article": "Every year, U.S. News & World Report asks experts to rank various diets to help the tens of millions of dieters in the United States and around the globe make informed dietary decisions that can help them achieve healthier lifestyles.\nThe DASH diet scored highest when it comes to healthy eating, followed by the TLC diet.\nThe panel evaluated 38 of the most popular or trendy diets this year.\nThe Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story (and the release it\u2019s based on) focus on the comparative rankings of different diets. Besides DASH, the MIND Diet, Mediterranean Diet, Fertility Diet, Biggest Loser, Weight Watchers and Atkins Diet are also very briefly compared and contrasted in different categories including weight loss, ease of following, safety and nutritional value.\nThe original news release does provide ranking numbers which could have improved our understanding of the comparisons.", "answer": 1}, {"article": "Watching her patients undergo bone marrow transplant ?\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nThe study was supported by funding from the National Institutes of Health and spinoff Juno Therapeutics, of which Greenberg is a scientific co-founder.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Without any information on the extent of the type of leukemia relapse risk that is the target of this research or any evidence that a reduction in relapse rates ultimately gives patients longer or better quality life, there is no way to make an informed comparison with existing treatments. Nevertheless, the release makes unsupported assertions that this treatment appears to be superior to conventional treatment. The release also leaves out any mention of similar experimental therapies.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is one of the biggest shortcomings of the story. Before considering a total hip replacement, a patient may be advised to try alternatives that might delay or avoid surgery, such as exercise to strengthen the muscles around the hip joint, the use of canes or walkers, and medication. The vast majority of patients with hip pain, and most even with hip arthritis, do not need a hip replacement. Conservative care can be highly effective at a fraction of the cost and risk. The story did not mention those possibilities.", "answer": 0}, {"article": "Ms.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\nIn the trial, sponsored by Roche and led by Dr. Paul B. Chapman of the Memorial Sloan-Kettering Cancer Center in New York, 38 percent of participants had to stop taking the drug or lower the dose because of side effects, including rash and joint pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately explained the comparisons between both new drugs and the older dacarbazine chemo drug.", "answer": 1}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We think that the story could have done a better job describing the current treatments.\u00a0 True, the story did note the use of Factor IX concentrate as the standard treatment but it did not describe how often the treatments are needed, the risks of those treatments (low but real risk of hepatitis and HIV) or that they work well.\u00a0 The editorial writer referred to the current treatment as \u201ccumbersome\u201d but that wasn\u2019t referenced in the story.", "answer": 0}, {"article": "Tobacco use accounts for some 85 percent of lung cancer cases in the U.S., and one estimate puts a smoker\u2019s lifetime absolute risk of developing lung cancer between 12 percent and 17 percent.\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nThe high so-called \u201cfalse positive\u201d rate is an issue, said Dr. James Hanley of McGill University, who also reviewed the findings for Reuters Health, but many mammograms also find lesions that turn out to be benign.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nAnd for lung cancer, doctors know there is a high false-positive rate and have a set protocol to follow in order to determine which lesions are dangerous, added Johnson.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story does not discuss alternatives. It would require only another sentence to at least note the reduction in the risk of lung cancer, heart disease and other ailments that come from quitting smoking.", "answer": 0}, {"article": "\u201cPills and rings should be sitting next to each other as options.\u201d\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A discussion of the alternatives is a real strength in the article. It mentions\u00a0other rings in development as well as the Truvada pill which offers some protection against HIV, and examines some pros and cons of the different methods.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no mention of carotid artery stenting. This omission is surprising, since the reporter has covered this alternative on several occasions:\n(Full text versions of some stories are behind a paywall.)", "answer": 0}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\nDoctors can also determine if a person\u2019s lung cancer is genetically vulnerable to the checkpoint inhibitor drugs tested in the current study.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\nThis combination of nivolumab and ipilimumab showed that the paired drugs could be more effective when begun as the first treatment, instead of chemotherapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy, which it says \u201ctherapy typically leads to only a 5% improvement in people\u2019s chances of living five years \u2014 but an up to 70% chance of being exposed to serious toxicities.\u201d (But, note that the story never provided information on immunotherapy\u2019s serious toxicities.)", "answer": 1}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\nMarylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made scanty reference to consumption of fish as a method of increasing omega-3 intake as well as the use of over-the-counter preparations of fish oil as means of increasing intake of omega-3 fatty acids. However. the story focused disproportionately on the fish oil product with FDA approval for one application. There was too much discussion of a single product, when many products exist. The story needed to give more information on diet and risks of mercury exposure.", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the author does mention radiation as the alternative and that the side effects of Erbitux plus radiation are similar to that of radiation alone, there is no mention of cisplatin and other newer chemotherapy drugs that are the current standard of care.", "answer": 0}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\nThe researchers say up to 14% of pregnant women may suffer from depression.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nWhile the story discussed antidepressants, there was no mention of how acupuncture compares to psychotherapy, another non-drug\u00a0alternative that does not put the fetus at any direct risk. \n\u00a0", "answer": 0}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\nA treatment traditionally used on patients with certain cancers is being tried on a small number of people with multiple sclerosis with \u201cremarkable results\u201d, according to a professor involved in the research.\nDoctors at Royal Hallamshire hospital in Sheffield stress that the treatment, so far given to about 20 patients over three years, is not suitable for everyone with the disease, which attacks nerves in the brain and spinal column.\nThe hospital is part of an international trial also involving patients in the US, Sweden and Brazil to see whether the treatment can benefit those with relapsing remitting multiple sclerosis, a form that involves flare-ups of symptoms such as loss of vision, fatigue, muscle problems and difficulties with balance that can last from a few days to a few months.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Aside from noting that there is no cure for this type of MS, the story offers no information about existing treatments such as drugs to lessen relapses and steroid treatments to cope with flare-ups. More detail could be provided about how this form of MS is currently treated. It also isn\u2019t clear whether the bone marrow treatment will affect long-term disability or not.", "answer": 0}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that\u00a0baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days.", "answer": 1}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nThe best advice for avoiding lung cancer remains to quit smoking, said NCI Director Dr. Harold Varmus.\nNor is it clear if the study results are applicable to all smokers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThis story highlights advice that quitting is the best way for smokers to avoid lung cancer.\n", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story compared boceprevir with another investigational drug called telaprevir. A discussion of other treatments for hepatitis C is not warranted given that this subset of patients did not respond to the standard drug therapies. However, the story failed to make it clear that boceprevir is used in conjuction with two standard drugs. ", "answer": 1}, {"article": "Dr Bonci said: \"rTMS is a non-invasive and very safe therapeutic approach which is used with other mental health and neurological conditions, such as depression and neuropathic pain.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nThe study indicated the safety of rTMS in patients with cocaine addiction.\nNow a group of researchers working in Italy and the USA have shown in a preliminary clinical study that cocaine use can be reduced by treatment with rTMS (repetitive Transcranial Magnetic Stimulation).\nAs author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states, \u201cThere is no effective drug treatment for cocaine addiction, with behavioural therapies being the main element of any treatment regime.\u201d The medicinal drugs used on members of the control group were intended to treat accompanying symptoms brought on by cocaine use. In addition, addiction specialists have found that some drugs do offer some small benefits clinically, but they are not FDA approved for cocaine addiction treatment.", "answer": 1}, {"article": "However, relatively little research has been conducted into ketamine's antidepressant effects in adolescents.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nThe latest study involved 13 young people ages 12 to 18 who had failed two previous trials of antidepressants.\nFive of the participants met the criteria for clinical response and remission.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The nature of this study was to investigate the potential use of ketamine as an alternative to other drug treatments.\u00a0 Participants had to have tried at least two previous drug approaches without success before they could qualify for inclusion in this study.\u00a0 So therefore, there clearly were alternatives considered and the story mentioned them.\nThe story would have benefited from a wider discussion of the treatment of adolescent depression, including the role of psychotherapy.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We only\u00a0get\u00a0a\u00a0passing\u00a0mention\u00a0of\u00a0drugs, and there are many available. Quickly fleshing out the efficacy of those drugs versus this TENS technique would have gone a long way in helping migraine sufferers who may be\u00a0desperate\u00a0to try the most effective, affordable, and least invasive treatment.", "answer": 0}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\nKohler said cognitive behavioral therapy -- where people learn to change the thoughts and habits that affect their sleep quality -- is a proven way to manage insomnia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Strong ending that addressed this criterion:\nAnother sleep specialist said the findings show \u201csome potential benefit\u201d from suvorexant, but he cautioned insomnia sufferers against relying completely on any drug.\n\u201cMedication can be important,\u201d said Dr. William Kohler, who directs the Florida Sleep Institute in Spring Hill. \u201cBut in the long run, the best methods for treating insomnia are behavioral techniques.\u201d\nKohler said cognitive behavioral therapy \u2014 where people learn to change the thoughts and habits that affect their sleep quality \u2014 is a proven way to manage insomnia. For most people, he said, medication should be a temporary treatment; behavior change is the long-term fix.\nBazil agreed: \u201cI look at most people with insomnia as someone who developed bad sleep habits.\u201d\nA drug, ideally used for a short time, may help encourage sleep and get people on the right track, Bazil said. \u201cBut those bad sleep habits \u2014 you\u2019ve got to address them too,\u201d he added.\n\u201cThe problem,\u201d Kohler noted, \u201cis that we don\u2019t want to make behavior changes. We want to pop a pill.\u201d", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no proven ways to\u00a0prevent prostate cancer (although supplements such as vitamin E and selenium have been found to be ineffective),\u00a0so we can\u2019t\u00a0fault this article for not mentioning any.\u00a0We\u2019ll call it not applicable.", "answer": 2}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provides some historical alternatives to CT screening for lung cancer (serial x-rays in the 1970s) and does indirectly describe the de facto alternative, that is, finding lung cancer as a result of symptoms.\u00a0 It does this by telling readers that lung cancer is rarely found curable in the absence of screening and providing estimates of chance of death within 5 years when diagnosed this way.\u00a0 ", "answer": 1}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention the various supplements, such as black cohosh, that are used to treat menopausal symptoms.", "answer": 0}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nAnywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years, so even small harms may outweigh the potential benefits, the Swiss scientists say.\nBut that test, which Grundy says is available for about $100, is controversial among some physicians.\nPuhan says, based on his assessment, perhaps 15 to 20 percent of older adults should be taking statins \u2013 far less than the 30 or 40 percent suggested by current medical guidelines.\nYet both the new guidelines and the latest study agree on an important point: Doctors and patients should spend more time reviewing the benefits and risks of statins, with attention paid to each person's particular circumstances.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative of not taking a statin was the key message here, and that\u2019s laudable. However, we have a couple of concerns.\nFirst, we learn that \u201csome statins were more effective than others, with atorvastatin (the generic name for Lipitor) being the best of the bunch.\u201d\u00a0 However, the story doesn\u2019t explain on what basis some statins are \u201cmore effective.\u201d In fact, some statins may be more effective at lower cholesterol, but the study found that no statin rises above others when it comes to the outcomes that counts most to patients \u2014 reducing cardiovascular deaths.\nAlso, the story doesn\u2019t mention lifestyle interventions \u2014 diet and exercise.", "answer": 0}, {"article": "For more on dietary supplements, visit the Office of Dietary Supplements of the U.S. National Institutes of Health.\nVinson said his team was not focused on the weight-loss impact of caffeine as much as that of unprocessed, unroasted coffee's primary ingredient: chlorogenic acid.\nIn one section, study participants, who were all between the ages of 22 and 26, consumed a capsule filled with 700 milligrams of green coffee extract.\nLona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern in Dallas, cautioned that the study is short on specifics, making it difficult to draw any conclusions.\nThe apparent result: Daily consumption of a small amount of green coffee extract translated into a nearly 11 percent drop in body weight, on average.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare green coffee extract with other approaches to weight loss, such as dietary changes or drugs.", "answer": 0}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nKing and her team are the first to show that a modest increase in dietary zinc reduces oxidative stress and damage to DNA.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternatives here are to eat more natural foods rich in zinc or to take dietary supplements. Some sources of zinc include oysters, red meat, poultry, beans, nuts, whole grains and breakfast cereals.\nSupplements contain several forms of zinc, including zinc gluconate, zinc sulfate and zinc acetate. According to the National Institutes of Health, research has not established whether differences exist among forms of zinc in absorption, bioavailability or tolerability. As we mentioned in the Costs section, a bottle of 100 zinc tablets is priced around $4 to $6.\nSince these alternatives are not discussed, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "For example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\nChrono's team is developing the first wearable transdermal drug delivery device that optimizes drug dosing, is embedded with sensor technology to track usage and is connected via Bluetooth to an evidence-based smartphone application that delivers real-time personalized behavioral support to keep users on track to achieve their goals.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the benefit of the doubt here. The news release does indeed compare this new device to nicotine patches, gum and prescription drugs, but it does so inaccurately. The issue being discussed here is craving control and this trial is moot regarding the control of smoking.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article\u00a0would have been stronger if it had\u00a0described\u00a0the range of treatments for Type 2 now in use,\u00a0from diet and exercise to medications and insulin. This would have helped readers understand the choices diabetics face\u2013a challenging lifetime regimen that is not always successful, or a somewhat risky surgery that might provide permanent relief.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nThe study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other diets such as alternate-day fasting.", "answer": 1}, {"article": "(Flexible sigmoidoscopy, which looks at the lower part of the large intestine, has been shown by randomized trials to prevent deaths from colorectal cancer but isn\u2019t reimbursed as well as colonoscopy and is on the decline in the U.S.)\n\nColonoscopy is the most popular test in the U.S.\n(Wender doesn\u2019t recommend the OTC tests that are available.)\nOnly if you get a positive result do you need to have a colonoscopy.\nBut there is a menu of options beyond colonoscopies \u2014 and they\u2019re not necessarily any better or worse, according to the USPSTF\u2019s recently finalized updated recommendations for screening among average-risk adults.\nAccording to public health experts, that\u2019s a bad thing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since this story is totally about the available alternatives for colorectal cancer screening, it easily gets a Satisfactory rating.\u00a0 \u00a0", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nAccording to Breteler\u2019s team, studies should continue to look at the relationship between antioxidant intake and dementia \u2014 including whether antioxidant consumption at different points in life might have different effects on dementia risk.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nBut the finding is in line with a previous study of U.S. adults that found that a higher intake of vitamin E, but not vitamin C or beta-carotene, was related to a lower risk of developing Alzheimer\u2019s over two years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is currently no proven method for preventing age-related dementia. We might have wished that this story had mentioned some other diet and\u00a0lifestyle choices that are\u00a0associated with reduced risk in observational studies. These include staying physically active, not smoking, eating a Mediterranean-style diet (rich\u00a0in\u00a0fruits and vegetables and omega-3 fatty acids), and keeping\u00a0your mind engaged in intellectually challenging pursuits.\u00a0 But since the evidence is kind of squishy for all of this, we rule this satisfactory. ", "answer": 1}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nBut those experiencing hip pain or stiffness have had more-limited options.\nDerek Ochiai, a surgeon with the Nirschl Orthopaedic Center in Arlington, who began performing hip arthroscopy six years ago, estimates that he did only about a dozen of the procedures that year.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n \nThe story briefly mentions rest and physical therapy, and implies that they do not work, but it is hardly a balanced discussion. Also, the story does not mention open surgical procedures, the historical \u201cgold standard,\u201d which can also restore the normal clearance that separates the femur and hip socket. There is no discussion of the relative benefits of the newer procedure compared with the options\u2013and no mention that there do not appear to be any clinical studies comparing treatments. ", "answer": 0}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe drug reduced by 87 percent the risk of disease progression or death.\nOther Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No comparison with other treatment approaches.", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Satisfactory mostly because of the inclusion of the comments by Dr Audeh about MRI, which is really the only acceptable alternative to mammography for followup of breast cancer survivors, and it is still unclear how MRI and mammography should be used in concert.", "answer": 1}, {"article": "\u201cIf you can give [someone like Robison] an idea of what emotions may be hidden behind a voice or face, then it enables his brain, without TMS, to change the way he approaches life and people.\u201d\n\nNevertheless, Pascual-Leone acknowledges that these changes can be challenging as well as beneficial, as Robison describes.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nPeople close to him questioned whether the risk was worth it.\nHis book is likely to spark even greater interest \u2014 and funding \u2014 in TMS as a non-medicinal way to treat symptoms associated with disabilities like autism, epilepsy, ADHD, and dementia.\n\u201cThe experience was richer and deeper, with an added layer of feeling,\u201d he writes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives\u2013either of alternative treatments the patient\u00a0received, or of general options\u00a0for people with autism.", "answer": 0}, {"article": "And I've seen patients who have gotten up in the middle of the night and they trip and fall on the tubing,\" he explained.\nHe believes that patients can play a role in reducing catheter use.\nAs for improving infection control in intensive care units, Huang said, \"further analysis may help us understand why this intervention didn't work.\"\n\"Patients and families should request that a catheter not be put in, and if there is one there, the patient should ask every day whether it is still needed,\" Saint suggested.\nHospital-acquired urinary tract infection rates rose nationwide during the same time period, Saint noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative is the status quo,\u00a0which is discussed in terms of its problems.", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions an alternative this way: \u201c\u2026\u00a0currently patients looking to part with their double chins must have fat removed through more invasive means, such as liposuction.\u201d\nWe\u2019ll give the story credit for noting an alternative to the 300 injections required with Kybella. But we wish the story had provided information about the comparative effectiveness of the two procedures, or at least a comment that at the moment, no such comparison can be made.", "answer": 1}, {"article": "For more information, please see www.arthrokinex.com\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nThe process works by using one's own blood \u2013 specifically the body's own anti-inflammatory proteins and human-growth elements \u2013 to end or ease pain and chronic injuries.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t name any alternatives for joint pain. For patients with mild symptoms, over-the-counter oral medicines like ibuprofen and naproxen can help. For some, physical treatments can help strengthen muscles and can improve function of the joint. At the other end of the spectrum, for patients with very severe arthritis, joint replacement is an invasive but effective option. However, for many with moderate symptoms, there is a need for treatments than can control symptoms. Injections into affected joints with other medicines including steroids and hyaluronic acid have been available for a long time. These treatments can have short-term benefit for some individuals, but don\u2019t help everyone.\u00a0 ", "answer": 0}, {"article": "\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\nHowever, the findings do not apply to every stroke victim.\nThe study showed that the time window could be expanded to 16 hours.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t make it clear enough that patients in the non-surgery group still received standard medical treatment for stroke. What does that consist of, and how effective is it? We\u2019re not told.", "answer": 0}, {"article": "CHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\nDr. Paul Chapman of Memorial Sloan-Kettering Cancer Center in New York and the study\u2019s lead investigator called the results an \u201cunprecedented level of difference\u201d for patients with advanced melanoma, who typically survive just eight months on current treatments.\nBristol-Myers\u2019 Yervoy was approved in March for patients with inoperable or metastatic melanoma, based on a previous study which showed the drug given alone extended survival by four months in patients who had failed other treatments.\nShe and others expect vemurafenib to be approved this year.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately described the comparison data reported in the two studies.", "answer": 1}, {"article": "22863 \n\nWilsot16@mcmaster.ca\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nResearchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no other pharmacological treatment for preventing the chlamydia infection currently available so we rate this \u201cnot applicable.\u201d However, it might have been noted that most public health experts recommend condoms for preventing this and other sexually transmitted diseases.", "answer": 2}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\nSeparately, Italian researchers reported that advanced lung cancer patients given the targeted therapy drug Tarceva as so-called maintenance treatment \u2014 after they finished a course of standard chemotherapy \u2014 lived a little bit longer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As the first study did not show that the drug can prevent cancer, no alternative needs to be mentioned. The story did mention a natural supplement that was recently studied for prevention; we think this nod was so fast and vague, it was more confusing than helpful. It almost felt like a non sequitur.\nThe story mentions that\u00a0less than half of patients\u00a0with\u00a0successfully treated lung cancer currently receive maintenance therapy thereafter. Besides no treatment, none of the alternatives are mentioned.", "answer": 0}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\nJust an avocado a day can significantly lower your cholesterol and reduce the risk of heart disease, a new study shows.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\nAvocados are rich in so-called healthy fats and other nutrients and the study, published in the Journal of the American Heart Association, shows the creamy fruit can work within weeks to lower cholesterol.\nAvocados are definitely not low-calorie food.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that there are multiple ways that people can change their diet to improve cardiovascular health \u2014 avocados are not the only way to go. For example, the story points to studies which found that consuming other foods high in monounsaturated fatty acids (such as olive oil) were linked to reduced risk of heart disease and stroke. The story also notes that saturated fats increase heart disease risk. Ergo, another way to reduce risk is to lower consumption of meat and butter, rather than eating avocados. The story does not mention additional ways to lower LDL cholesterol, such as taking statin drugs, increasing exercise, quitting smoking, or limiting alcohol intake.", "answer": 1}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\nMason believes the stem cells accelerated his recovery.\nBut it's hard to know what would have happened without them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternative therapies or avenues of research for spinal cord injuries.", "answer": 0}, {"article": "Research has shown that our unhealthy eating habits and sedentary lifestyles are playing a major role in the development of lifestyle-related metabolic diseases such as diabetes, heart disease and obesity.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nThe lower body weight of the mice in the fasting group was not the only effect.\nIn a further experiment, similar benefits were already seen after only six weeks of intermittent fasting.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the release is written as if it could help inform human obesity treatment or prevention, there is no discussion of how obesity is treated or prevented now and the many alternatives available. These include changes in exercise and diet patterns and bariatric surgery.", "answer": 0}, {"article": "First published on June 22, 2006 at 12:00 am\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nShe said adiponectin could play an important role in longevity and noted that higher levels could be associated with good diet and exercise.\nThe study did not examine whether the medication improved cognitive functioning.\nAnother researcher who presented a different study at the conference also emphasized the importance of staying active and maintaining a proper diet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Diet and exercise are mentioned as preferred means of counteracting some of the effects of aging, such as muscle loss and health problems of a sedentary lifestyle. The study mentions improved functioning (increased balance, heel-to-toe walking and stair climbing) with growth hormone, but a comparison of growth hormone with a structured exercise program for older adults is not mentioned. ", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention some other medications to lower blood sugar, such as sufonylureas and insulin. However, lifestyle interventions are very important for controlling blood sugar (as well as blood pressure and cholesterol) and are not mentioned at all. This is an important treatment area that should not be overlooked in diabetes. ", "answer": 0}, {"article": "It\u2019s this type of innovation that sets MPTC apart from other proton treatment centers.\u201d\n\nAbout the University of Maryland School of Medicine\n\nCommemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.\nMPTC offers a robust clinical trial program to all its patients to further evidence-based medicine.\nMPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.\nAt MPTC, each treatment room is equipped with the most advanced form of \u201cpencil beam\u201d proton therapy, which essentially paints the radiation onto the tumor while stopping precisely at the site of the tumor.\nRadiation oncologists at UMGCCC already use external thermal therapy to treat a range of cancers, but do not currently use it for cancers that are deeper in the body.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As mentioned above, a physician quoted in the news release states that the combined therapy might have an \u201ceven greater benefit\u201d than when proton therapy is combined with standard radiation therapy, but that is the only comparison made. The news release does not mention any more traditional methods of cancer treatment, such as surgery, chemotherapy or standard radiation alone nor how they compare to the new combination. ", "answer": 0}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\nThere is increasing evidence that computer-assisted training can help people with schizophrenia overcome some of their symptoms, with better outcomes in their daily lives.\n\u201cWe need a way of treating the cognitive symptoms of schizophrenia, such as problems with episodic memory, but slow progress is being made toward developing a drug treatment,\u201d said Barbara Sahakian from the department of psychiatry at Cambridge University.\nThey also improved their scores on the Global Assessment of Functioning (GAF) scale, which doctors use to rate the social, occupational and psychological functioning of adults.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says \u201cThere is increasing evidence that computer-assisted training can help people with schizophrenia overcome some of their symptoms,\u201d but doesn\u2019t tell us which symptoms or which types of training are relevant. The story also doesn\u2019t tell readers whether there are other possible pharmaceutical, lifestyle, or cognitive training interventions that may help schizophrenia patients retain or improve episodic memory. Indeed, other computer systems are being explored as well as stimulation of brain regions using electro-magnetic fields. And options being used in clinical practice\u00a0are skills training explained on the National Alliance on Mental Illness\u00a0website.", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n\u201cThe billing is complicated, and for many physicians that\u2019s enough of a deterrent to not bother.\u201d\n\nDr. Cooney herself had such care along with surgery and chemotherapy for ovarian cancer in 2008.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted in the competing reviews, the point of the study was to compare early palliative care with existing standard cancer treatment. However, this story, like the others, could have provided more information about what standard cancer treatment \u2014 the current \"existing alternative\" \u2014 entails.\u00a0", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe test involves inserting urine samples into the Odoreader that are then measured using algorithms developed by the research team at the University of Liverpool and UWE Bristol.\nThe positioning of the prostate gland which is very close to the bladder gives the urine profile a different algorithm if the man has cancer.\"\nWorking in collaboration with the University of the West of England's (UWE Bristol) Urological Institute team at Southmead Hospital and Bristol Royal Infirmary, the pilot study included 155 men presenting to urology clinics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story goes into some detail about how this test might compare with the PSA test and gives a brief mention of biopsies. The lead author states:\u00a0 \u201cThere is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.does indicate that the PSA test is problelmatic for false positives.\u201d", "answer": 1}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\nHealth benefits, including weight loss, seem to be a byproduct of the program, said Dr. David Katz, director of the Yale University Prevention Research Center.\n\"It [also] may be that when kids go to Head Start, it reduces stress in the household and frees up time and resources at home to dedicate to healthier eating patterns,\" she noted.\n\"This paper importantly suggests that some of the best strategies for controlling weight and promoting health may have little directly to do with either,\" said Katz, who wasn't involved in the study.\n\"The children may be served healthier meals at Head Start than other children.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not place these findings in context with other obesity prevention and treatment initiatives for children. This is an area that has been studied extensively.", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe research team retrospectively analyzed more than 100 cases of atypical moles.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions the current standard of practice but does not offer a data-based comparison, as we note in the \u201cquality of evidence section.\u201d", "answer": 1}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nDuring 15 years of follow-up, 747 patients were diagnosed with lung cancer.\nOur results suggesting that the risk associated with metformin might differ by smoking history were unexpected.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release investigates the possibility that metformin may decrease the risk of lung cancer in people who never smoked. This would have been an opportune place to add that not smoking \u2014 or quitting smoking, if you are a smoker \u2014 is probably the most important thing one can do to reduce the risk of lung cancer.", "answer": 0}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\nA week later, under no medication, participants returned to repeat the experiment.\nPTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any of the other treatment strategies for PTSD or show how this drug might compare with them.\nOne other drug that\u2019s been studied for its use in the blocking of learning conditioned fear is the beta blocking blood pressure drug propanolol. ", "answer": 0}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\nThe new study, in the Annals of Surgery, doesn\u2019t settle that question.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was the comparison between two surgical approaches.", "answer": 1}, {"article": "\"That's a very personal decision,\" Steiner said.\nFurther, decades of research still have not produced good evidence that self-exams make any difference in breast cancer survival.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\nShe said self-exams may not reveal tumors early enough to improve survival.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions mammograms as a better diagnostic option, yet the story also notes that this tool may may miss some cancers in the upper-outer quandrant of the breast.\u00a0 The story notes improved and more specific tactile breast self-exam methods as an option; however, there is little evidence that these techniques improve detection of early breast cancers in a large population.\u00a0 The story references current breast cancer screening guidelines from the American Cancer Society and U.S. Preventive Services Task Force. ", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nOther than saying that other studies failed to find benefits from beta-carotene supplements, the story fails to discuss what is known about how alpha-carotene might compare to other components of foods.", "answer": 0}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nThis places the VIPS device above standard physical examination tools used by emergency personnel that display specificity scores between 40 and 89 percent.\nThe VIPS device requires very little training to operate compared to that required to learn standard emergency examination skills, thereby reducing the possibility of human error during emergency diagnosis.\nIf so, the VIPS device could have widespread clinical implications, helping emergency personnel decide whether to take a patient to a comprehensive stroke center or a primary stroke center for treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study compares this device to a clinical diagnosis by neurologists and the release states that the device showed \u201c92 percent specificity\u201d which we are told is above the \u201cstandard physical examination tools used by emergency personnel that display specificity scores between 40 and 89 percent.\u201d\nBut as noted above, the better comparison would be comparing this device to CT scans given that mobile CT scanners are increasingly being used in ambulances.", "answer": 0}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the article talks about 235 million asthma sufferers across the world, it provides no description of the challenges they face or the limitations of current treatment options. It\u2019s not clear, therefore, why or for what types of people an alternative treatment is needed and what this treatment might have to offer over the status quo.", "answer": 0}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nTo overcome the challenges of conventional combination therapy, the NUS team of engineers developed the CURATE.AI platform, which uses the patient's own clinical data - such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood - to calibrate his or her unique response to treatment.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nOur clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "CURATE.AI is far from the only AI tool that has been considered for use in cancer treatment. For example, HealthNewsReview.org wrote last year about a (failed) attempt to incorporate IBM\u2019s Watson system into cancer treatment at M.D. Anderson Cancer Center. And there are hundreds of papers that address various attempts to use AI, machine learning, or artificial neural networks in the context of cancer treatment. Here\u2019s a review paper from 2006 that addresses 396 related papers that had already been published at that time. The release on CURATE.AI does not make clear how this new AI tool is different from or similar to the body of work in the field.\u00a0 We don\u2019t expect a news release to offer a detailed overview of how the new work differs from what came before it, but we do expect a release to provide at least a broad idea of what sets the new work apart.", "answer": 0}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nThe study did not assess longer-term pain reduction.\nWithin two hours, all participants reported essentially identical declines in pain, about four points on the scale.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nData on pain came from the participants' ratings; no information on side effects was collected.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story (and the study itself) are focused on the comparison of alternatives.", "answer": 1}, {"article": "\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\nTheir improvement was significantly more than the average seen in patients taking just medication, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison with any other approach for Alzheimer\u2019s disease.\nApart from telling us, \u201cTheir improvement was significantly more than the average seen in patients taking just medication,\u201d we are not provided with any meaningful comparison to other approaches.", "answer": 0}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nBut taking out wisdom teeth when there aren't any symptoms is where the professionals get into it.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately weighs the benefits of both approaches \u2014 early removal or waiting to see if complications develop later on.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\nAdditional research is needed to identify which women are more likely to experience severe labor pain and who would benefit the most from effective labor pain-control strategies to help reduce the risk and affect of pain on postpartum recovery.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\n\u201cAlthough we found an association between women who experience less pain during labor and lower risk for postpartum depression, we do not know if effective pain control with epidural analgesia will assure avoidance of the condition,\u201d said Dr. Lim.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The best comparison we get to alternatives is a bit of minor scaremongering. This release really should have brought more to bear on births where women choose to not to use an anesthetic, also called \u201cnatural\u201d birthing. It should also be noted that nitrous oxide is increasingly being offered as an alternative in hospitals around the US. That\u2019s worth noting.", "answer": 0}, {"article": "Studies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other tactics have been shown to boost older adults\u2019 memories, including aerobic exercise and some social and behavioral activities. But in this story, which focuses on a key finding about dietary restriction, it is not necessary to mention these options.\u00a0\u00a0 \n\u00a0", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\nAlthough the connection between breast cancer risk and fiber is a small one, fiber is \u201csomething that we know is healthy for you anyway,\u201d said Christina Clarke, a research scientist at the Cancer Prevention Institute of California in Fremont.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did touch on other risk factors:\u00a0 \u201calcohol drinking, weight, hormone replacement therapy and family history\u201d", "answer": 1}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\nAfter three months, 37 percent of participants in the acupressure group reported a 50 percent reduction in pain intensity.\nOnly 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the trial aimed to evaluate whether women achieved greater reduction from acupuncture as an add-on treatment than from \u201cusual care alone.\u201d Usual care was described as pain medication and hormonal contraceptives.\nThe release would have been improved had it made it explicit that the study participants continued to use other pain relief therapies while doing acupressure and that the acupressure study was designed to test the technique\u2019s value as an adjunct therapy.", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nThat's presumably why sufferers of plantar fasciitis feel the pain in the heel.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The discussion of alternatives is a real strength of this piece. Instead of relegating this coverage\u00a0to a throwaway line at the end of the piece as\u00a0many stories\u00a0do, this story\u00a0mentioned\u00a010 low-tech treatments that patients are advised to try before considering shockwave therapy. In addition,\u00a0the story\u00a0explained that nearly all\u00a0patients with heel pain eventually get better regardless of what kind of treatment they\u00a0receive.\u00a0\u00a0\u00a0", "answer": 1}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nLanser says it can be tricky to diagnose food allergies.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\nA new study published in the Annals of Allergy, Asthma & Immunology illuminates just how many people come to find out they can eat foods they've long avoided.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In one sense, the only alternative to having an oral food challenge is not having an oral food challenge, and possibly not discovering that a child has grown out of an allergy. That issue is covered in this story. Another important point is that skin prick tests have been found to produce misleading results in a large proportion of patients. There is a growing conviction among researchers and practitioners that the only way to confirm beyond doubt that an individual has a food allergy is to conduct a food challenge. That alternative was mentioned in the story, but more emphasis would have presented a fuller picture of the significance of the study findings.", "answer": 1}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\nThe research from the RTI International-University of Chapel Hill Evidence-based Practice Center was published today in the British Medical Journal.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\n\"Our findings indicate that both options should be considered effective initial treatment strategies.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the release is about comparative trials it didn\u2019t delve into what improvement means.", "answer": 1}, {"article": "The researchers compared breast cancer deaths in women who had a breast cancer diagnosis in counties that had screening with deaths in counties that did not.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough not discussed in detail, the story does mention that the United States Preventive Services Task Force has questioned the value of screening mammograms for women younger than 50, thus implying that not being screened is an option to consider.", "answer": 1}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nA once-a-day drug being developed to treat women with low libido proved to boost desire and led to better sex among female patients participating in late-stage studies, according to publications presented today during a medical meeting in Lyon, France.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story correctly indicates that there are no drugs currently approved to to treat acquired hypoactive sexual desire disorder in pre-menopausal women.\u00a0 The story does acknowledge that hyposexual desire disorder is multi-factorial and that a drug would not\u00a0address other\u00a0contributing factors.\u00a0", "answer": 1}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cOne is called \u2018best possible self,\u2019\u201d Eric Kim, who also co-led the study, told CBS News.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\nThey suggested a number of steps people can take to improve their level of optimism.\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does discuss healthy dietary choices and exercise.", "answer": 1}, {"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nDrinking less than five cups of coffee a day had a smaller but statistically significant protective effect: about 4% lower odds of mouth and throat cancer for each cup drunk daily.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was some discussion of whether the association could be attributable to caffeine or fruit and vegetable consumption, and what was seen in tea drinkers.\u00a0 We\u2019ll give the story the benefit of the doubt for mentioning these other factors, although, again, inappropriate \"protective\" or \"effect\" language was used in this discussion. \n", "answer": 1}, {"article": "DOI: 10.1016/j.ophtha.2016.04.026.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nThe ring is designed to be replaced by an ophthalmologist every six months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not compare the ring with existing approaches to help patients adhere to treatment plans, such as better physician-patient communication and simplified drug regimens. It also gives a quote from a study author saying, \u201cWhat is exciting is that this is just one of several sustained-release drug delivery methods designed to help patients who have trouble taking daily eye drops.\u201d But there\u2019s no elaboration to explain what these other methods are or whether they have been studied or approved for use in glaucoma patients.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative would be not getting a Tdap vaccine as a pregnant mother, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\n\"We're hoping this approach can bring regenerative medicine into the dentistry field,\" said Celiz.\nThe stem cell procedure is in the earliest stages of development, said Celiz.\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that root canals are the current standard of therapy.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions cognitive-behavioral therapy, aerobic exercise and substance-abuse programs as effective alternatives for individuals with treatment-resistant depression. It should also have mentioned electroconvulsive therapy (commonly referred to as \u201cshock therapy\u201d), which is highly effective\u00a0for depression and should be considered by patients with severe symptoms or when symptoms\u00a0do not respond to other therapies.", "answer": 1}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nThat warning was especially strong for those with a family history of allergies.\nThat advice has been amended, and newer evidence has shown that introducing foods earlier is actually better for preventing food allergies.\nMore research is necessary to figure out the ideal amounts of these allergens, the optimum times of introduction and the reasons behind the link.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not seem to require comparison of alternatives, since it isn\u2019t about treatments.", "answer": 2}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The treatment is put in context with other treatments.", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nDec. 1, 2011 (Chicago) -- An experimental treatment that involves spinal injections of ozone gas and steroids relieved pain in over two-thirds of 327 people with back problems related to a herniated disc.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Though the study described alternative treatments, it didn\u2019t actually state how the results reported here compare. A key deficiency of this study is that it didn\u2019t compare the treatment to common alternatives. Since there are good treatments available for herniated discs that aren\u2019t getting better on their own with conservative treatment, one can only comment on the current results in comparison to these alternatives. This was not done.", "answer": 0}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nBut vitamin D also influences cellular function in ways that could be beneficial in treating cancer, Ng said.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\n\"These findings are interesting, and show that vitamin D may have a role in improving outcomes in cancer care.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have mentioned how the findings compare with other similar factors \u2014 diet quality, exercise, stress reduction etc. \u2014 that might have an impact. However, since the evidence on these issues is similarly limited, this criterion is not really applicable", "answer": 2}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of talking about many alternatives that couples have for birth control.", "answer": 1}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story is about different intervals for bone density screening.", "answer": 1}, {"article": "\"Like many things, the evidence changes over time,\" says Hensrud.\nDr. Dong Shin, a head and neck specialist at Emory Winship Cancer Institute says this new study suggests \u201cthere is a hint of beneficial outcomes\" with coffee and oral cancer.\nHowever, coffee alone may not be the answer according to some experts.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\nBut he is concerned that the side effects of coffee are not addressed in this study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t comment \u2013 as the WebMD story did \u2013 on other factors analyzed in the study such as tea, fruits and vegetables. ", "answer": 0}, {"article": "A drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nFeb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion about alternative approaches for people with mild strokes. At best, the story compared the new treatment (in a sample of 4 patients!) with routine standard of care (unexplained).\u00a0 The problem is that the story never told us how the 4 patients treated with tPA fared.", "answer": 0}, {"article": ".\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nCertain grain foods, like pasta, are a great complement to a healthy well-balanced meal and provide plenty of opportunities for improving the diet,\" explains registered dietitian Diane Welland, Nutrition Communications Manager for the National Pasta Association.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss alternative diets that might provide the shortfall nutrients identified by the USDA.", "answer": 0}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does attempt to make comparisons and goes into a good amount of detail about similar products on the market, but here, again, it allows the company touting this algae-dervied product to make an unchallenged claim of superiority. \u201cThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said. The patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\u201d We don\u2019t think that provides readers with the sort of serious comparison they\u00a0deserve, especially in a market this\u00a0crowded.", "answer": 0}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nPeople who were taking medication for OCD continued to do so for the trial.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the article mentions alternative treatments (psychotherapy and medications), it doesn\u2019t compare them to outcomes claimed for TMS.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not adequately explain the comparison between the device and alternatives. For example, research has shown that patients with mild heart-failure can undergo training to take better care of themselves and reduce their number of hospitalizations, too.", "answer": 0}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nThe contributors are affiliated with one or more of the following institutions: Baylor College of Medicine, Peptides International, Inc. and Icahn School of Medicine at Mount Sinai.\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does the bare minimum here, stating, \u201cCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\u201d", "answer": 1}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nWhen they took leptin, their calorie burning increased to pre-diet levels.\nWhat is hard is to keep the weight off.\nEveryone who has dieted knows that losing weight is the easy part.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention of any other weight loss maintenance methods.", "answer": 0}, {"article": "...\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nHowever, the test cannot distinguish between the different atypical disorders, which doctors must rely on symptoms to diagnose.\nInstead, the cause is multiple system atrophy, a neurodegenerative disease.\nHe also believes the test will be used by specialists for Parkinson's patients who \"do not exhibit a very typical symptomatology\" or do not respond as expected to treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0discusses the alternative\u2013a spinal tap test.", "answer": 1}, {"article": "Paul J.D.\nWhiteside, a doctoral candidate in the MU Division of Food Systems and Bioengineering, devised a system that will not only improve the process, but will be safer for both clinicians and patients.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\nUsing various amplitudes and pulses, the instruments they developed were tested on the samples and showed great promise for the clinical setting.\nThe team is in the planning stages of developing a start-up company to commercialize the technique.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release does include claims that this experimental device is better than existing dermatological lasers, there are no details about how, or how much, better it might be. What\u2019s more, the release fails to mention other methods, including applying glycerol or mechanical vibration to improve laser light transmission through skin. The draft journal article cites other research into using ultrasound, but this somewhat similar technique was not mentioned in the news release.\nThe confusing mishmash of references to \u201copen-air transmission\u201d and sonoillumination is not useful to readers who don\u2019t dig into the conference or patent application materials.", "answer": 0}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release quotes a researcher who says \u201cthere hasn\u2019t been a lot shown to be very effective on a large scale\u201d for childhood obesity. That\u2019s true enough, but we thought the release needed to go a little bit further to earn a Satisfactory rating. This is a very active area of study, and the release could have given a few examples of what \u2014 besides peanuts \u2014 has been tried and what the results have been.", "answer": 0}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t even include a line about other stroke prevention research \u2013 dietary or otherwise.", "answer": 0}, {"article": "Through its divisions in 54 subfields of psychology and affiliations with 60 state, territorial and Canadian provincial associations, APA works to advance the creation, communication and application of psychological knowledge to benefit society and improve people's lives.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants' age, gender, feelings of well-being or level of social connectedness didn't affect the findings.\n\"The study findings are exciting because they demonstrate that it's never too late to take action to maximize the cognitive capacity of your brain,\" said lead researcher Megan Lenehan, PhD.\nSome participants in the control group may have been doing crossword puzzles or other mentally stimulating activities that boosted their cognitive capacity, Lenehan said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release refers to other studies including those that have utilized other methods not involving formal education.", "answer": 1}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\n\"There is no overall difference in recurrence rates or survival rates [between patients who got the bone drug and those who did not], except in older patients, defined as more than five years after menopause.\"\n\"The role of bisphosphonates in preventing cancer recurrence has been less clear,\" she said, noting that multiple studies have had conflicting findings.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nTHURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did point out that the women in this trial did receive standard therapy (and it did so more clearly than the other story we reviewed), though it did not specifically say what that treatment entails. We will give the story a satisfactory rating since it is not clear that there is a proven alternative that would provide the type of recurrence and survival benefits seen in a previous study of zoledronic acid for early stage breast cancer.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\nHicks and a team of researchers have been looking for an objective test that might help.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the spit test to a widely used concussion survey. However, many readers and listeners are likely to be confused about the basis of the comparison, and incorrectly believe that the researchers compared how well the tests guide patient care, when actually the new study looked only at the ability to predict reports of symptoms.", "answer": 1}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nColonoscopies are recommended for adults age 50 and over to help detect early signs of colorectal cancer.\nThe CDC says colonoscopy could reduce the number of colorectal cancer cases by as much as 60 percent.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nRegular colonoscopy physically examines the colon by inserting a lighted probe into the intestine and requires a sedative.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The American Cancer Society provides a comprehensive listing of screening methods for colon cancer based on the level of risk of an individual. The story mentions a standard colonoscopy as an alternative as well as DNA tests and stool sampling.", "answer": 1}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\n\"Instead, this study suggests exercise can be a type of medicine.\"\nWhen the same fluids were extracted before and after a non-running condition, the inflammation markers stayed at similar levels.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention of any alternatives. Many runners are told to switch to other forms of exercise as they get older to avoid joint pain. Do other forms of exercise produce the same benefits on inflammation?", "answer": 0}, {"article": ".\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nThe team then identified patients who took cholesterol-lowering medication before surgery.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\nVogel's research team reviewed nearly 20,000 cases where patients either had open surgery or an endovascular repair - a minimally invasive procedure that uses a catheter to access the aneurysm.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release compares surgery outcomes with or without statins.", "answer": 1}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nOne cancer surgeon who reviewed the findings was impressed.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly compares the use of Opdivo to the use of Yervoy, and cites an independent source as noting that Opdivo \u201cis superior to conventional chemotherapy for advanced metastatic disease.\u201d", "answer": 1}, {"article": "The U.S. Preventive Services Task Force recommendations state that most women begin mammography at age 50.\nBreast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nFifty percent of these women met either the ACS or the ASBS requirements for early mammography, Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other alternatives were discussed in the story besides the breast cancer risk assessment. But it seems like there likely are none\u2013you either have the risk assessment or none, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "\"People say, 'What's the harm in screening?'\nIt did find enough new data to recommend for the first time against screening for older men.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\nThe new review of the scientific literature found no evidence to alter that assessment for younger men.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was about the new recommendation regarding routine screening of men older than 75 years of age with PSA test;\u00a0 the story presented arguments for and against the use of the test.", "answer": 1}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nStandardized tests given at the start and end of the study showed that working memory, sometimes thought of as short-term memory, improved for those given 40 milligrams of insulin but not for those given the smaller dose or the placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Neither this story nor a competing story by Fox News compared the drug to other FDA-approved therapies for Alzheimer\u2019s or other insulin therapies. The news release actually explains that other therapies are out there for comparison, saying, \u201cPrevious trials had shown promising effects of nasally-administered insulin for adults with AD and MCI, but this study was the first to use insulin detemir, whose effects are longer-lasting than those of \u2018regular\u2019 insulin.\u201d", "answer": 0}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\n\"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease.\nMeta-analyses of the other types of clinical trials showed similar results.\nAnti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release make clear that these drugs would be aimed at patients currently not helped by any existing drugs, so a comparison with those other medications would not be very helpful here. The release could have included some non-pharmaceutical alternatives.", "answer": 2}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study is comparing two alternatives when quitting smoking\u2013either cold turkey or gradually. The story discusses these options, along with the use of nicotine replacement in both scenarios. That\u2019s enough to qualify as Satisfactory.\nHowever, another alternative the author didn\u2019t mention was medications that can help with cravings\u2013such as bupropion. What does the research say (if anything) about how those medications might augment quitting? That\u2019s important to discuss.", "answer": 1}, {"article": "\"Now I feel relieved.\"\n\"It does bolster our confidence that it's effective in the real world,\" said Dr. Bruce Hirsch, an attending physician in infectious diseases at North Shore University Hospital in Manhasset, N.Y., who was not involved with the study.\n\"This study helps me in terms of advising patients and prioritizing,\" Hirsch added.\n\"People 60 and over can consider talking to their physician about the possibility of receiving the vaccine to reduce their risk, and the doctor can evaluate if they are eligible,\" said Tseng.\nA study of a cross-section of adults enrolled with a health-management organization in southern California shows that the vaccine provides protection for many older adults without many side effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nWhile it may seem that the decision to vaccinate is a simple yes or no matter, this story does a nice job of expanding the question to include other vaccination priorities. It includes comments that point out that shingles, while terribly painful, is not contagious or life-threatening\u2026 and that considering the high cost of the shingles vaccine, it may be reasonable to place a higher priority on other vaccinations. The story does readers a service by addressing some of the real world choices people face, rather than merely considering a single intervention in a vacuum.", "answer": 1}, {"article": "Niki Munk, an assistant professor of health sciences in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis and one of the co-first authors of the study, said that the study's findings are important, given the large number of people who suffer low back pain in the U.S.\n\nLow back pain leads all disorders in years lost to disability in the U.S.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nMore than 50 percent of those who participated in the study experienced clinically meaningful improvements in their low back pain with disability, according to Munk.\nIn this study, patients were referred by a physician to a massage therapist.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We would like to give the release credit for mentioning that back pain is very complex, and that surgery is sometimes an option. However, we think the release falls short in not acknowledging that there has been extensive research on a variety of complementary approaches before this study including yoga, massage, acupuncture and exercise. The release could have provided that information about alternatives, as well as make some effort to tell us how massage compares with other non-invasive physical treatments.\nThe complexity of the problem, the option for surgery and the nature of chronic treatment are all relevant, as the release notes, but that\u2019s no substitute for mentioning other treatment alternatives, some of which, like physical therapy, are covered by insurance.", "answer": 0}, {"article": "Source: Brightling C, et al.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nResearchers out of the University of Leicester have developed a new asthma pill for the first time in 20 years, which they believe will significantly improve symptoms for those with severe asthma.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Current treatment options for asthma aren\u2019t mentioned.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Excellent comparison of alternatives.\u00a0 Excerpts:\n\u201cA big impediment to future Abraxane sales in pancreatic cancer could be that its median survival was almost three months less than that of Folfirinox, a combination of four generic cancer drugs.\nResults of a clinical trial published in 2011 showed that pancreatic cancer patients getting Folfirinox had a median survival of 11.1 months compared with 6.8 months for those getting gemcitabine.\nExperts cautioned that it was difficult to draw conclusions since Abraxane and Folfirinox were not compared directly in the same trial. Nonetheless, doctors are going to make treatment decisions based on the separate results.\u201d\nAnd:\n\u201cIn 2005 the Food and Drug Administration approved Tarceva, now sold by Roche and Astellas, to treat pancreatic cancer. In a clinical trial, those who got Tarceva plus gemcitabine had a median survival only 12 days longer than those who received a placebo plus gemcitabine.\u201d", "answer": 1}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nEddy said that the calculator, or others like it, could be integrated into electronic health records.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire focus of the story was a comparison of a \u201ctailored medicine\u201d approach to existing guidelines for treatment of high blood pressure.\nIt would have been interesting to explore whether this is the only model for tailoring clinical information to arrive at better clinical outcomes or whether there are other models available for this purpose.", "answer": 1}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nMusic, nature sounds and white (or pink) noise apps may still help improve sleep, she says\u2014which, in itself, is good for the body and for the brain.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\nThe researchers hope to develop an affordable device that people can use at home.\nOn one of those nights, headphone-clad participants were played a series of short bursts of pink noise during deep sleep, spaced out enough to prevent the brain from getting used to and ignoring them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does mention some other soothing sounds that might help people sleep better, such as music, nature sounds, or white noise apps. It would have been helpful to include some other strategies for improved sleep as well such as over-the-counter sleep aids, sleep hygiene (exercise, limiting naps, restricting certain foods before bedtime), and cognitive behavioral therapy.", "answer": 1}, {"article": ".\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\nTivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.)\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions alternatives to tivanisiran:\n\u201cDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general. However, the main treatment consists of artificial tears, in the form of drops, gel or creams. Preservative-free eye drops have generally been found to offer the best long-term response.\u201d\nThe American Optometric Association publishes a patient pamphlet that provides additional management options.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention of other drugs that may have a similar effect. No mention of harms or disadvantages of taking the drug, even as a single-dose. Skin problems have been reported in people taking nevirapine in combination with other HIV drugs. Liver toxicity has also been reported, but only with long-term use. ", "answer": 0}, {"article": "Only the third and fourth groups received dexamethasone.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\nBefore that, older patients were rarely subjected to major surgery, and significant research in this field has only been conducted for approximately 15-20 years.\nOne of the obstacles to reliable diagnosis and rehabilitation is a lack of practical and secure instruments for pre- and post-operative cognitive assessment.\nThe earliest trials with patients who developed POCD were performed after the 1950s.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Frankly, there\u2019s not a lot of research out there on steps to pro-actively reduce rates of cognitive dysfunction after anesthesia, and we\u2019re not aware of alternative interventions designed to do so.", "answer": 1}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nBut they had new symptoms that caused physicians to suspect heart disease \u2014 and nearly all had at least one risk factor like high blood pressure, diabetes or a history of smoking.\nResults of the federally funded trial \u2014 Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) \u2014 were presented at the American College of Cardiology\u2019s 64th Annual Scientific Session in San Diego.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The whole point of the study was to compare a newer and an older approach to diagnosing heart problems.", "answer": 1}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nProfessor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: \"Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No other alternative tests are mentioned.\u00a0\u00a0Cancer antigen 125, or CA-125, a test for screening for ovarian cancer, is recommended when there is high clinical suspicion (when the patient is having particular symptoms to suggest the presence of cancer).\nMentioning this test, and its pros and cons, would have provided useful context for readers wondering about how these preliminary results stack up against our current screening tests.\nThe release should also have noted that the US Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women. The American College of Obstetricians and Gynecologists does not support screening.\n\u00a0\n\u00a0", "answer": 0}, {"article": "\"Can't say,\" replies Dendreon COO Hans Bishop.\nThat's better than the only other approved treatment for such advanced cancers.\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nBut, after all, Provenge is just the first cancer immunotherapy on the market.\nThe theory is that the custom-made vaccine incites patients' immune cells to attack the cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the drug performed \"better than the only other approved treatment for such advanced cancers\" and that \"Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\" ", "answer": 1}, {"article": "The average age of the participants was 11.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\nBut, researchers believe it may interact with a brain receptor that plays a role in the development of seizures, Devinsky said.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nBut experts say these positive findings may have been influenced by a \"placebo effect.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The interest in marijuana constituents as possible treatments arose because existing alternatives\u2014anti-seizure drugs\u2014do not work with some patients. So a premise of this story is that existing alternatives are unsuccessful in this group of paitents.", "answer": 1}, {"article": "The difference between being treated five times versus 44 times is enormous,\" said Mr. Martin, a retired airline pilot.\nOther clinical trials at the UTSW Department of Radiation Oncology are seeking to expand the application of SBRT to high-risk (Stage III) prostate cancer patients.\nA range of clinical trials of SBRT therapy are under way at Simmons Cancer Center, including new investigations evaluating use of SBRT for cancers in the breast and larynx.\nTo reduce the side effects associated with SBRT, current clinical trials at UTSW are using a unique and biodegradable rectal spacer gel to protect the rectum.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release gives us some information about this treatment vs. traditional radiation and lists other important alternatives including prostatectomy (surgical removal of the prostate gland), brachytherapy (the implantation of small radioactive seeds), and external beam radiation. One alternative not mentioned \u2014 which is appropriate for low-risk cancers \u2014 is active surveillance (monitoring the patient and deferring active treatment).", "answer": 1}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\nRemember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nCalcium recommendations vary according to age.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention diet and weight bearing exercise as alternatives to calcium supplementation. However, more information about the advantages and disadvantages of the alternatives should have been provided. Other options, such as exercises to improve stability and interventions to prevent falls, could also have been mentioned.", "answer": 1}, {"article": "Hot flashes are a sudden rush of heat, followed by facial flushing and sweating, often followed by chills and clamminess.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause, says researcher Gary R. Elkins, PhD.\nIn an earlier study, Elkins and his Baylor colleagues showed that hypnosis dramatically reduced hot flash and night sweat frequency in breast cancer patients with treatment-related symptoms.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions hormone therapy as an effective treatment with risks, but does not go further into detail. The researcher is quoted as saying in the article, \u201cOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause.\u201d But how much more effective is hormone therapy? And what exactly are the risks? The researcher also adds that therapeutic hypnosis works \u201cas well or better\u201d than antidepressants or other non-hormonal therapies, but it would have helped if the story specifically described the non-hormonal alternatives.\nThe LA Times article gave a better description of the other complementary/alternative medicine treatments.", "answer": 0}, {"article": "Pain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\nThey note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nThe study was conducted by researchers from London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario; Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta; and Children's Hospital of Wisconsin, Milwaukee, Wisconsin.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This news release reports the results of a randomized superiority trial designed to specifically compare two alternatives. So the release scores well on this criterion.", "answer": 1}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nThe disease most often strikes adults after age 20, but it can develop in children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of vitamin D supplements, but the story discussed main sources of the vitamin, including milk, fish, fortified foods, and sunlight.\u00a0\u00a0 ", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe article compares the new surgical techniques to traditional total joint replacement, and explains why it may be better or worse than longstanding approaches.", "answer": 1}, {"article": "So Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nAt 15 weeks, visual acuity with eyeglasses improved by about 1.8 lines on the vision chart in the patched eyes and 2.3 lines in those who had acupuncture.\nThey assigned 43 children to the acupuncture group, and they received five treatments a week.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story weighs some of the pros and cons of acupuncture compared with the traditional patch therapy. It notes that the patch has the advantage of being inexpensive and that it can be worn at home, making it more convenient.", "answer": 1}, {"article": "\u201cIf we could essentially nip those within 60 hours or even 24 hours and then keep that at bay for at least 30 days, that\u2019s pretty compelling when you think of the alternative,\u201d Baker said.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nInterestingly, none of the patients who took the drug reported psychiatric side effects, such as abnormal dreams, insomnia, and anxiety \u2014 but 5 of the 11 women on the placebo reported such symptoms.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nThe only other treatment for postpartum depression is talk therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a barely passing satisfactory as the story does briefly acknowledge alternatives. The only reference to conventional antidepressant treatment is that it doesn\u2019t work as quickly as this experimental drug appears to. Talk therapy is mentioned, but there is no mention of its effectiveness. While it is true that antidepressants can take weeks, they and mood stabilizing drugs for women with bipolar disorder do treat postpartum depression. In women with a history of this highly recurrent condition, antidepressant treatment may be started or maintained\u00a0during pregnancy.", "answer": 1}, {"article": "And Owens says that people with medical conditions like ulcers, kidney problems, liver problems or bleeding disorders are more vulnerable, as are people who take blood-thinning drugs and NSAIDs.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\nThe Food and Drug Administration actually issued a warning against routinely taking aspirin to prevent heart disease in people without significantly high risk.\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\nConcerns have been raised about whether aspirin is really effective enough, when so many other medicines are available to help control heart disease risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main point of the story is a recommendation to modify existing aspirin use habits. \u00a0So it nicely sets up a comparison between current practice and recommended behavior. The story also nods to other approaches and medications (e.g. cholesterol and blood pressure drugs).", "answer": 1}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\nIn essence, the new intervention -- known as \"visually guided laser-balloon catheter\" -- enables doctors to much more accurately target the so-called \"misfiring cells\" that emit the irregular electrical impulses that can cause an erratic heartbeat.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, the comparison of the \"new approach\" with existing approaches is superficial and unhelpful.\u00a0 And there was no comparison of performance or outcomes data.\u00a0 Terribly incomplete on this point. ", "answer": 0}, {"article": "Andrew Keaveney, now 73, shattered his ankle in a fall from a truck while hanging flags as an American Legion volunteer.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nDr. Deland cited data showing that for some recent models, 90 percent of ankle replacements were still in place after an average of eight and a half years.\nDr. Brian Donley, an orthopedic surgeon who is director of the foot and ankle center at the Cleveland Clinic, says patients should always ask their doctor to disclose any financial interest in a device.\nEven with a successful implantation, patients should not necessarily expect to have the same ankles they did at 18.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article correctly indicates that ankle fusion is the only surgical option to joint replacement.\u00a0 Many experts consider ankle fusion to be a highly successful procedure that relieves pain for many patients despite some loss ankle flexibility.\u00a0 A more detailed comparison of the procedures would have been informative to the readers. In addition, the story\u00a0should have indicated that non-surgical options such as medication, physical therapy and orthotics, are the more common treatment approaches.\n", "answer": 0}, {"article": "About 94 percent were free of any invasive cancer, including new cancers at other sites or in the opposite breast.\nThe high-risk group was given chemotherapy and hormone-blocking drugs.\nThe study was sponsored by the National Cancer Institute.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the usual course of treatment, which is surgery followed by years of a hormone-blocking drug, as well as chemotherapy.", "answer": 1}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Most people over the age of 50 would be vastly better off following prudent health advice and visiting their doctor to discuss whether they should to be screened for specific treatable conditions such as high blood pressure, diabetes, breast cancer, high cholesterol, hypothyroidism or colorectal cancer, to name a few. The story doesn\u2019t mention that.", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nOther drug companies are at work on competing versions of the immune-enhancing antibody therapy.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that \"Other drug companies are at work on competing versions of the immune-enhancing antibody therapy.\"", "answer": 1}, {"article": "Those on beta blockers had a substantial reduction in the formation of distant cancers, or metastases, and of local recurrence.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\nPrevious research, Lichtenfeld said, has found a reduced rate of skin cancer among men who take another type of blood pressure-lowering drug.\n\"Our study was performed retrospectively, using patient notes [from women] that had received treatment in the late 1980s and 1990s,\" Powe said.\nFRIDAY, March 26, 2010 (HealthDay News) -- Treatment with blood pressure-lowering drugs known as beta blockers appears to help reduce the spread of breast cancer in women, a team of British and German researchers report.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly mentions the purported association between aspirin and reduced risk of breast cancer recurrence; however, it would have been useful if the story discussed some of the standard therapies used to prevent recurrence, including radiation therapy and hormone therapy. Furthermore, in the last 10-20 years since these women were treated, better hormonal therapies and other treatments (e.g. herceptin) have been introduced which may or may not influence results. \u00a0", "answer": 0}, {"article": "I hurt so bad, everything hurt,\" Marylin adds.\nDr. Saibal Kar performed the innovative procedure on Barletta at Cedars Sinai Hospital in Los Angeles.\n\"I was so happy that I was OK, that I had escaped the open heart,\" Barletta says.\nHe says it's in the final stages of testing at about 30 hospitals around the country.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although unclear about what exact heart valve problem was being treated, the story compared and contrasted the experience of two family members with the same medical condition treated with different options.\u00a0 The story painted a very positive picture for the use of the medical device vs. open heart surgery but gave no indication that both treatments may be more appropriate for specific categories of patients.\nThe story provided no indication that there might be medical management options for the treatment of heart valve disease.", "answer": 0}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "To its credit, the story does point out that people can take classes as well as use a device that monitors breathing to change their breathing habits. However, since the story is about ways to reduce stress and improve health, we think it had an obligation to discuss other evidence-based approaches for reaching this goal, including regular physical activity, certain types of psychotherapy, or even self-taught breathing exercises that don\u2019t require buying a device or paying for a class. And certainly the makers of the many competitors to the Spire device may well wonder why the article did not mention that other such devices are on the market.", "answer": 0}, {"article": "\"It's like 'Star Trek.'\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\nThen earlier this year, she went from coping with blindness to hoping she might see again.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to compare this artificial retina with similar products in clincial testing, or to other approaches to restoring vision that are in development. \nIt also fails to indicate what standard care is for patients with retinitis pigmentosa, and whether treatments exist to stablize or slow the progress of the disease. ", "answer": 0}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that eBx is being positioned as an alternative to longstanding treatments such as topical creams, freezing and surgery. It doesn\u2019t compare effectiveness outcomes between these competing approaches in a meaningful way, but we think the story does enough to clear the bar here.", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\nBut conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention is made that there is no cure for any of the strains of influenza virus and, therefore, most interventions focus solely on prevention and symptom management.\nThis is important information to include when both your opening and closing paragraphs imply the far-UVC light studied might prevent the spread of the flu in public places.", "answer": 0}, {"article": "Testing cholesterol in toddlers and babies?\nNinety percent of them started taking preventive medicines after finding out.\nThe study was led by Dr. David Wald at Queen Mary University of London.\nThe work was funded by the Medical Research Council, the British government\u2019s health research agency.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative here is no screening in early childhood.", "answer": 2}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\nThe proven way to avoid the effects of sleepiness on the road is to consistently get enough sleep, said Dr. Flaura Koplin Winston, a researcher at the University of Pennsylvania and the Children\u2019s Hospital of Philadelphia who wasn\u2019t involved in the study.\nFor the current study, researchers wanted to see if bright light might help reduce driving impairments related to sleep deprivation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An\u00a0independent source notes that the only \u201cproven\u201d way to avoid the effects of drowsiness when driving is \u201cto consistently get enough sleep.\u201d\u00a0 Other strategies for remaining alert behind the wheel are also mentioned.", "answer": 1}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention alternative treatments for migraines, of which there are many.", "answer": 0}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a thorough job in comparing alternatives. It mentions the effectiveness and side effects of hormone replacement therapy and even cites the results of the Women\u2019s Health Initiative. It also talks about other medications used to treat hot flashes and other alternative therapies, such as yoga, acupuncture, qi gong and meditation. However, the effectiveness of the other alternative therapies is not proven (beyond small, short term, and often un-blinded studies).", "answer": 1}, {"article": "They work in teams.\nThe men who were enrolled in Experience Corps, however, showed a .7 percent to 1.6 percent increase in brain volumes over the course of two years.\nCarlson notes that many cognitive intervention studies last one year or less.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While this study suggests that social activity (in a special program) may be nourishing to brain health, it does not compare or mention other research into possible methods for preserving brain mass and preventing cognitive decline. For instance, a healthy diet, exercise, not smoking, drug therapy, etc.", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares alternative strategies for weight loss, although not in great detail.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no mention of other strategies typically employed to reduce markers of heart disease, including other types of dietary changes, exercise and drugs such as statins (which are typically reserved for adults). The UCSF\u00a0news\u00a0release did include this type of information.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story strongly implies that pembrolizumab is better than existing cancer treatments for patients with the relevant genetic marker, but that is a claim that has yet to be tested, since none of the trials included any direct comparisons between the new drug and existing treatments.", "answer": 0}, {"article": "About 15 years ago, scientists discovered chemical messengers known as orexins, which are released by a relatively small brain region known as the lateral hypothalamus.\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story focuses on the use of drugs to help people with sleep disorders.\u00a0 While popular, other approaches including cognitive behavioral therapy have been shown to be far more beneficial in the long run that simple drug therapy. And there is no mention of the many non-drug approaches to dealing with sleep problems.", "answer": 0}, {"article": "\"I had a really bad headache,\" Aldrich told Regan.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nHe wants her to avoid exerting herself, physically and mentally, because a \"bump on the head\" is a lot more dangerous than it sounds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe broadcast fails to note alternative methods of determining when an athlete can safely return to play after a concussion, including inexpensive low-tech aids and clinical judgment. There is considerable debate in the sports medicine community on this point. The broadcast also does not elaborate on the potential disadvantages of the Impact system or on the potential advantages of its alternatives (traditional and electronic).\n", "answer": 0}, {"article": "We've found a way to block CatK only in bone tissue that we think will prevent these other negative effects.\"\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\nThe treatment could also potentially be used to treat a variety of other bone and cartilage diseases such as arthritis and certain bone cancers.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Existing treatments for osteoporosis including prescription drugs such as alendronate, risedronate, zoledronic acid and denosumab, as well as exercise and dietary changes, were not mentioned. The news release mentions \u201ca multi-billion-dollar pharmaceutical industry dedicated to finding treatments to stop its progression,\u201d implying that red sage could constitute a cost-effective alternative, but it doesn\u2019t delve into the effectiveness of current treatment options.", "answer": 0}, {"article": "Older age and African-American race are risk factors for colon cancer, and there is evidence linking obesity and a sedentary lifestyle to the disease as well.\nHenderson\u2019s team also found that the beneficial effect of HRT was stronger among women who had had a first-degree relative diagnosed with colon cancer.\nAmong these women, HRT use was linked to a 55 percent lower risk of the disease versus non-use.\nThe findings, reported in the American Journal of Epidemiology, support the theory that estrogen offers some protection against colon cancer.\nFamily history of colon cancer is an established risk factor for the disease, but only one study, according to Henderson\u2019s team, has looked at whether family history affects the link between HRT and colon cancer risk \u2014 and it found no evidence that it did.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least discussed other colon cancer risk factors:\u00a0", "answer": 1}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe double-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nThe people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said.\nIn memory tests, the people taking curcumin improved by 28 percent over the 18 months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no discussion of other therapies used in addressing memory or mood problems.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does\u00a0mention some other interventions used to prevent heart attacks, such as\u00a0typical medications taken to lower blood pressure or cholesterol.", "answer": 1}, {"article": ".\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\n\"Treatment then needs to happen as quickly as possible, and a mobile stroke unit may allow that to happen.\"\nThis takes a certain amount of time from the patient's symptom onset which prompted the 9-1-1 call.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does an OK job discussing how the approach being studied compares with the standard of care. It says:\n\u201cEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department. This takes a certain amount of time from the patient\u2019s symptom onset which prompted the 9-1-1 call.\u201d", "answer": 1}, {"article": "B vitamins, including B12 and folate, have been shown to help lower homocysteine levels, so high levels of the amino acid suggest low levels of B12.\nThe relationship between vitamin B12 and Alzheimer's risk is \"complex,\" says Dr. Sudha Seshadri, M.D., an associate professor of neurology at the Boston University School of Medicine and the author of an editorial accompanying the study.\n\"Lowering these in general is important for cardiovascular health, and this study strengthens our knowledge about its role in risk for Alzheimer's disease.\"\nDr. Sam Gandy, M.D., the associate director of the Alzheimer's Disease Research Center at the Mount Sinai School of Medicine, in New York City, says that it may make sense for people to get blood tests to measure their levels of B12 and folate.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\nWith ColonaryConcepts' lead formulation, 93.3% (14 of 15) of patients had a rating of excellent or good, with 40 of 45 colon segments rated as excellent or good on the Ottawa scale.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n\"Patients participating in the study were nearly four times more likely to recommend ECP to their friends and family as compared to the standard colonoscopy prep.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The clinical trial compares the outcomes of this colonoscopy prep to that of two existing, FDA-approved preps. But we\u2019re never told what those preps were. There are many approved preparations including combining Gatorade with polyethylene glycol, tablets and laxatives.\nThe release also could have mentioned that while colonoscopy is considered by some to be the gold standard, some groups, like the US Preventive Services Task Force, recognize other screening approaches including fecal occult blood screening and sigmoidoscopy. However, sometimes these procedures must be followed by a colonoscopy in the event of a positive screen.", "answer": 0}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not do an adequate job of describing this experimental approach and did not provide any information about the techniques currently in use for determining tumor margins. It is not a foregone conclusion that this technology would outperform other methods such as sequential sampling of tumor margins with intra-operative microscopic examination. ", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nA group of almost 3,200 patients, aged 58-74, had ultrasounds on their necks in 2002, before having their cognitive functions monitored for up to 14 years, from 2002 to 2016.\nThe study's findings have been met with cautious optimism by dementia organizations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that researchers are attempting to see if the test should be added as part of \u201croutine screening\u201d for risk factors. It would have been helpful to briefly explain what is currently included in routing screening.", "answer": 1}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nSmokers who took the pill, sold as Chantix in the U.S. and Champix elsewhere, were much more likely to quit after cutting back on cigarettes than smokers who didn\u2019t use the drug, the study found.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\n\u201cThis is very strong support for changing clinical practice to include gradual reduction aided by medication.\u201d\n\nSmoking is the leading cause of preventable death in the U.S., according to the Centers for Disease Control and Prevention.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does discuss (albeit briefly) alternatives such as nicotine gum and patches. However, the story does not discuss the fact that\u00a0bupropion is a competing drug that has been used as an aid to gradual smoking reduction and cessation. This is an important omission. Additionally, the story\u00a0would have added valuable context if it had discussed the actual success rates of people who try to quit smoking \u201ccold turkey\u201d or by using other treatment methods.", "answer": 0}, {"article": "\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nIn addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\nResearchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story cited the COURAGE study \u2013 \u201che Courage study, which tracked 2,287 patients for five years, showed stents weren\u2019t any better than a cocktail of medicines to treat patients suffering from chronic but stable chest pain.\u201d", "answer": 1}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\nFuture trials will seek to identify patients who would benefit most from beta-blocker use and the best beta-blocker for a specific tumor type based on adrenergic receptor expression.\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nFurther examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities.\nWith further research, they may also prove beneficial in conjunction with other treatment regimens and across other cancer types.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The relevant research is based on evaluating the use of beta blockers in conjunction with conventional chemotherapy, not as an alternative to chemotherapy or other courses of treatment. As such, we\u2019ll rate \u201cCompare Alternatives\u201d as not applicable.", "answer": 2}, {"article": "But the results do merit further research.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nThe results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While it didn\u2019t compare the drug to existing alternatives, it really couldn\u2019t because at present no head-to-head data exists about this drug compared to other antidiabetic therapies, just data comparing different doses to each other and placebo.\nComparing the drug\u2019s bleeding risks to that of aspirin is not directly relevant to this criterion because aspirin is not currently used to treat\u00a0hyperglycemia.", "answer": 2}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\nA formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story reported that the children in the particular study reported on had failed to respond to at least two antiseizure medications, the story did not provide information about treatment options for children with epilepsy or whether the diet would typically be used instead of or in addition to other treatments for epilepsy. \u00a0", "answer": 1}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\nWhile the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nPotentially, this early intervention could help those with preclinical Alzheimer's avoid or delay the most devastating symptoms.\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "If you simply looked\u00a0on our website, searching for past news about supposedly imminent Alzheimer\u2019s tests, you\u00a0would\u00a0get dizzy going down the trail of past promises. \u00a0Much less if you did a literature search.\nThis story provides no context about other work in the field, while providing no\u00a0information about\u00a0how the performance of this test sets its apart from others.", "answer": 0}, {"article": "Get the facts.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\nAll the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that abstinence, if it worked, could obviate the need for the vaccine.", "answer": 1}, {"article": "Dr. Stehling is a German Professor of Radiology, a former Associate Professor at Boston University and served as Research Assistant to Sir Peter Mansfield, Prof of Physics and Nobel Prize winner in Medicine in 2003 (for discoveries concerning magnetic resonance imaging).\nThe IRE treatment also had very low toxicity on the rectum and bladder, even in cases of advanced cancer infiltrating these structures in patients who were not candidates for surgery or radiation therapy anymore.\nUnlike other treatment procedures for prostate cancer therapy, image guided or irreversible electroporation (IRE) only destroys cells; vital tissue structures are not affected, making IRE the first tissue-selective form of therapy.\nData found that the most common side effects are either eliminated or greatly reduced using image guided treatment.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We would have liked to see the release outline the typical alternatives for a patient presenting with prostate cancer, and explain how this image-guided IRE therapy compares to other therapies.\nThe release states: \u201cUnlike other treatment procedures for prostate cancer therapy, image guided or IRE only destroys cells; vital tissue structures are not affected.\u201d But it doesn\u2019t outline side-by-side the alternatives for patients.\nCurrently, cryotherapy or other local therapies are not recommended as therapy for primary or\u00a0recurrent\u00a0prostate cancer due to lack of long-term data comparing these treatments with radiation and surgery, according to the  National Comprehensive Cancer Network (NCCN). For patients with recurrent cancer,\u00a0the typical treatments include hormone therapy, chemotherapy, immunotherapy, and radiopharmaceutical therapy. \u00a0Treatment choice for recurrent cancer would depend upon the initial stage and whether \u201crecurrence\u201d meant biochemical progression (PSA increase) or clinical evidence of progressive or metastatic cancer.\nIn this release, the group studied was not described well enough to know which alternative therapies would have been appropriate.\nA common problem with early-stage primary cancers is overtreatment. \u00a0An appropriate option for many men with low-risk cancers is \u201cactive surveillance\u201d \u2014 not receiving any active treatment because there is no evidence for benefit. \u00a0We do not know how many of the study subjects had low-risk cancers.", "answer": 0}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\n(Note that we're not talking about the all-out sprints of high-intensity interval training.)\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nThat exercise prescription was about the same as in the government guidelines.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the benefits of aerobic exercise on obesity and cardiovascular outcomes. It also mentions strength training, which we\u2019ll consider good enough for a satisfactory rating. A mention of other approaches \u2014 calorie-restricted diet, medications, even surgery in some cases \u2014 would also have earned the story a pass on this one.\n[Editor\u2019s note: this story was originally graded Not Satisfactory on this criterion, but has been change to Satisfactory for the reasons discussed below in the comments.]\u00a0", "answer": 1}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story mentions statin treatment for high cholesterol, it fails to tell readers that this trial does not provide evidence that would allow people to compare meaningful harms and benefits of this experimental drug to those of statins.", "answer": 0}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nThe procedures are designed to reduce the bulge of the hernia and make a patch so it doesn't protrude again.\nAfter five years, 28 percent of those who had the traditional procedure reported chronic pain, compared to 15 percent of the laparoscopic group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared two major surgical approaches and the story mentioned the existence of a third approach that wasn\u2019t tested.\u00a0 However, it didn\u2019t mention nonsurgical management or \u201cwatchful waiting,\u201d which may be an appropriate strategy for patients with minimal symptoms or who are asymptomatic. Since almost all hernia repairs are elective \u2013 meaning that they are designed to minimize pain and bulging\u00a0rather than preventing a potentially serious medical problem (such as bowel obstruction or incarceration in the hernia) \u2013 it is appropriate to mention that for many patients part of\u00a0the decision making process is whether to have surgery or not. Once one decides to have surgery, then the question of what is the best procedure becomes relevant. Some patients make the decision about whether to have surgery on not based upon the risks and benefits of the procedure, so that is why mentioning not having surgery is part of the comparison of treatment options.", "answer": 0}, {"article": "\"We are not going to reverse any of the chronic diseases in this country by changing the composition of the diet,\" Dr. Howard said.\nSome medical specialists emphasized that the study did not mean people should abandon low-fat diets.\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\n\"The studies were well designed,\" Dr. Freedman said, \"and the investigators tried to confirm popular hypotheses about the protective effect of diet against three major diseases in women.\"\nThat could mean that fat in the diet may have a small effect, Dr. Rossouw said, perhaps in some subgroups of women or over a longer period of time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article failed to provide context for the study diet in terms of typical diet, intended study diet, and actual study diet. Mention is made that there is more recent evidence suggesting that not all fats contribute equally to cardiovascular disease risk. Failed to mention caloric intake limitation for managing weight as an alternative to solely targeting fat consumption.", "answer": 0}, {"article": "Symptoms can include sadness, insomnia, difficulty concentrating and making decisions, feelings of shame or guilt, as well as difficulty bonding with the baby or thoughts about harming the baby.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\nOn average, the women spoke more than eight times and the calls typically lasted about 38 minutes, the researchers reported in the Journal of Advanced Nursing.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nIn the study, women with postpartum depression received telephone counseling from other women who had previously suffered from the disorder and recovered.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story implies that the major alternative for managing PPD is in-person counseling from a mental health professional. It also notes that many of the women had previously received treatment with medication, suggesting that this is an option for PPD.", "answer": 1}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\nShe agreed to the memory testing for the study.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nBefore the stimulation tests, the team determined the precise settings for each patient\u2019s high- and low-functioning states.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since there are really no alternatives as far as treatment goes, we\u2019ll rate this N/A.", "answer": 2}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThe survey included questions about health history and fitness habits.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\n\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\nThe researchers then cross-referenced this information with health department death records.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the focus of the story was the \u201cweekend warrior,\u201d several comments were included suggesting alternative exercise strategies, including: \u201cThis could be something as simple as a brisk walk\u00a0or other low-impact options for vigorous exercise about 20 minutes a day. \u00a0\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\u00a0This study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise. You just need to do it.\u201d", "answer": 1}, {"article": "While many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\nResearchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\n\"Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release explains the alternatives of clinic or hospital infusion compared to home infusion.", "answer": 1}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes two other medication options, metformin and sulfonylureas, but the story does not describe other medications, such as thiazolidinediones or insulin.\u00a0 Additionally, the story does not mention any lifestyle options to control blood sugar, such as eating a health diet, exercising, and losing weight.\u00a0 ", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is all about the comparison of screening to not screening.", "answer": 1}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\nAmgen last month applied for U.S. approval to market the drug for reduction of fractures and other skeletal-related problems in patients with advanced cancer.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "\"Our goal is to reach 100 percent.\"\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\nBut it's a huge step forward, especially for those who are skittish about a trip to the doctor.\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other screening alternatives, including colonoscopy and CT colonography (or virtual colonoscopy). But it does not mention traditional fecal occult blood testing, the mainstay stool test for decades. And it provides only a cursory comparison of the advantages/disadvantages of the new test compared with existing approaches.", "answer": 0}, {"article": "October 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nThis group of patients typically gets limited benefit from shoulder replacement with conventional implants, which rely on the rotator cuff muscles to provide shoulder movement.\nBut there are concerns about how well the results of RTSA will hold up over time in this group of patients.\nThe improvement was similar for patients with and without prior shoulder surgery.\nWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of any alternatives to this surgery in this release. This is surely something that should have been discussed. Alternative treatments such as superior capsular reconstruction should be considered prior to RSA, particularly for the patients with massive tears of the rotator cuff without signs of shoulder arthritis. Failures of RSA in a younger individual can be devastating, at times leaving individuals with no good options when the implant fails and the patient has lost a significant amount of bone related to the implantation of the prosthesis and destruction of bone that sometimes occurs with failure of the implant.", "answer": 0}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThe drug was pulled from the market in 1997, costing Wyeth millions of dollars.\nIf approved, lorcaserin would be Arena's first marketable product.\nArena has conducted safety studies on the drug, and no heart valve problems have been reported.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any information about other treatment options (currently available medications, lifestyle changes, and surgical interventions) that provide similar or superior weight loss results.", "answer": 0}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nThe research raises the possibility that singing in choir rehearsals could help to put people in the best possible position to receive treatment, maintain remission and support cancer patients.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\nThis research is exciting as it suggests that an activity as simple as singing could reduce some of this stress-induced suppression, helping to improve wellbeing and quality of life amongst patients and put them in the best position to receive treatment.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Many studies have given cancer patients access to meditation, massage and other forms of stress-reduction in order to influence their immune systems. Choir singing should be compared to those existing results to show us \u2014 does it lower cortisol as much as meditation, for example? This comparison would have helped make the release much better.\nPatients who do not already belong to a choir or sing regularly may in fact benefit more from other types of interventions to improve emotional well-being.", "answer": 0}, {"article": "Carl Alexander, a spokesman from the charity Cancer Research UK, said: \u201cThis study is an exciting example of how research can find clues in our genes to help us uncover those more likely to develop the disease.\nScientists have developed a spit test that could identify the men most at risk of developing prostate cancer.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nBy testing a man\u2019s DNA, researchers can look for genes linked to the disease, which one in seven men in the Western world will be diagnosed with in their lifetime.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned family history as one way to flag men at greater risk of developing prostate cancer.\nIt mentioned PSA tests, rectal exams and biopsies as ways to test for the disease.", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nPatients who underwent surgery saw significant reductions in their disease severity scores at post-surgical follow-up -- according to a 0 to 10 rating scale -- with disease severity scores in patients with psoriasis dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nThe researchers found 55 percent of patients with psoriasis and 62 percent of patients with psoriatic arthritis reported improvements in their disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It would have been nice to know how other patients losing weight in the conventional sense compared to these patients. Alternatives to bariatric surgery exist and should have been mentioned. Two alternatives to bariatric surgery for reduction of psoriasis symptoms \u2014\u00a0 conventional weight loss and other treatments for psoriasis (topical agents, medications, and UV treatment) \u2014 that would reduce symptoms at least as much as surgery should have been discussed here. Presumably patients who lost weight through non-surgical means would have also benefited from having their psoriasis symptoms reduced.", "answer": 0}, {"article": "\"Our body knows best.\"\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThat means the device only stimulates the vagus nerve when the stomach moves.\nWang's device has several advantages over an existing unit that stimulates the vagus nerve for weight loss.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does report that there is an existing FDA-approved device for weight loss that uses a similar vagus nerve stimulation method. However, as mentioned above, the release improperly makes claims of superiority that have yet to be tested.\nBesides implantable devices there are, of course, a whole hosts of non-invasive means of losing weight, including the newer drug liraglutide which may lead to losses greater than those seen with implantable devices.", "answer": 1}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nA 40-month study of more than 4,800 patients showed taking low doses of omega-3 fatty acids in margarine did not significantly reduce rates of serious heart attacks and other cardiovascular events, Dutch researchers said on Sunday.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reported that that salmon, herring and sardine are common sources of EPA-DHA, while ALA\u00a0is found in some vegetables.\u00a0 So alternatives were mentioned.\u00a0 And it mentioned drugs like Lovaza.\u00a0 There wasn\u2019t any real comparison, but there was the following important line of context about the new study: ", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\nWalking has not been shown to restore bone that is already lost to osteoporosis, but it can help preserve the bone density that a person has, said Dr. Carol Hartigan, a spine specialist at New England Baptist Hospital.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nBut remember: Not exercising also puts you at risk.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although mentioning several other forms of exercise or activity that may improve bone quality, the story failed to mention diet, lifestyle habits, or medications that may help prevent bone loss and fracture.", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\nMarb\u00e1n and his colleagues first presented this research at an American Heart Association conference in November.\nFurther research will hopefully also help answer those questions, she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives in this story. One might think that the only option for heart attack patients is to wait around until stem cell treatments become available. Even an additional line about alternatives would have been appreciated.\n\u00a0", "answer": 0}, {"article": "\"The concept is very simple,\" Lee said.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\nTNT doesn't require any laboratory-based procedures and may be implemented at the point of care.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nIn lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any alternatives or reference previous experimental attempts to use this technology. However, the release claims that multiple conditions could be treated with the technology, so it would be difficult to mention the array of alternatives that might be applicable. If this technology becomes a realistic alternative in people then alternatives would be important to describe.", "answer": 2}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned e-cigarettes in passing and mentioned the FDA\u2019s efforts to tackle smoking in general. However, there are a host of ways that federal policy might tackle smoking rates in this country that were not raised, including outlawing menthol cigarettes, placing further restrictions on advertising, and adding stronger language or graphic warnings on cigarette packaging.", "answer": 0}, {"article": "\"It is very big.\nResearchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nCapturing and counting those cells can provide information to patients and doctors about prognoses with certain types of metastatic cancers, the statement said.\nToner says the test is like a liquid biopsy and targets almost all solid cancers -- cancers found in \"solid\" organs like the breast or prostate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no meaningful discussion of any testing alternatives \u2013 only brief mention of another test from the same company making this new announcement \u2013 but without any details about how the two are different \u2013 much less anything about any other testing research.\u00a0 As Len Lichtenfeld of the American Cancer Society reminds readers:\u00a0\u201c\u2026we are seeing many tests that are being touted as important in answering various questions about the future behavior of an individual\u2019s cancer but we are not seeing the type of validation we need to know whether or not such claims are in fact clinically relevant.\u00a0 There are so many markers and genetic tests out there that even the most knowledgeable experts in the clinical treatment of patients with cancer are having a hard time separating the proverbial wheat from the chaff.\u201d\n\u00a0", "answer": 0}, {"article": "In men, T plays a key role in the development of male reproductive tissues as well as promoting secondary sexual characteristics such as increased muscle and bone mass and growth of body hair.\nThese findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.\nIn the non-treated control group, there were 21 deaths, 19 of which were related to CV events.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nThey found there were only two deaths in the TTh group and neither was related to CV events.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No other options are discussed.", "answer": 0}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even without detailing how the hypothetical tool might compare to existing alternatives, or fill a need, the story at least could\u2019ve told us that the reason further testing is needed is not just to repeat the research on a larger scale but also in order TO COMPARE the approach with what we\u2019re currently doing.", "answer": 0}, {"article": "Learn more about Mayo Clinic.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\nHe says these qualities make this class of drug much easier to use than the traditional blood thinners.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release compares apixaban to low molecular weight heparin (LMWH), although as mentioned above it does not discuss any harms of apixaban or quantify any of the health benefits with numbers. It does do a good job, however, of discussing possible problems with LMWH and why apixaban might be a good alternative medication.", "answer": 1}, {"article": "Bright-colored berries have long been a part of any healthy diet, owing mainly to the anthocyanins that give them their vibrant color and act as antioxidants to fight off damage to cells.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe results are particularly encouraging because they showed that a change in diet could affect heart-disease risk for relatively young women.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Like the other two stories, no alternatives are mentioned. To prevent heart attacks, patients can either take medications, such as blood-thinning and cholesterol-lowering drugs, or make lifestyle changes, like maintaining a healthy weight, exercising and not smoking.", "answer": 0}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nFirst, the bacterial infection itself could cause direct destruction of the tumor cells, Janku said.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned \u201cclassic immunotherapy\u201d as not seeming to work for most sarcomas, which are cancers that arise in connective tissue such as fat, muscle, and bone. However, it did not mention other treatment options such as radiation, surgery, or chemotherapy.\nAs a side note, most immunotherapies are very new\u2013with still-emerging side effects and unknown long-term benefits\u2013so we take issue with framing immunotherapy as \u201cclassic.\u201d Standard is perhaps a more accurate word.", "answer": 0}, {"article": "\"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments.\nWorking with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called \"triple positive\" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\nBorges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release quotes researcher Virginia Borges, MD, MMSc, director of the university\u2019s Breast Cancer Research Program saying that trials of other drugs have been \u201clackluster\u201d in their effects on breast cancers positive for both HER2 and estrogen receptors. Borges further suggests that tucatinib is more effective than other drugs in preventing brain metastases. The release notes that because tucatinib is a \u201csmall molecule,\u201d it can pass through the blood-brain barrier to interfere with brain metastasis, which is more common in HER2-positive breast cancers. However, there is no specific comparison of this ability with other drugs currently in use.", "answer": 0}, {"article": "The difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nIVs are one of the most common things in health care.\nKellum had no role in the two studies, which were discussed Tuesday at a critical care conference in San Antonio and published by the New England Journal of Medicine.\nThey\u2019re widely used in Europe and Australia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A discussion of other fluid replacement strategies is not germane given the subject of this study.", "answer": 2}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers aren\u2019t given any context about the diagnosis and treatment of precancerous esophageal lesions.\u00a0\u00a0 From this story, some readers might guess that strawberries are the only hope.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\nNocturia is usually related to normal changes in pregnancy that do not require treatment with Noctiva.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\nNoctiva is also not recommended for the treatment of nocturia in pregnant women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of other treatments for nocturnal polyuria including behavioral strategies such as fluid restriction and medications including the generic form of desmopressin (see the section on novelty).", "answer": 0}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\nBut many sufferers ultimately go blind.\nThere, engineers have partnered with Nanovision Biosciences Inc. to create a retinal implant that uses silicon nanowires smaller than the width of a cell to sense light entering the eye and stimulate retinal neurons.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0mentions current therapies for age-related macular degeneration, such as \u201cvitamins, laser surgery, stem cell treatments, and implantable miniature telescopes.\u201d The reader learns that these treatment slow the degenerative process but are not a cure. The story\u00a0also mentions a currently available artificial retina.\nIt also could have mentioned that many patients with AMD will not need any interventions as the process is slow for most.", "answer": 1}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article noted that some doctors may prescribe continous use of traditional pills, which can eliminate monthly periods; however, it doesn\u2019t mention whether any other reversible birth control methods may have similar effects. ", "answer": 1}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nIt's not clear whether the fish oil pills help people with established psychosis.\nThe study suggests that to prevent one case of psychosis, four high-risk young people must be treated.\nAmminger and colleagues warn against over-interpretation of their findings.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly compares the efficacy of fish oil supplements to antipsychotic medications and \u201cother interventions.\u201d However, more specific information on this would have been useful.\u00a0 Additionally, it would have been helpful to know that participants in both groups received psychosocial and psychological interventions. ", "answer": 1}, {"article": "In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\nCurrent practice guidelines permit the use of either anti-clotting therapy with aspirin or warfarin.\n\"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are other existing drugs (Xarelto and Pradaxa) used as warfarin replacements that were not mentioned.\u00a0 The absence of this information makes it appear that apixaban is the only game in town and it is clearly not.", "answer": 0}, {"article": "I'll keep going as long as I can enjoy what's to be enjoyed.\u201d\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\nIt worked in patients such as Eaton, whose heart attack was 11 years ago, Hare said.\nThe hope was that the immature adult stem cells would turn into heart muscle, replacing the scar tissue.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the efficacy of stem cell therapy to medication and pacemakers, however, the comparisons are not adequately made and are done through the filter of the study authors, who may be biased given their financial ties to the industry.\u00a0\n", "answer": 0}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nTwenty-two of the adenotonsillectomy patients, but only 2 of the controls, had a diagnosis of attention-deficit hyperactivity disorder.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In the story, there is no mention of other treatment options for ADHD or for sleep apnea. For example, CPAP machines should have been mentioned as a non-surgical alternative to adenotonsillectomy for sleep apnea.", "answer": 0}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nAccording to McEvoy, doctors should focus on patients\u2019 lifestyle and traditional risk factors such as smoking and obesity.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story ends with the researcher saying \u201cdoctors should focus on patients\u2019 lifestyle and traditional risk factors such as smoking and obesity.\u201d", "answer": 1}, {"article": "Related links:Department of PsychologyCentre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain\u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9alMAB-Mackay Rehabilitation Centre\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\n\u201cTablet computers offer many of the same benefits while being socially acceptable,\u201d says Aaron Johnson, the study\u2019s senior author, and an associate professor in the psychology department, and a member of the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares using a widely available consumer device to using more traditional and more expensive devices. We\u2019ll give them a Satisfactory for naming the CCTV device but we\u2019re never told what the other alternative magnification device was, although the release often refers to two traditional alternatives. We also would have liked some comparative prices and inclusion of other brands besides the Apple brand.", "answer": 1}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nNew research suggests the substance, a lipid known as POPG, may prevent RSV infection as well as limit the spread of the virus once infection has occurred.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\nIn addition, the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story only states that \"There is no vaccine or easy, effective treatment for RSV.\"\u00a0 Why not at least briefly mention what those treatments are and discuss their track record? And this is where we need an independent expert to help put the new research into the context of existing approaches. ", "answer": 0}, {"article": "\u201cThis isn\u2019t a magic bullet.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nOf 12 patients given the drug, all showed some decrease in symptoms of depression for at least three weeks.\nThe trial involved six men and six women, aged between 30 and 64, all diagnosed with treatment-resistant depression.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The text is clear that there are few alternatives if antidepressants and therapy don\u2019t work. The story would have been stronger if it had mentioned atypical antidepressants and electroconvulsive therapy as alternatives.", "answer": 1}, {"article": "Only 1.8 percent of men with PSA scores below 1.0 were diagnosed with prostate cancer, with only 0.04 percent dying of the disease.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\nOne caution, though, is that the study only looked at three surgeons performing RALP.\nEighty percent of men in the group had PSA levels below that threshold.\n\"A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t give any context on a number of points regarding alternatives. Each could have been addressed easily with a little re-wording or a few extra words.", "answer": 0}, {"article": "She exercised.\nEven more promising are the findings from the seven patients with early pancreatic cancer that were detectable through their protein levels.\nFurther, levels dropped when patients had surgery to remove their tumors, so the marker could also be used to follow the progression of the disease, Kalluri said.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternatives in this story or whether other research has gone in this direction and failed to yield a marketable test. While\u00a0there really aren\u2019t any good screening tests, there is another tumor marker (CA 19-9) that has been used for screening, but it does not readily detect the early-stage cancers. The study actually compared the new test with CA 19-9.", "answer": 0}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nEach surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\nThe IVC required cross-clamping in 24 cases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release did provide\u00a0a few comments about open surgery, the standard surgical approach. However, it provides only the associated complication rate. \u00a0A true comparison would have provided more supportive evidence.", "answer": 0}, {"article": "The mantra 'time is brain' still holds true.\"\nHowever, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\nThe DAWN trial results were presented at the European Stroke Organization Conference in May.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Readers of the release will get a general and adequate idea of the relative lack of options open to stroke victims who arrive at a hospital after the six-hour window considered optimal for mechanical clot removal. The alternative is not doing the procedure for late arrivals which is fairly clear from the release.", "answer": 1}, {"article": ".\nA new study shows that electro-acupuncture may be effective in providing some relief.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\nThey compared the benefits of using electro-acupuncture (the application of a pulsating electric current) to prescribing gabapentin, an anti-seizure medication frequently prescribed to treat sleep disturbances related to hot flashes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release points out that electro-acupuncture was compared with the drug gabapentin. But there are numerous other alternatives to both a fairly powerful drug with its own side effects and electro-acupuncture.\u00a0 There are many other ways to help one sleep while experiencing hot flashes such as non-hormonal medications and lifestyle changes \u2014 dressing in layers, lowering the thermostat, staying away from caffeine \u2014 to name a few.", "answer": 0}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nLower consumption levels were not associated with the risk.\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\nA very high consumption of non-fermented dairy products, on the other hand, was associated with an increased risk of incident coronary heart disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The headline suggests fermented dairy products may protect against heart attacks, but does not mention any other common sense steps that may be protective.\nExercise, not smoking, and a prudent plant-based diet are other habits known to be associated with lower risk.", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nThere are side effects, of course.\nStill, he cautions that the targeted treatments can't be considered cures.\nMore doctors are taking advantage of the information to treat patients with a targeted approach.\nThe chemo failure was the latest in a string of personal setbacks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least on one alternative is mentioned, e.g. \u201ctraditional chemotherapy\u201d (Temodar/temozolomide), so we\u2019ll rate the story satisfactory. However, it\u2019s important to note that radiation therapy is not discussed at all, and it is part of the standard of care alongside chemotherapy and surgery. There are other potential alternatives, too, including drugs that limit blood flow to cancerous tissue and immunotherapy techniques (aka \u201ccancer vaccines\u201d).", "answer": 1}, {"article": "It is also not available for pregnant women, people with heart conditions or very high blood pressure, patients with kidney disease or clotting disorders, patients on blood thinners, patients with a history of strokes or brain tumors and people with substance abuse issues.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\nThe trial participants all had tried existing medications, without success.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release never mentions the current alternative approaches used to treat essential tremors, either the pharmacological approach with drugs such as propranolol or primidone, or the neurosurgical approach of deep-brain stimulation.", "answer": 0}, {"article": "For more about healthy eating, visit the U.S. Centers for Disease Control and Prevention.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nEven a year or two of a better diet appears to have the power to affect survival rates, he said.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nThe findings paint a surprising picture of American health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t discuss anything besides healthier diets that might have contributed to increased longevity during the study period. More widespread use of effective medications (e.g. statin drugs)? Lower smoking rates? More regular physical activity? A line or two would about other relevant trends would have been welcome.", "answer": 0}, {"article": "MORE: With Early Breast Cancer Treatment, Less May be More: Studies\n\nCertain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nThe results also underscore the importance of eating whole fruit, rather than fruit juice.\nAbout half of the 90,000 women who participated in the Nurses\u2019 Health Study also answered questions about their typical diet while they were teens.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This one squeaks by, because it also addresses risk factors such as alcohol and red-meat consumption. However, it would have been better to place the work into a broader context of lifestyle factors that influence risk, such as exercise, maintaining a health weight and avoiding tobacco use.", "answer": 1}, {"article": "The results have not previously been published or presented.\nThe field-friendliness and high specificity offered by the C-Tb test could allow for improved targeted treatment of M. tuberculosis-infected persons in also in resource-constrained settings, where IGRAs are too complicated to implement.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nIn contacts, mirroring the findings with QFT-GIT, there was a strong trend in increasing C-Tb test positivity with M. tuberculosis exposure (figure 1).\nDr. Ruhwald said another advantage of C-Tb is that the measurement of infection, a 5mm or larger induration, is universal across patients with different risk factors, including HIV infection.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since the release is showing results of comparisons between existing tests for tuberculosis and the new C-Tb test, there clearly are alternatives, so we\u2019ll give it a satisfactory grade in this category.", "answer": 1}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nBarua and colleagues say they don't know the exact reasons for testosterone's apparent benefits for the heart and overall survival.\nMore research is needed, they say, to clarify how testosterone affects the cardiovascular system.\nTestosterone isn't prescribed with the goal of improving heart health, but that is a consideration in many cases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Information about other ways to reduce mortality from heart attacks or stroke \u2014 whether lifestyle changes or other types of drugs \u2014 is not mentioned.", "answer": 0}, {"article": "People who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nThat said, these experimental drugs carry the potential for serious side effects, including causing the immune system to go haywire.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nThe new study, which appears online Oct. 10 in the Archives of Neurology, is among the first to show the effects of an anti-amyloid drug in humans with Alzheimer's disease, but experts caution that while promising, more research is needed before this drug can be deemed safe or effective.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that \u201cThere are approximately one dozen therapies, including vaccines, for Alzheimer\u2019s disease that are currently in the pipeline\u201d \u2026and \u201cnone are ready for prime time.\u201d\nNice touch.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is discussion that conventional surgery\u2013intestinal tissue used to reconstruct the bladder\u2013 \"threatens further health complications\". These are briefly discussed, and include clogging of intestinal mucus or formation of kidney stones. There is no mention of disadvantages and potential health problems of the surgery with a reconstructed organ, or the possibility of the patient rejecting this organ. ", "answer": 0}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\nIf the ambulance took more than 13 minutes, the survival rate was 3.7 percent in the CPR group and 1.5 percent for the others - a difference that wasn\u2019t statistically meaningful.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In a way this story is all about the alternative to bystander CPR: doing nothing until the ambulance arrives. There really isn\u2019t another alternative that could have been discussed.", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a tough call. The study in question was designed to compare bariatric surgery against specific lifestyle therapies. And the story capably provides that comparison. But while it\u2019s a splendid thing to be able to \u201ccure\u201d diabetes in some obese patients who have weight loss surgery, it\u2019s also important to mention the role of medication and diet in maintaining good management of the disease and preventing complications. The story doesn\u2019t really address this. A word about strategies for preventing diabetes in the first place would also have been welcome here.", "answer": 0}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\nKomaroff also notes a recent increase in research funding by the National Institutes of Health, which has included a comprehensive in-house study aimed at unraveling the underlying causes of the condition.\nResearch findings from Stanford University released Monday could point the way to a long-sought diagnostic laboratory test for the condition, and possibly a first-ever treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reports some of the possible explanations for the failure of existing tests to accurately diagnose chronic fatigue.", "answer": 1}, {"article": "The surgically reconstructed knees and the conservatively treated joints experienced similar (and high) levels of early onset knee arthritis, a common occurrence after an A.C.L.\nTwenty-five percent of those in the physical therapy group eventually tore their meniscuses.\nThe second group received only physical therapy, with the option to have the operation later.\nThe authors of the study are less sure.\ntreatments, says Dr. Duncan Meuffels, an assistant professor of orthopedic surgery at Erasmus Medical Center in Rotterdam and lead author of The British Journal of Sports Medicine study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "His doctor prescribed a C.P.A.P.\nBut not everyone finds that Provent alleviates their apnea.\nIn those people, Provent typically doesn\u2019t work.\nIt is also more expensive, and it doesn\u2019t work for every patient.\n\u201cMy symptoms subsided dramatically.\u201d\n\nProvent works like a traditional C.P.A.P.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the Provent patch to the standard treatment, known as continuous positive airway pressure, but it does not explain that there are indeed other approaches including exercise and weight loss, oral appliances and surgery. One additional line in the story could have addressed this.", "answer": 0}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nThat patient is now considering an egg donor.\nInsurers don\u2019t cover it; after it became clear that patients were balking at the bill, Celmatix cut the price in half.\nAnd even the company\u2019s founder and CEO acknowledges the test can\u2019t provide clear and definitive answers on which treatments women should try next if they\u2019re struggling with infertility.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story would have been stronger had it provided more information about traditional diagnostic efforts. However, there was a useful comparative effort that was anecdotal, at the end of the story. A woman struggling with infertility, offered the test, asked her physician if the test\u2019s results would change the treatment strategy.\u00a0 The answer was \u201cno.\u201d", "answer": 1}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nLed by Zhang Zhang-jin at the School of Chinese Medicine, University of Hong Kong, the researchers used electroacupuncture to stimulate seven spots on the heads of 73 participants, who had suffered several bouts of depression in the last 7 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison was given with any other approach to depression.", "answer": 0}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\nBut this study suggests these methods also can help reduce spinal pain, she said.\nThe program led to a significant and clinically important reduction of pain, she said.\n\"People with chronic neck and/or back pain should be educated about their pain, [and] should be reassured,\" said lead researcher Anneleen Malfliet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give this a just-passing rating. There are several brief statements about alternatives.\u00a0Relevant statements include, \u201cPeople with chronic back pain often try painkillers and other treatments without success\u201d and \u201cThey assigned another 25 men and 35 women to standard care \u2014 exercise, and back and neck education.\u201d", "answer": 1}, {"article": "Most Australian adults have been infected with the herpes zoster virus and are at risk of shingles, even if they do not remember having chicken pox.\nLead researcher Professor Tony Cunningham from the Westmead Institute for Medical Research said the study shows that the vaccine stimulates production of a specific immune memory cell (CD4 T cells), generating a strong and sustained protection against the virus.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\nIt is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nThe vaccine also contains an adjuvant--a substance that helps your body fight off the virus.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release states:\nShingrix is different from most other vaccines. Many vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein\u2013known as glycoprotein E\u2013that comes from the outer shell of the herpes zoster virus.\nAs noted above, it would have been helpful if the release had stated how the established vaccine compared in the rate of effectiveness.", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story does a good job of comparing the status quo to benefits offered by Counsyl\u2019s new test. Another alternative to this test is to wait until pregnancy to screen. The Counsyl test would be best where one parent having a single copy of the defective gene would be enough to cause problems.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a pretty decent job of talking about PSA screening, conventional (PET) nuclear imaging, and genetic testing, and ultimately defines the new nuclear tests as \u201ccomplementary\u201d by quoting an independent sources.\nHowever, the story ideally also would have discussed alternatives for staging and determining recurrence, such as bone scans, CT scans and MRI.", "answer": 1}, {"article": "But she added, \u201cThe community hopes that if telaprevir is approved by the F.D.A.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nBut analysts expect the drug to cost tens of thousands of dollars for a course of treatment.\nThat is seen as essentially a cure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The comparison could have been more detailed, but, you do get the picture that this new drug will simply be an add on to existing therapies, albeit with the potential for cutting down the treatment time considerably. ", "answer": 1}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned physical therapy and pain medication as standard treatment for delayed radiation effects on muscles and joints. It did a good job describing how challenging it can be to manage.", "answer": 1}, {"article": "There's no definitive answer to that just yet, Wang said.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\nPrior research has shown exercise can improve mood, Wang added.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0Very brief mention is given to existing alternatives, such as exercise, sleep techniques and medication, but no discussion of the track record of how well the alternative methods work.\u00a0", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and bone marrow transplants as treatment options for leukemia.", "answer": 1}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nIn an ongoing clinical trial at 11 medical centers globally, researchers are using ultrasound waves to treat the source of essential tremor in the brain.\nBut the procedure brings lasting side effects in some patients, and its long-term usefulness is still being studied.\nNow a new trial finds that a treatment to kill off neurons in a certain region of the brain can do away with tremors in some patients who don\u2019t respond to drugs.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states, \u201cDoctors usually treat essential tremor with medication, but the drugs don\u2019t work well for all patients.\u201d That\u2019s true, and so we\u2019ll give this a Satisfactory rating for at least mentioning alternatives.\nBut it should be noted that other procedural treatment options were not compared or even mentioned in the story and received only a brief mention in one of the videos.\nThe current standard for tremor patients who don\u2019t respond to medication is deep-brain stimulation, in which a probe connected to a pacemaker is implanted in the thalamus to suppress the tremors. Gamma Knife thalamotomy, which delivers precise doses of radiation to the thalamus, is also considered to be a safe and effective therapy for patients who don\u2019t respond to medication.\nAlso, some patients have mild symptoms that can be treated with relaxation techniques and the avoidance of triggers such as caffeine.", "answer": 1}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nColic affects up to 28% of infants and has no known cause or cure.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there is no known cause or cure for infant colic. However,\u00a0the story should have noted that colic\u00a0goes away on it\u2019s own after several weeks, and is not a \"disease\", therefore may not need treatment. A close call, but satisfactory.", "answer": 1}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nFor starters, it can only protect against pregnancy, not STIs.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nTaking your temperature is what sets Natural Cycles and other apps like it apart from standard period-tracking apps.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article makes reference to other forms of birth control and their advantages and disadvantages with relationship to the Natural Cycles app. \u00a0This information helps the reader put the new information into greater context.\nThe writer also mentioned other apps that track a woman\u2019s monthly cycle, based on user data for when a period begins and ends.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story gives us the existing alternatives (shots) and puts the new oral drug in perspective. The comment from neurologist Mark Keegan about why a patient might choose not to switch is very telling and might have been put higher in the story.\n\n", "answer": 1}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story is a comparison of alternatives, comparing established methods with newer methods.", "answer": 1}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\n\"Further, the subjects in the study were not monitored for certain cognitive parameters until several years after the trial began, creating difficulty in determining accurately whether they experienced a decline in cognition or not.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\nEarlier results from the same study found that ginkgo did not prevent or slow the development of Alzheimer's or other dementias, DeKosky said.\nNo measurable effect from ginkgo is seen on cognition, Schneider said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In a story based on a study that pokes holes in some peoples\u2019 beliefs about a product to prevent cognitive decline, there could have been at least one line about other research into cognitive decline.\u00a0 ", "answer": 0}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\nBut some also want Sarepta to make the drug available to more patients on a compassionate basis even before approval.\nIt would also represent a success, after decades of setbacks, for the technology eteplirsen uses, called antisense, which is a way of turning off specific genes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story noted that there is at least one other drug in development and that there is a rather ineffective treatment available in the form of steroids.", "answer": 1}, {"article": "Some doctors say the increased rate of Caesareans is partially attributable to maternal demand: busy mothers may want to schedule their deliveries.\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nDoctors such as Stark say we need a better sense of what goes on while the baby is still in utero.\n\"There are certainly women who want timed, elective delivery surgically.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly mentions vaginal birth as the alternative to C-section.", "answer": 1}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\nIn the randomized study, 151 patients were implanted with the device.\nAbraham, along with lead author Dr. Maria Rosa Costanzo at Advocate Heart Institute in Naperville, IL, led the study at 31 hospitals in the United States, Germany and Poland.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We give this a borderline satisfactory rating. The release gives brief mention to a common treatment for sleep apnea \u2014 continuous \u201cpositive airway pressure,\u201d or CPAP devices \u2014\u00a0 but it provides little context other than to say \u201cmany patients don\u2019t tolerate them well and a recent study showed them to be harmful.\u201d\nThe release could have included more context to help a reader evaluate the traditional treatment compared to the surgical implant, or weigh risks vs. benefits of having the implant.", "answer": 1}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\nBut there's more work to be done to determine just how T-VEC can fit into the cancer-treatment landscape.\nBut cancer cells aren't as savvy, and T-VEC has its run of them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story does not compare the treatment with current standard treatments, it does explain that those comparisons were not done in the paper and that they need to be done now. Ideally this would have been communicated much higher up in the story, as this isn\u2019t an afterthought\u2013it is the key information to determine how this agent should be used. Otherwise, one is left with the impression that everyone with melanoma will be getting this treatment if and when it is approved by the FDA. That is far from the truth.", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a solid job of reporting on some of the landscape of research into other tests and other biomarkers for Alzheimer\u2019s disease.", "answer": 1}, {"article": "In the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency\u201d.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\nAntioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\n\u201cThe point that it can prevent the lung inflammation induced by ultrafine particles is established \u2013 there is no more doubt,\u201d Krutmann said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does provide at least one alternative strategy, though it wasn\u2019t explained clearly:\n\u201cAntioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u2018Personally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.'\u201d\nIt also mentioned the need to reduce harmful vehicle emissions, though it said more short-term solutions were needed.", "answer": 1}, {"article": "Subsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\nThese issues, they say, can be represented on a \u201cbrain map,\u201d the initial EEG readings that serve as a guide for treatment.\nThe findings prompted a boomlet of interest in which clinicians of varying degrees of respectability jumped into the field, making many unsupported claims about seeming miracle cures and tainting the treatment\u2019s reputation among academic experts.\nThe treatment is also gaining attention from mainstream researchers, including some former skeptics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story includes one comment refering to proven treatments, readers are short-changed by the lack of detail or any discussion of the weight of evidence backing alternatives as comapred to the vague and scarcely studied claims of benefit from neurofeedback.", "answer": 0}, {"article": "Since IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nYet most studies have found that IVF is superior to IVM.\nIVM can also help women who are adverse to injections or who have failed IVF, Luk said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a difficult call. Although it\u2019s possible that the story could have mentioned other assisted reproductive technologies beyond standard IVF and IVM, we think that discussion would be highly technical and probably beyond the scope of this article. We\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "They have gained nearly 8 percent since December 18.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nTasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story may have used company-supplied language when it reported that the condition \u201chas no approved treatment.\u201d\nThere is no approved prescription drug treatment.\nBut there are non-prescription-drug options that the story never mentioned:\u00a0 light therapy, hypnosis, stimulants, melatonin, to name a few.", "answer": 0}, {"article": "I am cancer-free,\" he says.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nIt turned out to be cancer.\nBut doctors decided to use a more sophisticated test \u2014 a CT scan that can detect tumors as small as a kernel of rice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention chest x-rays and stopping smoking as alternatives to CT screening.", "answer": 1}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Any comparison given was a one-sided, conflicted viewpoint, such as that given by the lead researcher:\nBut here\u2019s how the WSJ story offered a comparison through the eyes of someone not connected with the study:\n\u00a0", "answer": 0}, {"article": "\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\nSince amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nDoctors currently use a test known as amniocentesis to check whether a baby is likely to be born with Down\u2019s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t even mention any of the other research being done in this field to improve prenatal diagnosis.", "answer": 0}, {"article": "Recipients were at most seven years older or younger than the donors.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nOld age is not necessarily a barrier to kidney donation.\nThe study is in the Clinical Journal of the American Society of Nephrology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is a complicated measuring of risk and benefit for patients facing kidney transplants. Transplants are usually better than dialysis for patients, but transplants carry their own risks of infection, just to give one example. This\u00a0post did not include any context about the risk equation and how it might be changed if more organs from older donors were available.", "answer": 0}, {"article": "For more information, visit http://www.\nInvestigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nResearchers found a 38.8 percent reduction in chest X-rays in the investigational arm compared to no reduction in the control arm, with no missed pneumonia cases and no increase in any other adverse events.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nChest X-ray is considered the test of choice for diagnosing pneumonia in children, but the WHO estimates three-quarters of the world's population does not have access to radiography.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release adequately explains that chest X-rays are the diagnostic method of choice for determining cases of pneumonia, according to the World Health Organization. The study\u2019s primary goal was to determine if chest ultrasounds were an adequate alternative to chest X-rays. A non-imaging method used to diagnose pneumonia is a physical examination. ", "answer": 1}, {"article": "COLUMBIA, Mo.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release did not include information on what alternatives patients may have chosen who suffered recurrence after radiation, but did not elect to have the prostatectomy. However, we\u2019ll give them the benefit of a doubt since there are no clinical trials comparing options such as cryotherapy, surgery and brachytherapy.", "answer": 1}, {"article": "\u201cBut I point out that we don\u2019t yet have randomized, controlled-trials data to back it up.\nSuch findings are why she, Mowry and Pittas strongly advise people against taking more than the currently recommended upper daily limit of 4,000 IU, even though doses as high as 10,000 IU are available online and at many stores.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\nIn fact, the physician has wagered a few good bottles of champagne that none of three large randomized trials now underway will find proof of positive effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative here is to obtain vitamin D from foods, or not to supplement at all. The study covers both these options when it outlines the Institute of Medicine recommendations.", "answer": 1}, {"article": "Body temperature, heart and breathing rate normalize more quickly.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nNot only is the baby happier, she says, but his or her vitals are more stable.\nEven a little bit of kangaroo contact, he says, can be beneficial.\nThat \"magic\" can also happen between baby and father, too, says Gray, if there's skin-to-skin contact.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is a very brief, indirect discussion of what happens if\u00a0kangaroo care is not in place, which is that the newborn baby is placed in a bassinet or incubator, \u201csort of alone.\u201d That\u2019s just barely enough to rate satisfactory.", "answer": 1}, {"article": "Bochner and his colleagues Drs.\nAnne Marie Singh and Melanie Dispenza are now testing how successful the drug is at targeting allergies to food, such as tree nuts and peanuts.\nThis FDA-approved drug, ibrutinib, is currently on the market as a successful and less-toxic alternative to chemotherapy for patients with chronic lymphocytic leukemia and mantle cell lymphoma.\nThe cancer patients who were allergic to allergens such as cat dander and ragweed saw their allergic skin test reactivity reduced by 80 to 90 percent in one week, and this persisted with continued use of the drug for at least one to two months.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not compare this approach to existing allergies treatments. There are numerous over-the-counter and prescription medications available, along with air filters and masks for airborne allergens.", "answer": 0}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\nA smaller study in France with similar patients failed to find a benefit for the MitraClip.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated, \u201cUntil now, there has been little doctors can do\u201d for people with heart failure, aside from drugs to control symptoms. This is perhaps a little pessimistic as there are a number of different medications that have been shown to improve outcomes in heart failure patients.", "answer": 1}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\nThe researchers also found that BCG could reduce blood sugar elevations in mice that were caused by means other than autoimmune attack, raising the possibility that BCG vaccines could also be beneficial against type 2 diabetes.\nLong-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels.\nInitial clinical trial results, published in a 2012 PLOS One paper, reported that two doses of BCG spaced four weeks apart led to reductions in autoreactive T cells, an increase in Tregs and what turned out to be a transient increase in insulin production.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no known alternatives to insulin so we\u2019ll rate this Not Applicable. People with type I diabetes are dependent on insulin to manage their disease because their bodies to not produce insulin. It is the only established treatment other than pancreas transplant with other interventions \u2014 like diet and exercise \u2014 being secondary to the insulin replacement.\nTo date, their are no established forms of therapy based solely on an autoimmune mechanism to lower blood sugars as BCG is claimed to do by the study authors.", "answer": 2}, {"article": "The home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\nEarlier this year, the U.S. Preventive Services Task Force gave an \"A\" rating to HPV primary screening alone for women aged 30 to 65.\nFor the study, researchers mailed at-home, self-collection kits to low-income women in North Carolina who were overdue for screening by national guidelines.\nThe researchers compared the results from self- and clinician-samples - which were tested for high-risk HPV strains that are linked to cervical cancer - to the Pap results and the results of cervical biopsies collected during colposcopy, which is a secondary diagnostic test that confirms the presence of cervical pre-cancerous lesions among women with abnormal Pap smear results.\nResearchers provided study participants with self-collection brushes along with instructions for how to take a sample from inside the vagina.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares screening test results across three scenarios, including the standard screening protocol of on-site, clinician-collected sampling.", "answer": 1}, {"article": "Load up on berries.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\nAll of these effects could be beneficial, explains Robert Eckel, a preventive cardiologist at the University of Colorado.\nAnd when you eat a steady diet of them, they seem to have a number of positive health effects.\nIn recent years, regular consumption of berries has been linked to better brain health and a decreased risk of Type 2 diabetes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned. To prevent heart attacks, patients can either take medications, such as blood-thinning and cholesterol-lowering drugs, or make lifestyle changes, like maintaining a healthy weight, exercising and not smoking.", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe new analysis was published online Monday in Archives of Internal Medicine.\nAcupuncture is relatively safe and uncertainty over how it works shouldn't stop doctors from offering it as an option for patients struggling with pain, Avins said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly mentions that standard treatments for chronic pain include medications and\u00a0physical therapy. Close call, but good enough. We would have appreciated a comment about the relative value of these \u201cmainstream\u201d treatments.", "answer": 1}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\nThat is why the patients\u2019 tumors shrunk, the study suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story correctly mentions that treatment options for ovarian cancer are limited, but doesn\u2019t spell out what is available. In addition to chemotherapy, surgery is commonly performed to remove ovarian tumors, and other targeted therapies are under study.", "answer": 0}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nThere's no evidence drinking in your 20s or 30s has any health benefits.\nIt's also a source of \"non-essential liquid calories,\" a big concern in an overweight nation, he says.\nBut that's not the only reason, says Lori Mosca, a professor of medicine at Columbia University Medical Center and a spokesperson for the American Heart Association.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reporter interviewed two physicians who were knowledgeable about heart health \u2013 the cardiologist and the spokesperson for the American Heart Association (AHA). It was a missed opportunity to briefly explain some adjustments one can make to diet and lifestyle to fight heart disease as an alternative to a glass of red wine a day. For example, the AHA recommends 30 minutes of moderate exercise every day and a diet rich in fruits and vegetables to help control weight, blood pressure and cholesterol. An additional sentence along those lines would\u2019ve satisfied this criterion and, we think, improved the message for readers.", "answer": 0}, {"article": "It's OK to ask the question,\" Hoberman said.\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nIt's based on a slew of studies over the past couple of decades indicating that most children with ear infections get better without antibiotics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "By talking with the experts, such as Dr. Jerome Klein of Boston University and Dr. David Spiro of Oregon Health Sciences, the blog post does a great job comparing the wait-and-see approach with the antibiotic approach. It also\u00a0notes that the American Academy of Pediatrics endorses the wait and see approach and specifically speaks to the issue of correct diagnosis. We would have liked to have seen some definition of wait and see. And we\u00a0wish the story had provided more data to back up some of the assertions made by the doctors.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention amniocentesis, chorionic villus sampling and the quadruple screen as alternatives. The story should have also pointed out that no screening remains a viable option. News stories should include the perspective of someone who chose to forego testing. \u00a0 ", "answer": 1}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nTo be effective, all three compounds must be given together, the researchers said.\nWhether Souvenaid will slow the progression of Alzheimer's isn't known.\nIn addition, medical foods for Alzheimer's most likely won't be covered by insurance, he said.\nThere is, however, a longer trial going on that might answer that question, Wurtman said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of any other research in the field of memory boosting. A brief nod to what is known (exercise, stimulation such as puzzles, etc.) about reducing cognitive decline would have been appreciated.", "answer": 0}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\n\"There is clear evidence that supports the health benefits of circumcision,\" said Susan Blank, who led the 14-member task force that formulated the new policy being published in the journal Pediatrics.\nChapin and other critics argue that the scientific evidence is questionable.\nThey liken the procedure to female genital mutilation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative is no circumcision and was presented in the article.", "answer": 1}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nBut less than a third of victims get this essential help.\nThe CPR guidelines had been inching toward compression-only.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment makes clear that the two treatment options for observed adult cardiac arrest are conventional CPR and compression-only CPR. ", "answer": 1}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor.\nDoctors say simple adjustments to the device may solve that problem.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\nThe syndrome may follow 5 percent of all injuries, according to the Reflex Sympathetic Dystrophy Association, an advocacy group for people with chronic pain.\nBut spinal cord stimulators offer significant relief to only about half the patients who try them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news story mentions several alternatives to spinal stimulators\u2014bed rest, drugs, nerve blocks, and physical therapy. However, it neglects to point out the consensus view among pain experts that this is a treatment of last resort\u2014to be used only after everything else has failed, including surgery.", "answer": 1}, {"article": "Of those, 2,148 had taken lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken quetiapine.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\nIt is seen by patients, and some psychiatrists, as a dangerous drug.\n\u201cDifferent people will find that different treatments help with managing their mental health problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The research examined the side effect profiles of the most commonly used drugs to treat bipolar disorder, it also discusses \u201ctalk therapy\u201d (but not until the end of the story).", "answer": 1}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\nEarlier studies had proved that low-calorie diets could reduce weight and alter metabolism in obese people.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is about calorie restriction in overweight but non-obese people. But no alternative treatment options are discussed. ", "answer": 0}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\nThe cardiology community now prefers the endovascular approach.\n\u201cEvery patient differs in their aortic anatomical geometry so it can be hard to precisely ascertain the perfect sized graft, despite advances in CT imaging techniques, but newer patient-specific 3-D printed models may circumvent these challenges.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story isn\u2019t always clear about whether it\u2019s comparing the 3D technique with open surgery or with stent procedures that do not use the technology. In any case, there\u2019s no data to make the safety and effectiveness distinctions clear.\nThe story says \u201cdoctors sometimes use a stent to repair the aorta, but it doesn\u2019t always work since the aneurysms are often in places where a stent can\u2019t fit. And even if the stent does fit, patients often undergo a long, painful recovery.\u201d It says, \u201cUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\u201d\nThe story also does not make it clear that not every case requires surgery. According to the Mayo Clinic, \u201cDepending on the size and the rate at which your abdominal aortic aneurysm is growing, treatment may vary from watchful waiting to emergency surgery. Once an abdominal aortic aneurysm is found, doctors will closely monitor it so that surgery can be planned if it\u2019s necessary. Emergency surgery for a ruptured abdominal aortic aneurysm can be risky.\u201d", "answer": 0}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nThat's one of the most difficult steps to learn as a surgeon.\nShe also had questions about how the procedure was done with such a tiny incision.\nSome other experts in the field saw great promise in the research.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of\u00a0describing conventional cataract surgery as the main alternative to this new procedure.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of any\u00a0evidence-based strategies\u00a0for\u00a0achieving and maintaining weight loss \u2014 a significant gap considering how useless these\u00a0ketones are likely to be.", "answer": 0}, {"article": "They look impressive,\" said Dr. Gordon Weir of Joslin Diabetes Center in Boston.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nBurt and other diabetes experts called the results an important step forward.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The current standard therapy for type 1 diabetics is briefly discussed, e.g. daily insulin injections.\u00a0 ", "answer": 1}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cI had terrible pangs of sadness and despondency.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story spends time talking about ordinary vs. complicated grief, but it doesn\u2019t describe what might be the alternative ways of a person coping with dysfunction years after a loss. Is treatment for depression sometimes effective? What are the alternatives to the label of \u201ccomplicated grief?\u201d\nWe also found the description of the special therapy too brief. These few words were all we could find to define this new form: \u201cfocuses specifically on bereavement symptoms, and incorporates memories, photographs and recordings.\u201d We hoped for more detail about how this therapy might differ from more traditional forms of psychotherapy.", "answer": 0}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nDr. Paik, who is with the National Surgical Adjuvant Breast and Bowel Project, said that about 40 percent of women had intermediate levels of Her2.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Herceptin as a promising drug in the arsenal of breast cancer treatments; however, the story does not mention that Herceptin is given along with chemotherapy.\u00a0 We are also not told that women take Herceptin by infusion (IV), sometimes for up to a year.\u00a0 This may be play into the cost/benefit decision-making process of whether to retest formerly Her2/neu negative women, or whether it makes sense for Her2/neu women to now take the drug. ", "answer": 0}, {"article": "Use our submission form, or ask @juliaoftoronto on Twitter.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nSo, yes, the flu vaccine can prevent illness, but it's hard to detect major effects on public health in the data.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\nBeyond public health measures (making sure you have good hand hygiene and avoiding the office when you're sick), the flu shot is the best medical intervention we have for preventing infection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the meager alternatives to influenza vaccination \u2014 that is, proper hand washing hygiene and the isolation of flu patients from those free of the disease.", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t really any alternatives to BRCA testing for women with a strong family history of breast cancer, so we\u2019ll rate this not applicable.\nHowever, in just another line or two, the story could have noted that there are other, less common\u00a0genetic mutations that also confer an increased risk of breast cancer. And it could have mentioned that there are other options available to help estimate a woman\u2019s risk of breast cancer (e.g. the Gail model, Claus model, etc). These are not genetically\u00a0based\u00a0but some do account for family history to help refine risk estimates.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story made it clear that some scientists believe that the level of vitamin D intake is inadequate, there was no information about how one might determine if one had inadequate levels of vitamin D.\u00a0 The story did not include a very clear picture about what factors affect one's vitamin D status or conditions that might be particularly affected by vitamin D.\u00a0 Most importantly, a brief discussion about the widespread (and reliable) testing available to assess vitamin D status would have been helpful.\u00a0 And lastly \u2013\u00a0the story was very incomplete about sources of vitamin D if one were interested in increasing one's intake.", "answer": 0}, {"article": "\"We need people to swim against the stream.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison with existing alternatives, which leaves readers a bit confused. How is heart failure detected now and why would the world need this device? There are numerous diagnostic tests used in the diagnosis of heart failure, many of them as simple as a blood test or ultrasound.", "answer": 0}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\nA comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release lists things women should do to help relieve menopausal symptoms, but there are no comparisons of which ones may be more beneficial. Knowing which ones offered the strongest benefits would help women decide on which approaches to follow. It\u2019s unrealistic to suggest that all women would be willing or able to make all of the modifications recommended. We\u2019ve all heard these messages throughout our lives. A cancer diagnosis may be the incentive needed to make changes but women deserve to know which changes have the potential for the greatest\u00a0 benefit.", "answer": 0}, {"article": "Although total sleep deprivation or partial sleep deprivation can produce clinical improvement in depression symptoms within 24 hours, antidepressants are the most common treatment for depression.\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\nThe authors note that further research is needed to identify precisely how sleep deprivation causes rapid and significant reductions in depression severity.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\nThe results are published today in the Journal of Clinical Psychiatry.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that depression is most typically treated with anti-depressant drugs. We would have liked a little more context for readers on other non-drug treatments such as exercise and cognitive behavioral therapy.", "answer": 1}, {"article": "Visit http://www.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release briefly discusses alternatives in this sentence: \u201cPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\u201d It would have been helpful to note if the software compared favorably in terms of speed, accuracy, or both. What sort of testing was done? What were the results? How does that compare with baseline and follow-up CT scans?\nThe release also says that \u201cThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\u201d Thus the comparison is mentioned but it could have been made clearer.\u00a0 It also could have noted that medicine-based treatment (clot busting drugs) is an alternative to the procedure described here.", "answer": 1}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\nNow, according to scientists at the University of Colorado, there is even evidence that the healthy fat can boost your chances of getting pregnant.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of any other steps women might take to increase their odds of becoming pregnant when they are ready to start a family.", "answer": 0}, {"article": "In a hip replacement, an artificial joint comprising a ball and socket is implanted to replace the natural ball and socket in the pelvis, enabling movement that is typical of the hip joint.\nUsing the risk assessment tool, the researchers identified 192 of 1,009 patients as high risk for a dislocation after surgery.\nThis exhibit in greater details demonstrates the treatment algorithm, patient cases, and the success with use of the standardized stepwise risk assessment and treatment algorithm to address dislocation risk in patients with spinal deformity.\nThis led researchers to further develop a risk prediction tool to better identify which patients undergoing a hip replacement may be at higher risk for dislocation, and then implement a treatment algorithm to help reduce that risk.\nAll 192 patients underwent a total hip replacement through the high-risk algorithm, with dual mobility implants being used in 143 of the cases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since we\u2019re not aware of alternatives to this tool we\u2019ll rate this criteria Not Applicable.  ", "answer": 2}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does say that Entresto will be competing with generic versions of drugs called \u201cangiotensin-converting enzyme (ACE) inhibitors or somewhat similar angiotensin II receptor blockers.\u201d We\u2019ll award a Satisfactory on that basis. The story could have added value by making it clear that these drugs \u2014 or Entresto \u2014 would be used as part of a suite of treatments for heart failure. For example, depending on the cause of low, or reduced, heart ejection fraction (meaning your heart is not pumping out blood efficiently), treatment options may include surgically implanting a defibrillator, changes in diet and physical activity, or the prescription of other drugs (including betablockers or inotropes).", "answer": 1}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\n\u201cPhysicians are largely administering the diet by giving patients sheets of paper with foods to exclude,\u201d Chey says.\nIn 2014, IBS treatment guidelines from the American College of Gastroenterology said the diet showed promise, but that the quality of evidence was \u201cvery low.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions a number of alternatives, including other existing diets that seem to compete favorably with the low-FODMAP diet, such as medication, probiotics, and fiber supplements. The story notes that these other strategies \u201cstill have roles in treating IBS\u201d.", "answer": 1}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nThe U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nNo drug in this class is approved to treat patients with dementia-related psychosis.\nThe neurological disorder typically occurs in people over age 60, when cells in the brain that produce a chemical called dopamine become impaired or die.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The only alternative mentioned in the news release is the placebo used for comparison in the clinical trial. What about other treatment methods? According to patient advocacy groups, other government websites and review articles, there are numerous alternatives in use for treating PD-related hallucinations and delusions. Among them, according to the University of Florida College of Medicine:", "answer": 0}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\n\"The goal of this study was to find a safe and effected treatment option, and our initial results support 'as-needed' blood thinners and pulse monitoring as the alternative.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release presents \u201cas-needed anticoagulation\u201d drug therapy as an alternative to \u201clong-term, daily oral anticoagulation medications.\u201d The problem is that we\u2019re not sure what to do \u2013 take no medicine, daily medicine or this \u201cas needed\u201d medicine. We aren\u2019t told if the comparator is a daily anti-coagulation (such as warfarin, the standard treatment) or no anti-coagulation. It isn\u2019t clear and it is important.", "answer": 0}, {"article": "\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nPrevious research has shown benefits from similar web-based therapy in other settings.\nThe online program included sessions about how to put feelings of stress or despair into perspective.\nThe study involved interns at Yale University and the University of Southern California.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study in question compared access to a web based therapy plan to emailed reminders of available resources. \u00a0We would like to have seen some comment on the relative value of traditional individualized \u201ctalk\u201d therapy to compare to the web based program.", "answer": 0}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nThis protocol also has a cost-savings component, in addition to the patient safety and satisfaction aspects.\n\"This approach allows us to intervene at an earlier time rather than waiting for patients to come back in after the problem has already developed past the point of being able to manage it on an outpatient basis.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study mentions patients whose infections are detected during routine follow-up exams, but doesn\u2019t describe what steps are currently taken to catch post-operative infections. Do hospitals educate patients to recognize infections? Do staff follow up in any way, perhaps with phone calls? Those questions aren\u2019t answered.", "answer": 0}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nFor people who want to safely eat more seafood, the magazine recommended shrimp, scallops, sardines, salmon, oysters, squid and tilapia as the lowest-mercury seafood.\nCurrently fewer than one in five Americans eats the recommended two servings a week of fish.\nThe report also acknowledges the risk of mercury exposure from certain kinds of seafoods, and notes that women who are pregnant, nursing or may become pregnant should avoid certain kinds \u2014 tilefish, shark, swordfish and king mackerel \u2014 because of their high mercury content.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that health officials recommend fish that \u201care lower on the food chain and have accumulated less mercury in their tissue,\u201d such as sardines and salmon. The story also states that salmon contains significantly less mercury than tuna, and lists other types of seafood that are recommended by Consumer Reports as being low in mercury. We\u2019ll call that good enough for a satisfactory rating. The story could have mentioned other factors \u2014 for example, reading aloud to your child \u2014 that are also associated with improved childhood brain development.", "answer": 1}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\n\"Health Canada, the FDA and several health authorities worldwide have already approved health claims that barley lowers LDL cholesterol, but this is the first review showing the effects on other harmful lipids.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes brief mention of barley in comparison to oats. It states that \u201cbarley is higher in fibre, has twice the protein and almost half the calories of oats, which are important considerations for those with weight or dietary concerns,\u201d\u00a0 We aren\u2019t provided any quantification of the claim.\nThe release also skipped over some of the other common ways there are to lower cholesterol including medications, exercise, other foods and dietary supplements, and weight loss.", "answer": 0}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nFor the first time in Wisconsin, a research team will test a personalized cell therapy to treat a common and serious complication in bone-marrow transplant patients.\nUW team shows progress in search for new antibiotics\n\nCollecting bugs across the globe is paying off for a multidisciplinary research team at the University of Wisconsin-Madison.\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe Wisconsin Partnership Program at the UW School of Medicine and Public Health announces four new awards through its Collaborative Health Sciences Program.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release notes that\u00a0\u201cThis is the first time any therapy has been shown to stabilize memory loss over a year.\u201d That\u2019s all well and good, but how do the results compare with other FDA approved treatments for Alzheimer\u2019s disease or others that may be on the horizon? The release doesn\u2019t address this issue.", "answer": 0}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that hormone therapy is another treatment option for hot flashes, but it doesn\u2019t provide enough information\u00a0to allow the reader to compare the two approaches. The story should have mentioned that hormone therapy seems to be more effective than antidepressants at reducing hot flash symptoms, although the risks may also be greater. It also could have mentioned that complementary and alternative medicine approaches are often used for hot flashes.", "answer": 0}, {"article": "\u201cI\u2019ve had patients who wouldn\u2019t dream of not being treated,\u201d Dr. Berchuck said.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\nThe group getting the test began chemotherapy a median of about five months earlier.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Clearly no testing is the alternative to CA-125. The story could have also mentioned regular imaging tests as a way to monitor for recurrent cancer.", "answer": 1}, {"article": "Related: Common Knee Surgery May Not Help You\n\nOsteoarthritis can affect any joint when the cartilage wears off over time, often striking big joints like the knee, causing pain, swelling and stiffness.\nSome of the reported risks from the procedure include bleeding and infection.\nMarketed as \"Coolief\", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\nCoolief can be repeated if necessary, but it's not a permanent solution.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The text mentions treatment options and compares the radio frequency procedure with one of them.", "answer": 1}, {"article": "\"You are not putting yourself at risk of death or heart attack if you defer,\" and considering the safety worries about heart stents used to keep arteries open after angioplasty, it may be wise to wait, said Dr. Steven Nissen, a Cleveland Clinic heart specialist and president of the College of Cardiology.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nThose patients now should try drugs first, experts say.\nHalf of these low-risk patients received stents and medication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention medication as the alternative to stenting.", "answer": 1}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions that other organizations are \u201cexploring the role of pharmacogenomics,\u201d and it mentions one other specific test, GeneSight Psychotropic, which it describes as \u201csimilar to many used in hospitals.\u201d This is enough to merit a marginal Satisfactory score.\nIt does not say how similar the Genesight Psychotropic test is to the Genefolio test developed by the Avera Institute for Human Genetics, as we note above in the quantified benefits criterion. Thus, the article provides no data whatsoever about the clinical utility of Genefolio or of any other genetic tests other than GeneSight Psychotropic; instead, it focuses on the anecdotal story of how the Genefolio test helped a patient\u2019s doctor decide to prescribe for her a lower dose of an older antidepressant and on the positive results that produced.", "answer": 1}, {"article": "GlaxoSmith Kline and Eli Lilly supplied Lovaza and Raloxifene, respectively.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of any other approaches to reducing the potential risk of developing breast cancer although some preventative actions are readily known and could have been included. These include limiting alcohol, not smoking, controlling weight, breast-feeding and exercising.\nSince the focus of the research was on reducing risk by reducing breast density the most obvious alternative to taking omega-3 supplements is losing weight through diet.", "answer": 0}, {"article": "In undeveloped countries, 75,000 women die from pre-eclampsia each year.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\nIt detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\n\u201cWe identified 40 organic molecules to be significantly elevated and 5 that were reduced in plasma at 14 to 16 weeks\u2019 gestation,\u201d they wrote.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The article made it clear there are no validated diagnostic tests for preeclampsia early in pregnancy. ", "answer": 1}, {"article": "The investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This criterion does not apply with this story.", "answer": 2}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nAnd because it has few side effects, researchers are studying whether light therapy can help with depression during pregnancy and be used to treat elderly people with dementia.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\nExperts recommend consulting with a knowledgeable health care provider before starting treatment to rule out other medical conditions and to help with monitoring and adjusting bright-light exposure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the existing use of anti-depressant drugs for seasonal depression, but does not compare in detail the price or length of drug therapy vs. light therapy. This comparison would have been very helpful to consumers. Other alternatives \u2013 including cognitive behavioral therapy, psychotherapy or exercise \u2013 were not mentioned.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\n\"Diffusion kurtosis imaging has been introduced in DWI to provide important information on tissue structures at a microscopic level,\" said study lead author Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, Germany.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The lead researcher is quoted explaining that the new approach is not being presented as a substitute for current MRI protocols that use contrast imaging to detect malignancies. Diffusion kurtosis imaging simply adds to the spectrum of diagnostic tools. A statement detailing why the software algorithm might be superior to use of\u00a0gadolinium-based contrast agents that need to be injected intravenously would have made the comparison clearer.", "answer": 1}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nNewswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the study (as opposed to the news release) the authors say that they \u201calso found dietary manganese to be protective against cross-sectional nuclear cataract independent of vitamin C,\u201d but found no association between dietary magnesium and nuclear cataract progression and the lack of a dose response.\u201d\nThat muddies the waters a bit, but would have been nice to include \u2014 if only to underscore the fact that much about science is not clear. And we never learn from the release that other interventions, like reducing cigarette smoking and ultraviolet light exposure, may prevent or delay the development of cataract, or that diabetes and overweight are risk factors, too. The study itself underscored these points.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\nIf the FLT3 mutation is detected in blood or bone marrow samples using the LeukoStrat CDx FLT3 Mutation Assay, the patient may be eligible for treatment with Rydapt in combination with chemotherapy.\nThe FDA granted the approval of Rydapt to Novartis Pharmaceuticals Corporation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The new medication was used in combination with standard chemotherapy. That tells us the alternative was standard chemotherapy alone, an important comparison.", "answer": 1}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\nThe threshold CAPS score for diagnosis of PTSD is 50.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions other treatments for PTSD (such as SSRI antidepressants) even though we don\u2019t learn how effective those treatments are compared to N-acetylcysteine. The lead researcher very helpfully mentions that the drug should not be used without cognitive behavioral therapy or other forms of psychological counseling.\nThe news release places the results of the study in a positive light noting, \u201cCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD. Although selective serotonin reuptake inhibitors have been approved by the FDA for treatment of PTSD, pharmacological treatments for co-occurring PTSD/SUD have yielded suboptimal results.\u201d\nWhile SSRI\u2019s have been the most studied to date, other drugs that have been studied in preliminary trials could have been mentioned, including prozosin, prazosin, guanfacine, atomoxetine, topiramate, memantine, acamprosate, and ketamine. A 2014 article in Addictive Behaviors journal describes some of these: \u201cPharmacological treatment of comorbid PTSD and substance use disorder: recent progress.\u201d (Addictive behaviors\u00a039.2 (2014): 428-433.)", "answer": 1}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nHourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\nThat said, a doctor with a Zeltiq device isn\u2019t hard for patients to find.\nDoctors on the advisory board for Zeltiq Aesthetics have put the word out about it on television news segments.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article could have devoted more space to comparing these procedures to the process, benefits, and risks of liposuction. It could have distinguished between the two new treatments and the existing heat treatments and topical creams also sold by some of the same dermatologists, chiropractors, plastic surgeons and web infomercials that support Zeltic and Zerona. It does get points, however, for mentioning two new ultrasound products about to enter the market. \u00a0 ", "answer": 0}, {"article": "Guadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\nThe clinical trial included 22 patients with metastatic colorectal cancer who had been treated previously with irinotecan and whose disease was progressing.\nThe drug combination is being tested in an ongoing phase II clinical trial (NCT01896856) in a larger group of metastatic colorectal cancer patients at multiple institutions to determine the effectiveness of the dual therapy compared with chemotherapy regimens that do not include guadecitabine, says Azad.\nThe study also showed signs that guadecitabine reduced methylation among the cancer cells.\nThere was one death during the study, possibly resulting from febrile neutropenia caused by the treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a lot of drugs, and drug combinations, that are approved for use in colorectal cancer chemotherapy. Given that the release explicitly states that the study was not done to assess the potential benefits of guadecitabine, we don\u2019t expect it to compare the drug\u2019s performance to those other drugs.", "answer": 2}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\nGenius\u2122 3D MAMMOGRAPHY\u2122 exams have been available in the U.S. since 2011, and are only available on the Hologic Selenia\u00ae Dimensions\u00ae mammography system.\nThis study brought together the principal investigators from the groundbreaking 2014 study on 3D MAMMOGRAPHY\u2122 exams, also published in JAMA, this time led by Elizabeth Rafferty, MD, a co-author on the prior study.3 A total of 452,320 examinations (278,906 conventional mammograms compared to 173,414 Genius\u2122 3D MAMMOGRAPHY\u2122 exams), were analyzed.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The purpose of study compared\u00a0digital mammography alone with digital mammography with the addition of 3D mammography.", "answer": 1}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nIn clinical trials, the skin creams are linked to a higher rate of redness, irritation and rash.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe essence of this story is an attempt to compare topical NSAIDs with pills and other pain treatments. As noted above, though, the story does not mention that most people with minor pains feel better after awhile even if they don\u2019t take any pain relief medication. It also should have mentioned that the difference between placebo and active treatment groups in the clinical trials is often slim.", "answer": 1}, {"article": "Then, the newly copied viruses break out of the cell, spreading to other cells nearby and repeating the process.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although, as noted above, the article compares the claims for the new drug to Tamiflu with respect to mode and speed of action, it doesn\u2019t mention vaccination or other symptomatic treatment, nor does it give any quantitative information that would enable accurate comparisons of cost, safety or effectiveness.", "answer": 0}, {"article": "\"They say, 'Oh my God, this has changed my life.\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nDoctors who treat women with low libidos tore apart the JAMA study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The \u2018alternative\u2019 in the clinical studies was, presumably, a placebo, yet as some commentators have noted, the drug has never been tested against a more holistic approach that acknowledges the complexity of female sexuality and which address physical, psychological, and social factors.", "answer": 0}, {"article": "At 40Hz the flicker of the light is barely discernible and would be \u201cnot offensive at all\u201d for a person to have in the background.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nBoosting this synchronous brain activity appeared to act as a cue for the brain\u2019s immune cells, prompting them to absorb the sticky amyloid proteins that are the most visible hallmarks of the disease in the brain\u2019s of people with Alzheimer\u2019s.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Overall, this story feels inappropriately weighted in several ways, and a lack of background information about the state of the science in treatment for Alzheimer\u2019s disease is one of them. The recently failed Eli Lilly trial is mentioned, but there\u2019s no explanation of other prevention and treatment approaches (some of which are based on an entirely different model of the disease) that are currently under investigation.\nThere\u2019s also no sense of just how little can be done for Alzheimer\u2019s patients at this point in time, nor indeed how devastating the condition is for victims and their families. That kind of information would have provided a much-needed context for the results of the study.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\nMandato stressed that no one in the study required sedation to undergo the procedure.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that the new procedure was a \u201cclear simple alternative to standard migraine treatments,\u201d but it did not detail what those treatments were. And what\u2019s simple about image-guided therapy and a spaghetti-sized catheter? The story could have added that a whole range of medications exist to treat migraines, such as pain relievers like aspirin, to preventative medications like anti-seizure drugs, to Botox.", "answer": 0}, {"article": "For example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nHowever, despite the availability of TNF inhibitors, \u201conly about half of psoriatic arthritis patients who are given TNF inhibitors get better,\u201d said Genovese.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There was a good explanation about the alternatives \u2014 drugs\u00a0like the TNF inhibitors already on the market such as adalimumab, etanercept and infliximab \u2014 but that\u00a0\u201conly about half of psoriatic arthritis patients who are given TNF inhibitors get better.\u201d We also learn that \u201canother approved monoclonal-antibody that targets IL-17, secukinumab, was approved in 2016 for psoriatic arthritis.\u201d", "answer": 1}, {"article": "The U.S. National Cancer Institute has more about colon and rectal cancer.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to detail any existing alternatives for colorectal cancer, such as targeted drug therapies for people with advanced colon cancer.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains the risks of having an elective c-section at 37, 38 and 39 weeks. This information can help women and their doctors determine when to schedule an elective surgery.\n\u00a0", "answer": 1}, {"article": "S. Bagla; R. Piechowiak; T. Hartman; J. Orlando; A. Isaacson; Vascular Institute of Virginia, Woodbridge, VA; UNC Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill.\nThis prospective, multicenter clinical trial evaluated 13 patients with severe osteoarthritis pain.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\nThe treatment was successfully completed in all 13 patients, with no adverse events.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions medications and specifically opioids as one treatment for knee OA. According to the American Academy of Orthopaedic Surgeons, alternatives also include exercise, over-the-counter anti-inflammatory medications such as ibuprofen and naproxen sodium, and corticosteroid injections.", "answer": 1}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nHowever, these treatments are often associated with significant immune-related toxicities.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nPrevious MD Anderson research showed that bacteria in the gut influence patient response to ICI therapy, and other evidence suggests modifying the microbiome in mice can alter their response to immunotherapy.\nBoth patients in the study had a complete resolution of their colitis following treatment with FMT.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text explains that traditional treatment of severe gastrointestinal symptoms involves steroids and drugs that may suppress the efficacy of immunotherapy and suppress an individual\u2019s immune system, while generating their own unpleasant side effects.", "answer": 1}, {"article": "Anal Cancer Fund, and a philanthropic donation.\nThe study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapy therapies.\nThe study revealed encouraging correlations between immunologic biomarkers and responses to treatment.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Immunotherapy may offer a less toxic alternative to traditional chemotherapy, but there is no mention of that here. In fact, there is no attempt to describe the relative advantages and disadvantages of nivolmab versus the traditional treatment protocol. The release also neglects to mention that human papillomavirus (HPV) vaccine has been proven to prevent anal precancerous lesions and has the potential to make this tumor even more rare.", "answer": 0}, {"article": ".\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\nOther research is being conducted to find markers for lung cancer, though much of it focuses on substances that can be found in the blood, Spira said.\nIf it shows a malignancy, a biopsy still would be needed to confirm the cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a good job of describing current tests and what they can and cannot do. And it notes that although there are serious efforts to develop blood tests\u00a0that can predict response to treatment and even early cases of lung cancer, these are likely years away from clinical use.", "answer": 1}, {"article": "Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nThis provides information about the development of tumours long before being visible on CT or detected by ctDNA.\nPancreatic cancer is currently very difficult to detect while it is still resectable.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention how pancreatic cancer is currently diagnosed \u2014 CT scan, biopsy, carbohydrate antigen (CA) 19-9\u00a0blood test that measures the CA 19-9 level in the blood \u2014 and how this test might compare.", "answer": 0}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nNow, new research from Chalmers has shown that the protein parvalbumin, which is very common in many fish species, may be contributing to this effect.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\nThe team is therefore keen to research this topic further, to see if the discovery relating to Parkinson's disease could have implications for other neurodegenerative disorders as well.\n\"It will be very interesting to study how parvalbumin distributes within human tissues in more depth.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives to preventing Parkinson\u2019s and other neurodegenerative diseases are mentioned. On the surface this omission may seem justified since there are none.\nBut perhaps it would help readers to tell them this up front. The following is our suggested wording:\n\u201cPlease note there are no interventions of any kind proven to prevent any neurodegenerative disease. Furthermore, no cause and effect relationship between amyloid (of any kind) and these diseases have ever been established. Finally, this is an in vitro study, so no conclusions regarding clinical efficacy in humans can be made.\u201d", "answer": 0}, {"article": "\u201cModels are models,\u201d Lin said.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nDr. Kenneth Lin of Georgetown University Medical Center, a former staffer at the USPSTF, said crediting PSA tests with reducing prostate cancer mortality by around 30 percent was probably an overstatement, especially since mathematical models are only models.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\nBottom line: Screened men\u2019s cancers were detected earlier than unscreened men\u2019s, and more frequent screening advanced detection more.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This research is specifically about comparing the value of screening for prostate cancer vs not screening. New biomarkers and variations on the PSA test itself, along with other screening modalities, such as digital rectal exam, are not mentioned and were not addressed in the studies that are described.", "answer": 1}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\nSo a coalition of groups including the March of Dimes Foundation and the National Council of La Raza has petitioned the FDA to change its stance and allow corn masa flour to be fortified with folic acid.\nMichael Dunn, the Brigham Young University food scientist who led the study, cannot comment on the test results while they're under FDA review, but he has previously called them encouraging.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never really discusses the alternative of taking vitamin supplements.\nStandard preventive advice for women of childbearing age who are considering pregnancy is to take a multivitamin in order to have enough folic acid for any future pregnancy. But this advice may be unheeded, vitamins may be too expensive, or pregnancy may be unintended.", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story mentioned the uncertainty about whether Lucentis is any better\u00a0 than the cheaper Avastin, and mentioned an upcoming trial comparing the two in age-related macular degeneration. ", "answer": 1}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nZiman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\nPatients who returned a positive result would still need a biopsy to confirm the blood test and determine how far the cancer had developed, Ziman said.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nHowever, she stressed the fact this new test has not undergone clinical trials.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job in providing the current diagnostic methods.\nThe story seemed to give mixed messages about the value of screening with the new blood test. An investigator is quoted as noting that\u00a0current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous. \u00a0Elsewhere, the release notes that you still need a biopsy to evaluate a positive blood test. \u00a0Clearly, a clinician visit and biopsy will always be required to diagnosis a cancer.\nAside from self-examination, having a clinician perform a skin exam during routine examinations is another alternative to the blood test\u2013but is not addressed in the story.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The primary focus of this story is explaining why cognitive behavioral therapy is the better alternative for treating insomnia due to the negative side effects of insomnia drugs. The story also includes a great deal of practical information about \u201csleep hygiene,\u201d as well.", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nThe device is intended for patients 75 and older with severe to profound vision impairment that has been stable over time due to blind spots from end-stage AMD.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nBefore implantation, patients will be trained with an external telescopic device to see if they may benefit from the product.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that \"Despite advancements in therapies for macular degeneration, \u2018retina specialists still did not have a treatment for the many wet and dry AMD patients who progressed to end-stage disease.\u2019 \"", "answer": 1}, {"article": "He was not involved in the study.\nThey also saw a 12 percent reduction in the risk of death from cancer, although those findings also were not statistically significant.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nResearchers said they planned to continue to follow the study group to monitor the effect of vitamin intake over time, and said additional studies would be needed to see if there were similar benefits for women or younger men.\n\u201cIt doesn\u2019t seem like there is any particular risk associated with taking a vitamin and there might be a small benefit,\u201d said Dr. David Weinberg, chief of the department of medicine at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t\u00a0compare multivitamins with\u00a0other steps\u00a0that may be helpful for preventing cancer, such as a healthy diet, exercise, and not smoking. The AP made these comparisons.", "answer": 0}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nDr. Ramsey, a professor of pediatrics at the University of Washington, was briefed on the results by Vertex.\nThe company is awaiting results of a second trial of the drug, this one in younger children.\nShe said other results of the trial were encouraging.\nPatients continued to take either drug or placebo for another 24 weeks and the improvement was sustained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It summarizes the alternative treatments for CF. It would\u2019ve been interesting to note what other therapies subjects in this study received.", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\nThey recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\nResearchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several foods that are rich in selenium and can help boost dietary intake.\u00a0It\u00a0didn\u2019t\u00a0discuss how the effects of selenium supplements compare with those of statin drugs or other cholesterol-lowering interventions, but it does make it clear that supplements are not necessary and not recommended in the U.S.\u00a0We\u2019ll rule it satisfactory.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reporting in this article is problematic with regards to treatment options. Notwithstanding mention of pills ( a little vague) for which this device may substitute, the title \u201cSafer method found to treat heart failure\u201d is drawing conclusions prematurely. In addition, this treatment is not currently being suggested as a replacement to the daily \u201cwater pills\u201d that many patients with heart failure take but rather as a substitute for the diuretics administered IV for decompensated heart failure patients. This point is not made clear in the article. Use of the term \u201cpill\u201d is inappropriate as the filtration was compared with medication administered IV, not by mouth.", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that conventional synthetic disease-modifying anti-rheumatic drugs such as methotrexate can prevent joint damage and loss of function. It adds that biologic therapy \u2014 usually a tissue necrosis factor inhibitor \u2014 is reserved for those who either don\u2019t respond, or respond inadequately.", "answer": 1}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does not provide detailed comparisons of red palm oil to other oils\u2026 or other ways of getting health benefits for the heart or other organs\u2026 there are some specifics about how various processing methods affect the oil and some brief references to other types of cooking oils. And again, the overall message is that there is not enough evidence to support claims that red palm oil has any special health benefits, which implies that it is not better than alternatives.", "answer": 1}, {"article": "The skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\nSeven weeks after surgery, Baez concluded the pain and effort had been worth the result: an end to the recurrent skin infections in her thighs and abdominal folds.\nIntense discomfort that interferes with activity is a common problem after bariatric surgery, says plastic surgeon Sarah Holland, an instructor at Columbia University Medical Center in New York -- and it can be almost constant.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While presenting quite an unpleasant picture of what excess skin following the loss of a large amount of weight might be like, the article failed to provide any other options that consumers might choose to manage excess skin.", "answer": 0}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nBut here's the catch: Avastin costs more than $8,000 a month.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\nBut gratitude is tinged with worry, because the Food and Drug Administration is considering the unusual step of revoking its approval of Avastin as a treatment for metastatic breast cancer.\nDoctors told Gilbert she'd be lucky to be alive in five years, but with chemotherapy and radiation, she fought off the cancer, again.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly discusses radiation and other chemotherapy treatments for metastatic breast cancer; however, there are many other treatments that could have been mentioned.\u00a0 It would take just a few more words.\u00a0 ", "answer": 0}, {"article": "A systematic review of C.B.T.\nMy sleep log also helped me be more objective.\nRecognizing that\u2019s not really so bad helped me relax, and relaxing helped me get more and better sleep.\nMany nights I might have considered \u201cbad\u201d \u2014 and fretted over \u2014 were ones in which I got only one hour less sleep than my target of seven hours.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of explaining the alternatives of CBT, or behavioral vs. drug therapy for insomnia. It might have been interesting to compare \u201cno treatment\u201d at all to the others.", "answer": 1}, {"article": "\"You've got to have a teacher right there in front of you teaching according to experience,\" he said.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\nHe added, however, that meditation would work as well among whites and other populations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story hints at\u00a0factors that can help reduce risk: diet, exercise, not smoking, cholesterol-lowering drugs, etc. But it never directly addresses this criterion. Not quite good enough.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not touch upon other hair loss therapies, including how they compare to the new cooling cap.\nTo treat hair loss doctors can recommend drugs, such as minoxidil (better known as Rogaine), which is an over-the-counter liquid or foam that patients can rub into their scalps to regrow hair and to prevent further hair loss. Physicians can also suggest hair transplant or restoration surgery to treat permanent hair loss.\nIn laser therapy, a low-level laser device is used to treat men and women with pattern baldness.\nIf patients don\u2019t respond to the above treatments, they can try wearing hairpieces and wigs, whose costs may be covered by insurance. It\u2019s also important to note that hair loss from chemotherapy is temporary for many women so more information about the duration of benefit may lead some women to conclude that short-term hair loss is an acceptable alternative.", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nDr. Hunter Wessells, who wasn't involved in the study, called the additional fluid intake \"substantial,\" leading to a corresponding increase in urine output.\nHalf of the women in the study were asked to consume 1.5 liters of water, or about 6 cups, each day in addition to their usual daily fluid intake.\nYoung women plagued by UTIs who drank an additional 6 cups of water each day were nearly half -- 48 percent -- as likely as a control group to have another infection, the study showed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not discuss alternatives to drinking extra water but there may not be any. According to the National Institute of Diabetes and Digestive and Kidney Disease, \u201cExperts don\u2019t think eating, diet, and nutrition play a role in preventing or treating bladder infections.\u201d\nChanges in hygiene habits \u2014 such as emptying the bladder after sex \u2014 can reduce the frequency of UTIs.", "answer": 2}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated that \"Twenty percent of miminally conscious patients recover well enough to return to the community and resume their lives\" and that those suffering from traumatic brain injury have few options.\u00a0 However \u2013 it did not provide any insight as to what the treatment options are.\u00a0 ", "answer": 0}, {"article": ".\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nResearcher Dr. Harri Hemila, of the University of Helsinki in Finland, reviewed 13 placebo-controlled trials examining the effect of zinc lozenges on cold infections.\nTUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not talk about existing strategies to relieve cold symptoms, and so, does not satisfactorily place the new research into context. A quick look at the National Institute for Allergies and Infectious Diseases website includes these: resting in bed, drinking plenty of fluids, gargling with warm salt water, using a decongestant or saline nasal spray, among others.", "answer": 0}, {"article": "In general, though, \"the more options that are available to migraine headache patients, the better,\" Waltman said.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nAccording to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine.\nResearch involving 800 patients ultimately led to the approval of Zecuity.\nCalled Zecuity, the patch contains sumatriptan, one of the most widely prescribed medications for migraines.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternative delivery systems for migraine medication, including pills, sprays, and injections (although as mentioned above, it doesn\u2019t compare the efficacy of these different approaches). The story could have also mentioned that there are a variety of non-triptan\u00a0drugs, including NSAID pain relievers, that can be\u00a0effective for treating acute migraine attacks.", "answer": 1}, {"article": "All rights reserved.\nHe said a gene test may have made him more comfortable with that decision.\nConversely, the test also suggested some tumors were more aggressive than doctors had believed.\nThe newest test was developed by Genomic Health Inc., which has sold a similar one for breast cancer since 2004.\n\"You can shop for a toaster\" better than for prostate treatment, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one.\u00a0 It covered a lot of ground and we don\u2019t want to ding it for what it might have done a bit better.\nIt at least gave data comparing one of the new tests with \u201cone current method.\u201d\nIt at least said the new test is \u201csimilar to tests used now for certain breast and colon cancers.\u201d\nAnd it at least reported that \u201cDoctors now base risk estimates on factors such as a man\u2019s age and how aggressive cells look from biopsies that give 12 to 14 tissue samples. But tumors often are spread out and vary from one spot to the other.\u201d", "answer": 1}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\nAbout 3 percent of kids who undergo the procedure experience bleeding during the two-week recovery period, Hackett said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is about a comparison between tonsillectomies and watchful waiting, the primary two alternatives in dealing with either recurrent sore throats and obstructive breathing.\nThe published studies note that watchful waiting includes antibiotic therapy.\u00a0 ", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n\"Whether it's this vaccine or another one someone else develops, I don't think we'll be continuing with the type of flu vaccines that we have at the moment.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "Breast cancer is the second-leading cause of cancer death among U.S. women, after lung cancer.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nHis team calculated that a woman who gets a yearly mammogram starting at age 40 cuts her risk of dying from breast cancer by 71 percent compared to a 23 percent reduction in risk if a woman followed the task force recommendations.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article fails to mention the disadvantages of annual mammography screening beginning at age 40.\u00a0 By not including balanced information, the article may lead readers to believe this new analysis is totally accurate.\u00a0 The choice of declining screening was not presented as a reasonable option.", "answer": 0}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never pointed out that everyday fruits and vegetables can be good sources of antioxidants.\u00a0They are usually less expensive than antioxidant \u201csuperfruits\u201d and have less fat and sugar than chocolate. In addition, drinks such as coffee, green tea, and red wine are also rich in antioxidants.\u00a0And clearly, eating a variety of different foods is the best approach to overall health.", "answer": 0}, {"article": "But this is important enough and impressive enough to tell people about,\" said Robert Temple of the Food and Drug Administration, who spoke to reporters about the findings.\nAll new drugs are tested on pregnant animals to see whether they cause malformations, but those tests can be misleading.\nIt's considered unethical to include pregnant women in studies of new drugs unless the medication is intended to treat pregnancy-related conditions.\nExposure to ACE inhibitors early in pregnancy nearly tripled the risk of birth defects, the study showed.\nAs a consequence, the labels on nearly all medications carry a statement saying their safety to fetuses has not been established.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article included a list of other medications that may be used to to lower blood pressure. However these suffer from the same lack of clinical testing of their safety for use in pregnant women. The story discussed the impact of pregnancy on blood pressure \u2013 lowering it for some women and raising it in others.", "answer": 1}, {"article": "Lisinopril is a member of a drug family called ACE (angiotensin-converting enzyme) inhibitors.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nBut the evidence is not sufficient to support routine use of angiotensin receptor blockers to prevent Alzheimer's disease, Wolozin said.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did note other observational studies that have \"implicated various molecules\" in dementia.\u00a0 We\u2019ll again give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nMany of them took part in the clinical trial, and all have gotten extensive training by Grupp and others.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "First of all, the story makes clear that CAR T-cell treatment \u2014 if approved \u2014 would be available only to those for whom conventional treatments have not worked. That\u2019s a key point. Second, the story does articulate the difference between this form of immunotherapy (which is customized to the patient) and other immunotherapy techniques, which are so-called \u201ccheckpoint inhibitors\u201d and are not individualized. As mentioned earlier, we would have liked to have seen more data on the success rates of standard treatment vs these treatments.", "answer": 1}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is about alternatives, on its face, about the alternative of taking or not taking hormone replacement therapy. We wish there had been a sentence or two more on how\u00a0other methods are available to women to ease symptoms.", "answer": 1}, {"article": "Pancreatic cancer is the fourth leading cause of death from cancer in the United States.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nOnly about 6 percent of those with the diagnosis live longer than five years.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nThe study is published in this week\u2019s issue of the New England Journal of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We thought USA Today did a much better job, ending their story with this independent expert perspective:\n\u201c\u2026doctors are testing other drug combinations to treat pancreatic cancer. She\u2019s hopeful that these combinations will work as well or better than Folfirinox, with fewer serious side effects. Folfirinox \u201cis going to be one of a host of options\u201d for patients, Azad says \u201d\nThere was no independent perspective in this story and no such comparison with other approaches being researched for pancreatic cancer.", "answer": 0}, {"article": "If you're loading up on vitamin C and zinc to stave off the sniffles, you should try an earlier bedtime instead.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nPeople who regularly sleep six hours or less each night are four times more likely to get a cold than people who sleep just an hour longer, a new study finds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any meaningful discussion of possible alternatives to reducing colds such as frequent hand-washing. As noted above, the benefit of more sleep = less colds comes at a cost of having less awake time to do things. Some people might be better off having more colds! That makes alternatives potentially important.", "answer": 0}, {"article": "The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\nThey also found the drug to be safe and well tolerated.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Surgery is the only other therapy mentioned in this news release.\nIt does not mention two other common treatments: needling and enzyme injections (physical and chemical attempts to break up contractures, respectively).", "answer": 0}, {"article": "But for others, doctors may prescribe a more invasive treatment that involves injecting hyaluronic acid in to the knee, called viscosupplementation.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\nIn a meta-analysis of 177 reports that included data on more than 12,000 patients with osteoarthritis in the knee, researchers at the Institute of Social and Preventive Medicine at the University of Bern in Switzerland concluded that the treatment \"has minimal benefits and potential for harm.\"\nNow, a new report questions the efficacy of this treatment for osteoarthritis in the knee.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison of data were provided.", "answer": 0}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\nIt tested that drug for numerous uses, including herniated disks.\nWith its belated success, BioSpecifics has sold off its ointment business.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares costs and outcomes for Xiaflex with open surgery and needle aponeurotomy.", "answer": 1}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\nBut the fact is that many men \u2014 and women \u2014 simply do not accept baldness easily.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\napproval process.\u201d\n\nFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses a number of alternatives, and even provides price information for some. It says, for example, \u201cFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\u201d We do wish, though, that some comparative effectiveness information had been given.", "answer": 1}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\n\u201cSo the other eye needs to have good distance vision without glasses,\u201d Hamilton says, adding that sometimes people have laser surgery to improve the distance vision in the eye that won\u2019t be getting an implant to improve vision close-up.\n\u201cThere\u2019s a healing process after the inlay is put in that requires eye drops be put in on a daily basis for around three months,\" says Hamilton.\nThe most recent to receive approval, the \u201cRaindrop\u201d, is made mostly from water and works by reshaping the cornea helping the eye to focus better on close-up objects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We weren\u2019t satisfied with the story weighing the risks vs. benefits of these two surgical implants, Raindrop and KAMRA. The story did not compare the two of them to give people any idea of how they differ. Many patients who are candidates for vision correction for near vision may use glasses to correct it. The implant surgery carries risks, which include worsening vision, according to an FDA announcement\u00a0on the Raindrop device.", "answer": 0}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\nOne of the biggest proponents of this approach is John Featherstone, dean of the University of California, San Francisco School of Dentistry.\nWhen Featherstone put his patients on personal treatment plans, he found the strategy worked.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not quantify the benefits of these new preventive treatments, or similar approaches, so it fails to give readers a useful comparison with standard dental care or advice for most adults\u2013such as\u00a0fluoride toothpastes, community water fluoridation, flossing, and mouthwashes.", "answer": 0}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\n\"We worked closely with Moy Park, Waitrose and the Royal College of Surgeons in Ireland, to deliver an innovative, nutrient-rich food, that increases omega-3 levels in consumers, naturally.\n\"This science has demonstrated the importance of food nutrients to promote good health and prevent ill health.\nWe are also focusing our research efforts on producing sustainable and nutrient rich pork, beef and milk, with scientifically proven health claims.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019ll give this category a Satisfactory since the alternative to this new, supposedly enhanced feed is regular chicken feed now on the market.\u00a0 The story also mentions that the primary source of omega-3 fatty acids is oily fish and/or dietary supplements.", "answer": 1}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression.\nA new trial that makes use of the drug in pill form is slated to get under way next year, Moskal noted.\nBecause the drug targets these areas of the brain it might also help people with other problems such as schizophrenia, bipolar disorder, anxiety and Alzheimer's disease, the researchers suggested.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the most popular drugs on the market, which include Prozac, Paxil, Zoloft and Lexapro. The lead researcher is also quoted in saying that all current medications take longer to start working and to take full effect for most people.\u00a0 Satisfactory \u2013 but just barely \u2013 since it didn\u2019t mention other major treatment options (therapy, exercise, self-help).", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThey used maternity, medical billing and demographic data to investigate the odds of small-for-gestational age birth, pre-term birth and low birth weight for low-income women receiving care from a midwife, GP, or OB.\n\"But more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\"\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release met our threshold here by saying midwives, general practitioners, and obstetricians \u201care all qualified to provide safe prenatal care for women during their pregnancy, labour and birth, but each offer a different style of care that matches different women\u2019s preferences and needs.\u201d", "answer": 1}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\n\"Individualized acupuncture is a safe and good therapeutic option for the treatment of patients with fibromyalgia,\" said lead researcher Dr. Jorge Vas, of the pain treatment unit at Dona Mercedes Primary Health Center in Seville, Spain.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Acupuncture is considered to be an alternative, or complement, to traditional western medicine. The story mentions that most fibromyalgia patients take medications for pain, depression,\u00a0and other symptoms, and that they may also receive other alternative therapies, such as massage.", "answer": 1}, {"article": "Her back hurts, and surgeons have replaced her left knee once and her right hip twice.\nWrist replacement is much more complicated than hip and knee replacement.\nPotential patients must be evaluated for other causes of pain, Collins noted, because problems with thumbs or other hand parts can make the wrist hurt.\nOccasionally, other conditions must be addressed in addition to joint damage.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article outlines some alternatives to wrist replacement surgery (e.g. medications, physical therapy, and fusion)\u2014and briefly sketches their advantages and disadvantages. There are other surgical treatments for wrist arthritis as well, though the evidence to support them is also sparse.", "answer": 1}, {"article": "The study appeared online May 13 in The Annals of Rheumatic Diseases.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\nThe authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe story does not mention whether other factors (e.g. behavioral, environmental, genetic) might also reduce the risk of RA. For example, one of the purposes of the Swedish study was to see whether oral contraceptives\u2014containing hormones that rise during pregnancy\u2014protect women against rheumatoid arthritis. The study concluded that they do not.\n", "answer": 0}, {"article": "For more information, visit www.idri.org.\nBased on data generated in preclinical studies, the vaccine candidate, called LepVax, has progressed to Phase I clinical testing in the United States, the first stage of safety testing in human volunteers.\nA viable vaccine to prevent and/or treat leprosy is the next step in the effort to bring this disease to an end.\nScientists at IDRI, along with national and international collaborators including the National Hansen's Disease Program and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with financial support from American Leprosy Missions, have developed a promising leprosy vaccine candidate designed to help treat leprosy and prevent exposed individuals from developing disease and the resulting disabilities.\nWith recent developments in vaccine technology, IDRI scientists can now induce protective responses even after infection, meaning it could be possible to prevent disease development in people already infected with the leprosy bacterium.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that there are no other leprosy vaccine candidates, despite the fact that multiple countries (including India and Brazil) already use a leprosy vaccine (though the effectiveness of that vaccine is widely debated). The release would have been stronger if it had noted this vaccine and articulated how LepVax aims to improve on it.\nThe release notes that drug therapies do exist for leprosy, though it focuses on the drawbacks associated with treatment rather than the extent to which the treatment is effective. The release also refers to \u201cprevious attempts\u201d \u2014 presumably at developing a vaccine \u2014 \u201cthat have used vaccines primarily developed for other diseases.\u201d But it doesn\u2019t discuss how effective these \u201cprevious attempts\u201d have been. For example, a 1996 paper in The Lancet reported that a modified vaccination regime involving the so-called BCG vaccine, which is also used to vaccinate against tuberculosis, gave at least 50 percent protection against leprosy.\nPresumably the goal of LepVax is to improve the efficacy of leprosy vaccination, but the release would have been stronger if it had addressed this and provided the relevant context. Again, the idea that it increased humoral and cellular responses to those already exposed requires further explanation (this was noted in the description on clinical trials.gov).", "answer": 0}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nThe headaches almost never came with nausea, and I had medications that typically ousted them within an hour or two.\nSo for those of us who get numerous migraines each month, the prospect of a new approach feels almost life-changing.\nI alternated among four different, neurologist-recommended supplements, all to no avail.\nI experimented with an elimination diet that left me eating nothing but broccoli and white rice, but still the migraines came.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gives plenty of details:\nA number of people prescribed medications for depression, high blood pressure and epilepsy discovered migraine relief, too. Now, many of those drugs, including propranolol and topiramate, have been tested and approved for migraine. But no one drug works for everyone, and side effects can prove intolerable or downright unpleasant.\nThe writer also describes her own quest for relief:\nSince that day more than 17 years ago, I have tried six preventive prescription medications. Not one helped. I alternated among four different, neurologist-recommended supplements, all to no avail. I received bi-monthly injections of magnesium and participated in one of the first clinical trials of Botox. And while Botox seemed to decrease my migraines by one or two per month, it wasn\u2019t enough to bother fighting about it with a new insurance company. I exercised regularly. I experimented with an elimination diet that left me eating nothing but broccoli and white rice, but still the migraines came. I averaged about 15 to 20 each month.", "answer": 1}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nIt\u2019s too soon to tell if resistant starch can help people weight.\nEven if you heat them up again, they retain their new resistant starches.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions different types of carbs and lists a variety of foods that contain resistant starches.", "answer": 1}, {"article": "\u201cI would be with Ava during the day, and then when Jay got home, he would stay with Ava, and I would spend time with Audrey,\u201d she said.\nBut her parents had hope that the transplant would keep her cancer at bay.\nIt seemed an equally promising target that could broaden the therapy\u2019s impact, researchers thought.\nThe doctors assured the family that it was typical leukemia \u2014 and curable.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes a point of noting that, at present, CAR T-cell therapy is used only when all other courses of action \u2014 chemotherapy, bone marrow transplants, etc. \u2014 have failed.", "answer": 1}, {"article": "African-American women are more likely than white women to report hot flashes.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nAn antidepressant can help alleviate hot flashes that plague many menopausal women, according to new federally funded research.\nSince then, many women have been suffering through hot flashes and searching for effective alternatives.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions hormone replacement, it gives readers the impression that this approach is no longer used for the treatment of hot flashes because the risks outweigh the benefits. In fact,\u00a0women with more bothersome menopausal symptoms may still use\u00a0hormones for short-term relief, concluding that the benefits for them individually still outweigh the risks. This story should have spent some more time putting the benefits and risks of antidepressants in context with those of hormone replacement. Also, many women try complementary and alternative medicine treatments.", "answer": 0}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece discusses several interventions, and offers a graphic representation of recovery rates for individuals in Great Britain across five therapeutic modalities. But, there is no mention of psychiatric medications. Since those are frequently helpful in short-term situations and at least for moderate depression, they should have been included in the comparisons.", "answer": 0}, {"article": "It matters.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nThat finding opened the door to potential targeted, molecular therapies for melanoma, which has been sorely lacking in effective treatments.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\nThe average survival time for someone diagnosed with melanoma is nine to 11 months, added Chapman, who is an attending physician in the Melanoma Sarcoma Service at Memorial Sloan-Kettering Cancer Center in New York City.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that only about 15% of patients respond to the standard treatments for\u00a0metastatic melanoma\u00a0\u2014 chemotherapy and interleukin-2. But it veers into questionable\u00a0territory when it allows an expert to claim\u00a0that \"the best defense against melanoma is to get your skin examined regularly by a professional who knows what to look for.\"\u00a0In fact, recent guidelines from the U.S. Preventive Services Task Force conclude that there is insufficient evidence to tell if regular screening helps prevent deaths from skin cancer. A thorough discussion of this issue would have included an opposing\u00a0comment about the uncertainty of the\u00a0evidence. \u00a0", "answer": 0}, {"article": "For at least 2,000 years Chinese healers have used acupuncture to treat pain and other ailments.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nBut that result has been called into question because the patients in the sham group probably figured out they were not getting the real thing.\nThere is little dispute that people feel better after receiving the treatment, in which thin needles are inserted deeply into the skin at specific points on the body.\nBut in this study, the patients in the \u201creal\u201d acupuncture group all received needles inserted in the same way.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "      \n\n\n \n\n \nThe article mentions several alternative treatments for the three conditions discussed in the article\u2014and, in the online version at least, the study links can lead readers to further information.\n\u00a0\n ", "answer": 1}, {"article": "Delyth Morgan, chief executive at Breast Cancer Now, which funded the research, said: \u201cThis is a really crucial discovery.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Some discussion of other avenues of research into hormone therapy resistance would have been helpful, especially other therapies that are further along in human clinical trials.", "answer": 0}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nIndividuals in the strategy-based reasoning training showed a greater change in cortical thickness and connectivity compared to individuals who received the knowledge-based training.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares strategy-based training against knowledge-based training. But the release neglected to mention other approaches to treating TBI. Since the focus here is on cognitive impairments, the release might have mentioned some common treatments such cognitive behavior therapy and occupational therapy.", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\nThe test may be particularly valuable for families that harbor sex-linked genetic disorders like hemophilia, they add.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story explains the existing alternatives \u2013 ultrasound and more invasive sampling methods. But it doesn\u2019t do as good a job as the competing NY Times story in describing other types of tests (urine tests) that have been developed.", "answer": 0}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nCT is the preferred noninvasive technology for assessing the condition of heart arteries, whether there is narrowing that might end with the total blockage that causes a heart attack, Schoepf said.\nThat difference helps explain why there are so few studies doing head-to-head comparison of CT versus MRI, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that CT and MRI are each used for different reasons, but it implies\u00a0erroneously\u00a0that either is an all-around alternative to catheterization, and thus the \"best\" way to detect coronary artery disease.", "answer": 0}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nTan\u2019s team studied 1,575 people with an average age of 67 who were free of dementia.\nFotuhi recommends his patients get 1,000 mg per day of DHA, a nutrient that increases blood flow in the brain, reduces inflammation in the brain, heart and elsewhere, and reduces the toxic aggregation of amyloid in the brain.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternative sources of omega-3 fatty acids and recommends the MyPlate government dietary guide. Other alternatives for dementia prevention such as exercise and mental stimulation could have been mentioned as well.\n\u00a0", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\nThey found 5,930 cases of Type 2 diabetes.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, you can turn to the comments left after the story online to see what readers would have liked to have seen.\u00a0 Excerpts of the comments:", "answer": 0}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nHowever, the study found the tablet triggered an increase in the hormone Aldosterone, which helps regulate both blood pressure and bodily fluids.\nThe study, presented by Australian heart researcher Philip Barter, who oversaw Pfizer's torcetrapib clinical trials, concluded torcetrapib caused \"off-target\" effects, including deaths, elevated blood pressure, cardiovascular problems and a possible link to cancers.\nPfizer suspended development of the tablet, its most important experimental drug, after it caused an increase in deaths and heart problems in clinical trial volunteers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention other, established ways to raise HDL, such as exercise, statins, moderate alcohol consumption, etc., even though\u00a0these have modest effects on HDL.", "answer": 0}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nIn a pilot study, the drug appeared to reduce symptoms of rheumatoid arthritis.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nThe Weinblatt study and an editorial by NIH researchers Juan Rivera, PhD, and Robert A. Colbert, MD, PhD, appear in the Sept. 30 issue of the New England Journal of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story drops readers into this supposed battle between this new drug and methotrexate, but it does not explain why these two drugs are being compared. Nor does it explain, as HealthDay does, that this drug is part of a new class of drugs in various stages of development.", "answer": 0}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\nEighty-seven volunteers aged 16 to 34 with Down syndrome were enrolled in the phase 2, randomized, controlled trial.\n\"This new research adds to the growing body of evidence that suggests compounds in green tea, such as EGCG, may support cognitive health.\"\nFORT LAUDERDALE, Fla., July 26, 2016 /PRNewswire/ -- New research published in Lancet Neurology and reported by CNN has found using a green tea extract (decaffeinated) in combination with cognitive training improves some measures of cognition and behavior in subjects with Down syndrome.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Researchers point out in their journal article that there is no approved intervention to improve cognitive deficits in individuals with Down\u2019s syndrome. General treatment approaches include early intervention and educational, physical, speech-language, occupational and emotional/behavioral therapies, according to the National Institutes of Health. Regarding drugs and supplements, the agency adds, \u201cNo controlled clinical studies of these medications for Down syndrome have demonstrated their safety and efficacy, however.\u201d\nBut the release contains none of this context and makes no mention of potential treatment alternatives, which is why we rate it Not Satisfactory here.", "answer": 0}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nAhlquist noted that the test still needs to be refined.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nDr. Floriano Marchetti, an assistant professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the new test could be an important adjunct to colon cancer screening if it proves itself in further study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare the new approach with other similar approaches now in development, and did not give adequate data-driven comparisons with other screening methods that are now used.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news story neglected to mention other safe methods of controlling weight in postmenopausal women. These include calorie-watching and exercise.", "answer": 0}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addresses the current standard of care for low-risk prostate cancers, active surveillance, along with treatments for more aggressive disease. But as noted above, we don\u2019t think the description of active surveillance is accurate, the description of radical therapy is excessively gloomy, and the story doesn\u2019t warn that people treated with VTP will likely need to follow the same protocol involved with active surveillance. For these reasons we think the comparison is Not Satisfactory.", "answer": 0}, {"article": "CT (computed tomography), sometimes called CAT (computed axial tomography), is performed by computerized machines that scan patients with X-rays to create three-dimensional cross-sectional images of organs and other parts of the body, providing far greater detail than standard single X-rays.\nA child's risk may run as high as one case of cancer for every 500 scans, experts say.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger.\nThe concern comes from the fact that CT scans expose patients to much more radiation than standard X-rays.\nSome say part of the blame lies with physicians who have financial interests in imaging facilities.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other kinds of tests, such as blood tests, MRIs or\u00a0ultrasound.", "answer": 1}, {"article": "\"We can get that whole process of what a meal does without actually having the meal,\" he said.\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nThe study also found other benefits.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention surgical treatment of morbid obesity, but it prematurely suggests that the drug would be superior, despite an absence of evidence. A more suitable comparison may have been other medications for obesity and their mechanism of action.", "answer": 0}, {"article": "Why?\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n\u201cEven in a country with universal health insurance coverage (such as Canada), disparities in resources, expertise, or the number of healthcare providers working during weekends\u201d may affect the stroke mortality rate, the researchers concluded.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As with the HealthDay report, this criterion is not applicable for this story.", "answer": 2}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nDon't start popping lutein in supplement form based on these results, he noted.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nTUESDAY, Nov. 15, 2011 (HealthDay News) -- An apple a day won't necessarily keep the doctor away, but three kiwis just might help, at least according to a small study that showed that the brown, fuzzy fruit may lower blood pressure levels.\nDr. Elliott M. Antman, a professor of medicine at Harvard Medical School in Boston, said that while promising, the new study is small.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story the benefit of the doubt because it at least mentioned the DASH diet, which is the main dietary intervention recommended in primary care for prehypertension and mild hypertension. The DASH diet is only a little more efficacious than the reported kiwi intervention. (for nonhypertensive patients, the DASH diet lowers the systolic BP 7.1 mm Hg).", "answer": 1}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nBut there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nThis study was presented at a medical conference.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no meaningful comparison with other approaches. \nOne last time, let\u2019s look at how the competing Wall Street Journal story tried to give such context:\u00a0\n\"When you have drugs that act in different ways and each is giving some measurable benefit, that is significant progress in a field where new agents have come along very rarely in the past,\" says Steve K. Clinton, director of prostate and genitourinary oncology at Ohio State University\u2019s James Cancer Hospital and Research Institute, Columbus. Dr. Clinton wasn\u2019t involved in the current study and doesn\u2019t have consulting relationships with the companies.\u00a0\nThat\u2019s an example of the kind of context \u2013 the kind of comparison \u2013 we look for in such stories. ", "answer": 0}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nUsing this technology is still seen as a stopgap, however, while a biological solution to diabetes is sought.\nAll patients felt self-conscious wearing the device, Ritholz noted.\nRitholz's team found that people who were better at coping with the frustration of using the device were more successful at keeping their blood sugar under control.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The artificial pancreas approach isn\u2019t compared to any other alternatives, if only because the article never identifies the comparator group as those using the insulin pump.", "answer": 0}, {"article": "\"We're extraordinarily encouraged by what we see with this data,\" says Mitchel Berger, chairman of neurosurgery at the University of California, San Francisco and director of its center for brain tumors.\nThe treatment can cause a dangerous swelling in the brain that can lead to seizures and other complications, the researchers found.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nThe Duke researchers have started a follow-up study combining the treatment with a chemotherapy drug to try to improve the results.\nThe experimental treatment seems to have extended survival in a small group of patients with glioblastoma who faced a grim prognosis because standard treatments had failed, Duke University researchers say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned standard treatment without getting specifics, and also mentioned plans to combine this treatment with chemotherapy and other drugs. It could have also mentioned other studies that are attempting to find a cure for glioblastoma.", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nIn patients with atrial fibrillation, the risk of stroke is usually measured using the so-called CHADS score, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions\u00a0use of aspirin and\u00a0notes that \u201caspirin\u2019s benefit in cutting the risk of dementia is limited.\u201d\nHowever, aspirin is not really recommended as an alternative to blood thinners (guidelines don\u2019t recommend this anymore, so we were\u00a0surprised to see it mentioned). But beyond this, there aren\u2019t any real alternatives.", "answer": 1}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\nThe study \"shows that the gastric bypass procedure compared to sleeve gastrectomy or adjustable gastric banding produces more weight loss and it was sustained over the long term,\" Gould said.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nCompared to the non-surgical group, the bypass group weighed 21 percent less than at the start of the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is another strong point of the story. The study compared the longer term weight-loss outcomes of the three primary bariatric surgical procedures.", "answer": 1}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nColonoscopy, used in millions of Americans every year, is just one of many methods to detect abnormalities.\nAllen, of Minnesota Gastroenterology PA, said this risk factor might be taken into consideration when deciding when to screen, but that so far more studies were needed before recommending colonoscopy at younger ages.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story very briefly mentions one alternative to colonoscopy, the stool test for blood. While this is the most widely-available alternative, there are other alternatives, including CT Colography, sigmoidoscopy, barium enema, and the choice to not have screening at all.", "answer": 1}, {"article": "March 16, 2010 -- An experimental type of highly focused radiation therapy may control inoperable lung cancer tumors and help people with the deadly disease live longer.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nResearchers say that rate of tumor control is more than double that found with conventional radiation treatment for inoperable lung cancer.\nA new study shows stereotactic body radiation therapy (SBRT) effectively controlled more than 87% of early-stage inoperable non-small-cell lung cancer tumors for up to three years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes surgery and conventional radiation as possible alternatives to SBRT.", "answer": 1}, {"article": "Researchers have two main theories on why light therapy works.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nLight therapy is cheap, easy to use and comes with few side effects compared to medication such as antidepressants, said lead author Raymond Lam, a professor of psychiatry at the University of British Columbia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even in a short word count, this story did convey that there are alternatives, including antidepressants and psychotherapy.", "answer": 1}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\nHe added, however, that the studies confirm the potential of cancer vaccines.\n\u201cIt is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies.\nTwo personalized cancer vaccines have been found to be safe and effective at treating people with melanoma, scientists have announced.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0\nThe story doesn\u2019t mention any other treatment options for melanoma by name but states that additional research is needed to determine the effectiveness of these vaccines in comparison to existing options.\nThe story could have been improved by including information about the prevalence of cancer recurrence among cancer patients using existing treatment options such as surgery and chemotherapy.\nOne of the trials described was conducted in people who had had surgery and no other treatment options. It would have been helpful to include the length of time to tumor recurrence in people who had not received any other interventions.", "answer": 0}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nDrew Pardoll, director of Hopkins\u2019 Bloomberg-Kimmel Institute for Cancer Immunotherapy, said that it is too early to know whether the findings will translate into longer survival.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that most patients diagnosed with advanced lung cancer \u201cinitially receive chemotherapy, which provides only marginal benefit\u201d and \u201cresearchers are trying to develop and use more effective approaches earlier.\u201d", "answer": 1}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nAmong a number of cautions the researchers point to in this work is that physical activity is related to other behaviors and lifestyle factors, and women who are more physically active may be different from women who are less active in many ways.\nWhitcomb says, \"We don't know what to make of the finding that high intensity physical activity may have different biological effects than walking, but our study doesn't offer enough detail to get at why vigorous activity would work differently than other levels.\"\nThe researchers also note that the overall generalizability of this work is limited because the study population may not be representative of the general population with regard to fecundability, and exercise habits may differ in women with prior miscarriage compared to those without.\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "What other types of physical activity were measured? Many women might be left wondering if other forms of exercise are just as good as walking. It might have helped to clarify this (and if the study did not address this, then make that clear to readers). It would also help readers to note what the \u201cdose\u201d of exercise was that was associated with a positive effect on fertility.\nThere is a statement included from the lead author that could confuse people:\nOne of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses [except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight and obese.\nThat\u2019s a lot of caveats! And many women \u2014 overweight or not, with previous miscarriages or not \u2014 might be left wondering if their form of exercise helps or hinders their chances at conception.", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to compare pain relief from the standard drug treatment with that of high-flow oxygen. The study itself failed to do this, but a diligent reporter would have dug to find outcomes data on the drug treatment. ", "answer": 0}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\nTom Judd, who lives near Portland, Oregon, knows what it is like to be diagnosed with a deadly cancer for which there is no approved drug.\nHe is a leading expert on MCC and a pioneer of immunotherapy for the disease.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mentions of, or comparisons to, other therapies.\nStandard therapies include surgery, radiation and chemotherapy.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nThree months ago, he noticed his vision was distorted.\nShe's had two doses of Lucentis.\nIt's not a cure, but it's a blessing for Rochelle Faller.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any of the existing treatments, such as Avastin or laser therapy, although it does list preventive strategies, such as smoking cessation and treatment of hypertension. ", "answer": 0}, {"article": "We share our bodies with trillions of microbes that live on our skin, in our noses, in the gut.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\nWednesday\u2019s research sheds new light on the skin\u2019s microbiome \u2014 suggesting that one day it may be possible to restore the right balance of good bugs to treat skin disorders, too.\nHis team tested five volunteers with atopic dermatitis who had Staph aureus growing on their skin\u2019s surface \u2014 what\u2019s called colonization \u2014 but didn\u2019t have an infection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gives a tiny mention to the alternative for skin infections\u2013antibiotics. This is a barely passing satisfactory:\n\u201cIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\u201d", "answer": 1}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nOn each visit, the participants ate a weight-maintaining diet for five days.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story does not compare alternatives. It does state that this new therapy of brain stimulation would be combined with existing known treatments for obesity, such as exercise. The first line of the release states \u201c\u2026 when combined with diet and exercise.\u201d This was a lost opportunity later in the story to discuss intensive behavior changes interventions and surgical treatment for severe obesity with known efficacy.", "answer": 0}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nEating bitter melon could also have a beneficial effect, Ray said.\nFor the study, Ray's team treated human breast cancer cells with bitter melon extract, which is sold in U.S. health food stores and over the Internet.\nMarji McCullough, strategic director of nutritional epidemiology at the American Cancer Society, expressed interest in the findings.\n\"But before recommending bitter melon extract supplements for cancer prevention, we need appropriate clinical trials to establish its safety and efficacy in humans.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included the American Cancer Society expert\u2019s recommendations for breast cancer prevention. ", "answer": 1}, {"article": "Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\nThe study supports CCTA use for an initial, noninvasive evaluation of patients with known or suspected stable coronary artery disease.\nDr. Kaufmann said that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularization procedure such as bypass or angioplasty.\nThe results show that cardiac hybrid imaging is an excellent long-term predictor of adverse cardiac events in patients evaluated for coronary artery disease.\nThe shear stress information could help identify lesions that do not yet have an impact on ischemia but will in the future.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release is clear that the study is testing an alternative to the standard approach for evaluating cardiovasular\u00a0risk in patients with suspected coronary artery disease.", "answer": 1}, {"article": "In contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\nSignificant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\nStudy participants were tested for hearing, a variety of cognitive functions, levels of important hormones and height and weight at the outset of the study and at several follow-up visits for up to eight years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does make multiple comparisons to studies of other therapies. We do not feel that this was framed properly in the release, but we address this in the quality of evidence section.", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nBefore you start popping elderberries, beware: eating them raw can make you sick.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll rate the story satisfactory here since it does mention two approved antiviral drugs. However, it doesn\u2019t include any references to proven methods of reducing the risk of catching or spreading a virus, such as frequent and thorough hand washing, eating a healthy diet, getting enough sleep, and staying home when sick. An extra sentence would have been sufficient to provide this important context.", "answer": 1}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nAlso, at two years after surgery, data were available for less than half the patients.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nFinally, surgery isn't without risk.\nA year after surgery more than 80 percent of patients were no longer taking any of the diabetes medicines they had been on before the operations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThere is no information about alternative approaches. Even in a brief blog post, just a line about alternatives would satisfy this criterion. ", "answer": 0}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nThe other half of the patients got standard treatment, which didn\u2019t include the procedure.\nRemoving the clot wasn\u2019t better than standard care in either group \u2014 those with a lot or a little brain tissue to lose.\nThe results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians.\nThe three studies reported this week (which will eventually be published in the New England Journal of Medicine) tested the hypothesis in a rigorous way.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was based on the studies\u2019 comparison of alternative approaches.", "answer": 1}, {"article": "''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nO'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.\nThis may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\nIn the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer shouldn't panic.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternative treatments are not mentioned but the piece explains that metastatic triple-negative breast cancer is very difficult to treat & that many currently available treatments are not effective.", "answer": 1}, {"article": "\"There are a number of components that lead to a man having normal fertility potential,\" Brannigan said.\nAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one.\nThere are several characteristics of sperm alone \u2014 at least three that aren't addressed by SpermCheck \u2014 that affect male fertility.\nScott said she wished the test had been available when the couple was struggling to conceive their first child.\nThe male reproductive system should not be oversimplified, Brannigan said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provides a lengthy list of fertility problems that are not addressed by this home test, but, presumably, would be addressed in a fertility clinic.", "answer": 1}, {"article": "Still, the extent of the benefit was not clear.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nLaaksi said that larger clinical trials looking at different doses of vitamin D are still needed before the vitamin can be recommended for curbing the risk of respiratory infections.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\nSome past research has indeed found that people with relatively lower vitamin D levels in their blood tend to have higher rates of respiratory infections than those with higher levels of the vitamin, said Dr. Ilkka Laaksi of the University of Tampere in Finland, the lead researcher on the new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that experts generally recommend supplements only when people aren\u2019t getting enough vitamin D from their diet or sunlight. And as noted above, the story points out that supplements expose people to some risks of vitamin D toxicity.", "answer": 1}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nHowever, not every surgeon is embracing the same-day trend.\nDavidovitch makes it clear that this kind of surgery is not one-size-fits-all.\nThe surgery is meant to restore range of motion and help relieve arthritic pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted above, the story exaggerates the differences between hip replacements billed as \u201csame-day\u201d and those that give patients more conservative timelines.", "answer": 0}, {"article": "Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\nThe patients received 10 such injections during a single catheterization procedure.\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story puts this approach into the context of attempts to help people who have angina despite available treatments.", "answer": 1}, {"article": "\u201cI am aware of the fact that given our level of ignorance, everything seems simple and straightforward,\u201d he says.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\nWhat\u2019s more, they also surmised that only a specialized set of beta cells were equipped to make insulin, and that once diabetes set in, too few of these cells remained to pump out the critical hormone.\nAnd while insulin injections are an effective way to break down the glucose, keeping track of blood sugar levels with regular finger pricks and repeated insulin shots aren\u2019t an ideal way to treat a chronic disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a number of oral medications that can help make up for lagging insulin production, either by stimulating beta cells to produce more insulin or\u00a0making tissues more sensitive to\u00a0the insulin that is being produced. The story didn\u2019t mention any of these.", "answer": 0}, {"article": "\"Take some individual responsibility to stay healthy during the flu season,\" said Health and Human Services Secretary Kathleen Sebelius, who scheduled her own seasonal shot for Friday.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nBut different manufacturers make different formulations of the vaccine, so more evidence was needed.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nThe winter flu vaccine is widely available now, and U.S. health authorities urged people to get it out of the way now before swine flu shots start arriving in mid-October.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe focus of this story is on the effectiveness of different immunization schedules and doses. However, as part of the background information, it could have noted that even after receiving a flu shot, public health officials are urging people to minimize close contact with other people, use good hygiene, and stay home when sick in order to reduce the likelihood of spreading or catching flu viruses.", "answer": 0}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because there likely are no alternatives to a statin that would be recommended, we\u2019ll rate this N/A.", "answer": 2}, {"article": "Lobular breast cancer forms in the milk glands.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nIn the study, 880 women developed breast cancer during six years of follow-up.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At the very least, the story included the fact that \"Other supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John\u2019s wort, which are often taken to relieve some of the symptoms of menopause.\" ", "answer": 1}, {"article": "\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nThe study was funded by the U.S. National Institute on Drug Abuse and the U.S. National Institute on Alcohol Abuse and Alcoholism.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no reference to alternatives other than comments from one source that \u201cthat new ways of treating alcoholism are much needed.\u201d It could have told readers about naltrexone, acamprosate, or disulfiram, which are already approved by the FDA for the treatment of alcohol dependence (alcoholism). There is no mention of the role of behavioral and psychiatric treatments as alternative or adjunctive care for alcoholics.", "answer": 0}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nThe researchers found that women eating dried apples lowered their total cholesterol by 14 percent.\nThe researchers theorized that the nutrients in apples may reduce inflammation in the body.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No, apples weren\u2019t compared with anything else \u2013 dietary, other lifestyle options, or drugs \u2013 to lower cholesterol levels.\u00a0 So even if readers could grasp the scope of the relative risk reduction figures given, they weren\u2019t put into the context of what else is done to lower cholesterol levels.\u00a0 Bigger impact?\u00a0 Smaller?\u00a0 Same?", "answer": 0}, {"article": "6 Kowdley KV, et al.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release offers a comparison with the current standard of care: \u201cWhile direct-acting antivirals have been used to treat and cure adult patients with HCV,4-7 until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.\u201d", "answer": 1}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe tool, called an endovascular stent retrieval device, is made up of wire mesh that resembles a tiny ring of chicken wire, Powers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to endovascular clot retrieval is no procedure, and is made clear in the article.", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\n\"HCA may be preferred as a therapy over CA (potassium citrate).\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release provides a brief summary of common advice for kidney stone prevention, including drinking lots of water, avoiding certain foods, and often recommending citrate. The release does not discuss medical treatments for serious kidney stones, but then hydroxycitrate is being proposed only as an additional preventive treatment.", "answer": 1}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\nAs well, at least when used as single agents, these agents tend to confer side effects that patients find much more tolerable than those associated with chemotherapy.\nOf those who completed therapy, two patients had a partial response for an overall response rate of 9.1 percent, and there was a stable disease rate of 54.5 percent.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not mention or compare any of the alternatives. According to Cancer.Net, approved treatments (depending on the type and stage of the thyroid cancer) include surgery, hormone treatment, radioactive iodine, external-beam radiation, chemotherapy and other therapies that target the immune system.", "answer": 0}, {"article": "A Buck Institute press release on the study stated: \"None of the patients were able to stick to the entire protocol.\nBredesen said that to simplify the program, they are connecting patients with health coaches.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nBredesen noted, too, that the MEND protocol was suitable for patients in the early stages of Alzheimer's.\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention alternatives. But many interventions, including drugs, have been tried to reverse memory loss and none have been found to work, so we\u2019ll rate this as N/A.", "answer": 2}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Barely satisfactory, as the story at least nodded in the direction of other HDL-boosting drugs.", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\nThere\u2019s good research into how AA works, but it\u2019d be good to figure out if SMART, LifeRing, and Women for Sobriety work in a similar way.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u2019s main focus is to compare popular 12-step programs with their alternatives. And it explains why alternatives are necessary, since many people object to the spiritual component of AA. It would have been useful to also include outcomes associated with medication for alcohol use disorder, as well as outcomes when there is no formal treatment.", "answer": 1}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nThe outcome was excellent, but the recovery was long and horrible.\nStill, \u201cit has significant cost savings\u201d compared with surgery, Ferrell says.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is basically touting a possible new therapy as an alternative to traditional rotator cuff surgery, but it does a poor job of comparing them in an evidence-based manner.", "answer": 0}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story indicated that the current laboratory screening test for prostate cancer (PSA) has low specificity and that because it doesn\u2019t distinguish aggressive disease from that which is less aggressive, it leads to unnecessary treatment. \u00a0The story was strongly suggestive that the test reported on had the potential to reduce both of these.\u00a0 But it didn\u2019t offer any data-driven comparison \u2013 limited though that possibility may have been given the early stage of this research.\u00a0 But it also didn\u2019t compare this test with other urine tests trying to do the same thing. ", "answer": 0}, {"article": "\u201cHowever, we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation,\u201d he said.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThe early-stage Phase I trial of GSK\u2019s vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford\u2019s Jenner Institute, said it was \u201cencouraging\u201d that the shot also prompted responses from the immune system.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are several other vaccines under development for prevention of Ebola, which we\u2019ll call good enough for a satisfactory rating. We would have liked to have seen a few more comments about approaches other than vaccines for prevention and treatment. Good hygiene practices are the first line of defense for prevention. Several antiviral drugs are in the pipeline including Z-Mapp for treatment. \u00a0And finally, antibodies extracted from the blood of survivors have been used.", "answer": 1}, {"article": "It is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThere's a growing body of research to suggest that both are probably good for you.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did not mention other ways to decrease cardiovascular mortality risk.", "answer": 0}, {"article": "For someone eating 2,000 calories, that\u2019s about 200 calories, or 20 grams of saturated fat\n\u2022 1/3 of the total fat consumed daily allocated for saturated fat; if consuming 60 grams of fat daily, no more than 20 grams should come from saturated fat.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nEat less saturated fat for better heart health: that\u2019s been the conventional wisdom based on decades of scientific study.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of talking about the complicated recommendations regarding diet, as well as medications, specifically statins.", "answer": 1}, {"article": "\"Anything we can do to get those rates up has the potential to save lives.\nResearchers set out to determine if this phenomenon, called the \"Mozart Effect,\" played a role in the detection rates of precancerous polyps during colonoscopies.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nBetter detection of these so-called adenomatous polyps could save lives, the study authors noted, as survival rates for colorectal cancer are better than 90 percent if the disease is detected early.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Was music the only option for improving detection?\u00a0 Experience of the physician is probably closely related to detection rate, as well as number of procedures done per year. Let\u2019s give Mozart his due, but let\u2019s analyze the evidence on other alternative explanations as well.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the different sports drinks for athletes and water for the rest of us.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on flu.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nIt could offer a new, inexpensive way to eliminate airborne flu viruses in indoor public spaces such as hospitals, doctors' offices, schools, airports and aircraft, said the team from Columbia University Medical Center in New York City.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nTwo flu experts were encouraged by the findings.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does well to quote one independent source who reminds readers that hand-washing, immunization, and antiviral medications remain important in protecting against the flu.", "answer": 1}, {"article": "\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\n\"It actually supports the idea of actionable things women can do before they become pregnant, and right as conception happens.\"\nThe Norwegian researchers do admit that more studies should be done to confirm the link.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t any proven strategies to reduce autism risk, although research suggests a link to maternal smoking, the father\u2019s age at conception (older than 40 = higher risk), and exposure to air pollution and pesticides. The story could have mentioned these, but we won\u2019t ding it for not doing so. The best we can rule it is Not Applicable.", "answer": 2}, {"article": "\u201cThere are a lot of questions.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe authors report that the dead tissue required surgical removal.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned TURP and open surgery to treatment of BPH but failed to provide insight about how effective these might be in a population of men similar to those in the study reported on. \u00a0Without this information, it is not possible to size up how the new procedure compares. Additionally, the story downplayed the extensive experience with laser prostatectomy and microwave thermotherapy\u2013effective alternatives to TURP (and thermotherapy is also an outpatient procedure).", "answer": 0}, {"article": "Jean-Charles Sanchez says.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\nAs their case is not a priority, it often takes a long time for the majority of patients to return home without risk of sequelae, except for bad memories.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release stated that the \u201conly reliable diagnosis is the CT Scan, which is only available in some hospitals and, in addition to being expensive, exposes patients to radiations.\u201d\nThis is misleading. In fact, diagnosing a concussion is complicated. Patients are usually assessed by a doctor using the Glasgow Coma Scale\u2014a series of physical tests for determining the level of consciousness. A CT scan can also be used in order to detect severe brain injury such as bleeding and swelling. However, patients suspected of having a concussion don\u2019t always show signs of brain damage when scanned.", "answer": 0}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nIt is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\nShe said the benefits of the online therapy include easy access to the treatment and flexibility in times for completing the sessions, which \"is really helpful for those juggling work and family demands.\"\nChronic insomnia is a strong risk factor for post-traumatic stress disorder, depression and substance abuse, absenteeism and occupational accidents, Taylor said.\nHe noted that that cognitive behavioral therapy is \"a multifaceted intervention that can be difficult to administer without the benefit of a therapist.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release describes how two types of CBTi (online and in-person) compared. It mentions medications are used as a therapy for about 10 percent of the deployed military but that they can leave people groggy and with slow cognitive processing and reaction times \u2014 which are dangerous in conflict zones.", "answer": 1}, {"article": "Over the last decade, the makers of medical devices have developed techniques that have widened diabetes management options beyond pricking the finger several times a day to test blood glucose levels.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nEven so, Dr. Kowalski said, using separate devices that are not designed to work in concert poses limits to treatment, particularly overnight.\nBased on algorithms like the ones used in the Lancet study, the devices would continually monitor glucose levels, calibrate insulin dosages and then dispense insulin in real time \u2014 automating a delivery task performed by a nurse in the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes currently available technology for glucose monitoring and insulin infusion. It describes the limitations of current approaches for managing insulin, especially during the overnight period. The story is a bit misleading in that it leaves the impression that all type 1 diabetics are currently using pumps at night.\u00a0 This is not actually the case.\u00a0 Most people are doing self monitoring of blood glucose and making judgement calls on whether and how much insulin to administer.\u00a0However, the story does enough for a satisfactory in our view.", "answer": 1}, {"article": "Liver cancer is the second-leading primary cause of cancer-related deaths worldwide.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nThis study tested regorafenib's effectiveness as a second-line therapy on 573 patients previously treated with sorafenib, 194 of whom were given a placebo.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that patients in the study had already been treated with sorafenib, and that sorafenib is the \u201conly other drug with proven clinical benefit\u201d in treating HCC. That\u2019s enough to earn it a satisfactory rating here. However, it would have been stronger if it had mentioned other elements of treatment, such as surgery, chemotherapy and radiation therapy. In addition, hospice or palliative care programs for patients who had run out of treatment options might result in improvement in outcomes.", "answer": 1}, {"article": "Previous recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nOur study challenges previous studies because our results show conclusively that the vaccines show similar protection when both direct and indirect effects are taken into account.\"\nThis study was funded by the Canadian Institutes for Health Research.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since the study looked a two forms of influenza vaccine administration, it obviously addresses the question of comparing alternatives.", "answer": 1}, {"article": "\u201cThe difference is, the length of stay is cut in half,\u201d he said.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nStudies have disagreed on whether the outcomes of these surgeries are better when using the robotic system versus other minimally invasive techniques.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In the two cases cited, the article at least briefly describes what treatment without the machines would have been like. In each case, it\u2019s open-heart surgery, which carries higher risks in the patients described. \nBut it would have been valuable to know where robot-assisted surgery falls among treatment choices\u2013including non-robot-assisted minimally invasive surgeries and non-surgical options\u2013for someone found with clogged coronary arteries, for instance. \u00a0", "answer": 0}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\nThose found not to carry the gene could be given the drug after having surgery and radiotherapy for their primary tumour in an effort to prevent the cancer from spreading.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t name any alternatives for preventing metastasis in women with breast cancer.\u00a0 It would have been helpful to note in the news release that the drug was given in addition to \u201cstandard\u00a0adjuvant systemic therapy, \u201d according to the journal article, which presumably would include chemotherapy and hormone therapy.", "answer": 0}, {"article": "Heart disease is the leading cause of death among women, yet breast cancer is often the most feared.\nFuture prospective trials are needed to see what the prognostic significance of breast arterial calcification might be.\n\"This information is available on every mammogram, with no additional cost or radiation exposure, and our research suggests breast arterial calcification is as good as the standard risk factor-based estimate for predicting risk,\" Hecht said.\nTo date, there is no consensus on using CAC as a screening test, though a very large outcome study of 39,000 subjects is underway in the Netherlands.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions alternatives, the standard risk assessment tools, as the Framingham Risk Score and the 2013 Cholesterol Guidelines Pooled Cohort Equations. Although it\u2019s questionable, as noted above, if there is an accurate comparison.", "answer": 1}, {"article": "The researchers from Harvard's T.H.\nShe said that recently more evidence has come to light suggesting a relationship between dietary fiber and breast cancer risk, and that eating more fiber would be a simple way to reduce risk.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nIn an accompanying editorial, Duke University Medical Center's Dr. Kimberly Blackwell said there's longstanding evidence that dietary fiber may cut down on circulating estrogen levels through changes in the gut microbiome.\n\"Women are doing themselves a huge favor in terms of breast cancer prevention if they increase the amount of dietary fiber intake earlier in life rather than later.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note that increasing dietary fiber consumption \u201cis just one mechanism by which we can reduce risk,\u201d but it doesn\u2019t mention any of the other mechanisms. Exercise, maintaining a healthy weight, getting sufficient sleep and limiting alcohol consumption can also help reduce breast cancer risk.", "answer": 0}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are three full graphs in a 12 graph story about the standard treatments and off-label treatments. I felt like I knew more about the state of premature ejaculation medicine after reading this story than I did about the actual success of these two trials.", "answer": 1}, {"article": "But when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story walks through the iteration of wearable screens for those with low vision, and it also mentions two competing models aside from the eSight 3. We also get a passing mention of an unnamed \u201csurgical procedure.\u201d\nStargardt disease has no treatment, according to the National Eye Institute, though other \u201clow vision\u201d conditions can be treated with retinal implants, and some are responsive to other types of surgery. However, since there are many diseases or conditions that can lead to low vision and legal blindness, and news stories aren\u2019t supposed to be encyclopedic entries, we\u2019ll mark this one satisfactory.", "answer": 1}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\nHowever, those same anti-hormonal effects can help prevent acne outbreaks in women.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is comparing two alternatives. It would have been helpful to mention that there are other ways of dealing with acne besides just these two methods. There are a number of prudent approaches to treating acne before turning to prescription medications.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\nThe researchers caution that the reliable detection of small to moderate risks and benefits of drug therapies requires cogent data from large-scale randomized trials designed a priori to test the hypothesis.\nIn their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\nThe trial was conducted for 12 weeks on about 8,000 long-term smokers and included equal subgroups of those without as well as with psychiatric disorders.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that patients assigned to Chantix in the EAGLES trial \u201cachieved significantly higher abstinence rates at 12 weeks than those assigned to placebo, nicotine patch or bupropion.\u201d We give the release credit for naming some common alternatives for smoking cessation that were evaluated alongside Chantix in the trial but wish it had defined the comparison more concretely.", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss other interventions that can reduce the risk of colorectal cancer, such as screening either by colonoscopy or fecal occult blood testing.\nThe story does mention regular exercise, not smoking, and limiting alcohol intake, but only to the extent that those are all things that are recommended by the Seventh Day Adventist church. The story would have been better if it had made an explicit link between those behaviors and cancer risk.", "answer": 0}, {"article": "The findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nAn estimated 12 million Americans suffer from food allergies, including about 2.2 million children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states, correctly, that there are no approved treatments for food allergies. ", "answer": 1}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nHe told her bluntly that her pain was caused by arthritis, not the torn cartilage.\nAnd the answer, Dr. Modic reported, is that it did not.\nThat led Dr. Felson and his colleagues to do the first and so far the only large study of knees, asking what is normal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a good job of providing an alternative to routine early imaging tests \u2013 specifically, the old fashioned careful history and physical examination. The story could have focused more on the fact that these are increasingly becoming lost medical arts as imaging tests become more ubiquitous.", "answer": 1}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\nDiscovered by NIH-funded scientists, Proove\u00ae has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions no alternatives to the use of this algorithm. Most doctors already ask patients about their substance use and abuse history and other important lifestyle and environmental factors before prescribing opioids to them. In addition, in March 2016, the CDC issued a \u201cGuideline for Prescribing Opioids for Chronic Pain,\u201d intended to help doctors decide which of their patients truly need opioids and when to use alternative treatments to manage patients\u2019 pain.\nAnother company, Canterbury Healthcare, is marketing a similar genetic test for opioid addiction susceptibility.", "answer": 0}, {"article": "But study author Anna Giuliano believes that, \"vaccinating males would have a direct benefit that men would receive, as well as a community benefit.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\nAmong participants who completed the three-vaccine series, Gardasil afforded 90 percent protection against HPV.\nUptake of the vaccine, which costs about $390 for the 3-shot regimen, has been far from universal among girls.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not explain the existing treatment (or lack of treatment) for HPV infections in young men. Although far from perfect as a preventive, the use of condoms could have been given some space in the story along with limiting the number of sexual partners or abstinence. ", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does state that the current first steps in evaluating a breast lump are mammography & ultrasound.\u00a0 These screening tools are not readily available in developing countries & in some rural areas of the United States.", "answer": 1}, {"article": "\"Aim for an average of three, 8-ounce cups of coffee per day in the morning after eating breakfast.\"\nCoffee was the main, or only source, of caffeine among people in the study.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nThe findings will appear in the Journal of Alzheimer's Disease.\nPeople whose memory loss did not progress all had blood caffeine levels higher than this level, the study shows.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t any proven strategies to reduce Alzheimer\u2019s risk. However, there are a number of lifestyle factors \u2014 exercise, healthy diet, etc.\u2013 that have at least as much evidence to support them as coffee. The story could have mentioned these.", "answer": 0}, {"article": "\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nPeople need to realize that in obesity treatment, just as in hypertension therapy, one drug won\u2019t fit all, Aronne said.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nThe media attention that followed would scare patients off diet pills for years \u2014 a fear that continues today.\nThey won\u2019t make a morbidly obese patient model-thin, but they\u2019ll shave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol, experts say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did mention diet and exercise, but did not mention weight-loss surgery and didn\u2019t explain how weight-loss drugs stack up against other interventions.", "answer": 0}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nThese symptoms qualify as PMS in 20% to 30% of pre-menopausal women.\nMore than 200 different symptoms have been associated with PMS, including emotional symptoms such as: stress, anxiety, insomnia, fatigue, mood swings, emotional sensitivity and/or changes in libido.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other than mentioning anti-depressants, which are not routinely prescribed for PMS, the release does not discuss any of the many other alternatives to managing PMS/PMDD symptom relief. Many interventions have been studied, from exercising (from which there is insufficient evidence) to other CAM therapies. According to a review published in American Family Physician journal, \u201cA 2009 systematic review found 62 studies of herbal supplements, vitamins, and minerals with published claims for PMS symptom relief, only 10 of which were [randomized controlled trials] RCTs.\u201d The review found that data are insufficient to evaluate the effectiveness of ginkgo, saffron, St. John\u2019s wort, soy, or vitamin E, because only one study existed for each. However, results suggested that chasteberry and vitamin B6 may reduce PMS symptoms.\u201d \u00a0Other pharmacologic interventions include: SSRIs, oral-contraceptives, GnRH agonists, and anxyolitics.\nThe release might have been strengthened somewhat if there had been some acknowledgement of some other non-pharmalogical interventions.", "answer": 0}, {"article": "Concussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nIn the new study, researchers have demonstrated that a blood test can now accurately diagnose a concussion using a form of blood profiling known as metabolomics.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nLONDON, ON - Scientists from Children's Health Research Institute, a program of Lawson Health Research Institute, and Western University have developed a new blood test that identifies with greater than 90 per cent certainty whether or not an adolescent athlete has suffered a concussion.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions that there are other ways to diagnose a concussion. It notes:\n\u201cDiagnosis of a clinically significant concussion, or a mild traumatic brain injury, can be difficult as it currently relies on a combination of patient symptom assessment and clinician judgement.\u201d\n\u201cThis new method\u2026is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients\u201d\nWe\u2019ll rate it borderline satisfactory for giving a nod to alternative tests. However, the release would have been more informative if it had included some actual numbers comparing the potential test with traditional tests and other blood tests in development.", "answer": 1}, {"article": "So our recommendation is not to consume any alcohol at all,\" Pressman tells WebMD.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nMothers were first asked about their alcohol use when the kids were 9 months old.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\nChildren in high-income households tend to perform better on behavioral and cognitive tests -- which could mask some possible harms from their mothers' light drinking during pregnancy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story outlines the choices women make\u2026 stopping all drinking during pregnancy, reducing drinking, or continuing to drink as usual.", "answer": 1}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes a brief mentoin of only one alternative to zinc: antibiotics. It says, \u201cThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\u201d What? Most doctors will tell you that antibiotics are ineffective against the common cold, and that they are mainly given as a placebo to make patients feel like they are taking action. Raising the issue of antibiotics without explaining that they don\u2019t really work is a disservice to readers.\u00a0We would have liked to have seen some comment on the best ways to protect yourself and your family from getting a cold besides zinc products. A few words about hand hygiene and keeping your hands away from your eyes, mouth and nose would have been helpful to the readers.", "answer": 0}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nIn an early-stage study conducted by Geron, the therapy showed potential in repairing spinal injury in four of the five patients tested, without any adverse events.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Severe spinal cord damage is unfortunately irreversible, but treatments to improve nerve function exist. These include medications, such as intravenous methylprednisolone for acute spinal cord injuries, and surgery to remove foreign objects that are compressing the spine. Rehabilitation nurses and physical therapists could also work with patients to maintain and strengthen muscle function.\nSince the article does not mention any of these alternatives, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": ".\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nMore than 70 percent of patients surveyed reported moderate to significant improvement in their condition.\n\"After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a large number of treatment options for patients with pain due to various conditions but none are mentioned here except for the misleading assertion in the headline that cannabis was compared with opioids. As mentioned earlier, the release doesn\u2019t acknowledge that there was no comparison to other therapies in this observational study. Rather, the release tends to dismiss them in terms of side effects using opioids as an example. There are other medicinal and non-medicinal therapies that could be used.", "answer": 0}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nIdentifying a Disappearing, Yet Critical Piece of Gut Health\n\nDr. Henrick's previously published findings, which are the basis for the Evivo test, show an inverse correlation between rising infant fecal pH, reduced acetate and lactate, and lower levels of beneficial Bifidobacterium, proving that the infant gut microbiome has been rapidly changing over the last three generations.\nThe generational loss of this good bacteria in the infant gut allows for potentially harmful bacteria such as E. Coli and Clostridia to thrive, which are linked to higher risk of short- and long-term health issues such as colic, eczema, allergies, diabetes, and obesity.\n\"The ability to quickly measure levels of Bifidobacterium in a stool sample would enable pediatricians to identify babies with low levels of these beneficial bacteria and take appropriate action.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives to a test discovering low levels of Bifidobacterium are noted \u2014\u00a0that is, other than using Evivo probiotic products to raise them. One option not mentioned is to ignore the test entirely and not use any medical product like Evivo probiotics (or similar), since studies that the release links to say long-term research is required to suss out any definitive link between low or high levels of Bifidobacterium\u00a0in a baby\u2019s gut and\u00a0their health later in life.\nAdditionally, people could avoid antibiotics (the primary cause of shifts in the microbiome) and feed their children a variety of foods which probably results in healthy colonization.", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story simply states that the blood and \"enriched serum\" approach works \"without turning to synthetic fillers or invasive laser treatments or peels.\"\u00a0 But no evidence of any comparison was given. ", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned that Gilenya was compared with another drug, but it doesn\u2019t go into specifics. It also doesn\u2019t mention that corticosteroid medications can be used to reduce inflammation.", "answer": 0}, {"article": "\"One or our aging center's goals is to help people maintain their independence and live safely at home for as long as possible.\"\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Neither the news release nor the study makes any mention of other possible interventions that might result in fewer or less-serious falls. For example,\u00a0balance programs such as Tai Chi are known to decrease fall risk. Other steps that may help include the installation of hand rails, the use of carpeting on steps, the use of bright-colored tape on steps to increase depth perception, etc.", "answer": 0}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nBurgoon\u2019s group has persuaded some states to bar physical therapists from the practice.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\nAbout 6,000 have taken courses in dry needling in the past few years, Zylstra says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We would have liked to have seen more exploration of alternatives \u2014 or shall\u00a0we say the standard of care \u2014 for injuries like the one described in the lead, runner\u2019s knee. We\u2019re not given a strong idea of what the evidence says is\u00a0generally the right path to choose for practitioners and patients. We know the toolkit for pain is quite shallow, but physical therapy, diet, exercise, carefully targeted medication, and, at times, surgical interventions all have long track records. We would have liked to have seen more weight given to the proven techniques along the way.", "answer": 0}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of the impact of other lifestyle choices beyond consumption of multivitamins that have demonstrate effect on reducing the risk of heart attack. \u00a0Adopting other risk reduction behaviors is a more powerful way to reduce risk of heart attack.", "answer": 0}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of how this treatment compares to alternatives. Readers are not told that such comparisons have not yet been studied.", "answer": 0}, {"article": ".\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nIn all patients, only one reduction technique was performed per patient.\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The research compared specific anatomic differences seen with two recognized surgical approaches to reduction mammaplasty.", "answer": 1}, {"article": "Novel standard for research in malnutrition may save lives\n\nProfessor Henrik Friis, the senior author on the paper, points to the importance of the collaboration between university researchers and humanitarian organizations:\n\n\"It has been a new way to conduct research, that we tested the effect of nutritional supplements used mainly by aid agencies, employing very advanced research methods in remote rural areas where humanitarian organization are working, and not at the university hospitals.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nResearchers from the University of Copenhagen and humanitarian organizations have conducted a large study in Burkina Faso in West Africa treating more than 1600 children with acute malnutrition.\nThe main Treatfood results are presented in the paper: Effectiveness of food supplements in increasing fat-free tissue accretion in children with moderate acute malnutrition: A randomised 2 \u00d7 2 \u00d7 3 factorial trial in Burkina Faso, published in the open access medical journal PLOS Medicine.\nPrevious research has focused on treatment of severe acute malnutrition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study is all about comparing widely used alternatives about which there have been long standing questions of relative benefit.", "answer": 1}, {"article": "Learn more about omega-3 fatty acids, including DHA, and infant health from the March of Dimes.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\nBut, she added that the supplements did appear to be safe for pregnant women to take.\nThe treatment group received 400 milligrams of DHA each day, beginning when they were between 18 and 22 weeks pregnant.\nRamakrishnan said Mexican women tend to be deficient in DHA, much like many American women are.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study reported on the use of an algae derived DHA supplement and possible health benefits observed in infants born to mothers who consumed them. \u00a0While suggesting that fish derived DHA could be problematic due to mercury contamination, the story failed to educate readers about other DHA containing food that could be consumed to obtain the recommended levels of intake during pregnancy.\nKeeping small babies out of public places, not smoking, hand washing, and breast milk are all ways of decreasing the incidence of and improving recovery from viral illnesses.", "answer": 0}, {"article": "Good overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\nThat was after accounting for other factors, such as smoking.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study didn\u2019t mention any other factors that we know can promote healthy aging, including a healthy diet and physical activity. That could have been done in just another additional line.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nThe therapy was nine sessions on average plus exercises to do at home, which experts say is key to success.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\nThe treatment involved two to three hour-long sessions a week, including strengthening exercises, balancing and massage.\n\"I felt better within two weeks\" on physical therapy, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was a study comparing alternative treatment approaches.", "answer": 1}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\nBias was unclear in most of the studies, and only five used stopwatches to measure IELT, which is the \u201cgold standard\u201d for premature ejaculation studies, Patrick said.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\nTogether, the two acupuncture studies found that the treatment slightly increased intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study noted that the various alternatives were compared against placebo or alternative treatments. It would have been useful to know how the various herbal remedies compared against what is considered by many physicians to be a reference standard\u2013the off-label use of an SSRI antidepressant, such as paroxetine.", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nThe studies in the review comprised more than 4,000 women who were up to 20 weeks pregnant.\nUnfortunately, medicines to relieve morning sickness have a checkered history.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses many different treatments for morning sickness and\u00a0reports that they all lack good-quality evidence to support their use.", "answer": 1}, {"article": "\"And in that case, I see this as just a waste of money.\"\n\"[But] this work adds an important piece of information to the autism puzzle,\" she said.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\n\"It adds evidence of functional impairment in brain connectivity in autism and brings us a step closer to a better understanding of this disorder.\nUsing MRI imaging, the team searched for differences in brain activity patterns in the microstructure of white matter tissue in 80 autism patients between the ages of 10 and 35.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no attempt to explain how autism is currently diagnosed or what this new information might do for patients in comparison to existing methods of diagnosing and managing the autism disorders.", "answer": 0}, {"article": "Vertigo -- episodes of dizziness that can last for minutes or days -- may be triggered by a number of health issues, ranging from an inner ear disorder to tumors.\nThirty-five study participants had this form of vertigo.\nPreventative medication was given to 20 of the 35 people with the newly detected type of vertigo.\nOf these, one-third saw their symptoms reduced or they recovered completely.\nIn some cases, the cause is unclear.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes a proposed new diagnosis so suggesting alternatives doesn\u2019t apply.", "answer": 2}, {"article": "\"I just think it's too early really,\" said one, who spoke on the condition of anonymity for that reason.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\nThe study cost $105 million, most of it provided by the National Institutes of Health.\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Good job comparing this vaccine approach with other vaccines. ", "answer": 1}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\n\"About 5 to 7 million children are bedwetters, and the causes fall into three main groups: bladder issues, sleep-related problems and the kidneys,\" he explained.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\nChildren with sleep apnea can be difficult to rouse, which may cause the bedwetting, said Dr. Dennis Kitsko, an otolaryngologist at the Children's Hospital of Pittsburgh.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job talking about the different causes of bed wetting but not the potential treatments. \u201cThere are many other causes of bedwetting, Lakshmanan said. \u201cAbout 5 to 7 million children are bedwetters, and the causes fall into three main groups: bladder issues, sleep-related problems and the kidneys,\u201d he explained. \u201cThe children in this study wet the bed due to sleep-related problems.\u201d We would have particularly liked to hear an estimate for the number of children who resolve bedwetting (even \u201cabnormal\u201d bedwetting into grade school) on their own. From a healthcare perspective and a parenting perspective, do we really want to do operations on kids to end this annoyance?", "answer": 0}, {"article": "The most common exam offered for asymptomatic patients seeking supplemental screening is a whole breast screening ultrasound examination.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares the cancer detection rates of abbreviated breast MRI with mammography and digital tomosynthesis (DBT), or 3D mammography. However, it didn\u2019t compare it with the most common screening alternative for these types of breasts \u2014 whole breast screening ultrasound \u2014 since as the release said, ultrasound carries \u201chigher rates of false positives.\u201d\nAs noted above, we wish the release would have noted the rate of false positives associated with abbreviated MRI screening.", "answer": 1}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nCurrently, the standard treatment includes a combination of psychotherapy and prescription medications such as mood stabilizers and antipsychotics.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions the standard treatments for bipolar disorder:\n\u201cCurrently, the standard treatment (of bipolar illness) includes a combination of psychotherapy and prescription medications such as mood stabilizers and antipsychotics.\u201d", "answer": 1}, {"article": "They found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n\u201cIt shows the enduring and long-term benefit of taking statins, including the extent to which they reduce the risk of dying from heart disease, which can only be seen in a study of this length.\n\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is not adequately explained. While a 20-year study sounds impressive, we\u2019re not told about other similar treatments and lifestyle changes.", "answer": 0}, {"article": "DCIS affects one out of every five women diagnosed with breast cancer in the United States, and is often treated with surgery followed by radiation therapy and/or hormonal therapy.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\nConducted in collaboration with Partnership for Health Analytic Research, this prospective study analyzed 115 patients from 10 cancer centers in the United States.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss alternatives to the Oncotype DX DCIS Score, except for the absence of such testing. But since there are no other commercially available tumor genomic tests for DCIS, we\u2019ll rate the story Not Applicable here.", "answer": 2}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions antidepressants, anesthetic ointments and cream, and behavioral therapies as alternatives for PE.", "answer": 1}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\nThat means many unsuspecting patients are getting considerably more radiation than they need for an adequate CT image.\nSmith-Bindman says neither doctors nor patients appreciate the amount of radiation exposure that U.S. patients are accumulating from CT scans.\nA separate study in the journal documents needlessly high radiation exposures from CT scans at four San Francisco-area hospitals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several other testing options, such as simpler CT tests, conventional X-rays, ultrasound or MRI that involve less or no\u00a0radiation.", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was story about the failure of one combination therapy to outperform the single, simpler, less expensive therapy. \u00a0It did not, however, provide information about other means of lowering risks from cardiovascular disease. \u00a0These should have been mentioned in order to put the results of the ENHANCE study into perspective.", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention how pancreatic cancer is currently diagnosed. Tests to identify pancreatic cancer in patients include, but aren\u2019t limited to, physical exams to look for the presence of jaundice, blood tests, imaging tests and biopsy.", "answer": 0}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\nCardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\n\" Study participants were advised to \"start low and go slow,\" and some were even able to get rid of their canes after six months of exercise, which Gill says they found particularly rewarding.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The most likely alternative is a rehab program that would incorporate many of the same elements as the study protocol.", "answer": 2}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article explains the current guidelines, and the variations in recommendations that are based on previous calculations of risk. Implicit in the story is the fact that these are \u201cguidelines,\u201d and not prescriptive rules; and that there must always be interpretations and exceptions to them.", "answer": 1}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nThe risk rose if the mothers or the children had a high-risk gene form.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\nStill, she says, the finding points to a gene-environment interaction that may possibly help explain some cases of autism.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have mentioned a healthful diet as a means to ensure adequate intake of folate and other nutrients that are important for fetal development.", "answer": 0}, {"article": "ADVERSE EVENTS \n\nNasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nStudy 2 is a prospective, single-arm, multicenter, open-label clinical trial in which participants used TrueTear\u2122 to stimulate tear production for 180 days.\nAll device-related adverse events were mild in nature.\nLast May, Allergan announced positive results from two pivotal trials for TrueTear\u2122 that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release includes quotes calling the device a breakthrough and touting its superiority to other dry eye treatments, without clearly noting that neither of the studies mentioned in the release compared the device to other treatments.\nIt also doesn\u2019t name any alternative treatments now in use, including artificial tears, and immunosuppresant drugs and tear duct plugs.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nThe story does refer to standard treatments; however, it portrays standard treatment as often inadequate for the type of patient featured in the story. The editorial accompanying the key research article on this treatment says that the fact that most of the control group participants in the trial reported doing better while they were in the trial may indicate that they had not been getting optimal standard treatment beforehand. The editorial author says bronchial thermoplasty should not be considered unless a patient has first been \u201csubmitted to a rigorous treatment protocol.\u201d In other words, when people with asthma say that standard treatment isn\u2019t working, the real problem may be that they haven\u2019t actually been treated properly.", "answer": 0}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWhile the researchers saw improvements in all participants who added some physical activity to their routine, those who got more exercise saw greater changes.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nThe researchers relied on movement monitors and self-reporting to measure physical activity outside study sessions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any alternatives to walking as a physical exercise. Multiple studies have shown benefits to the elderly from resistance training, cardiovascular endurance training, balance and flexibility training.", "answer": 0}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nTwo to three times a week was not enough, the researchers found in an earlier study.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nAnd the exercise needs to be performed four to five times a week.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It\u2019s not clear if there are any viable alternatives to exercise for the outcomes addressed in this study. The subjects selected for this study \u2014 if they, indeed, have less flexible left ventricles \u2014 are potentially comparable to patients with what is called \u2018heart failure with a preserved ejection fraction (or, HFpEF; with ejection fracture being a way to measure the efficiency of the heart as a pump). The paper mentions the medication, spironolactone, as \u2018the only treatment strategy recommended (class II recommendation) to counteract the debilitating effects of HFpEF.\u201d The news release could have mentioned this alternative, but we won\u2019t dock points for not doing so. We\u2019ll rate it not applicable.", "answer": 2}, {"article": "Heart researchers have long known that plaques in coronary arteries start out as pimplelike bumps but get waxy and hard and filled with calcium as time passes.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nCurrent guidelines have vastly increased the number of people who are eligible to take statins.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternative risk calculators that include lifestyle and other factors, which people on the fence can use to help clarify their thinking about statin treatment. It also does not clearly point out that people who are uncertain about statin treatment can try the drug to see if they experience bothersome side effects. In other words, there are alternative ways for people to gather information that could help them decide about statin treatment.", "answer": 0}, {"article": "Find out more about brain health at the Alzheimer's Association.\nThe study, published in the Feb. 28 issue of the journal Neurology, did not prove that omega-3 fatty acids prevent mental decline, merely that there may be an association between consumption of fatty acids and brain health.\nTan added, however, that it remains possible that factors they did not control for, such as fruit and vegetable consumption, are really responsible for the brain benefits.\nThe researchers took into account various health and lifestyle factors, including age, education and body mass index, to explore whether other differences among the people with low levels of omega-3s could help explain their more rapid brain aging.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of other habits or behaviors, such as exercise and mental stimulation, that are associated with maintenance of cognitive function with age. The story also did not mention other potential sources of omega-3 fatty acids, as CNN did.", "answer": 0}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that other drugs are employed to treat migraines, but it didn\u2019t mention any by name.\nThe Wall Street Journal story never discussed non-pharmacologic therapies. Yet addressing triggers related to diet, stress, sleep deprivation, and medication side-effects are front-line preventive treatments for migraines. And they are certainly viable alternatives to Botox injections.\nAnd since Botox injections have never been compared to other standard treatments for chronic migraines in clinical trials, it is quite possible that those interventions could be superior to Botox injections.", "answer": 0}, {"article": "Keytruda thereby met its main goal of the study.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nPatients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make clear that Keytruda was being compared to docetaxel, so we\u2019ll award a Satisfactory here. Again, however, it would have been very good to know how well Keytruda compared to docetaxel. Was the improvement in overall survival time, and in postponing progression for patients with high-expressing PD-L1 cancers, a meaningful one? Even if Merck declined to provide that information, the story could say that. Are they still crunching the numbers? Or the story could have included input from independent experts on what a \u201cmeaningful\u201d improvement might look like; reasons to be optimistic; reasons to be cautious.", "answer": 1}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nBut Priddy adapted quickly to his second implant and can now talk on the telephone all he wants.\nIn the meantime, he hopes to inspire others like him to get cochlear implants.\nWhen Priddy's implant was turned on six weeks later, he couldn't decipher the sounds he was hearing, but he was definitely hearing them.\nJust two years ago, he feared he might not hear anything again.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions no other treatment options. Is there anything short of surgery that might help?", "answer": 0}, {"article": "Each stage was 15 minutes.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nA new study suggests that continuous movement while sitting may increase metabolic rate more than standing at a desk.\nParticipants in the study familiarized themselves with the workstations during one visit.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No other alternative devices that promote leg movement while seated were mentioned. But in fact there are a ton of other options to stimulate movement while seated \u2014 from balance balls to leg and arm peddlers (and some are also significantly less expensive).", "answer": 0}, {"article": "Kychman is an advisor to Boehringer Ingelheim and serves on their speakers' bureau, services for which he is compensated.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nData suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story indicates that\u00a0an alternative drug called the Intrinsa testosterone patch\u00a0is available in Europe, but not in the U.S.\u00a0The story also notes a difference between\u00a0these dugs; Intrinsa\u00a0is a hormonal treatment compared to flibanserin which is a non-hormonal.\u00a0", "answer": 1}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nThe results of the trial met the expectations of Hoffer and his team of researchers.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\nWith these findings, it appears the I-Portal goggle may be a solution.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release says that mild traumatic brain injury is usually diagnosed through physical exam findings. One of the study authors adds the goggle does not require baseline testing \u2014 which includes assessments to gauge reaction time, memory capacity, speed of mental processing, and executive functioning of the brain, according to the Sports Concussion Institute.\nIt would have been interesting to compare the sensitivity/specificity numbers of the goggle to those of the physical exam (with baseline testing). Sure, 95 percent specificity sounds pretty good itself, but what accuracy can physicians achieve the traditional way (aka through the physical exam)?\nAlthough the news release doesn\u2019t address this, we feel it did a Satisfactory job here by mentioning the alternative.", "answer": 1}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nHowever, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\nAn aspirin a day could keep skin cancer away, according to a new report in the journal Cancer.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were no direct references to alternative methods for preventing skin cancer \u2014 like using sunscreen, avoiding midday sun, etc.\u00a0 Even an additional line could have satisfied this criterion.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately compares alternatives and discusses the overall lack of any effective medication for Alzheimer\u2019s disease.\nAs noted above, however, a discussion of competing hypotheses about the origins of the disease, along with related potential treatment strategies, would have been useful to include.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention made of other approaches to bone loss such as engaging in weight bearing exercise, or prescription medications to enhance bone building or inhibit bone resorption.", "answer": 0}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nBy considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\nImportantly, the benefit of treatment was strongly driven by improvements in pain and discomfort as well as self-care.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release comments on medicines used for treating trigeminal neuralgia, their mention focuses on very severe side effects. However, no information is provided about the use of these medicines in the patients participating in this study. Only by directly comparing different forms of treatment can one determine their relative benefits. It is also worth mentioning that some patients will have spontaneous improvement, so it isn\u2019t clear if it was the radiation treatment, or just the passage of time that helped.", "answer": 0}, {"article": "\"It's clearly muddying the waters,\" he said.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\nBoth Kopans and Dr. Otis W. Brawley, the American Cancer Society's chief medical officer, criticized the research team's short follow-up period -- just 2.2 years of observation, on average.\nThe analysis, published in the Sept. 23 issue of the New England Journal of Medicine, raises new questions about the benefits versus risks of screening mammography and is already reigniting tensions over its frequency of use in the United States.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have done a better job explaining that self-exams are also another common, although also controversial, means of detecting breast cancer and that gene testing has given rise to a subgroup of patients with the BRCA1 and BRCA2 gene mutations who have opted for aggressive prevention measures, such as complete breast removal. Cancer is a complicated disease, and some of this could have been captured, even in the limited space.\nEven more broadly, it never explicity addressed the option of foregoing mammography in any detail \u2013 which is hard to overlook in this case. ", "answer": 0}, {"article": "\"When it finally happened, he just very calmly said, 'Yep, I felt it on my index finger,' \" Gaunt recalls.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\nAnd there's no good way to control them without implanting electrodes in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not give readers any sense of what else is out there for an amputee, including other prosthetics such as one from 2014 that provides \u201csensory\u201d info without need of a brain implant. (The electrodes are implanted in the patient\u2019s arm.)\nIt also does not provide context that many people with upper limb amputations choose to use less-high-tech prosthetics because these last longer and are more durable or because they cost less.", "answer": 0}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nHe is responsible for the institute's public health campaign called Mind Your Risks.\nKoroshetz is using all of these approaches.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story indirectly discusses alternatives\u2013such as exercise and diet.", "answer": 1}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\nThe new study involved 52 patients with floaters who received one session of either the YAG laser treatment or a \"sham\" placebo laser treatment.\nThe new research was led by Dr. Chirag Shah and Dr. Jeffrey Heier of Ophthalmic Consultants of Boston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that there are alternatives to the YAG laser treatments:\u00a0 \u201cThere are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\u201d Some discussion of the effectiveness of surgery and education would have been useful, however.", "answer": 1}, {"article": "\"Platelets are an amazing substance.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nIt's called Platelet Rich Plasma therapy \u2014 or PRP.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\nA leading sports medicine expert, he believes we can speed up the body's ability to heal itself with a remarkably simple technique.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of the range of surgical and nonsurgical alternatives for various forms of knee pain, including the torn knee ligament profiled in the athlete\u2019s story. Not only was there no mention of treatment options, it also isn\u2019t even clear what the treatment is indicated for. The athlete had a torn ligament. There are many ligaments in the knee and one could imagine that the treatment is for a meniscal tear, but this is never stated anywhere in the piece. If one knew what the indication was, one could then present current treatments that are available.\u00a0The creaky joint mention at the end only confusing things more. This implies arthritis \u2013 something that the athlete didn\u2019t even have (by report). It leave the listener/reader thinking that this could work for knee pain of any cause \u2013 something that past experience would say is very unlikely. ", "answer": 0}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nHitachi has delivered the first hospital based spot scanning system in May 2008 and has treated over 1,500 patients to date.\nPBT improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy.\nIn fiscal year 2015 (ending March 2016), one of Hitachi's new PBT site is planning to start treatment of patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not mention the alternatives to PBT. The more widely available alternative to proton therapy is photon radiotherapy. The hardware costs for a proton center are approximately twice that of a photon facility.", "answer": 0}, {"article": "Your office thermostat is set for men's comfort.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nThe participants fell into four groups: those with no use or low use of marijuana, early chronic users, those who only smoked during their teens and those who began using it later and continued using the drug.\nA study published by the American Psychological Association in the journal Psychology of Addictive Behaviors this week should alleviate some of the worst fears.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is not an\u00a0applicable category for this story topic. However, it is interesting to consider whether teens who use marijuana are not\u00a0using alcohol, and whether that may lower their risk of harms from alcohol use.", "answer": 2}, {"article": "Investigators evaluated the effect of the USPSTF guideline on the number and distribution of new prostate cancer diagnoses in the U.S.\nThis study helped quantify the potential benefits (reduced harms of over diagnosis and overtreatment of low risk disease and disease found in elderly men) and potential harms (missed opportunities to diagnose important cancers in men who may benefit from treatment).\nHowever, the study also identified a drop of 28.1% in diagnoses of intermediate risk disease and 23.1% in high risk prostate cancer one year after the draft guideline, which could result in missing important opportunities to spare men with higher risk cancers from progressive disease and cancer death.\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternatives are to screen (or at least screen more selectively) vs. not to screen. Although the story at least raises the comparison, the only way to truly compare the alternatives is to look at mortality outcomes, ideally with randomized trials. We have data from the ERSPC (European Randomised Study of Screening for Prostate Cancer) showing that screening reduces mortality by about 1/1000; the US PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trials was negative. A key message is that men need to make informed decisions and be aware that a potential trade off with not screening is that the risk of dying from prostate cancer might be slightly increased. However, the current study is unable to provide data to quantitate that risk.", "answer": 1}, {"article": "So which one is right for you?\nThe prep for both the virtual and actual colonoscopy is the same \u2014 the dreaded \u201ccolon cleanse\u201d that many patients find is the worst part of the procedure.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nVirtual colonoscopy is a good option for those who can\u2019t be sedated for colonoscopy, or who simply can\u2019t tolerate the scope.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story creates a false dichotomy \u2013 as if screening is a choice between regular colonoscopy or CT colonoscopy.\u00a0 And it inaccurately states that \u201cthe American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years.\u201d\u00a0 That is not, for example, what the American Cancer Society recommends.\nOn the ACS website, a range of choices are presented \u2013 not just virtual colonoscopy \u2013 making the story\u2019s statement misleading at best.\u00a0 The ACS website states:\nBeginning at age 50, both men and women should follow one of these testing schedules:\nAnd it\u2019s odd that the story never mentioned a new statement by the American College of Obstetricians and Gynecologists reminding women that they have a range of screening options including high-sensitivity guaiac fecal occult blood test or fecal immunochemical test. ", "answer": 0}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nTheir effectiveness rivals that of sterilization.\nOf the many embarrassing health statistics in this country, the huge number of unwanted pregnancies is perhaps the easiest to rectify.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did a great job of outlining many different alternative methods of contraception and their effectiveness.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Mixed bag:\nThe story does a good job of comparing alternatives from the standpoint of effectiveness.\u00a0 However it neglects any consideration of how they compare in terms of side effects and cost.\n\u00a0", "answer": 0}, {"article": "We were going to get patients out of the hospital quicker, have better potency and incontinence outcomes,\u201d he told Reuters Health.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nHu and his team analyzed surgery data from a national government database to see if the costlier robotic surgeries were cost effective with extra benefits over older techniques.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\nDavid Penson, a surgeon at Vanderbilt University Medical Center who was not part of the study, said more consideration should have been given to the state of patients afterwards.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was on a study comparing robot-assisted surgery with two other surgical techniques.", "answer": 1}, {"article": "\u201cHeating ducts that have mold and spores in them can make respiratory symptoms worse in the winter when hot air is blowing through them.\nThe app also provides Mayo Clinic \u201cmessage cards\u201d that give relevant information and recommendations for ways to keep your indoor environment healthy.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not talk about any of the other air quality monitoring devices that are on the market, at all. And there are a lot of them. We\u2019ll come back to this under \u201cNovelty.\u201d", "answer": 0}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nBottom Line: Obese patients who underwent weight-loss surgery had a lower rate of death from any cause compared with obese adults who received nonsurgical care to manage their obesity.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The nonsurgical alternatives to treating obesity are not clearly explained in this news release.", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was on different dietary approaches to weight loss.", "answer": 1}, {"article": "About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nAdditionally, laser treatment was given if DME persisted without continual improvement after six months of injections.\nSubsequently, injections were resumed if DME worsened.\nLaser treatment alone was the standard treatment for DME until widespread adoption of anti-VEGF drugs a few years ago.\nThe three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Corrective laser surgery is named as the alternative therapy to drugs.", "answer": 1}, {"article": "...\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nThe study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively.\nConfirmation of these findings in ongoing clinical trials may results in improved pharmacologic treatment for moderate to severe BED,\" the study concludes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release\u00a0identifies cognitive behavior therapy and psychotherapy as alternatives, but offers no comparison in outcomes other than to make the point that few health care providers use the behavioral alternatives.", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternatives in the piece, but there are several.", "answer": 0}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\nSimilar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not discuss currently recommended screening practices and their benefits or drawbacks. In addition to colonoscopy and sigmoidoscopy, newer high sensitivity stool testing has good sensitivity and specificity for detecting colon cancers and can be done at home.", "answer": 0}, {"article": "But are they receiving it?\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Smokeless tobacco products are clearly the comparable product here and the topic of the release.", "answer": 1}, {"article": "All rights reserved.\nThat is less effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\nAmerica's favorite dietary supplements, multivitamins, modestly lowered the risk for cancer in healthy male doctors who took them for more than a decade, the first large study to test these pills has found.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nCancer experts said the results need to be confirmed by another study before recommending multivitamins to the public.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that multivitamins are\u00a0\u201cless effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\u201d We\u2019ll call this good enough for a satisfactory, but we do quibble with the story\u2019s broad assertions regarding the effectiveness of these lifestyle recommendations. With the exception of smoking cessation, which is certainly effective for preventing cancer, it\u2019s never been conclusively proven\u00a0that dietary changes or exercise can reduce cancer risk. In fact, recent research suggests that fruits and vegetables \u2014 long thought to be strong cancer fighters \u2014 actually have little or no effect on cancer risk. Obesity is emerging\u00a0as the main diet-related culprit when it comes to cancer, something the story could have\u00a0been more precise about.", "answer": 1}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\nCurrently, TXA is not generally used in emergency rooms to treat trauma patients, but Roberts believes that this study could change that.\n\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nDr. Jerrold H. Levy, deputy chair for research at Emory University School of Medicine in Atlanta and author of an accompanying journal editorial, said that, \"these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Unlike the\u00a0competing coverage from the AP and NPR, this story\u00a0mentions the fact that there are other drugs\u00a0which help promote clotting and might be useful\u00a0for trauma patients. The story correctly warns that the benefits of TXA\u00a0can\u2019t be generalized to other drugs without additional research. \u00a0", "answer": 1}, {"article": ".\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\nCo-authors on the paper were Benjamin Chafee, DDS, MPH, PhD, assistant professor of preventive and restorative dental sciences and director of the Global Oral Health program, and Beate Rechmann, research associate, both from the UCSF School of Dentistry.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the strictest possible way, the release does not directly talk about all the different ways of preventing dental caries. But we were glad that the release discussed the improvements that happened for some patients in the control group who received fewer products. We are glad the release talks about possibly following up on this, in case the lesser products could still benefit many patients.\nExcerpt:\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects. While not as significant as the CAMBRA group in this study, the risk level of these patients dropped more dramatically over time than for those in the 2012 UCSF CAMBRA study.\nIt was surprising to see the benefits gained by the control group,\u201d Rechmann said. \u201cMore research is needed to see if the products and treatment administered to this group function in the way we speculate, and if so, they might be made easily available to dental patients. Doing so can change the whole picture of caries control.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Rest is the standard recommended care for concussion.\nIn terms of alternatives for tracking concussion symptoms, there does seem to be a plethora of apps available, which the story didn\u2019t mention.", "answer": 2}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\nThe company hopes to win FDA approval to market the new drug later this year.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story misses one huge point. How does this drug do when compared to diet and exercise? The story mentions that the drug is not as effective as two existing drugs, but doesn\u2019t compare it to other weight loss treatments. If people walked 30 minutes a day and ate a balanced diet, would they lose more than 12 pounds on average in a year\u2019s time? (Ask that Subway pitchman.)", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nHowever, if this test could be done in really young children, it might help identify autism so that treatment can begin early, Lopez-Alberola suggested.\nThis test costs no more than a standard MRI, which runs around $1,500, Hirsch noted.\nAlthough this study was done with school-aged children and teens, the same test can be done with children as young as 18 months, Hirsch noted.\nHirsch noted the study is preliminary and, as such, has some limitations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not go into much detail about the alternatives to MRI\u00a0screening, but it does say that most chlidren are diagnosed by a clinician, not through any biological screening or brain scan.", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself was about comparing two treatments, and this story was superior to the NPR story and the Associated Press story we reviewed in making those comparisons clear.\nStill, we would have liked to have seen some comments on the third alternative available to people with coronary artery disease, medical treatment.\u00a0 Without some mention, people with coronary artery disease may be led to believe that there are only interventional options. For many this is not the case.", "answer": 1}, {"article": "As examples, smoking rates were highest among those without a graduate education degree certificate and lowest among those with a graduate degree; higher among those living below the poverty level versus above it; and higher among some minorities such as American Indians and Alaska Natives, multiple- race individuals and blacks.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\nSix of the eight cases found in the screening were considered potentially curable with surgery.\nThat study also provided the first broad evidence that low-dose computed tomography, or LDCT, was a more effective screening tool than the traditional chest X-ray.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The focus appears to be on getting lung cancer screenings or not getting them \u2014 rather than on the virtues of any particular diagnostic technique (though there is one reference to the use of low-dose computed tomography (LDCT) technology rather than conventional chest X-rays). As such, we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\nThe stem cells are known to form fresh brain cells in youth, but the process slows down dramatically in adults.\nThe animals died months earlier than healthy control animals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is all about basic research that suggests an approach that one day might slow, or possibly reverse, the aging process.\u00a0 There are no real alternatives available now to affect the aging process beyond lifestyle choices that might be healthier and appropriate treatments for illnesses that might otherwise shorten lifespans.", "answer": 2}, {"article": "Tobacco kills one-third to one-half of those who smoke.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison with other lung cancer prevention approaches and not even with parallel human research in this field \u2013 as the HealthDay story did in at least mentioning a small human study of metformin in colorectal cancer patients. ", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe report neglects to mention \u201ctreatments\u201d other than chocolate that might improve the endothelial function of these subjects. Among these is low-cost, fat-free, calorie-burning exercise.\n", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\nAnd, she said, these studies show that you don't necessarily need to get to your \"ideal body weight\" to make substantial improvements to your health.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the story\u2019s focus on blood pressure, it\u00a0should have\u00a0mentioned how the results of this study might compare to treatment with blood pressure medication.", "answer": 0}, {"article": "Pregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\nThe Baylor scientists were able to correct for those variables.\nThe research in question involved mice, not women.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nHow does this relate to our own species?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story refers repeatedly to \u201cexercise,\u201d the only physical activity studied here was mice running on an exercise wheel, and not other forms of vigorous activity. That\u2019s the limitations of mouse research, and why these sorts of stories should be reported on sparingly.", "answer": 0}, {"article": "When nicotine enters the body, it binds to the same receptors in the brain that acetylcholine binds to, resulting in smoking's rewarding and reinforcement effects.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release nods briefly to the existence of other medications for smoking cessation and how galantamine would differ.\n\u201cOur goal in investigating these different repurposed medications is not to replace the medications that are already available,\u201d she said. \u201cWe know that they\u2019re effective. Our goal is to target different populations of smokers who may be more likely to experience these cognitive deficits.\u201d\nAlthough it doesn\u2019t specifically mention any other smoking cessation tools and techniques by name or discuss how successful galantamine might be in comparison, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "The F.D.A.\nDr. Gold said there were about 100,000 men who get such a diagnosis each year.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the only approved treatment for the cancers Provenge treats is Taxotere, which has been shown to extend life by three months. \nThis may be technically accurate as stated. But the American Cancer Society lists at least eight other chemotherapy agents used to treat advanced prostate cancer. ", "answer": 0}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\nBut proton beam therapy is at the heart of the debate over rising health-care costs.\n\"There is no good evidence, medical evidence that it is better than the current state of the art intensity modular radiation therapy,\" Stock said.\nAt double the cost of standard treatments, many experts say it's being used without proof it's more effective.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other radiation treatments, such as intensity-modulator radiation therapy, as the alternative to proton beam therapy.", "answer": 1}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\nThe effect was more apparent and developed earlier when patients were treated with a combination of anti-TNF\u03b1 and anti-IFN?, both at extra-low doses.\nThe current study investigated the impact of the combination of drugs on cardiovascular events.\nProfessor Babaeva's previous research showed that treatment with anticytokine drugs can decrease the activity of rheumatoid arthritis.\nWe recommend this new approach for preventing cardiovascular events in patients with moderate disease activity who are not receiving the standard biologics and who do not have severe complications.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a range of alternatives (statins, antihypertensives, anticoagulants) that can help reduce cardiovascular risk in patients but none of these alternatives are mentioned in the context of the study. Even one line acknowledging the existence of these alternatives would have rendered this a much more satisfactory release.", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly hints at the other common treatments: drugs (notably antidepressants) and talk therapies like cognitive behavioral therapy.", "answer": 1}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nNewswise \u2014 Eating a type of powdered food supplement, based on a molecule produced by bacteria in the gut, reduces cravings for high-calorie foods such as chocolate, cake and pizza, a new study suggests.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that eating the amount of fiber to produce the same effects on the gut biome as the experimental supplement would be difficult, and notes that the average amount of daily fiber intake in the UK is just 15 grams, compared to the 60 grams that would be needed. As noted in the summary above, an alternative inulin-based product is already on the market. That would have been a useful addition to the release.", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because of the included quote about statins, we\u2019ll award a satisfactory rating. The story could have mentioned how bergamot compares to other supplements that claim to lower cholesterol, and provided general information about a diet low in saturated fats and high in plant sources of foods.", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nIt will be \"a few years\" before it could be more widely available, Montgomery said.\nLead researcher Dr. Stanley Jordan agreed that more work is necessary.\nThey come back, Montgomery said -- and the results of that comeback vary from patient to patient.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the existence of other desensitization efforts. But it could have done a much better job of comparing such efforts and their likely impact to programs designed to increase the supply of tissue matched organs and to suppress rejection of donor organs.", "answer": 1}, {"article": "For more details and to read the full study, please visit the For The Media website.\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions three treatment options for eye floaters \u2014 patient education and observation, surgery, and laser treatment \u2014 but didn\u2019t comment on how these treatments compared in effectiveness. That\u2019s probably because the study did not compare laser surgery against other treatments for eye floaters.\nThe American Association of Opthalmology, as of 2015, viewed the evidence for laser treatment benefits as too limited to offer its official support.", "answer": 1}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\nThe biosynthetic corneas also became sensitive to touch and the treated eyes began producing normal tears, the researchers said.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the treatment to human tissue transplants. It could have pointed out that the study was not designed as a direct comparison with people who received a human cornea transplant.", "answer": 1}, {"article": "The results were published in Wednesday\u2019s edition of the Journal of the American Medical Assn.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nMothers who took folic acid supplements around the time they became pregnant were less likely to have children with an autism spectrum disorder, a new study has found.\nThese children were more likely to be born to women who did not take folic acid.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no broadly-recommended ways to reduce autism risk.", "answer": 2}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The news story summarizes the main alternative to the two drugs associated with heart valve disease. (\u201cThe main treatment is a medicine called levodopa, which the body converts to dopamine\u2026\u201d) However, it neglects to mention whether levodopa also has side effects that readers might want to evaluate. More importantly,\u00a0it fails to point out that other medicines in this drug class (e.g. lisuride, pramipexole, ropinorole) are available which are not associated with heart valve disease, information readers might find useful and reassuring.", "answer": 0}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\nThe cap is not yet available to consumers, although the lead researcher, Dr. Eric Nofzinger, has plans to bring it to market, Buysse said.\nBecause this study was extremely small and presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal and confirmed in larger studies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included some good context:\n\u201cMedications can help, although many people complain of side effects, Kohler said. The most effective treatment is cognitive behavior therapy, which involves changes such as avoiding cigarettes, alcohol and caffeine before bed, and getting plenty of bright light in the morning but turning off the TV, computer and dimming the lights during a wind-down period, among other techniques for improving \u201csleep hygiene.\u201d", "answer": 1}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nAs to apixaban's expected higher price tag, Ansell said that since the drug does not require monitoring and the incidence of stroke and major bleeding are less, savings in doctors' visits and stroke treatment should more than compensate.\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compared the outcome measure of apixabane to warafarin; in addition, it indicated that there is another medication in the same category that has been recently approved by the FDA.", "answer": 1}, {"article": "\u201cDr.\nThe procedure results in diminished post-operative pain, quicker recovery time, improved mobility, and an excellent aesthetic outcome for patients.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\nValley was the first hospital in northern New Jersey where an innovative technique \u2013 called pre-pectoral placement of a tissue expander -- was utilized during breast reconstruction surgery following a mastectomy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Options for reconstructive breast surgeries are as numerous as they are nuanced, depending on the needs of the patient. However, none of them \u2014 one-stage implant surgeries, muscle flap surgeries, etc. \u2014 get even a passing mention.\nIn the context of this procedure, it would have been helpful to clear up the alternatives, including the more-common procedure of getting an implant beneath the chest muscle (where it\u2019s less likely to cause complications).\nIt should always be stressed that there is no one-size-fits-all approach to breast cancer reconstruction. Factors taken into account include the patient\u2019s constitution, other medical problems, location of the cancer in the breast, type of cancer, need for preoperative or postoperative chemotherapy, need for radiation therapy, and patient preferences for cosmetic outcome. In addition, extensive discussion needs to be held regarding the potential complications of each reconstructive approach.", "answer": 0}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\nRichard Neal, professor of primary care oncology at the University of Leeds who was not involved in the research, welcomed the study.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no relevant alternatives to discuss.", "answer": 2}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nThis story does report that this pill has not been compared to other treatments for fibromyalgia. But it fails to put this approach of attempting to improve sleep into context with treatments that directly address the pain and other major symptoms of fibromyalgia. Also, as mentioned above, the story does not tell readers that some of the same researchers (and others) have previously reported the results of larger studies of other drugs intended to improve the sleep of people with fibromyalgia. Nor does this story mention any of the common (non-drug) steps people with fibromyalgia can take to improve their sleep.", "answer": 0}, {"article": "Even incurable causes of age-related vision loss such as glaucoma and age-related macular degeneration \u201care highly treatable, so we can reduce the amount of vision loss that people suffer from if they\u2019re detected early.\u201d\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nOver the course of the study, average visual decline was roughly equivalent to losing the ability to read one line of an eye chart.\nWhile mental function at one check-up was also related to vision at the following exam, the effect of vision on subsequent mental function was significantly stronger.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several approaches to maintaining eyesight. Mentioning other possible approaches to preventing cognitive decline (diet, exercise, etc.) would\u2019ve been a bonus.", "answer": 1}, {"article": "Olive oil users may, for example, have higher incomes, eat better overall or exercise more often than people who never use the oil.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nThe study found a correlation between people\u2019s olive oil use and their stroke risk, he told Reuters Health \u2014 but that doesn\u2019t necessarily translate into cause-and-effect.\nWhat\u2019s needed, he said, are clinical trials where people are randomly assigned to use olive oil or not, then followed over time to see who suffers a stroke.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least mentioned other factors that could be at play \u2013 \u201cno single food is consumed in isolation, he points out in his editorial. Olive oil is one part of the Mediterranean diet that has been tied to heart benefits. The diet also boasts plenty of fruits and vegetables, legumes, whole grains, fish and moderate amounts of red wine.\u201d", "answer": 1}, {"article": "But even without prostate treatment, 21 of the 27 men showed decreased levels of PSA.\nSymptom scores on the IPSS test also showed improvement.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\nAll the men had moderate to severe gum disease, for which they received treatment.\nSix participants showed no changes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "How is prostatitis currently treated? How do the results reported here compare with those treatments? The release doesn\u2019t say.", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\nThat's in contrast to patients with musculoskeletal problems such as low back pain, in whom low PSEQ scores predict poor treatment outcomes.\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\nThe study evaluated the performance of one such questionnaire--the Pain Self Efficacy Questionnaire (PSEQ)--in migraine surgery patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is another important criterion which the news release did not meet. And even though the published study did not address alternatives either, we still encourage news release writers to include this background for interested readers \u2014 both patients and journalists.\nPresumably, patients who turn to surgery have been resistant to the usual interventions and if so, this should be clarified in the news release.\nThere are many alternatives to migraine treatment, from prophylactic daily medications to Botox injections. In fact, Botox injections operate on the same mechanism that the migraine surgery does: the botulinum toxin is injected into facial nerves to paralyze them and release pressure on the nerves surrounding the face. Botox injections for migraines have been well-studied and proven to be effective; the procedure was approved by the FDA in 2010. Unlike the surgery however, the Botox injections are not permanent \u2014 though they also appear to carry fewer side effects. It would make the most sense to compare the surgery to Botox injections, but neither the researchers nor the news release did this. Nor did they compare the migraine surgery to any other migraine treatments. Instead, they compared results from the patient questionnaire to patients that suffered other chronic pain ailments, such as lower back pain. They said that migraine patients reported greater improvement than lower back pain patients, but this tells us very little because the two conditions are so different.", "answer": 0}, {"article": "The retina is the light-sensing nerve tissue at the back of the eye.\nFrom there, clinical trials will be designed to test potential benefit in patients with later-stage age-related macular degeneration.\nCurrently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release included no discussion of alternative approaches or other research being done on age-related macular degeneration.\nThere\u00a0are ongoing early clinical trials of stem cells in the treatment of AMD using cells differently derived than the ones reported here. So there are \u201calternatives\u201d to this particular type of stem cell therapy that also may show promise.\u00a0There are a few reports from Japan and elsewhere suggesting that there are alternatives to \u201cbolus injections\u201d of stem cells that may pose risks.\nIn addition, some current federal clinical trials have found that some vitamin and mineral supplements appear to reduce the risk of late-onset of the disease by as much as 25 percent.\nSo this is not the only work being done in this field, as the news release might suggest to some journalists or to the general public. \u00a0Even a brief mention of other research would have been important context to improve\u00a0public comprehension.", "answer": 0}, {"article": "\"Are you angry?\"\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes standardized behavioral rating scales, and the fact that clinicians and caregivers are involved in screening patients for suicide risk. But it lacks details on what those screenings are called, how and when they are done, and what qualitative and health record-related risks they look for (e.g. mental health conditions,\u00a0acute\u00a0stress, history of suicide attempts, behavior changes, and more). Having at least a basic description of how patients are typically screened for suicide risk and subsequent observation would have made this release a lot stronger.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nWickii Vigneswaran, MD, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology.\nImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\nWhile the procedure cannot cure mesothelioma, it can help control the buildup of fluid, improve breathing and lessen cancer pain.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not compare other treatments to pleurectomy and decortication. Although no cure is available, there are other types of surgeries to help treat mesothelioma. These include procedures to decrease fluid build-up (pleurodesis), to remove as much cancer as possible (debulking) and to remove a lung and surrounding tissue. Patients could also undergo chemotherapy or radiation therapy to kill cancer cells. \nSince none of these options are discussed in the news release, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "I didn\u2019t even know I had cancer until after the surgery to remove the tumor,\u201d Hopper told NBC News.\n\u201cThe average survival rate for all malignant brain tumor patients is only 34.7 percent,\u201d the group says.\nTwo patients died during the trial.\nThe Duke team tested 61 glioma patients over five years.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned standard treatment for glioblastoma can include surgery, chemotherapy, and radiation.\nHowever, the story would have been stronger if had mentioned that there are other experimental viral treatments under study for glioblastoma.", "answer": 1}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nIn a new study published in the journal Obstetrics & Gynecology, researchers discovered that the hormonal IUD and the implant are highly effective a year after they are currently approved for use.\nThe implants are currently approved for three years, and the hormonal IUD used in the study is approved for five.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The authors might have briefly mentioned the pros and cons of different methods other than implants and IUDs \u2014 such as birth control pills and condoms.", "answer": 0}, {"article": "[3] Yokell et al.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\n[5] In addition to the risk of an opioid overdose associated with an opioid use disorder, there may be an increased risk of life-threatening OIRD even when patients take a prescribed dose of an opioid as directed.\nEVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present.\nThe following warnings and precautions should be taken when administering EVZIO:\n\u2022 Due to the duration of action, keep the patient under continued surveillance and repeated doses of naloxone should be administered, as necessary, while awaiting emergency medical assistance.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives were offered. Besides the injectable forms of naloxone, a Narcan nasal spray is also on the market.\nThe National Institute of Allergy and Infectious Disease provides a listing of diffferent forms of naloxone.", "answer": 0}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nFIT goes one step further than MI, as it makes use of multisensory imagery to explore these changes by teaching clients how to elicit and practice motivational imagery themselves.\nSo FIT comes in with the key aim of encouraging someone to come up with their own imagery of what change might look and feel like to them, how it might be achieved and kept up, even when challenges arise.\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release addresses this, sort of, when it states: \u201cMost people agree that in order to lose weight, you need to eat less and exercise more, but in many cases, people simply aren\u2019t motivated enough to heed this advice \u2013 however much they might agree with it. So FIT comes in with the key aim of encouraging someone to come up with their own imagery of what change might look and feel like to them, how it might be achieved and kept up, even when challenges arise.\u201d That\u2019s enough to earn it a satisfactory ranking, particularly since it is consistent with the underlying study. However, it would be more valuable to see how effective FIT is when used in conjunction with proven weight loss techniques.", "answer": 1}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe microparticles are inserted using a catheter run through a pinhole-sized incision, in a procedure that lasts between 45 and 90 minutes, Bagla said.\nMuch of the pain that comes from knee arthritis actually stems from inflammation in the lining of the knee joint, also called the synovium, Bagla said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions joint replacement and medications to reduce knee pain. However, it doesn\u2019t mention steroids, hyaluronic acid, plasma protein derivatives, physical therapy and less invasive surgical procedures. The point is that there are a number of options, none particularly good, but readers should be aware that they exist and are used.", "answer": 0}, {"article": "\u2022 Khin NA, et.al.\nTo put this into context, an analysis of placebo-controlled data from three prior studies conducted by Duru and Fantino determined that a minimum change in MADRS of 1.9 was clinically meaningful.2 In addition, the average difference is between 2-3 points for currently approved antidepressants vs. placebo.3\n\nSafety results were consistent with previous studies of esketamine in younger adult populations.\nIf approved by the U.S. Food and Drug Administration (FDA), esketamine would be one of the first new approaches to treat refractory major depressive disorder available to patients in the last 50 years.\nThe study defined treatment-resistant as patients who had not responded to two or more currently available antidepressants of adequate dose and duration in the current episode of depression.\nEsketamine nasal spray has an acceptable safety and tolerability profile, based on the adverse event data from both Phase 3 studies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The trials at issue here are specifically aimed at patients for whom two or more antidepressants did not work. However, there are some additional alternatives for treatment-resistant depression which could have been included in the release, such as electroconvulsive therapy and atypical antidepressants. Many people with depression are given selective serotonin reuptake inhibitor, or SSRI (Prozac, Lexapro, Zoloft and others) or similar medications by their primary care doctor, and if that fails, are given another medication in the same class or in the serotonin and norepinephrine reuptake inhibitors (SNRI) class of medications. Psychiatrists have a larger arsenal of medications and therapies to try.", "answer": 0}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\n\u201cBased on current evidence, bisphosphonates should not be used for prevention of colorectal cancer,\u201d Jacobs said.\nIndeed, it found a higher risk of throat cancer in patients on the medication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Both this story and the HealthDay story ended with Jacobs from the American Cancer Society helping put the findings in context. In this story, he made a more forceful statement, saying \u201cBased on current evidence, bisphosphonates should not be used for prevention of colorectal cancer.\u201d Then, he said the same thing that he said in the HealthDay story:\u00a0\u201cFortunately, there are proven ways to help prevent colorectal cancer. In particular, all Americans, 50 or older, should get a screening test so that precancerous polyps can be detected and removed before they turn into cancer.\u201d", "answer": 1}, {"article": ".\nAfter 18 months, the women who received the placebo halted the injections.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\nThe researchers continued to follow up with the women for seven years after the growth hormone treatment was halted to monitor their bone density, fractures and perception of their quality of life.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not mention other osteoporosis treatment options \u2014 such as bisphosphonates, fall prevention interventions, etc. \u2014 at all, making it impossible for readers to determine how the growth hormone therapy performed relative to other courses of action.", "answer": 0}, {"article": "\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nDeath from any cause occurred in 7.5 percent of Januvia patients versus 7.3 percent for placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare the drug to any alternatives, only to a placebo. It does not point out that the medications the subjects were already taking seemed to be just as effective without adding the new drug.", "answer": 0}, {"article": "\u201cManaged care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,\u201d they wrote in the Health Affairs blog.\nExecutives at CVS Health, a leading pharmacy benefits manager, recently said that PCSK9 inhibitors might cost $7,000 to $12,000 a year and would strain health care budgets because so many people might use them.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article briefly compared PCSK9 inhibitors to statins, or other lipid-lowering drugs like Lipitor, stating that this new class of cholesterol drugs reduced bad cholesterol to lower levels than statins. It also mentioned the drug niacin, which did not protect against heart attacks and strokes, despite it raising good cholesterol levels and moderately lowering bad cholesterol.\nHowever, a more thorough discussion on traditional treatments would have been welcome. For example, why are other lipid-lowering medications needed if there are already quite a few out on the market? The AP story addressed this question, explaining many people cannot tolerate statins or get enough help from them.", "answer": 1}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\nEven if bone density did not increase, improvements in posture and balance that can accrue from the practice of yoga can be protective, Dr. Fishman said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions the tolerability of osteoporosis drugs, though the study wasn\u2019t a comparison between the two. \u00a0While the study didn\u2019t examine this, comparing yoga\u2019s effects against alternative\u00a0weight-bearing exercise forms (running, walking) might merit a mention.", "answer": 1}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention existing treatments, nor does it mention other experimental treatments for advanced melanoma that are also being presented at this same meeting.", "answer": 0}, {"article": "The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nThe researchers wrote that study results support the hypothesis that oxidative stress caused by cigarette smoking reduces the amount of ascorbic acid, a component of vitamin C, available to the body.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nThis study was funded by the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We were glad to see this important caveat relating to an alternative intervention included:\n\u201cHelping mothers quit smoking should remain the primary goal for health professionals and public health officials.\u201d", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Diet, exercise, and not smoking are all mentioned as important factors for stroke prevention.", "answer": 1}, {"article": "CHICAGO (Reuters) - U.S. researchers have developed tiny nanoparticle robots that can travel through a patient\u2019s blood and into tumors where they deliver a therapy that turns off an important cancer gene.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nTumor samples taken from three people with melanoma showed the nanoparticles found their way inside tumor cells.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\n\u201cWe\u2019re excited about it because there is a lot of skepticism whenever any new technology comes in,\u201d said Davis, a consultant to privately held Calando Pharmaceuticals Inc, which is developing the therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story acknowledged that other research teams are exploring using fats or lipids to reach the target.\u00a0 ", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other options for treating chronic low back pain were mentioned. ", "answer": 0}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0should have discussed how the results stack up against traditional exercise training regimens, which were tested recently in a much larger clinical trial. It also could\u00a0have discussed how the benefits\u00a0of tai chi compare with those of medication, which is the mainstay of heart failure treatment.", "answer": 0}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although two of the lifestyle recommendations for management of pre-hypertension (i.e. low-salt diet and regular exercise) were mentioned, the article relied on the New England Journal of Medicine article for estimates for the efficacy of lifestyle interventions to reduce hypertension instead of studies of these (and other lifestyle) interventions. Individuals receiving either the drug or placebo in this trial also received printed materals about lifestyle modifications and review and reinforcement of diet and exercise at all visits. This means that the study was really about the potential benefit of the drug in addition to usual lifestyle recommendations. That should have been made clear. ", "answer": 0}, {"article": ".\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nOverall, 41,028 mammograms were performed with 5,196 callbacks (12.7% recall rate), 1,164 biopsies, and 326 cancers detected.\nThere was also a lower positive biopsy rate among women ages 40-49 compared with women over 50.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release didn\u2019t discuss breast MRIs or other ways of detecting cancer in younger women. While there are other procedures, such as ultrasounds, that can detect breast cancer, mammograms remain the gold standard of breast cancer screening.", "answer": 0}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\nThe researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The survival benefit for women who were treated with eribulin is clearly presented.\u00a0 The article also included the definition of the treatment of the physician\u2019s choice that was\u00a0used by the study authors.", "answer": 1}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\nThe device alone reduced that to about one seizure a year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not adequately compare the device to alternatives and gives the impression that this is the best treatment choice. It says for example, \u201cAbout 3 million Americans have epilepsy, and for about one-third of them, drugs alone do not control their seizures.\u201d It does not say what the one-third referenced do to supplement the drugs.\u00a0It tends to leave readers with the idea that for at least that subset of the patient population, this device is the only alternative.", "answer": 0}, {"article": "It needs to be tested in large trials,\" he said.\nAnother trial in 2013, however, suggested that removing clots was not beneficial, he added.\nJolly said the lesson from his team's trial is that clot removal should be used only as a rescue treatment when an angioplasty fails to clear an artery.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\n\"There has been some controversy about removing blood clots during the treatment of heart attacks,\" said lead researcher Dr. Sanjit Jolly, an associate professor of cardiology at McMaster University in Hamilton, Ontario.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative here is clearly to do the angioplasty without clot removal. That is satisfactorily established. We wish the story had been a bit clearer about the different techniques available for clot removal, however. The story talks about \u201cmanual\u201d vs. \u201cmechanical\u201d removal, but never explains what that means. The press release notes that with \u201cmanual\u201d clot removal,\u201dthe surgeon uses a syringe to create suction to remove clots,\u201d whereas mechanical removal \u201cuses machinery to create the suction.\u201d", "answer": 1}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nDBS is a type of brain surgery, and comes with risks like bleeding, infection and need for more surgeries.\nIf ultimately successful, DBS could become a treatment used in tandem with physical rehabilitation.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does point out that the standard treatment for stroke victims who suffer a disability is physical therapy. However,\u00a0clot busting drugs and other early intervention methods are also being tried as means to improve stroke outcomes.", "answer": 1}, {"article": "Many researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story did not provide any information about other approaches to reducing risk of colon cancer. It would take a line to do so. ", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The column ended with one alternative suggestion from a professor of opthalmology:\u00a0 \u201cIt would make more sense to spend your money on something that\u2019s proven to help. Like a tutor.\u201d", "answer": 1}, {"article": "Guidelines also suggest that pregnant women not drink more than two cups a day.\nThere\u2019s almost no evidence for that at all.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\nBut it\u2019s way past time that we stopped viewing coffee as something we all need to cut back on.\nThat may change soon.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not really applicable in this setting, though tea research might have been used as a comparison.", "answer": 2}, {"article": "Though these children are larger, they do not have increased rates of obesity,\" Wu added.\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nBut Rabin, who was not involved in the study, did add a few caveats about the findings.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since there is little existing research in this area, the inclusion of another alternative would be difficult.", "answer": 2}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give story a not applicable in this category since there currently is no proven successful treatment against Ebola.", "answer": 2}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\n\"If it can eventually be shown that this technique can reliably identify which children will indeed develop autism, then we will have a valuable tool for early detection,\" Ewen said.\nDr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore, said the study is well done and looks promising, but needs to be replicated.\nThe algorithms can detect subtle patterns in the lines created by EEGs that the human eye might miss, Bosl explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "When reading this story, one starts to think that doctors have no idea how to diagnose autism, and yet autism diagnoses clearly are on the rise. (Prevalence being on the rise is a matter of debate.) How this diagnostic approach compares to existing methods or emerging methods, such as the MRI scan described in the December study, remain a mystery.\u00a0Even a brief mention of MRI or behaviors that parents and pediatricians might observe and refer for additional testing would have been helpful.", "answer": 0}, {"article": "An estimated 25 million to 45 million Americans suffer from irritable bowel syndrome, or IBS, a gastrointestinal condition that can cause miserable symptoms.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nWithout proof of a physical cause, some doctors considered IBS a psychological disorder.\nBut that could finally change with the introduction of two simple new blood tests for spotting the disease.\n\"I'm not saying the symptoms went away,\" she said, but she \"started to feel more whole.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even a mention of an alternative (such as how IBS is currently diagnosed) would have merited a satisfactory, but there is no mention of alternatives.", "answer": 0}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nThere is no such screening tool currently in use.\nOne expert said the study is an important step but definitely needs follow-up work.\nBut none proved as accurate as CA-125 after a Harvard scientist developed a mathematical model combining trends in test results and a patient's age.\nLu said the study isn't large enough to justify recommending yet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is clear to say that there is no good existing screening method and that using CA-125 alone has been proven inneffective.", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThis is far less sensitive than PSA, which catches 87 percent of tumors, but if the two tests are used together they can help rule out the need for unnecessary surgery or radiation.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nA study last year estimated that more than 1 million men in the United States alone had been needlessly treated for prostate tumors that likely would never have killed them.\nThey said Gen-Probe\u2019s Progensa PCA3 test caught about half the actual cases of prostate cancer in men who had abnormal PSA levels or digital rectal exams, and had about a 20 percent \u201cfalse positive\u201d rate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The outcomes from this test were compared to that of the PSA test. \u00a0There could have been at least a line, however, about the many other tests currently being tested for their ability to diagnose and predict the future course of prostate cancer. For example, on the same day this study was presented at the American Urological Association meeting, at least one other study about another prostate test looking for increased levels of genetic material was presented at the same meeting.\u00a0 ", "answer": 0}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\nObviously, the process will have to be refined and optimized before it's actually used for treatment.\nThe experiment proceeded just as planned, as biopsies later showed.\nThe precision of the process is crucial to limiting side effects, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of other targeted therapy research \u2013 something the Reuters story at least briefly described. ", "answer": 0}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nIn 2014, the first HIF-2 inhibitor, an oral drug known as PT2385, entered clinical trials in patients with advanced or metastatic renal clear cell carcinoma.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the treatment was compared to another kidney cancer drug,\u00a0sunitinib, we don\u2019t really learn what other alternative treatments outside of sunitinib or PT2399 are used to treat kidney cancer.", "answer": 0}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "What other dietary patterns might be beneficial for reducing cognitive decline? Are exercise or other lifestyle factors (e.g. education) associated with cognitive benefits as we get older? The story doesn\u2019t explore these questions.", "answer": 0}, {"article": "\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nIt is often administered as a gel, patch, injection or implant (pellet).\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release states that this oral form of testosterone was compared with T gel. It also names other delivery forms including a patch, injection or implant (pellet) ", "answer": 1}, {"article": "Lucinda Bateman is a doctor at the Fatigue Consultation Clinic in Salt Lake City who specializes in chronic fatigue syndrome.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nShe says some patients get caught in a \"push and crash\" cycle.\nA study published this year in the Lancet found that a form of talk therapy, as well as exercise, offered relief for some patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare this approach to any alternatives; other options include antidepressant medications (in fact about 1/3 of patients were on an antidepressant).", "answer": 0}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\nInstead of destroying the bacteria, the ingredients in the fruit weakened the bacteria by preventing them from producing the toxins it uses as weapons to damage tissue.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nIts leaves and bark are used to treat wounds, ulcers, burns and skin infections, Quave said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternatives are antibiotics and other infection-fighting drugs, and the story discusses how those have become less effective in recent years.", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nThe integration of palliative care improves symptom control and decreases unwanted health care use, yet many patients are never offered these services.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\nConsultation with the palliative care team included establishment of goals of care, advance care plans using standardized communication protocols, transition planning and symptom assessment and treatment using the Edmonton Symptom Assessment Scale (ESAS).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Alternatives to palliative care for late-stage cancer patients are described clearly.", "answer": 1}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\nFor Alyssa Gold, the AMH test was a wakeup call.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nTurns out there\u2019s a simple blood test that could tell her.\nShe\u2019s grateful to the Baby Deadline Test for giving her that option.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were no alternatives\u2013or the lack thereof\u2013mentioned in the story. Readers should be informed: How do other long-term fertility-detection methods compare to this one?", "answer": 0}, {"article": "1 Yiou et al.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\n\"Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside.\"\nIntracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release said that 9 million men affected by ED don\u2019t respond to standard\u00a0pharmacological treatments such as Viagra, Levitra and Cialis. However, it didn\u2019t make any mention of other types of treatments, such as lifestyle changes (quitting smoking and drinking), psychological counseling, vacuum erection devices or surgery. There are a number of other treatments available for ED that is unresponsive to standard medications. None of these other treatments including devices, injections or surgical implants are ideal, so the search for new treatment options is warranted. But the unstated implication that stem cell therapy should be the next choice after a medicine trial is problematic.", "answer": 0}, {"article": ".\nThe PSMA-inhibiting theranostic agent, called PSMA-617, is still in its initial stages, but it could be ideal for the treatment of patients with hormone-refractory prostate cancers, which are notoriously difficult to control and linked to poor prognosis.\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nDiagnosis and therapy with the theranostic agent PSMA-617 could offer more effective and sensitive visualization, better staging and significantly higher therapeutic potential.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other attempts at creating this type of imaging/therapy drug are mentioned, and the fact that metastatic prostate cancer is currently difficult to control and has a poor prognosis implies that there are few successful alternatives. We\u2019ll award a Satisfactory, although the release could have made it clearer that targeted therapies are only a subset of treatments for metastatic cancer \u2014 which also includes various chemotherapies and the Provenge vaccine.", "answer": 1}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n\u201cAlthough this method is not ready for normal diagnostic situations, any step to easier diagnosis is welcome,\u201d said Terry Brugha, professor of psychiatry at the University of Leicester.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that autism is currently diagnosed via interviews and patient observation. \u00a0", "answer": 1}, {"article": "But from the beginning, Mr. Hladik resisted.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHe died at home in November, a year and a half after saying no to dialysis.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions peritoneal dialysis, which can be done at home, but fewer than 10 percent of patients opt for that. It would have been useful to know why home-based dialysis is so underused.", "answer": 1}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\nThat means, Dr. H. Gilbert Welch of Dartmouth wrote in an additional analysis in an accompanying editorial, that mammography could have reduced the breast cancer death rate by as little as 2 percent, an amount so small that it is not really different from zero.\nThe question was, Did the program of mammograms and optimal new treatment with coordinated teams of surgeons, pathologists, oncologists, radiologists and nurses lower the breast cancer death rate?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story notes that improved treatments appear to have reduced the breast cancer death rate even among women who did not have regular screening mammograms. Not being screened was clearly acknowledged as an alternative, something not all competing stories explicitly addressed. ", "answer": 1}, {"article": "MRI has long been known as an effective breast cancer screening modality that offers better sensitivity than mammography and ultrasound.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release includes a comparison with breast ultrasound. It found that supplemental MRI screening\u00a0is useful for women with average risk of cancer who exhibit a range of breast densities and that it is superior to the alternative of breast ultrasound\u00a0for this purpose.", "answer": 1}, {"article": "\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nThese at-risk individuals may have weak or transient psychotic symptoms, and already show schizophrenia-like brain changes, Dr. G. Paul Amminger of The University of Melbourne in Australia, a researcher on the study, told Reuters Health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does compare treatment with fish oil/omega-3 PUFA\u00a0supplements to\u00a0an alternative treatment with antipsychotic medications.\u00a0\u00a0 In addition, the story reports on potential harms of treatment with antipsychotic medication.", "answer": 1}, {"article": "In the United States study, 80% of the children on antibiotics felt better on the seventh day of treatment; 74% of the children taking a placebo also felt better on the seventh day.\nRosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nIn treatment outcomes for pain, there was no difference, he notes.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately describes the rationale supporting watchful waiting, which is the primary alternative to antibiotics for an acute ear infection.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the article does mention cryo, seeds, and other forms of surgery for prostate cancer, the article doesn\u2019t mention other treatments, which could include active monitoring or radiation. Viewers are left with the impression that surgery is needed and is really the only option for treating prostate cancer. ", "answer": 0}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nSide effects \u2013 experienced by 93.4 percent of patients in the CBD group and 74.6 percent of those treated with placebo \u2013 were generally reported as mild or moderate in severity.\nThis new, randomized, controlled clinical study eliminated those concerns as participants and their physicians did not know if they were on CBD or placebo, say the study authors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the trial, patients in the experimental group had Epidiolex \u201cadded to their existing treatment over a 14-week period,\u201d so it is obvious that other treatments are available. But these standard medications are not alternatives to cannabidiol. Instead, cannabidiol is an add-on treatment, not an alternative to existing drugs. The release could have named those standard medications and noted that other cannabidiol compounds are being studied in people with epilepsy.", "answer": 0}, {"article": "The agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nAlthough DHEA is included in some dietary supplements, the efficacy and safety of those products have not been established for diagnosing, curing, mitigating, treating or preventing any disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives in this short news release. There are many interventions available now for vulvar and vaginal atrophy (VVA), including hormonal and non-hormonal therapies.\nOver-the-counter treatments include non-hormonal vaginal moisturizers for VVA symptoms, as well as lubricants to alleviate pain during sexual intercourse. Water-based vaginal moisturizers are available as liquids, gels or ovules and are inserted every few days. Silicone or water-based vaginal lubricants are shorter acting than moisturizers and are applied right before sexual activity.\nPostmenopausal women can also opt for low-dose vaginal estrogen preparations in the form of creams, rings or tablets to treat their VVA.\nSince none of these options are mentioned in the news release, we give it an Not Satisfactory rating here.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The treatment options discussed are taking one multivitamin a day (which was not found to increase advanced prostate cancer risk) and\u00a0 taking more than one multivitamin a day, which was found to be correlated with increased risk.\nThe story didn\u2019t provide information about other options for decreasing prostate cancer risk, or other factors that increase prostate cancer risk. \u00a0 \n\u00a0", "answer": 0}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\u2022 19 percent lower in women who had breastfed for up to six months.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nThe Association has strict policies to prevent these relationships from influencing the science content.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\n\"Some studies have reported that breastfeeding may reduce the rates of breast cancer, ovarian cancer and risk of developing Type 2 diabetes in mothers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does a nice job here, stating: \u201cBreastfeeding is only one of many factors that could potentially protect against stroke. Others include getting adequate exercise, choosing healthy foods, not smoking and seeking treatment if needed to keep your blood pressure, cholesterol and blood sugar in the normal range.\u201d\nNot all of the alternatives have been proven to protect against stroke but listing them is a worthwhile reminder that lifestyle changes might reduce their risk.", "answer": 1}, {"article": "But the F.D.A.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nShe said veins as large as a Sharpie marker can be tackled with foam sclerotherapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses surgery for varicose veins in the past tense, suggesting that it is no longer used. (\"It entailed ripping out the groin-to-ankle vein with a wire via an incision.\") In fact,\u00a0as discussed above, the supposed long-term superiority of newer techniques over surgery has not yet been proven, and surgery still has a place in the treatment of certain types of varicose veins, especially larger veins.\u00a0The story also failed to mention\u00a0lifestyle changes, such as weight loss or\u00a0avoiding standing or sitting for long periods, which are typically the first line treatment for this condition.\u00a0\u00a0As the story was in the fashion section,\u00a0they should have also mentioned makeup, hosiery, etc, in addition to therapeutic interventions that a doctor might recommend. ", "answer": 0}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\nHe said, \"Relief of symptoms in patients with atrial fibrillation can be challenging.\"\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\nIn addition, many patients need to continue blood thinners and medications that control irregular heartbeats after the procedure, she explained.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains\u00a0that medication is the first-line treatment: \u201cFor those whose atrial fibrillation can\u2019t be controlled with medications, catheter ablation may be recommended.\u201d\nWe do wish the story had made it clear that few people with atrial fibrillation fall into the group needing ablation.", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the potential of vaccines with the benefits of existing medications for addiction\u2013and notes that the\u00a0available drugs might work better.\u00a0We would like\u00a0to have\u00a0seen more ink given\u00a0to the role of\u00a0behavioral\u00a0approaches in the management of addiction, which are supported by considerable evidence. However,\u00a0the story does acknowledge\u00a0that\u00a0vaccines \u201cwould likely be used alongside psychological therapy.\u201d\u00a0We\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nJen Gunter, an OB-GYN and pain medicine specialist, noted that the idea of using TENS for menstrual pain is actually very sound.\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\nAnd there's not a whole lot they can do beyond trying to blunt it with pain-relieving pills or oral contraceptives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The\u00a0story notes\u00a0that oral contraceptives and analgesics are also used, and that\u00a0traditional TENS units are also widely available.", "answer": 1}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story did mention at the very end how the pace of weight loss with the product reported on compared with weight loss following gastric bypass surgery, the story ought to have provided better insight about the long-term outcomes in those who have gastric bypass and those who chose not to have surgery to help manage their excess weight. \u00a0That way, readers could compare the two commonly utilized surgical options and understand the differences between them. The story hints at this by paraphrasing a study author saying that Lap-Band patients, \u201cmay have less weight loss and more complications than those who choose other weight loss surgeries.\u201d But it never provides any evidence to back that claim. We also would have liked to have seen some comment about diet and exercise.", "answer": 0}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nThese women will suffer the harms of early screening.\nBut the vast majority of women will never develop breast cancer during their 40s.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Interesting this story never mentioned that the study was comparing breast cancer tumors detected by patient/doctor to those detected by mammograms.", "answer": 0}, {"article": "Your skin clears up.\nThe final diet was the three-week Quantum Wellness Cleanse, which Oprah Winfrey made famous.\nRenowned weight loss surgeon, Dr. Mitchell Roslin said the short-term payoff is all in the science.\nVolpe said she noticed results when her pants began getting baggy around her legs.\nBut \"GMA\" viewer Janine Efron had less success while trying the Martha's Vineyard Diet Detox, which consists of shakes rich in antioxidants and proteins.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment provided commentary about three difference cleanses.\u00a0 But there was no discussion of alternative options for people who are overweight and fatigued, such as making healthy lifestyle changes like weight loss or physical activity. ", "answer": 0}, {"article": ".\nFurthermore, restarting therapy with the new oral anticoagulant dabigatran was associated with a lower risk of recurrent hemorrhage in these cases than the old standby drug warfarin.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\nMore than 1,500 of those people suffered a major bleeding event while using one of the drugs.\nThey then followed nearly 90,000 people who had filled prescriptions for the anticoagulants warfarin, which has been used as a medication since 1954, and dabigatran, which was approved by the U.S. Food and Drug Administration in 2010.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release focuses on the potential for superior outcomes with a new anticoagulant compared with warfarin, the traditional medication. However, there are other new anticoagulants on the market and they were not mentioned.", "answer": 0}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job showing how the standard interventions for heart disease stacked up against each other in this study. We wish that some mention had been made of diet and exercise and that at least a sentence had been included about whether there might be differences in outcomes seen as a result of different medication patterns. The story doesn\u2019t make it clear what exactly the patients were taking.", "answer": 1}, {"article": "After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\nPatients with good clinical response then received reduced radiation.\nEligible patients received three courses of induction chemotherapy with the drugs cisplatin, paclitaxel, and cetuximab.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The\u00a0release summarizes a study that compares low dose and high dose radiation, and notes that\u00a0chemotherapy was also part of the treatment regimen for the patients. It\u00a0states that all of the patient volunteers were candidates for surgery, which is another\u00a0alternative or adjunct therapy for these types of cancers.", "answer": 1}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\nBased on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nHe noted that generating more evidence of effective use is \"a good thing.\"\nGW Pharmaceuticals, a company that is developing cannabidiol medicines, helped subsidize the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is not a deep comparison of alternatives in this piece, but we give it credit for quoting an independent expert saying, \u201cInterestingly, it looks similar to our other seizure medications in terms of efficacy and tolerability. \u2026 So, sadly, not a home run for most patients but another tool in our treatment regimen.\u201d", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\n\"And so I would caution against anybody in the U.S. increasing their selenium intake based on what we found, because we also know there's an increased risk for type 2 diabetes when you increase selenium intake if you are already at a high level of blood selenium levels.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0notes that\u00a0bread in the U.S. is a good source of selenium, and that U.S. consumers generally have no need to take a supplement. So, there\u2019s really no need to talk about alternatives. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\nThe Clickometrics\u00ae adaptive data science platform continuously personalizes user experience to drive cognitive and behavioral outcomes.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Many other therapies for major depression have been developed, and some of them use technological approaches. Besides these, there are also drugs, psychotherapy and exercise with known benefits. The release would have been stronger if it had listed some of what is already known to work, and explained how the new therapy fit into that context. Is it cheaper? More effective? Easier for rural patients to access?", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0This story mentions that this compound is among a group of compounds being studied for their ability to accurately identify Alzheimer\u2019s disease prior to post mortem examination of the brain. \u00a0It is unfortunate that this story (not whatever was reported in April) failed to discuss how the compound in the study, florbetavir differs from the other compounds under study.\nBecause PET tracers must be produced in a cyclotron and used quickly. \u00a0This limits the use of PET scans to those center that have a cyclotron or are located near a commercial supplier. \u00a0Florbetavir has a longer interval that other tracers under study and may well be the most notable attribute of the drug.\nWe\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\nThere was even a hint that the drug helped to slow the decline in functioning.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not include background on existing treatments.", "answer": 0}, {"article": "Autistic children are prone to seizures.\nGeier's promotional materials said he has treated hundreds of children with Lupron and has launched nine ASD Centers in eight states.\nThe drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nLupron critics said autism parents may not understand the dangers.\nShe said Geier plans to continue the Lupron for several months to see if it helps Marco's other autistic behavior.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Good job on this as well.\u00a0 The story states that \"untested autism treatments have flourished.\"\u00a0 And it ends with: \n       \n \n ", "answer": 1}, {"article": "\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nThese compounds minimize one of the risk factors for cancer, inflammation within the body.\nThe researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While there\u2019s no proven strategy to prevent prostate cancer, there is general advice for reducing overall cancer risk such as quitting smoking, maintaining a healthy weight, exercising, and eating a variety of plant foods. Current treatment options include watchful waiting, active surveillance, hormone therapy, chemotherapy, radiation therapy and surgery. These aren\u2019t mentioned.\nSpeaking of prevention and treatment in the same release really oversimplifies the issues. There are studies showing that chemoprevention with 5-alpha reductase inhibitors can reduce the risk of prostate cancer, although the FDA will not allow manufacturers to suggest these compounds prevent cancer because these agents were associated with an increased risk for high-grade cancers. Treatment options completely depend upon the stage of the cancer\u2013thus range from conservative management to aggressive attempts at curative therapy to palliative care. The role of these substances in any of these settings is obviously completely unknown.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nThere\u2019s no one route of infection, but sources include pedicures and locker room showers.\nPodiatrists have begun using a laser treatment that combats the infection \u2014 or wastes their patients\u2019 money because it doesn\u2019t work, depending on whom you ask.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention multiple alternatives, but it also knocks each one of them down. Lamisil \u201chas been associated with rare cases of serious liver problems\u201d and other \u201cpotential side effects include diarrhea, headache, rashes and changes in taste.\u201d Then the story quotes a podiatrist who does not use lasers but never says what he does use. Instead, he lists a litany of treatments that don\u2019t work. \u201cFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root. Home remedies such as tea tree oil, bleach and vinegar also don\u2019t work, he says.\u201d Then we are introduced to Richard, the first-name-only guy with foot fungus. He is presented as a success story for laser treatments. The story says, \u201chis nails were fully cleared of the yellowed, thickened look after a year.\u201d We think that, on balance, the story did not fairly compare the new approach with existing alternatives. Instead, it stacked the deck against these alternatives, leading readers to conclude that lasers would be the best choice.", "answer": 0}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIt is a serious intervention to improve health.\nThe CHORI-bar is intended as a non-traditional means to positively impact the obesity epidemic by initiating a healthier metabolism without requiring sudden drastic behavioral changes.\nFormulation development was guided by over 15 small clinical trials to ensure that beneficial properties of the bar were retained.\nDevelopment of the CHORI-bar has also been guided by Dr. Mark Shigenaga's insights into the importance of a healthy gut supported by optimal nutrition for disease prevention.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story notes, \u201cConventional approaches that encourage weight loss by improving dietary habits, reducing caloric intake and modifying activity can be successful, but prove difficult for many to initiate and sustain.\u201d We\u2019ll call that sufficient for a Satisfactory rating here.", "answer": 1}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nParticipants received the study medication in addition to any stable treatments they were already receiving.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nThis is a randomised, controlled trial, but what we found were exploratory outcomes; in other words, it wasn't the main result that we were testing.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Bipolar disorder is fairly well-defined in the release, and it\u2019s mentioned \u201cthere is a great need for better treatments for the depressive phase.\u201d However, current alternative treatments such as medications, light therapy or electroconvulsive therapy (ETC) in severe cases are not mentioned.", "answer": 0}, {"article": "\"First, I think it's very important that we investigate potential new therapies, and that we shouldn't be dissuaded from doing that just because something can be misused,\" he said.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\nDr. Michael Mithoefer, author of the earlier study on MDMA and PTSD, also urged further exploration of the medicinal potential of the drug.\n\"More controlled research is needed to establish whether MDMA can safely and effectively add to psychotherapy for some conditions and, if so, what the mechanisms of these effects are,\" Bedi said.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of other alternative approaches to help people socialize.", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We will give the story a satisfactory rating on this criterion because it does discuss existing methods for monitoring medication adherence and it makes clear that the apps mentioned still need to be studied. However, the overall tone of the story implies confidence that the apps will prove themselves to be more efficient than current methods, which is a proposition that has yet to be adequately tested.", "answer": 1}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\nAnd there\u2019s another major problem with the use of many antidepressants in children: They may increase suicidal thoughts and behavior.\nIt\u2019s notoriously hard to treat depression in kids\u2014the antidepressants we rely on to treat adults seem to be less effective and more dangerous when used on younger minds.\nGuidelines from the psychiatric associations in most countries recommend that doctors first try psychotherapy, or \u201ctalk therapy,\u201d which is has been shown to work, at least by participants\u2019 own assessment of their depression levels (it\u2019s very hard to test therapy against a placebo, for obvious reasons).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses cognitive behavioral therapy, which it says is recommended by guidelines from the psychiatric associations in most countries and \u201chas been shown to work, at least by participants\u2019 own assessment of their depression levels.\u201d It also mentions the high cost of cognitive behavioral therapy and the fact that it \u201cmay not always be readily available,\u201d which could explain the growing reliance on antidepressant drugs.\nHowever, the story is incorrect when it states Prozac is the only drug approved to treat depression in people under 18. Escitalopram (Lexapro) is also approved by the FDA to treat adolescents for depression.\nIt also offers up conflicting information.\u00a0In the last sentence, it\u00a0links to a Cochrane meta-analysis and says\u00a0\u201ctherapy and medication are more effective together than in isolation.\u201d But that\u2019s not what the analysis concluded. Instead, it said: \u201cWe do not know whether psychological therapy, antidepressant medication or a combination of the two is most effective to treat depressive disorders in children and adolescents.\u201d", "answer": 0}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\nEarlier this year, Ray\u2019s team published an analysis of previous aspirin trials showing the medication did not prevent deaths from heart disease or cancer, and was likely to cause more harm than good.\nBecause the study wasn\u2019t a clinical trial, it\u2019s hard to know if the findings can be chalked up to aspirin or if something else is at play.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The WebMD story did a better job on this simply by including one line about \u201cother strategies will also reduce the risk of cancer\u201d \u2013 regular physical activity, healthy weight, not smoking.", "answer": 0}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nThe results for both techniques were very positive.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nHe found that not only did the practice activate different parts of the brain, it also seemed to impact the body in ways that matter for health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is effectively all about comparing alternatives, though\u2013again\u2013it should have made clear that MBSR and CBT were used in conjunction with conventional medical treatment, and it left out discussion of other well-known non-medication treatment methods, such as exercise.", "answer": 1}, {"article": "TUHS neither provides nor controls the provision of health care.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\nThey show, for the first time in an animal model, that tau pathology - the second-most important lesion in the brain in patients with Alzheimer's disease - can be reversed by a drug.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release would have been improved if it had acknowledged the multiple failures over many decades of other once promising drugs for dementia tested in animals. The take-home message should be that these disorders, and brain chemistry in general, are complicated, and although research may bring hope, it has yet to bring effective treatments.", "answer": 0}, {"article": "Anderson Cancer Center in Houston.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nNumerous vaccines to prevent breast cancer recurrence are currently under study, he noted.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Barely satisfactory \u2013 the story at least mentioned that \u201cNumerous vaccines to prevent breast cancer recurrence are currently under study.\u201d", "answer": 1}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nOne thing that is clear, the researcher stressed, is that Doppler ultrasound is not necessary for women with average, healthy pregnancies.\nTypically, high-risk women would receive other types prenatal testing as well, such as electronic fetal-heart monitoring.\nBut in the new review, researchers found that across 16 studies of more than 10,000 high-risk pregnancies, Doppler ultrasound testing was linked to a 29 percent reduction in fetal and newborn deaths.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe story says other types of testing, including electronic fetal-heart monitoring, may also be done during high-risk pregnancies. \n", "answer": 1}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no discussion about how the effectiveness of a dairy-supplemented Mediterranean diet might compare to a traditional Mediterranean diet as it relates to heart disease risk. The release claims a\u00a0dairy-supplemented Mediterranean diet \u201cis more effective\u201d than a low-fat diet but offers no data to back up the claim.", "answer": 0}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\nThe study found that to date, the new drug appears to be both safe and well-tolerated.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\n\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nThe team added that the new medication appears to tackle MS by a different type of mechanism than other available options, and apparently works by curtailing the onset of permanent tissue damage while limiting acute inflammation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes an unchallenged comment that \u201coral drugs are much better than shots,\u201d without explaining why or what sort of evidence supports this claim. It redeems itself, though, by explaining that the inability to draw clear comparisons between the experimental drug and current alternatives is one of the study\u2019s short points. \u201cLaquinimod was not, however, tested against currently existing treatment alternatives, the authors stressed,\u201d the story says. \u201cThe team added that the new medication appears to tackle MS by a different type of mechanism than other available options, and apparently works by curtailing the onset of permanent tissue damage while limiting acute inflammation. Then Dr. Gary Birnbaum, director of the MS Treatment and Research Center at the Minneapolis Clinic of Neurology,\u00a0provides\u00a0readers with a good summation of why this new drug, while not necessarily\u00a0a silver bullet, could be\u00a0clinically beneficial.\u00a0\u201cAnd MS is probably not a single disease,\u201d Birnbaum says. \u201cSo different medications may work better for some and not others, which is why this new drug could end up being an important addition to the armamentarium.\u201d He adds, though, \u201cHowever, we still need to have a head-to-head comparison with other drugs.\u201d", "answer": 1}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nAlmost all the patients mounted an immune response.\nHe appeared to be beating the cancer with the combination therapy.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\nThe response was better with the highest dose of Temodar.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was a story about additional treatments that might be used in conjunction with currently utilized therapy.\u00a0 It was clear that surgery, radiation and standard chemotherapy are used.\u00a0 ", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This should have been the entire point of the story, but there is really no comparison. Just broad statements made about MRIs being superior, etc.", "answer": 0}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\nThe altona RT-PCR assay failed to detect a small number of EVD cases that tested positive by both RDT and by an alternative RT-PCR test (Trombley), all with relatively low amounts of virus.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is\u00a0definitely a strong part of the release\u00a0\u2014 the new test is compared to two manufacturers\u2019 versions of the standard RT-PCR test.\u00a0But the release doesn\u2019t mention\u00a0other diagnostic tests, including virus isolation and ELISA.", "answer": 1}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nThe phase 1 and 2 study was sponsored by GlaxoSmithKline, which developed both drugs.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other new drugs have recently been approved for the treatment of advanced melanoma. The story did not mention these or compare results.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Non-surgical and drug alternatives for treating pain from osteoarthritis of the knee were not discussed. Also, the story starts out by saying \u201cKnee osteoarthritis, or arthritis of the knees, is a difficult-to-treat and painful condition affecting millions of people.\u201d Many patients have mild symptoms that are well controlled with medicine, exercise, physical therapy and other simpler and less expensive treatments than discussed here. The article should have mentioned these and said that the treatments discussed are considered for those not responding to these other, first-line therapies.", "answer": 0}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n\"Modafinil was found to have an effect on impulsivity in healthy individuals and so would be able to have an even bigger effect on food addicts, who are lacking in certain types of dopamine,\" said Professor Vlaev.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention of alternatives to the use of the narcolepsy drugs studied as a means of weight control. The release could have acknowledged there are numerous appetite-control drugs, countless diets and exercise strategies available for to help change eating patterns.", "answer": 0}, {"article": "Pop a Tylenol and take a brisk walk for protection against prostate cancer?\nThe findings are in line with previous research suggesting that physical activity may help reduce the risk of disease-related death in certain cases of prostate cancer.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nAdditionally, daily acetaminophen was associated with a 51% reduced risk of developing an aggressive form of the disease.\nMen who took acetaminophen for less than five years saw no protective benefit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Neither finding was put into the context of other treatment/prevention approaches for prostate cancer. For example, the 5-alpha reductase inhibitor drugs (finasteride and dutasteride) have been rigorously evaluated for chemoprevention.", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article concludes with the bottom line for weight loss, cutting calories and exercising are the key, regardless of the type of diet.", "answer": 1}, {"article": "\u201cWe need more information on how this works precisely in people before we can advise them to take anything,\u201d he said.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\nBut as a supplement, Basis and similar products only have to be shown to be safe for humans to take, with labels that are not misleading.\nIndeed, one scientist not involved with Elysium questions the company\u2019s marketing pitch, saying there is too little information to know what Basis can do.\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We give the story credit for mentioning that each of the active ingredients in Basis are already available in separate pills. But since the story is about a company that claims to offer healthier aging in a pill, we thought it was especially important to mention non-chemical approaches that are also associated with healthy aging, such as a good diet and exercise. The story didn\u2019t do that.", "answer": 0}, {"article": ".\nBottom Line: The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release spells out some specific features of abemaciclib that explain why researchers think it has potential advantages over a similar drug that is already FDA-approved. However, this comparison puts the new drug in an entirely positive light, which it has yet to demonstrate it deserves. We\u2019ll dock points for that concern here. Since the comparison with the competing drug also speaks to abemaciclib\u2019s novelty, we\u2019ll award a Satisfactory for that criterion (see below) so as not to double-ding the release. ", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story provided even less background than other stories about current methods for assessing dyslexia and responses to interventions.", "answer": 0}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "How Victoza performs in reducing severe cardiovascular events compared to rival drugs is mentioned numerous times. It is worth noting that there was no mention that the drug is given by injection. For individuals with diabetes reading the article, this oversight is important in that it may make them more inclined to oral medicines that are easier to take.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not state whether there are any intrinsic advantages or disadvantages to the \u201cnew\u201d vaccine. It also fails to note that FluMist is not approved for use in high-risk patients. Nor does it describe other actions people can take to prevent the flu. In addition to vaccination, the Centers for Disease Control and Prevention recommend several measures (http://www.cdc.gov/flu/protect/habits.htm).", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives. What are the traditional treatments for knee arthritis pain and chronic neck pain? Or for pain management in general? A few words about over the counter analgesics, massage, or other proven therapies would have been helpful.", "answer": 0}, {"article": "This will help for that,\u201d Destounis said.\n\u201cOur results indicate that in 1,000 women screened for 10 years, three breast cancer deaths would be prevented,\u201d Duffy said, adding that most of the deaths prevented would have occurred more than a decade after the screening had started.\n\u201cI think for anybody who was beginning to have their faith shaken in the value of mammography, these data show mammography is quite valuable as a public health approach to reducing deaths from breast cancer,\u201d Smith said.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\nDr. Stamatia Destounis, a radiologist at Elizabeth Wende Breast Care in Rochester, New York, who was not involved in the study, said radiologists have been quoting results of the Swedish study for years and the new findings show breast cancer screening is \u201ceven more of a benefit than we understood.\u201d\n\nShe said sweeping changes in the U.S. screening guidelines two years ago that scaled back recommendations on breast cancer screening caused a lot of confusion among doctors and patients about the benefits of mammograms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story only briefly touches on the fact that \u201ceveryone must make up their own mind\u201d regarding mammography, but it\u2019s not explicit about the fact that women may choose not to have routine mammograms. In addition, the story indicates that the U.S. Preventive Services Task Force made their recommendations against routine screening in women 40-49 to avoid unnecessary biopsies and anxiety, but it should be mentioned that these recommendations were also implemented to minimize needless treatment, including surgery, chemotherapy and radiation therapy.", "answer": 0}, {"article": "The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\n\"We thought that if aspirin can inhibit aromatase, it ought to reduce the likelihood that breast cancer would develop and it could also be an effective way to improve breast cancer patients' prognosis once they no longer take the more potent aromatase inhibitors.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a host of things that women can do to reduce their risk of breast cancer. However, none of these things are mutually exclusive. One can be physically active and limit alcohol intake, for example. None of these other ways to reduce breast cancer risk are mentioned.", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0notes, in\u00a0passing, that mood stabilizing drugs are used.\u00a0 It doesn't say anthing about other options (such as psychosocial treatments) and whether any of these treatments work.\u00a0 ", "answer": 0}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nThe study did not continue long enough to discover whether the lower risk of developing cancer in the opposite breast translated into a lower risk of death.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Continuing aromatase inhibitor was compared to not continuing it. There was a brief mention that study participants had taken another drug, tamoxifen, before starting letrozole. However, we\u2019d have liked to have seen details on what other long-term alternatives women have for preventing recurrence.", "answer": 0}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nIn a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nMarybeth Thorsgaard, a Medtronic spokeswoman, said the company was close to completing a clinical trial involving the use of Infuse in anterior cervical fusion.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe treatment of back and neck pain is hotly debated, but this story does not mention any of the non-surgical approaches nor does it provide any context about the outcomes of spinal fusion procedures.\n\u00a0", "answer": 0}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions CT scans as the current primary tool for hospital-based diagnosis, so we\u2019ll count this as Satisfactory.\nHowever, given that the story does talk about these blood tests possibly being used by athletic trainers, we\u2019d have liked to have seen a brief comparison\u00a0of what\u2019s currently used in sports settings, such as the\u00a0Standardized Assessment of Concussion, which measures cognition and a timed tandem gait test of balance.", "answer": 1}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nDr. Charles Kahi of the Indiana University School of Medicine, in Indianapolis, noted that the rate found in the new study was a bit higher than previously reported.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says, \"Another less expensive test is fecal occult blood testing, which involves taking stool specimens at home and mailing them to the doctor\u2019s office or medical lab. The US Preventive Services Task Force, an independent panel of medical experts appointed by the federal government, recommends screening people aged 50 to 75 for the disease, but does not specify which test is best.\" There could have been some mention of how effective fecal occult blood testing is and whether similar studies have been done on that type of screening.", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\nDoctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nSince then, about 650 patients across the country have had the procedure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that avoiding allergens and using inhaled medications are enough to keep asthma under control in most patients.", "answer": 1}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nAmong the possible explanations offered for the disparities are that the European study included only symptomatic patients, who may have had more advanced disease, and that the North American trial carefully screened the doctors doing the stenting procedure, including only highly skilled physicians with a lot of experience.\nLong-term follow-up of patients, which was two and a half years on average but is continuing, found both groups at equal risk of suffering a stroke that should have been prevented by the procedure: 2 percent of those in the stent group compared with 2.4 percent of the surgical patients.\nStrokes had a higher impact on the patient\u2019s quality of life, the study reported.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story doesn\u2019t give enough attention to the question of whether one should intervene at all in asymptomatic patients.\u00a0 It states that surgery\u00a0\"has\u00a0been shown to be more effective than medical therapy alone\" for preventing strokes, but it is not\u00a0clear that this is true for asymptomatic patients. \u00a0", "answer": 0}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quotes a specialist saying that women with macromastia who do not have surgery can wear special reinforced bras, sports bras or even two bras, and can treat pain with analgesics and rashes with ointments. ", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned for treatment of either HER2-positive or triple negative breast cancer. This is a major oversight given that a variety of treatments, such as Herceptin, are available for HER2-positive breast cancer.", "answer": 0}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The goal\u00a0of the news release is in fact to accomplish this very criterion. The release accurately states, \u201cUsual care for neck pain generally consists of prescribed medications and visits to physical therapists and other health care professionals.\u201d", "answer": 1}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\nKeeping blood pressure controlled, not smoking, exercising regularly, and eating a healthy diet that is low in salt and rich in fruits and vegetables can also help reduce stroke risk, she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story ends, appropriately, with this: \u201cKeeping blood pressure controlled, not smoking, exercising regularly, and eating a healthy diet that is low in salt and rich in fruits and vegetables can also help reduce stroke risk.\u201d", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nBased on these findings, Hennekens and colleagues are drafting an investigator initiated research grant proposal to the National Institutes of Health (NIH) under the direction of co-author Patrick E. McBride, M.D., M.P.H., professor of medicine and interim associate dean for faculty affairs at the University of Wisconsin School of Medicine and Public Health.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not mention the availability of inexpensive plaque-disclosing tablets. Consumers would want to know if such tablets might be an alternative to the very pricey Plaque HD toothpaste, an important point that the study did not explore. The release also does not discuss the potential effect of brushing frequency or duration.", "answer": 0}, {"article": "Traumatic injuries to the head, often from car accidents, tend to sever brain cell connections and leave many neurons intact.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nThis means by definition that the young woman has transitioned from an unresponsive, vegetative state to a sometimes responsive condition known as a minimally conscious state, Dr. Laureys said in an interview.\nDr. Nicholas Schiff, a neuroscientist at Weill Cornell Medical College in New York, said that the study provided \u201cknock-down, drag-out\u201d evidence for mental awareness, but that it was not clear \u201cwhether we\u2019ll see this in one out of 100 vegetative patients, or one out of 1,000, or ever again.\u201d\n\nIn a more recent exam, more than 11 months after her injury, the patient exhibited a sign of responsiveness: she tracked with her eyes a small mirror, as it was moved slowly to her right, and could fixate on objects for more than five seconds, said Dr. Steven Laureys, a neurologist at the University of Li\u00e8ge and an author of the study.\nMs. Schiavo suffered far more profound brain damage than the woman in the study and was unresponsive for some 15 years, according to neurologists who examined her.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention standard bedside methods of diagnosis, but does not mention other imaging techniques such as PET. The story could have also provided more detail about the pros and cons of the different methods.", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nThe label warns that evidence is limited.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that peanut butter can be diluted with water to make a soupy, infant-friendly, peanut-containing food at less cost than the packaged powder product.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nThe new research, published today (Thursday) in The Lancet Oncology, shows that even women with specific genetic changes conveying resistance to hormone therapy can benefit from the new drug combination.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\nThis trial is an exciting example of one of the most promising approaches to overcoming drug resistance, by combining drugs with different mechanisms of action to block off cancer's escape routes.\nThe international study, led in the UK by Dr Nicholas Turner, from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, updates the results of a major phase III trial published last year.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Throughout the news release, comparison between the drug combination is made with the alternative of taking only one of the drugs, fulvestrant, plus placebo. Several clinical endpoints are reported, all showing the clear advantage of the drug combination.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that other manufacturers make implants that may be just as good as or better than the Gender Knee for women. We wish the story had included an additional sentence on nonsurgical alternatives to remind readers that surgery is a matter of patient preference\u2014and many patients choose to opt out.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nDo melatonin supplements really help people sleep?\nBut the scientific evidence has been slim.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that melatonin was as effective as the prescription medications Ambien or Lunesta.", "answer": 1}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did talk about NSAIDs and birth control pills as other alternatives to help alleviate menstrual cramps.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story reported on the comparison of rimonabant as compared to placebo in a group of individuals with type-two diabetes whose sugar levels were not adequately controlled using diet alone.\u00a0 Although rimonabant may be the first in a new class of drugs that may someday be used in the treatment of diabetes, the story failed to mention the pharmacologic and lifestyle approaches currently used to treat diabetes.\u00a0 It did not mention the clear evidence that intensive behavioral counseling for weight loss is effective in improving health outcomes in obese adults, and improving blood sugar control in diabetic patients. ", "answer": 0}, {"article": "In addition, we saw that several smaller brain areas actually started to grow in response to training,\" says Ulrik Dalgas.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nDrugs can counter this development, but we saw a tendency that training further minimises brain shrinkage in patients already receiving medication.\nA bigger and more in-depth on-going study will help to clarify this, and may also lead to improved treatment options, says Ulrik Dalgas.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions drugs as a treatment option for patients with MS. These include immunosuppressants, like corticosteroids to reduce nerve inflammation and beta interferons to reduce the frequency and severity of relapses. Plasma exchanges can also help patients who haven\u2019t responded to steroids and whose symptoms are new and severe.\nOther treatments options include physical therapy and muscle relaxants to help relieve MS signs and symptoms.\nAlthough we would have liked more detail on established therapies, we feel the mention of medication was good enough for a Satisfactory rating here.", "answer": 1}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nTopiramate also has blood pressure-lowering effects, she says.\nThose who took the medium dose of the pill lost 8% of their body weight at six months and 8.2% by one year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no information about how well this product works in comparison with other approaches to weight loss.", "answer": 0}, {"article": "RotaTeq \"generally appears to have a better safety profile than the earlier vaccine,\" said Umesh D. Parashar, a medical epidemiologist at the CDC.\nThe federal Centers for Disease Control and Prevention and the manufacturer, Merck & Co. Inc. of Whitehouse Station, N.J., have promised elaborate studies to catch any safety problems.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention of alternatives.", "answer": 0}, {"article": "\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\nLipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that \"Drugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks.\"\u00a0 In fact inexpensive drugs\u00a0(such as nonsteroidals) or others, such as triptans, \u00a0are effective in the aura phase.  So we think the discussion of alternative options is incomplete. \n\u00a0", "answer": 0}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nThe device also included a defibrillator used to shock dangerous heart beats back into normal rhythm.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion about alternatives.", "answer": 0}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nOf the five patients with extra-pelvic lymph node involvement, four achieved an undetectable PSA after ADT and surgery, while the fifth needed radiation to reach this milestone.\nUltimately, four (27%) achieved the proposed end point, a PSA of 150 ng/dL at 20 months after the start of ADT, which remained undetectable in two patients for 27 and 46 months, respectively.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the results of the three-pronged treatment approach were better than would have been achieved with any of the treatment options on their own. However, it doesn\u2019t provide evidence for this statement. Because the treatment was offered to a small, highly-selected group of patients and the study did not have a control group, the validity of this claim is uncertain.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is, in effect, all about comparing alternatives \u2014 bilateral versus staged knee replacement. One thing that\u2019s not made clear anywhere in the story is whether the knee replacements in question for any or all of the studies were total knee replacements, partial knee replacements, or both. Are there differences in cost? Benefits? Risks? That would have been useful to include.", "answer": 1}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\nIn the new study, doctors used the medications as part of a package of treatments and worked to keep the doses as low as possible minimizing their bad effects.\nAbout half got the combined approach and half received treatment as usual.\nDr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were good explanations of the two alternatives being compared by the research itself \u2014 the drug-focused standard and the more comprehensive integrated care.", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other options for managing menopause symptoms are not noted.", "answer": 0}, {"article": "47(5) pp.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\nThe Agency for Healthcare Research and Quality (AHRQ) reported significant improvements in the safety of metabolic/bariatric surgery due in large part to improved laparoscopic techniques.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\nSix months after the balloons were removed, 89.5 percent of the average total weight lost during the treatment period was maintained.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release tells readers that the trial results indicate the balloon and counseling were more effective than lifestyle counseling alone. It also says that bariatric surgery is the most effective obesity treatment and it does refer to \u201cother intragastric balloons.\u201d However, these vague references to alternatives do not provide readers meaningful information, especially since the release never specifically notes that the trial did not compare this balloon to other similar devices.\nIt\u2019s worth noting that behavioral weight management programs generally result in 5-10 percent weight losses at 6 months to 1 year. When comparing Look AHEAD\u2019s (a lifestyle intervention program) one year data, average weight loss was greater than achieved with Obalon at 8.6 percent.", "answer": 0}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nPatients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\nThe researchers followed the women for one year after they had finished chemotherapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did a satisfactory job of mentioning one major alternative to the reviewed procedure.", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story did mention that fibromyalgia is traditionally treated with a 'cocktail of off-label drugs including antidepressants and painkillers', this is really not an adequate description of the the treatment options.\u00a0 In fact, one of the drugs that may be included in this 'cocktail' is the very drug that is being reported on.", "answer": 0}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nBut they also thought a drug to treat the disease was in reach.\nAt the time, scientists predicted that a genetic test for CF was just around the corner.\nThey're also likely to be expensive.\nWhile not quite a cure, the drug is extremely effective for some CF patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of what people typically do to treat cystic fibrosis and what advantage, if any, this drug brings. The mention of the clinical trial says that a patient was given a placebo and then the drug. But have tests been done comparing existing treatments to this new treatment?\nA Wall Street Journal story on the drug last February at least mentioned that until now patients took \u201cmedicines that only tackled the symptoms of the disease, such as antibiotics to treat the infections. Patients typically spent a few hours each day wearing vibrating vests to dislodge mucus build-up.\u201d", "answer": 0}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\nSUNDAY, April 14, 2013 (HealthDay News) -- A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Granted, as already noted, the \u201cindependent\u201d expert discussed \u201cmultiple different technologies for doing this kind of very localized approach.\u201d\u00a0 But he also stated his own preference for stereotactic radiosurgery and the story didn\u2019t include any data/evidence comparison to help readers. This represents a major flaw in the reporting.\u00a0 There are multiple approaches to treatment currently including surgery, chemotherapy, radiofrequency ablation, stereotatic and other forms of radiation and proton beam therapy.\u00a0 There are data on the success of each of these in improving survival in patients with metastatic disease.", "answer": 0}, {"article": "Zinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nPreviously zinc lozenges containing citric acid were shown to be ineffective in treating colds because citric acid binds zinc ions very tightly and no free zinc is released.\nBecause of the somewhat stronger binding, zinc gluconate has been proposed to be less suitable constituent for lozenges.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention alternative sources of zinc and alternative treatments for cold symptoms. Zinc is available in a number of common foods \u2014 beef, lamb, cashews, and chocolate among others.", "answer": 0}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no radiologic or other non-surgical diagnostic alternatives for evaluating the spread of microinvasive breast cancer to the axillary lymph nodes, so we rate this Not Applicable.", "answer": 2}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nThe drug, known as 10-1074, may also offer a new way to prevent viral infection in people who are at high risk to acquire HIV, the virus that causes AIDS.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that broadly neutralizing antibodies may eventually be an alternative to currently available antiviral therapy as well as pre-exposure prophylaxis, PrEP, (a lower dose of antiviral therapy taken as prevention). The current study doesn\u2019t look at clinical outcomes so the comparison may be premature, although it\u2019s presented in a pretty general way.", "answer": 1}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\nThis can lead to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.\u201d\n\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\nThe new drug works by forcing cancer cells to use their mitochondria, the \u2018power house\u2019 of a cell, to generate the energy necessary to function.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "One researcher does talk about a comparison with existing treatments and why new therapies are needed.\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.", "answer": 1}, {"article": "How (Study Design): This was a randomized clinical trial (RCT).\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nStudy Limitations: The results apply only to pain after two hours.\nAbout 1 in 5 patients required additional medication to control their pain.\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The entire release (and the study it is discussing) are based on the comparison of alternatives for addressing acute pain in an emergency room environment.", "answer": 1}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\nCommenting on the study, Robert Robinson and Harold Adams from the University of Iowa in the United States, said it could change the way doctors treat stroke victims in future, but more research is needed to see if the effects continue over time.\nThere were also more independent patients and depression was less common in the Prozac group than in the placebo group, and side effects of the drug were rare and mild, researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, the story reported only what was in the study but fell short on context. It notes that all subjects in the study received physiotherapy, which means Prozac was compared to physiotherapy alone. But it didn\u2019t describe the established medications routinely used in patients after a stroke, thereby making Prozac and SSRIs were the only drugs to be considered. ", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nThey had lower brain volume, indicating shrinkage comparable to two additional years of aging.\nCAVEATS Most participants were white.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of alternatives (such as exercise, mental stimulation) to omega-3s for preserving cognitive function.", "answer": 0}, {"article": "New guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nNeurologists say that only about one-third of those who could benefit by migraine-preventing medication actually use it.\nThe guidelines will be published in Tuesday\u2019s edition of the journal Neurology.\nMany migraines can be prevented by taking medication every day.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Unlike the USA Today story we reviewed, non-drug approaches were not mentioned.\u00a0 Despite the fact that the story was based on a set of guidelines for drug treatments, we would have liked to have seen a few words on non-pharmacologic approaches including stress reduction, diet, etc.", "answer": 0}, {"article": "They find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nOverall, Avastin, like several other targeted agents have led to therapeutic advances in lung cancer, he added.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\nOverall, 3 percent of the patients died due to adverse events associated with Avastin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion about whether there are other drugs that may be used in conjunction with the standard treatment for metastatic non-squamous non-small cell lung cancer to improve patient outcomes. \u00a0And since the story did not discuss how the use of Avastin changes outcomes, it failed to report on how this new approach compared with existing treatment.", "answer": 0}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\n\u201cThe accuracy of this approach was very similar to that of computer-assisted laboratory analysis, even when it was performed by untrained users with no clinical background,\u201d they wrote in the study.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nCurrently, they\u2019re required to make office visits to a urologist for several months to ensure that the operation was successful.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers are not given any details on the obvious alternative\u2013going to a clinic for testing, or using one of the other already-available at-home devices. These and other details aren\u2019t addressed, and they\u2019re important in establishing the significance of the new prototype device.", "answer": 0}, {"article": "For more on heart failure, visit the U.S. National Heart, Lung, and Blood Institute.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\nBut by subjecting a patient's breath to a rigorous but fast analysis of the hundreds of so-called volatile organic compounds contained therein, the study team said it has so far been able to correctly diagnose heart failure among newly hospitalized patients with a 100 percent accuracy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does list some of the standard tests for heart failure. It also notes that the research is too preliminary to tell whether this sort of breath test would be any better. However, it is likely that readers will get the impression that the new test is an advance, even though there have not been any experiments done to compare different methods.\nThe story could have compared with the B-type Natriuretic Peptide (BNP) blood test (an inexpensive blood test).", "answer": 1}, {"article": "Politicians started giving scary speeches about rationing health care.\nThere\u2019s an intuitive argument for why 3-D mammography might be more accurate.\n\u201cThe standard type of mammography that\u2019s used all over the country today may very well be better than what was used in that trial.\nTrials like this are the gold standard of medical evidence.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article compares existing 2-D mammorgraphy\u00a0imaging with the new 3-D imaging throughout the piece.\u00a0 While it does present 3-D imaging as superior because of its ostensibly improved sensitivity and specificity, the article provides no scientific evidence to support that view.\nFor patients the information that matters most is\u00a0which imaging mode\u00a0improves survival.\u00a0 Both the article and Hologic\u2019s Andy Smith note that a study of whether 3-D imaging improves patient survival versus 2-D imaging will take a long time and \u201cwon\u2019t be available for decades.\u201d\u00a0\u00a0Because of that fact,\u00a0the story had an even greater obligation to provide readers with\u00a0balanced information about this latest imaging technique and to include any available evidence supporting the superiority of 3-D imaging that this article suggests.\nNonethless, since some attempt at comparison was made, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "Cook, who lives in Baltimore, began to suffer from debilitating symptoms: She had problems with her short-term memory; she had constant headaches and couldn't concentrate; her vision became blurry and dark; and her hearing was altered, so that all sounds were jumbled and very loud.\nOver the past decade, doctors in the United States and internationally have begun using it to treat mTBIs.\nHyperbaric therapy, he said, can return them to full function, even years after the injury.\nPatients typically receive between 40 and 60 hour-long hyperbaric treatments spread over two to three months.\nThe nature of the human brain makes it particularly susceptible to chronic injury.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s mentioned that post-concussion syndrome has proven difficult to treat, with existing therapies having varied success at targeting symptoms, but not addressing the cause.", "answer": 1}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nMore generally, Serpell said, the popular idea that pets make you happier \u201cis not a harmless distortion.\nCherry-picked positive results also are a problem, as he says happens in promotional materials from the Human-Animal Bond Research Initiative (HABRI).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s not clear what the direct alternatives would be here, so we\u2019ll rate this as not applicable. However, the story could have talked first-line treatments such as medications and traditional talk therapy. Therapy animals are meant to extend those mainstream treatments, not replace them.", "answer": 2}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nBut in terms of their bacterial colonies, the infants swabbed with the microbes closely resembled vaginally delivered babies, she found, especially in the first week of life.\nAnal samples from the swabbed group, oddly, contained the highest abundance of bacteria usually found in the mouth.\nAnd all infants delivered by C-section were exposed to antibiotics, which also may have reduced the number and variety of bacteria colonizing them.\nA larger study of vaginal microbial transfer is underway at N.Y.U., Dr. Dominguez-Bello said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll rate this as Not Applicable. There is an outstanding hypothesis that colonization of the newborn with \u2018friendly\u201d bacteria from the mother\u2019s vaginal secretions confers some advantages. This study merely test the ability to colonize a newborn delivered by cesarean delivery artificially. There aren\u2019t really any alternatives to discuss here.", "answer": 2}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself compared Avastin to standard therapy, and the story reports enough of the comparison to earn a score. However, we see a few ways the comparisons in this story could\u2019ve been sharper. (See our comments under the \u201cBenefits\u201d criterion for a related critique.)\nWe\u2019ve logged confusion about pitting Avastin to Lucentis. There may be a good reason, but we don\u2019t think WSJ readers get it. The only use of Lucentis discussed is in grown-up eyes. Is it compared to Avastin just because they\u2019re \u201csimilar\u201d drugs and because Lucentis has at least some eye indication? Or is Lucentis actually used off-label, or such use has been proposed, in this disease? Without that missing piece of the narrative, it\u2019s kind of difficult to weigh the meaning of Avastin\u2019s cost and pharmacologic advantages over Lucentis.\nIt may be hard to find perfectly balanced patient testimonials for a story like this, but it\u2019s worth pointing out that the Henry family\u2019s experiences may not be the most level illustration of this study\u2019s results.\u00a0Evelyn had a great outcome from Avastin.\u00a0Her sister\u00a0Grace had the laser and a very regrettable outcome, losing an eye from glaucoma. For one thing, it\u2019s only implied that the culprit was the treatment, not her disease, which, we\u2019re told is associated with retinal detachment as opposed to glaucoma \u2014 but the article could\u2019ve been clearer about causality here. More importantly, the relative side effects of these two procedures were never discussed in the scientific portion of the article, and we don\u2019t see any discussion of the potential for very serious side effects from the laser. If it is such a distinguishing factor as to color the entire testimonial section, we would\u2019ve liked to hear about it in the discussion of pros, cons, and research.\n", "answer": 1}, {"article": "To win road races?\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\nIn one of these studies it looks like running very intensely (faster than an eight-minute mile, more than four hours a week) increases your risk of death relative to not running at all.\nWe may tend to attribute the health of this group to their running habits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear early on that it is not looking at other forms of exercise, but explains the concept of \u201cmetabolic equivalent of task\u201d measurements (or METS) which can be used to determine the \u201cenergy intensity\u201d of various activities. It does mention a few other activities, such as yoga and cycle spinning, that may also be associated with mortality benefits. Presumably, one could use the METs associated with other exercises \u2014 such as bicycling, swimming or rowing \u2014 to find which exercises/paces are comparable to jogging 5-7 mph. However, that would take some homework, because while the story explains what METs are, it doesn\u2019t tell readers how many METs are associated with the \u201coptimal\u201d moderate jogging pace.", "answer": 1}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nThe concern was that the drug might be preventing cancers that never spread.\nWith this new analysis, many prostate cancer specialists, including Dr. Scardino, say their view of the drug has completely changed.\nMaybe, they thought, by shrinking the prostate, the drug was just making it easier to find aggressive tumors.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not adequately describe the option of not taking this drug as a preventive measure.\u00a0 A lot of space was given to the arguments for prescribing a drug without mentioning the possibility of the clinician having a shared decision-making discussion with the man about not taking the drug \u2013 and about the potential tradeoffs of this or any other prostate cancer treatment.\u00a0 ", "answer": 0}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nByron Caughey, Ph.D., a senior investigator in NIAID\u2019s Laboratory of Persistent Viral Diseases, is available to comment on this study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release says \u201ctest results were available within two days, compared to related assays that require up to 13 days.\u201d\nHowever, it doesn\u2019t say how the faster test compares in terms of accuracy. The study says early detection is helpful in part because \u201cthe accuracy of diagnoses based on other clinical indices is poorest in the earlier phases of disease.\u201d", "answer": 1}, {"article": "With Cognivue, patients sit before a video screen that shows a series of images, such as a group of dots, that move around and fluctuate in clarity.\nDuffy said his tool holds promise as a relatively inexpensive and easy way to test people\u2019s memory and ability to think.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\nIt is not intended to be a standalone diagnostic tool, and its effectiveness for people with less than 12 years of education is not proven.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job in providing the reader with other testing methods and a bit about their complexity and time requirements.\u00a0 We are told that the new approach is as good if not better that existing instruments.\u00a0 So, we are giving the story a Satisfactory rating.\u00a0 But again, we are never given any data supporting that viewpoint.", "answer": 1}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\n\"Future studies should examine which people or patients may need to limit their intake of saturated fat,\" assistant professor Simon Nitter Dankel points out, who led the study together with the director of the laboratory clinics, professor Gunnar Mellgren, at Haukeland university hospital in Bergen, Norway.\n\"Participants on the very-high-fat diet also had substantial improvements in several important cardiometabolic risk factors, such as ectopic fat storage, blood pressure, blood lipids (triglycerides), insulin and blood sugar.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is about comparing two diets \u2014 one high in \u201clowly\u201d processed fats (butter, cream and cold-pressed oils) and another high in carbohydrates.\nThe release does not give us details of the diets (what to consume and how much) so it\u2019s almost impossible to compare them.", "answer": 0}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nStill, this study will not answer the question of whether it is safe to use the hormone for years, even decades, which would be necessary to maintain any benefits.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\nThen again, this may be a realistic population to study, given that many candidates for hormone therapy are likely to have such health issues.\nAlthough testosterone can cause overgrowth of the prostate, studies have not shown harm to urinary function, Dr. Morgentaler said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article\u00a0could have mentioned \u00a0lifestyle changes, such as getting more exercise and\u00a0quitting smoking, that may improve libido,\u00a0combat fatigue,\u00a0and increase sexual function.\u00a0But since there\u2019s not much evidence that these or other approaches are effective,\u00a0we don\u2019t think the article should be dinged for failing to mention them. We\u2019ll rule it Not Applicable in this case. ", "answer": 2}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nTwo existing drugs, in combination, have shown significant promise in promoting weight loss, according to a new report.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Adequate.\u00a0 The story stated:", "answer": 1}, {"article": "And I am a lunch buddy at one of the schools nearby,\" she says.\nIf that happens, Williams says, then patients may never get to the point where they need a telescope in their eye.\nColby says that's also why patients need to learn to use the implanted telescope eye for near activities.\nPractically all the patients in the telescope study with Orr had their vision improve.\nFor one, the treatment doesn't work for those who have had cataract surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, this could be a model for other stories. It places the new surgery in the context of existing surgeries and compares it to drug treatments, even explaining how those treatments and surgeries are performed, all in just a few sentences. Every story should have a section like this: \n\"Cataract surgery removes the natural lens and, in most cases, replaces it with an artificial lens, which means there is no foundation for the telescope. And for patients who are in the early stages of macular degeneration, Williams says that medications approved just six years ago are effective and a lot less invasive than the telescope. The drugs are injected directly into the eye on a monthly basis. And with this treatment, doctors are able to prevent severe visual loss in over 90 percent of patients. In nearly half of all patients, visual improvement is significant.\"\u00a0\nThe only thing that would have made this better is if the reporter had asked at least one more source besides Williams for comments and context.", "answer": 1}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nThere\u2019s some evidence that when students sleep better, they perform better in school as well.\nFor one, teens need more sleep than adults: about eight or nine hours a night, compared with about the six or seven their parents require.\nWhen it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are alternative public health measures that might get teens to sleep more (for example, a public education campaign). This context would have been helpful: What are the other options, and how effective might they be?", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions FDA approved drugs: \u201cThere are four FDA-approved drugs for Alzheimer\u2019s, which affects 5.5 million people in the US: donepezil (sold as Aricept), galantamine (Razadyne), rivastigmine (Exelon), and memantine (Namenda). But none is a cure, and none affects the destruction of neurons and synapses, which causes the disease\u2019s memory loss and cognitive catastrophe.\u201d It also highlights that this new agent works in a different way from existing medications.", "answer": 1}, {"article": "Autologous CD34?\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\nEncouraging early clinical trials suggest that cell therapy is an attractive treatment option for these patients, especially trials in which subjects were transplanted with autologous (self-donated) CD34+ cells.\"\nThe patients, who were unresponsive to other treatments, were considered to have no other options (refractory).\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In order to fully appreciate any new or emerging treatment, it\u2019s important to compare it to existing techniques that address the same problem. The release does mention \u201cconventional medical treatments\u201d and \u201crevascularization\u201d but doesn\u2019t explain what those things are nor does it offer any comparisons with this developing therapy. There are a host of other treatments out there, from surgical interventions to pharmaceutical treatments.", "answer": 0}, {"article": "For more information about the study contact ket.study@unsw.edu.au or call 02 9382 9509.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nPrevious studies into ketamine treatments for older people with depression - which are limited to just five case reports - show mixed success, with findings limited by small sample sizes.\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is the one area where more information was greatly needed. The release notes that ketamine therapy is intended for treatment-resistant patients, but we learn nothing about about the effectiveness of other therapies, like anti-depressants, electroconvulsive therapy (ECT), cognitive behavioral therapy, etc.", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\nAlthough they give many epileptics a better quality of life, they do not affect the course of the disease, only its symptoms.\nAs Dr. Devinsky noted, seizures in turn may produce further inflammation, perpetuating the cycle.\nResearchers hope that anti-inflammatories may help ameliorate epilepsy\u2019s underlying causes.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not do a good job comparing alternatives. For example, it mentions in passing that the same child who is being used as proof of a \u201cmiracle intervention\u201d with anti-inflammatories is also on a restrictive diet, without providing any information about the proof \u2014 if any \u2014 of the efficacy of these types of diets.", "answer": 0}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nThat might also indicate whether it could be used in tests to indicate the disease.\nFor that reason, tests that spot antibodies to citrullinated proteins are already used to diagnose the disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release provides some information about the cyclic citrullinated peptide (CCP) test, the standard test used, and states that the new blood test appears to be more accurate and reliable in comparison. The true alternative is actually to wait until symptoms develop.", "answer": 1}, {"article": "\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\n\"With our method we identify all normal and all Down syndrome [pregnancies],\" Patsalis said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No discussion of how this compares with any of the other approaches being studied in this field.", "answer": 0}, {"article": "Both are reasonable options.\u201d\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not detail other available alternatives, such as muscle strengthening exercises, surgery, or other medications.", "answer": 0}, {"article": "\"This is one more reason to consume fruits and vegetables - at least 5 a day - and it's good to include tomatoes in that mix,\" Willett said.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York.\nIf we don't eat enough lycopene-packed foods, experts suspect too many free radicals get left in the body, damaging blood vessels by helping to form fatty deposits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story suggests that we consume a mix of fruits and vegetables every day, because, as one expert put it: \u201c\u2026we don\u2019t know if there is really anything unique about tomatoes apart from other fruits and vegetables that reduce stroke risk.\u201d\nThe story could have mentioned other controllable factors associated with stroke risk, including tobacco use, obesity, and heavy alcohol consumption.", "answer": 1}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\nNearly 9,000 of the study participants died in the period.\nUlf Ekelund at the Norwegian School of Sport Sciences in Oslo said the study emphasised what researchers have found time and again: that even a small amount of regular exercise wards off death.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the impact of different activity levels on early death risk.", "answer": 1}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\nThe study's first author, Yosef Koronyo, a research associate at Cedars-Sinai and a scientist and inventor at NeuroVision, said the latest findings cap a decade of study that has produced several landmark discoveries.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted, there is a passing reference to other types of diagnostic tools but no true comparisons.", "answer": 0}, {"article": "Attention, memory, and language improved.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other lifestyle or medical interventions are not mentioned in the release. The published review article itself cited other lifestyle interventions.", "answer": 0}, {"article": "In addition, BCG alters metabolism so cells consume higher levels of glucose, drawing more of it out of the blood, in a process called aerobic glycolysis.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\nAfter the vaccine showed signs of effectiveness, an additional six patients were vaccinated five years ago, and 111 more recently.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nThe BCG vaccine lowered A1c levels 9 percent to 16 percent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only alternative is insulin, and the story makes clear that even with the vaccine, patients still need to take it, but in smaller doses.", "answer": 2}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\"This is the first study in humans to examine the association between flavonoids and risk of developing Parkinson's disease ,\" says researcher Xiang Gao, MD, PhD, of the Harvard School of Public Health in Boston, in a news release.\nIf confirmed, flavonoids may be a natural and healthy way to reduce your risk of developing Parkinson's disease .\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s not even a line about other research looking at other factors to lower Parkinson\u2019s risk.\u00a0 There\u2019s also no discussion of other research looking at potential benefits of flavonoids.", "answer": 0}, {"article": "The average age of people in both groups was 73.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nWith this new analysis, they were able to predict cognitive decline with 89 percent accuracy when looking at the whole brain.\nThe researchers found that people who went on to experience cognitive decline had significantly more signs of damage to their white matter.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Mentioned were the Mini-Mental State Examination questionnaire, testing for the high-risk form of the gene ApoE, and PET scans to look for plaques of Alzheimer\u2019s proteins in the brain.", "answer": 1}, {"article": ".\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nThe findings also underscore the importance of flu vaccination for this risk group.\nPast studies have suggested that flu antiviral therapy is safe and beneficial for pregnant women.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Oseltamivir is one of two FDA approved antivirals for treating influenza. The other is zanamivir. The\u00a0 FDA has taken a very murky approach to recommending these drugs during pregnancy. The FDA website states, \u201cBoth drugs are designated \u201cPregnancy Category C,\u201d\u00a0which means that they have not been studied in pregnant women. However, Pregnancy Category C does NOT mean the drug cannot be used\u00a0in pregnant women. \u00a0Pregnant women can and should receive a category C drug when the possible benefits of using the drug are more likely than the possible risk of harm to the woman or her baby.\u201d\nThe release could have acknowledged the existence of zanamivir and whether similar observations were made about its effectiveness.", "answer": 0}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\nThat may explain why the B vaccine appears to offer some protection against Neisseria gonorrhea.\nThere are vaccines for several Neisseria meningitidis strains, but designing a vaccine to protect against the B strain was a particularly difficult nut to crack.\nClinical trials will need to be conducted to see if the effect researchers have observed is actually due to the meningococcal B vaccine.\nResearchers in Quebec say they saw the same phenomenon after a meningitis outbreak there, and previously published data from Cuba and Norway also hint of the vaccine\u2019s unexpected benefit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no discussion of other strategies to address the spread of gonorrhea. The CDC has urged the development of new treatments for gonorrhea. Public health education, including condom use, can prevent new cases. A report sponsored by health agencies in the U.S. and the United Kingdom highlighted the need for strong data-driven public health surveillance to better understand how resistant strains evolve and get transmitted, as well as point-of-care diagnostic testing to identify resistant strains. At least a line or two discussing these alternatives would have informed readers that the vaccine isn\u2019t the only solution.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An independent expert says in the story:\n\u201c\u2026patients often ask about caffeine as a weight-loss aid. \u201cI tell them it\u2019s definitely not going to be as helpful as 30 minutes of exercise.\u201d (He) says a little caffeine before a workout might help a person exercise harder and longer, which could theoretically help them control their weight. But the real credit would go to the exercise, not the caffeine.", "answer": 1}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nNow, with about 75 percent of mammograms adding it, it is even more common, Fenton said.\nOne limitation of the study, he said, is that the researchers cannot say for sure it was the computer-aided detection that made the difference.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\nThe additional tests that turn out to be unnecessary, because no cancer is found, are not desirable, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "By explaining the limitations & benefits of adding CAD to standard mammography readings, the article informs readers about both methods.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did not include mention of any other approaches to obesity treatment though there certainly are other options.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than a recommendation to keep folate intake to somewhere less than 1,000 micrograms per day, there were no treatment recommendations in this story, nor alternative treatment options presented.\u00a0 A treatment option for colorectal cancer prevention is removal of the precursor lesion, polyps via surveillance colonoscopy.", "answer": 0}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nThis will assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release seems to be favorably comparing this breath test, which is a screening test, to conventional diagnostic methods, including endoscopy, even though there is not yet any evidence to support comparisons.\nThe release would have been improved with a more careful distinction of who the screening test is geared for \u2014 is it a screening tool for healthy people to help rule out cancer or is it only for those with cancer symptoms? ", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there are effective existing treatments for opioid withdrawal.\nScientific studies have indicated that the most effective treatment for opioid withdrawal includes the\u00a0medically supervised use of opioid medications such as methadone.", "answer": 1}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nProgram, researchers in Madrid implemented a three-year healthy lifestyle intervention for 3 to 5 year olds that used their school, teachers and families to promote cardiovascular health through healthy diet, increased physical activity, understanding of the human body and managing emotions.\n\"Until now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The use of education for preschool-aged children to prevent cardiovascular disease appears novel, and we are not aware of a direct alternative \u201ceducation\u201d that exists. We\u2019ll rule this one Not Applicable.", "answer": 2}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nA little larger than a quarter, it\u2019s almost like a tiny lab stuck to the skin \u2014 and a study published Wednesday found it worked on sweaty bicyclists, sticking even during a long-distance race in Arizona.\nThe skin-like sweat patch adds a capability called microfluidics, capturing and analyzing tiny amounts of body fluid.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does state that the patch was shown in the study to be just as good as a pad sent to a laboratory for analysis in terms of collecting sweat samples. But there\u2019s no comparison with other alternatives for monitoring health measures such as blood tests, and in the case of dehydration, good old-fashioned thirst.", "answer": 0}, {"article": "Normally, cells in the pancreas work to release insulin, a hormone that can process sugar and either send it to cells that need it for energy or store it as fat for future energy needs.\nBut in a paper published in the , researchers in the UK describe a landmark study in which people with diabetes went into remission\u2014just by losing weight.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nAll of the people had been diagnosed with type 2 diabetes in the six years preceding the study.\nThe current study takes that work a step further and shows that it\u2019s possible to actually reverse the disease in people who have been diagnosed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions gastric bypass surgery as another method to dramatic weight loss and that has been shown to reverse diabetes. It also mentioned the high cost of and risk of complications from gastric bypass. Unfortunately, readers cannot compare the cost and harms of the managed diet approach, as the story omits their mention.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\n\"This study adds to the literature on vaginal laser therapy for GSM.\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release names some of the many treatments available for managing menopause symptoms through this quote from the executive director of NAMS:\nUntil more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.", "answer": 1}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the main focus of the story is\u00a0blood tests, the apparent alternative would be no blood tests.", "answer": 2}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not do a good job comparing nicotine gum to going cold turkey, counseling or other therapies. Some of the studies mentioned talk about a combination of therapies that include gum and counseling. We would have liked to have seen a better comparison to give readers the best sense of what choice they should make if considering quitting smoking.", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nThe Weight Watchers group also had a bigger improvement in a measure of long-term control of their blood sugar, which can reduce the risk for serious problems related to Type 2 diabetes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers some comparison of the intervention group vs the standard of care group, but does not mention other possible approaches to weight loss such as competing meal replacement plans, liquid supplement diets, exercise-based programs, bariatric surgery and primary prevention in the form of nutritional education among high risk groups.\nWe already know that intensive interventions for exercise and diet are needed for weight management. It would be useful to know how Weight Watchers compares to these other intensive interventions in terms of cost and effectiveness. In its assessment of a review of comparable meal control programs, the American Academy of Family Physicians found that:\n\u201cAt 12 months, Weight Watchers participants achieved at least 2.6 percent greater weight loss than the control group, and Jenny Craig users saw at least 4.9 percent greater weight loss than the control group.\u201d\n\u201cOther programs, including NutriSystem, showed comparable weight-loss results in the short term, but the study said additional research is needed to determine their long-term results.\u201d", "answer": 0}, {"article": "They had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\nA first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments, two studies suggest, and could soon add a more expensive but easier to manage treatment option to the booming market.\nDenosumab would be the first osteoporosis treatment that is such a monoclonal antibody \u2014 a type of immune cell cloned from the same parent cell to bind to a specific substance.\nSpine bone density loss was far smaller for those given the drug.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story discusses several alternative drug options for treating osteoporosis, including vitamins, pills, patches, nasal sprays, and intravenously and subcutaneously injected drugs.\u00a0 Comparisons in efficacy between denosumab and some of these alternatives are provided.\u00a0 More information comparing the absolute risk reduction for spine fractures would have been a nice addition, as well.\u00a0\u00a0 ", "answer": 1}, {"article": "A final decision is expected by the end of June, according to the documents.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\nThe review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Warfarin (Coumadin) is mentioned but no meaningful comparison is provided.\nAs we noted previously, the comments are out of context, not in the advisory document and relate to the use of the drugs in patients with stroke and not acute coronary syndrome.", "answer": 0}, {"article": "\"I say, 'Go for it!'\nThat, he says, will be the next big advance in sinus treatment.\nForeman wrote a column about her surgery.\nOn the monitor, you can see the miniature instruments he's using to cut away inflamed tissue and snip away pieces of eggshell-thin bone that block Butler's sinuses and give her nonstop headaches.\nBut surgery rarely cures them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u2019s sidebar\u00a0gives detailed descriptions of alternatives to surgery, including nasal irrigation and corticosteroid nasal sprays.", "answer": 1}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThis is the first time a randomised, double-blind, clinical trial has shown that a nutritional intervention can help to conserve the ability of patients with very early AD (pre-dementia) to carry out everyday tasks, such as paying bills, or finding your way around, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) - a combined measure for the ability to think and perform everyday tasks.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\nThe LipiDiDiet study illustrates that this nutritional intervention can help to conserve brain tissue and also memory and patients' ability to perform everyday tasks - possibly the most troubling aspects of the disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the release makes it clear \u2014 and accurately so \u2014 that there are no pharmaceutical treatments for dementia, it also states \u201cWe have known for a while that diet can reduce the risk of developing dementia.\u201d We disagree. No diet has ever been shown to reduce the risk of dementia. The best we\u2019ve got are epidemiological studies that show an association between diet and dementia risk. That\u2019s not the same as reducing risk. The release also says that \u201csingle nutrients simply aren\u2019t powerful enough to fight a disease like Alzheimer\u2019s alone.\u201d That\u2019s a gross oversimplification that could lead people to think that more is better when it comes to vitamins and dementia.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have done a better job of explaining what treatments users of ayahuasca tried before taking the extreme step of traveling to the Amazon. The lead describes one U.S. Army vet who \u201ctried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\u201d\u00a0 But there\u2019s no indication that the reporter attempted to contact a clinician who treated the vet, or one who treats vets with similar conditions, to find out what specific therapies are used and their rate of efficacy.", "answer": 0}, {"article": "As it happens, on Christmas Eve, my daughter (who, at 17, is wee no more) woke up with a wicked pain in her ear.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nOne of the studies noted that while antibiotics -- specifically, amoxicillin paired with clavulanate -- shortened the duration of symptoms, half the children on placebo eventually got better without the aid of those drugs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does note that more than half of children got better in one of the studies even though they didn\u2019t receive antibiotics, the story doesn\u2019t give a fair hearing to \u201cwatchful waiting\u201d or explain why it is recommended as an option for\u00a0some children with ear infections. According to data presented in these guidelines,\u00a0\u00a0antibiotics\u00a0shorten ear infections\u00a0by one day in 5% to 14% of children,\u00a0but the\u00a0majority of children will\u00a0get better without them. Antibiotics also lead to side effects in 5% to 10% of children, infrequent serious side effects, and\u00a0may contribute to antibacterial resistance. Provided with this full information,\u00a0different parents may make different choices about whether to treat their children immediately with\u00a0antibiotics for an ear infection.\nCNN, by comparison, ended its piece with a strong take-home message about the shared decision-making conversation parents should now have with their pediatricians. ", "answer": 0}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\n\u201cRobotics increases the chance that a hysterectomy can be done by laparoscopy,\u201d he added.\nMore research is needed to be able to compare long-term outcomes, wrote the researchers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was based on a systematic review of studies of three surgical approaches to endometrial cancer. The story did a nice job briefly explaining the differences in the surgical techniques and the differences seen in the study.", "answer": 1}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was mention of the two different screening methods used in these studies \u2014 PET and cerebral spinal fluid test \u2014 but no discussion of which method was more precise or if they yielded similar accuracy. In addition, it would have been helpful to know the accuracy of clinical diagnosis of\u00a0AD \u2014 it\u2019s given in one of the papers, for comparison.", "answer": 0}, {"article": "It's the same,\" Rodriguez noted.\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nAfter 24 weeks, some of the doses were adjusted.\nTo test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.\nDescribing the targeting of B cells as an \"innovative therapeutic approach,\" Kappos and his colleagues reported that in testing among 218 patients, the drug's impact on lesions was \"rapid and pronounced.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We only had the Mayo expert\u2019s broad comments comparing ocrelizumab and rituximab \u2013 but no comparative data on benefits and harms were provided.", "answer": 0}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any insight about how this dietary intervention compares with other approaches (exercise or drugs) for attaining the benefits suggested from the \u201dMediterranean diet\u2019.\u00a0 Even a line would have helped readers think about this context.", "answer": 0}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This topic is not addressed directly. The nature of the study design implies that perhaps there are no alternatives, given that subjects are described as having \"refractory\" breast cancers, and given that there are baseline data regarding a median of 7 other therapies for metastatic disease. However, the abstract states that the range of prior therapies was as low as 1, so the role of possible alternatives is not clear. Because the end of the article mentions other trials that are comparing T-DM1 to other therapies, it would seem that a more explicit discussion of alternatives \u2014 or that there were no alternatives for these subjects \u2014 would clarify the potential treatment role of T-DM1.", "answer": 2}, {"article": "\u201cShe would wake up in the middle of the night with night terrors at a very young age, she stopped napping around 15 months \u2026 any type of change in our schedule could set off an epic tantrum.\u201d\n\nOakes didn\u2019t know it then, but her daughter Mallory was one of more than 10 percent of American children living with attention deficit hyperactivity disorder (ADHD)\n\n\u201cShe was diagnosed in first grade after there were some difficulties in the classroom,\u201d Amy said.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cIf you get a child who has really strong left brain and delayed right brain, those are kids that may be labeled with attentional problems or behavioral problems or social issues,\u201d Melillo said.\n\u201cThere were times I remember saying to my husband that her behaviors are holding our family hostage because it could be one meltdown a day, it could be five meltdowns a day,\u201d Amy said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions drugs that are often prescribed for children with behavioral disorders. But it does not offer any evidence-based comparison of approaches.\u00a0While offering the Brain Balance system as a superior treatment,\u00a0the story\u00a0does not provide the context that some of the elements of the Brain center\u2019s treatment are also offered in traditional therapeutic centers.\nThis line in the story \u2013 \u201cwith doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms\u201d \u2013 also demands some further explanation. \u00a0This statement makes the use of antipsychotics and antidepressants sound commonplace. \u00a0It would be the rare and controversial practice to use these.", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a pretty good job of explaining alternatives to the relatively new immunotherapies, as well as some treatment cost comparisons. As stated earlier, the discussion was weighted toward immunotherapy and not OTC and prescription medications.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nScientists at Tufts University identified the foods that seem to contribute the most to the risk.\nAs most nutrition studies show, it's excessive consumption that drives up the risk.\nOne challenge: People who have healthy diets often have other healthy habits, too \u2014 such as getting regular exercise.\nAnd eating more \u2014 or less \u2014 of just 10 types of food can help raise or lower the risk of death from these causes, the researchers found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses exercise as another lifestyle factor that might be associated with reduced risk of death. Smoking could also have been mentioned.\nAs well, stress\u00a0management and solid social connections are believed to be important lifestyle factors affecting health, yet unlikely to be captured in those nutrition-related questionnaires.", "answer": 1}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nOf the 444 patients with lung cancer, 318 died during the three years of follow-up, the researchers wrote.\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Smoking cessation\u00a0would be far more effective than increased soy consumption\u00a0for reducing lung cancer rates in American women. The story was not clear about this fact.", "answer": 0}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\n\"This finding requires a confirmatory trial, including whether high daily doses of vitamin D, rather than high monthly doses, makes patients less likely to fall,\" Ginde said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says that there are not enough good options for preventing ARIs, but it does not adequately explain the options.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThere were 294 deaths (9.7 percent) among non-heart-failure patients not treated with Plavix and 285 deaths (9.4 percent) among non-heart failure patients who were given the drug.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion about the impact other medications in the same class as Plavix have in the populations studied.", "answer": 0}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nInfants in the partial treatment group fared better than untreated infants.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nSteroids are a standard treatment for pregnant women likely to deliver before 34 weeks because these drugs are known to reduce the chance of complications and death among premature infants.\nOverall, these findings suggest that starting steroid treatment promptly \u2014 even if the likelihood of completion is low \u2014 is beneficial when extremely premature birth is imminent.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Alternative therapies are not discussed in the news release. For women who are more likely to deliver prematurely, they may receive a progesterone shot \u2014 the most common being the 17-OHPC shot \u2014 to prevent preterm birth. Other medications, such as tocolytics, which include ritodrine, magnesium sulfate, calcium channel blockers and indomethacin, can be administered to delay delivery. Additionally, women in preterm labor usually are given antibiotics, as some studies have suggested that antibiotics may prolong pregnancy and reduce problems in the newborn.\nSince none of these alternatives are mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\nAnother concern is that the tests may pick up on markers that are never destined to be cancer, something already known to occur in blood tests for prostate cancer, Kopetz said.\nDoctors, however, need an indication of how many patients will get a false positive result, something that can only be determined in a very large clinical trial, said Vogelstein.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The true alternative to these tests is routine cancer screening using proven screening methods recommended by the US Preventive Services Task Force. In fact, the whole name \u201cliquid biopsies\u201d is wrong. These are not biopsies at all, they are screening tests for healthy people that look for biomarkers of cancer in the blood. But we don\u2019t know what kind of clinical significance they have or if they will lead to better outcomes. Neither story gave a full explanation of the alternative screening approaches, although this story did mention colonoscopies (which are one such screening method) as well as screening tests for prostate cancer. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Those with a higher PSA velocity \u2014 the level rose more than a count of 0.35 a year \u2014 had a 54 percent survival rate, while those whose PSA rose more slowly had a 92 percent survival rate.\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nThe study is far from proof that making health decisions based on so-called PSA velocity can really save lives.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not adequately talk about options, whether that's treatment options once cancer is diagnosed or\u00a0alternatives to screening.\u00a0 For instance, the story doesn't mention the typical screening scenario (how often is it done, what does it involve?) nor does it mention the alternative of not screening, which is reasonable given that\u00a0experts don't know if screening or even early treatment saves lives.\u00a0 \u00a0 ", "answer": 0}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not present alternative ways of reducing cancer risk. Some other news reports specifically noted that avoiding smoking and obesity are both known to reduce cancer risk.", "answer": 0}, {"article": ".\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does compare the most common types of medical weight loss interventions that involve making changes to the stomach. However, there is no real discussion of alternatives, such as pharmaceutical interventions, attending counseling or support groups, and lifestyle changes involving diet and exercise. This is an important oversight given that, even with a surgical or endoscopic procedure, these other interventions are likely to play an important role in helping patients keep off any weight that they lose. What would the outcome be for\u00a0patients who only\u00a0went to a \u201ccenter of excellence\u201d weight loss facility for a full year?", "answer": 0}, {"article": "When I feel a bit depressed, for whatever reason, I go back to those letters and they are very exciting.\"\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\nOther centers, however, are currently in development.\nSo far, it is not effective against all types of cancer.\n\"It would be much less expensive making it more possible for a hospital to afford it -- a smaller system can already treat a relatively large number of patients per year.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Let\u2019s take a look a the alternatives mentioned:\nThere is no mention of other forms of targeted radiation therapy and importantly, their relative merit in cancer treatment as compared to proton beam therapy.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions ongoing studies with the goal of improving the vaccine so that protection against bird flu could be accomplished with loser doses.", "answer": 1}, {"article": "For more on aspirin, visit the National Institutes of Health.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\n\"These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,\" the study team noted in a news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Some of the other news stories about this study pointed out that avoiding smoking and obesity are known to reduce cancer risk. This story should also have pointed out these options, which also do not have potential adverse effects.", "answer": 0}, {"article": ".\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nThis has implications for the treatment of acute tendon injuries and chronic tendon disease.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Alternatives to the use of stem cells for treating inflamed tendons get no space in this text. Standard therapies including physical therapy and anti-inflammatory medicines are not mentioned.", "answer": 0}, {"article": "Visit the American Heart Association for more on statins.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is only about the concept of prevention, and not about a specific therapy regimen that is being suggested. In light of that, we can call it \u201cnot applicable.\u201d", "answer": 2}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We would have liked to have a comment or two on the parallel developments ongoing in this field. Coronary artery disease is more than a singe blockage. It is a systemic disease that is progressive unless systemic interventions are employed. Aggressive medical therapy is now viewed as an essential element to ongoing care and should have been included for completeness", "answer": 0}]